[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "The efficacy of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) assay was assessed by analyzing nasal swabs and swabs from other body sites for the presence of MRSA in a low-prevalence area. From 681 patients with a high risk for MRSA carriage, 1,601 specimens were collected and transported in Amies agar. After discordant analysis, the sensitivity, specificity, positive predictive value, and negative predictive value of the BD GeneOhm MRSA assay were 84.3%, 99.2%, 88.4%, and 98.9%, respectively, compared to culture.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "746d6125a1ae4b47b8868da9703ff04b", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[81, 81], [47, 47], [12, 12], [31, 31]], "char_spans": [[457, 460], [248, 251], [76, 79], [178, 181]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["of", 13], ["the", 16], ["BD", 20], ["GeneOhm", 23], ["methicillin", 31], ["-", 42], ["resistant", 43], ["Staphylococcus", 53], ["aureus", 68], ["(", 75], ["MRSA", 76], [")", 80], ["assay", 82], ["was", 88], ["assessed", 92], ["by", 101], ["analyzing", 104], ["nasal", 114], ["swabs", 120], ["and", 126], ["swabs", 130], ["from", 136], ["other", 141], ["body", 147], ["sites", 152], ["for", 158], ["the", 162], ["presence", 166], ["of", 175], ["MRSA", 178], ["in", 183], ["a", 186], ["low", 188], ["-", 191], ["prevalence", 192], ["area", 203], [".", 207], ["From", 209], ["681", 214], ["patients", 218], ["with", 227], ["a", 232], ["high", 234], ["risk", 239], ["for", 244], ["MRSA", 248], ["carriage", 253], [",", 261], ["1,601", 263], ["specimens", 269], ["were", 279], ["collected", 284], ["and", 294], ["transported", 298], ["in", 310], ["Amies", 313], ["agar", 319], [".", 323], ["After", 325], ["discordant", 331], ["analysis", 342], [",", 350], ["the", 352], ["sensitivity", 356], [",", 367], ["specificity", 369], [",", 380], ["positive", 382], ["predictive", 391], ["value", 402], [",", 407], ["and", 409], ["negative", 413], ["predictive", 422], ["value", 433], ["of", 439], ["the", 442], ["BD", 446], ["GeneOhm", 449], ["MRSA", 457], ["assay", 462], ["were", 468], ["84.3", 473], ["%", 477], [",", 478], ["99.2", 480], ["%", 484], [",", 485], ["88.4", 487], ["%", 491], [",", 492], ["and", 494], ["98.9", 498], ["%", 502], [",", 503], ["respectively", 505], [",", 517], ["compared", 519], ["to", 528], ["culture", 531], [".", 538]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "ZFHX1B encodes Smad-interacting protein 1, a transcriptional corepressor involved in the transforming growth factors beta (TGFbeta) signaling pathway. ZFHX1B mutations cause a complex developmental phenotype characterized by severe mental retardation (MR) and multiple congenital defects. We compared the distribution of ZFHX1B transcripts during mouse and human embryogenesis as well as in adult mice and humans. This showed that this gene is strongly transcribed at an early stage in the developing peripheral and central nervous systems of both mice and humans, in all neuronal regions of the brains of 25-week human fetuses and adult mice, and at varying levels in numerous nonneural tissues. Northern blot analysis suggested that ZFHX1B undergoes tissue-specific alternative splicing in both species. These results strongly suggest that ZFHX1B determines the transcriptional levels of target genes in various tissues through the combinatorial interactions of its isoforms with different Smad proteins. Thus, as well as causing neural defects, ZFHX1B mutations may also cause other malformations.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "8870a7ba64174735af9856e72fd82aaa", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[0, 0], [24, 24], [120, 120], [136, 136], [168, 168], [49, 49]], "char_spans": [[0, 5], [151, 156], [735, 740], [842, 847], [1048, 1053], [321, 326]]}]}], "context_tokens": [["ZFHX1B", 0], ["encodes", 7], ["Smad", 15], ["-", 19], ["interacting", 20], ["protein", 32], ["1", 40], [",", 41], ["a", 43], ["transcriptional", 45], ["corepressor", 61], ["involved", 73], ["in", 82], ["the", 85], ["transforming", 89], ["growth", 102], ["factors", 109], ["beta", 117], ["(", 122], ["TGFbeta", 123], [")", 130], ["signaling", 132], ["pathway", 142], [".", 149], ["ZFHX1B", 151], ["mutations", 158], ["cause", 168], ["a", 174], ["complex", 176], ["developmental", 184], ["phenotype", 198], ["characterized", 208], ["by", 222], ["severe", 225], ["mental", 232], ["retardation", 239], ["(", 251], ["MR", 252], [")", 254], ["and", 256], ["multiple", 260], ["congenital", 269], ["defects", 280], [".", 287], ["We", 289], ["compared", 292], ["the", 301], ["distribution", 305], ["of", 318], ["ZFHX1B", 321], ["transcripts", 328], ["during", 340], ["mouse", 347], ["and", 353], ["human", 357], ["embryogenesis", 363], ["as", 377], ["well", 380], ["as", 385], ["in", 388], ["adult", 391], ["mice", 397], ["and", 402], ["humans", 406], [".", 412], ["This", 414], ["showed", 419], ["that", 426], ["this", 431], ["gene", 436], ["is", 441], ["strongly", 444], ["transcribed", 453], ["at", 465], ["an", 468], ["early", 471], ["stage", 477], ["in", 483], ["the", 486], ["developing", 490], ["peripheral", 501], ["and", 512], ["central", 516], ["nervous", 524], ["systems", 532], ["of", 540], ["both", 543], ["mice", 548], ["and", 553], ["humans", 557], [",", 563], ["in", 565], ["all", 568], ["neuronal", 572], ["regions", 581], ["of", 589], ["the", 592], ["brains", 596], ["of", 603], ["25-week", 606], ["human", 614], ["fetuses", 620], ["and", 628], ["adult", 632], ["mice", 638], [",", 642], ["and", 644], ["at", 648], ["varying", 651], ["levels", 659], ["in", 666], ["numerous", 669], ["nonneural", 678], ["tissues", 688], [".", 695], ["Northern", 697], ["blot", 706], ["analysis", 711], ["suggested", 720], ["that", 730], ["ZFHX1B", 735], ["undergoes", 742], ["tissue", 752], ["-", 758], ["specific", 759], ["alternative", 768], ["splicing", 780], ["in", 789], ["both", 792], ["species", 797], [".", 804], ["These", 806], ["results", 812], ["strongly", 820], ["suggest", 829], ["that", 837], ["ZFHX1B", 842], ["determines", 849], ["the", 860], ["transcriptional", 864], ["levels", 880], ["of", 887], ["target", 890], ["genes", 897], ["in", 903], ["various", 906], ["tissues", 914], ["through", 922], ["the", 930], ["combinatorial", 934], ["interactions", 948], ["of", 961], ["its", 964], ["isoforms", 968], ["with", 977], ["different", 982], ["Smad", 992], ["proteins", 997], [".", 1005], ["Thus", 1007], [",", 1011], ["as", 1013], ["well", 1016], ["as", 1021], ["causing", 1024], ["neural", 1032], ["defects", 1039], [",", 1046], ["ZFHX1B", 1048], ["mutations", 1055], ["may", 1065], ["also", 1069], ["cause", 1074], ["other", 1080], ["malformations", 1086], [".", 1099]]}
{"context": "The reactive oxygen-generating NADPH oxidases (Noxes) function in a variety of biological roles, and can be broadly classified into those that are regulated by subunit interactions and those that are regulated by calcium. The prototypical subunit-regulated Nox, Nox2, is the membrane-associated catalytic subunit of the phagocyte NADPH-oxidase. Nox2 forms a heterodimer with the integral membrane protein, p22phox, and this heterodimer binds to the regulatory subunits p47phox, p67phox, p40phox and the small GTPase Rac, triggering superoxide generation. Nox-organizer protein 1 (NOXO1) and Nox-activator 1 (NOXA1), respective homologs of p47phox and p67phox, together with p22phox and Rac, activate Nox1, a non-phagocytic homolog of Nox2. NOXO1 and p22phox also regulate Nox3, whereas Nox4 requires only p22phox. In this study, we have assembled and analyzed amino acid sequences of Nox regulatory subunit orthologs from vertebrates, a urochordate, an echinoderm, a mollusc, a cnidarian, a choanoflagellate, fungi and a slime mold amoeba to investigate the evolutionary history of these subunits. Ancestral p47phox, p67phox, and p22phox genes are broadly seen in the metazoa, except for the ecdysozoans. The choanoflagellate Monosiga brevicollis, the unicellular organism that is the closest relatives of multicellular animals, encodes early prototypes of p22phox, p47phox as well as the earliest known Nox2-like ancestor of the Nox1-3 subfamily. p67phox- and p47phox-like genes are seen in the sea urchin Strongylocentrotus purpuratus and the limpet Lottia gigantea that also possess Nox2-like co-orthologs of vertebrate Nox1-3. Duplication of primordial p47phox and p67phox genes occurred in vertebrates, with the duplicated branches evolving into NOXO1 and NOXA1. Analysis of characteristic domains of regulatory subunits suggests a novel view of the evolution of Nox: in fish, p40phox participated in regulating both Nox1 and Nox2, but after the appearance of mammals, Nox1 (but not Nox2) became independent of p40phox. In the fish Oryzias latipes, a NOXO1 ortholog retains an autoinhibitory region that is characteristic of mammalian p47phox, and this was subsequently lost from NOXO1 in later vertebrates. Detailed amino acid sequence comparisons identified both putative key residues conserved in characteristic domains and previously unidentified conserved regions. Also, candidate organizer/activator proteins in fungi and amoeba are identified and hypothetical activation models are suggested. This is the first report to provide the comprehensive view of the molecular evolution of regulatory subunits for Nox enzymes. This approach provides clues for understanding the evolution of biochemical and physiological functions for regulatory-subunit-dependent Nox enzymes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "c9411266b7014dedb3a042e1c5632fa7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[128, 128], [288, 288], [349, 349], [338, 338], [255, 255]], "char_spans": [[700, 703], [1623, 1626], [1974, 1977], [1922, 1925], [1430, 1433]]}]}], "context_tokens": [["The", 0], ["reactive", 4], ["oxygen", 13], ["-", 19], ["generating", 20], ["NADPH", 31], ["oxidases", 37], ["(", 46], ["Noxes", 47], [")", 52], ["function", 54], ["in", 63], ["a", 66], ["variety", 68], ["of", 76], ["biological", 79], ["roles", 90], [",", 95], ["and", 97], ["can", 101], ["be", 105], ["broadly", 108], ["classified", 116], ["into", 127], ["those", 132], ["that", 138], ["are", 143], ["regulated", 147], ["by", 157], ["subunit", 160], ["interactions", 168], ["and", 181], ["those", 185], ["that", 191], ["are", 196], ["regulated", 200], ["by", 210], ["calcium", 213], [".", 220], ["The", 222], ["prototypical", 226], ["subunit", 239], ["-", 246], ["regulated", 247], ["Nox", 257], [",", 260], ["Nox2", 262], [",", 266], ["is", 268], ["the", 271], ["membrane", 275], ["-", 283], ["associated", 284], ["catalytic", 295], ["subunit", 305], ["of", 313], ["the", 316], ["phagocyte", 320], ["NADPH", 330], ["-", 335], ["oxidase", 336], [".", 343], ["Nox2", 345], ["forms", 350], ["a", 356], ["heterodimer", 358], ["with", 370], ["the", 375], ["integral", 379], ["membrane", 388], ["protein", 397], [",", 404], ["p22phox", 406], [",", 413], ["and", 415], ["this", 419], ["heterodimer", 424], ["binds", 436], ["to", 442], ["the", 445], ["regulatory", 449], ["subunits", 460], ["p47phox", 469], [",", 476], ["p67phox", 478], [",", 485], ["p40phox", 487], ["and", 495], ["the", 499], ["small", 503], ["GTPase", 509], ["Rac", 516], [",", 519], ["triggering", 521], ["superoxide", 532], ["generation", 543], [".", 553], ["Nox", 555], ["-", 558], ["organizer", 559], ["protein", 569], ["1", 577], ["(", 579], ["NOXO1", 580], [")", 585], ["and", 587], ["Nox", 591], ["-", 594], ["activator", 595], ["1", 605], ["(", 607], ["NOXA1", 608], [")", 613], [",", 614], ["respective", 616], ["homologs", 627], ["of", 636], ["p47phox", 639], ["and", 647], ["p67phox", 651], [",", 658], ["together", 660], ["with", 669], ["p22phox", 674], ["and", 682], ["Rac", 686], [",", 689], ["activate", 691], ["Nox1", 700], [",", 704], ["a", 706], ["non", 708], ["-", 711], ["phagocytic", 712], ["homolog", 723], ["of", 731], ["Nox2", 734], [".", 738], ["NOXO1", 740], ["and", 746], ["p22phox", 750], ["also", 758], ["regulate", 763], ["Nox3", 772], [",", 776], ["whereas", 778], ["Nox4", 786], ["requires", 791], ["only", 800], ["p22phox", 805], [".", 812], ["In", 814], ["this", 817], ["study", 822], [",", 827], ["we", 829], ["have", 832], ["assembled", 837], ["and", 847], ["analyzed", 851], ["amino", 860], ["acid", 866], ["sequences", 871], ["of", 881], ["Nox", 884], ["regulatory", 888], ["subunit", 899], ["orthologs", 907], ["from", 917], ["vertebrates", 922], [",", 933], ["a", 935], ["urochordate", 937], [",", 948], ["an", 950], ["echinoderm", 953], [",", 963], ["a", 965], ["mollusc", 967], [",", 974], ["a", 976], ["cnidarian", 978], [",", 987], ["a", 989], ["choanoflagellate", 991], [",", 1007], ["fungi", 1009], ["and", 1015], ["a", 1019], ["slime", 1021], ["mold", 1027], ["amoeba", 1032], ["to", 1039], ["investigate", 1042], ["the", 1054], ["evolutionary", 1058], ["history", 1071], ["of", 1079], ["these", 1082], ["subunits", 1088], [".", 1096], ["Ancestral", 1098], ["p47phox", 1108], [",", 1115], ["p67phox", 1117], [",", 1124], ["and", 1126], ["p22phox", 1130], ["genes", 1138], ["are", 1144], ["broadly", 1148], ["seen", 1156], ["in", 1161], ["the", 1164], ["metazoa", 1168], [",", 1175], ["except", 1177], ["for", 1184], ["the", 1188], ["ecdysozoans", 1192], [".", 1203], ["The", 1205], ["choanoflagellate", 1209], ["Monosiga", 1226], ["brevicollis", 1235], [",", 1246], ["the", 1248], ["unicellular", 1252], ["organism", 1264], ["that", 1273], ["is", 1278], ["the", 1281], ["closest", 1285], ["relatives", 1293], ["of", 1303], ["multicellular", 1306], ["animals", 1320], [",", 1327], ["encodes", 1329], ["early", 1337], ["prototypes", 1343], ["of", 1354], ["p22phox", 1357], [",", 1364], ["p47phox", 1366], ["as", 1374], ["well", 1377], ["as", 1382], ["the", 1385], ["earliest", 1389], ["known", 1398], ["Nox2-like", 1404], ["ancestor", 1414], ["of", 1423], ["the", 1426], ["Nox1", 1430], ["-", 1434], ["3", 1435], ["subfamily", 1437], [".", 1446], ["p67phox-", 1448], ["and", 1457], ["p47phox", 1461], ["-", 1468], ["like", 1469], ["genes", 1474], ["are", 1480], ["seen", 1484], ["in", 1489], ["the", 1492], ["sea", 1496], ["urchin", 1500], ["Strongylocentrotus", 1507], ["purpuratus", 1526], ["and", 1537], ["the", 1541], ["limpet", 1545], ["Lottia", 1552], ["gigantea", 1559], ["that", 1568], ["also", 1573], ["possess", 1578], ["Nox2-like", 1586], ["co", 1596], ["-", 1598], ["orthologs", 1599], ["of", 1609], ["vertebrate", 1612], ["Nox1", 1623], ["-", 1627], ["3", 1628], [".", 1629], ["Duplication", 1631], ["of", 1643], ["primordial", 1646], ["p47phox", 1657], ["and", 1665], ["p67phox", 1669], ["genes", 1677], ["occurred", 1683], ["in", 1692], ["vertebrates", 1695], [",", 1706], ["with", 1708], ["the", 1713], ["duplicated", 1717], ["branches", 1728], ["evolving", 1737], ["into", 1746], ["NOXO1", 1751], ["and", 1757], ["NOXA1", 1761], [".", 1766], ["Analysis", 1768], ["of", 1777], ["characteristic", 1780], ["domains", 1795], ["of", 1803], ["regulatory", 1806], ["subunits", 1817], ["suggests", 1826], ["a", 1835], ["novel", 1837], ["view", 1843], ["of", 1848], ["the", 1851], ["evolution", 1855], ["of", 1865], ["Nox", 1868], [":", 1871], ["in", 1873], ["fish", 1876], [",", 1880], ["p40phox", 1882], ["participated", 1890], ["in", 1903], ["regulating", 1906], ["both", 1917], ["Nox1", 1922], ["and", 1927], ["Nox2", 1931], [",", 1935], ["but", 1937], ["after", 1941], ["the", 1947], ["appearance", 1951], ["of", 1962], ["mammals", 1965], [",", 1972], ["Nox1", 1974], ["(", 1979], ["but", 1980], ["not", 1984], ["Nox2", 1988], [")", 1992], ["became", 1994], ["independent", 2001], ["of", 2013], ["p40phox", 2016], [".", 2023], ["In", 2025], ["the", 2028], ["fish", 2032], ["Oryzias", 2037], ["latipes", 2045], [",", 2052], ["a", 2054], ["NOXO1", 2056], ["ortholog", 2062], ["retains", 2071], ["an", 2079], ["autoinhibitory", 2082], ["region", 2097], ["that", 2104], ["is", 2109], ["characteristic", 2112], ["of", 2127], ["mammalian", 2130], ["p47phox", 2140], [",", 2147], ["and", 2149], ["this", 2153], ["was", 2158], ["subsequently", 2162], ["lost", 2175], ["from", 2180], ["NOXO1", 2185], ["in", 2191], ["later", 2194], ["vertebrates", 2200], [".", 2211], ["Detailed", 2213], ["amino", 2222], ["acid", 2228], ["sequence", 2233], ["comparisons", 2242], ["identified", 2254], ["both", 2265], ["putative", 2270], ["key", 2279], ["residues", 2283], ["conserved", 2292], ["in", 2302], ["characteristic", 2305], ["domains", 2320], ["and", 2328], ["previously", 2332], ["unidentified", 2343], ["conserved", 2356], ["regions", 2366], [".", 2373], ["Also", 2375], [",", 2379], ["candidate", 2381], ["organizer", 2391], ["/", 2400], ["activator", 2401], ["proteins", 2411], ["in", 2420], ["fungi", 2423], ["and", 2429], ["amoeba", 2433], ["are", 2440], ["identified", 2444], ["and", 2455], ["hypothetical", 2459], ["activation", 2472], ["models", 2483], ["are", 2490], ["suggested", 2494], [".", 2503], ["This", 2505], ["is", 2510], ["the", 2513], ["first", 2517], ["report", 2523], ["to", 2530], ["provide", 2533], ["the", 2541], ["comprehensive", 2545], ["view", 2559], ["of", 2564], ["the", 2567], ["molecular", 2571], ["evolution", 2581], ["of", 2591], ["regulatory", 2594], ["subunits", 2605], ["for", 2614], ["Nox", 2618], ["enzymes", 2622], [".", 2629], ["This", 2631], ["approach", 2636], ["provides", 2645], ["clues", 2654], ["for", 2660], ["understanding", 2664], ["the", 2678], ["evolution", 2682], ["of", 2692], ["biochemical", 2695], ["and", 2707], ["physiological", 2711], ["functions", 2725], ["for", 2735], ["regulatory", 2739], ["-", 2749], ["subunit", 2750], ["-", 2757], ["dependent", 2758], ["Nox", 2768], ["enzymes", 2772], [".", 2779]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "CADASIL is the most prominent inherited form of vascular dementia. The main clinical features include migraine with aura, stroke, mood disturbances, and cognitive decline, with a mid-life (30s-60s) adult onset. Genetic testing is the gold standard for the diagnosis. CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue. Only a couple of splice site mutations have been reported. In a few pathologically defined patients, genetic mutations remain unidentified. We report a family with late-onset CADASIL phenotype carrying a novel intronic deletion in the NOTCH3 gene (c.341-26_24delAAC). Transcript analysis revealed a splicing alteration, with the complete intron 3 retention. The insertion was in-frame and encoded an extra 25 amino acids, including 1 cysteine. This is the first report of an aberrant splicing event of the NOTCH3 gene associated with a mutation far away from the canonical splice site. Our finding suggests that the assays used to evaluate splicing should be mandatory in the diagnostic setting of genetically undefined CADASIL cases.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "dabfffc898254535a9a607a6650d2562", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [146, 146]], "char_spans": [[357, 364], [809, 816]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["the", 11], ["most", 15], ["prominent", 20], ["inherited", 30], ["form", 40], ["of", 45], ["vascular", 48], ["dementia", 57], [".", 65], ["The", 67], ["main", 71], ["clinical", 76], ["features", 85], ["include", 94], ["migraine", 102], ["with", 111], ["aura", 116], [",", 120], ["stroke", 122], [",", 128], ["mood", 130], ["disturbances", 135], [",", 147], ["and", 149], ["cognitive", 153], ["decline", 163], [",", 170], ["with", 172], ["a", 177], ["mid", 179], ["-", 182], ["life", 183], ["(", 188], ["30s-60s", 189], [")", 196], ["adult", 198], ["onset", 204], [".", 209], ["Genetic", 211], ["testing", 219], ["is", 227], ["the", 230], ["gold", 234], ["standard", 239], ["for", 248], ["the", 252], ["diagnosis", 256], [".", 265], ["CADASIL", 267], ["is", 275], ["caused", 278], ["mostly", 285], ["by", 292], ["missense", 295], ["mutations", 304], ["in", 314], ["the", 317], ["NOTCH3", 321], ["gene", 328], [",", 332], ["invariably", 334], ["involving", 345], ["a", 355], ["cysteine", 357], ["residue", 366], [".", 373], ["Only", 375], ["a", 380], ["couple", 382], ["of", 389], ["splice", 392], ["site", 399], ["mutations", 404], ["have", 414], ["been", 419], ["reported", 424], [".", 432], ["In", 434], ["a", 437], ["few", 439], ["pathologically", 443], ["defined", 458], ["patients", 466], [",", 474], ["genetic", 476], ["mutations", 484], ["remain", 494], ["unidentified", 501], [".", 513], ["We", 515], ["report", 518], ["a", 525], ["family", 527], ["with", 534], ["late", 539], ["-", 543], ["onset", 544], ["CADASIL", 550], ["phenotype", 558], ["carrying", 568], ["a", 577], ["novel", 579], ["intronic", 585], ["deletion", 594], ["in", 603], ["the", 606], ["NOTCH3", 610], ["gene", 617], ["(", 622], ["c.341", 623], ["-", 628], ["26_24delAAC", 629], [")", 640], [".", 641], ["Transcript", 643], ["analysis", 654], ["revealed", 663], ["a", 672], ["splicing", 674], ["alteration", 683], [",", 693], ["with", 695], ["the", 700], ["complete", 704], ["intron", 713], ["3", 720], ["retention", 722], [".", 731], ["The", 733], ["insertion", 737], ["was", 747], ["in", 751], ["-", 753], ["frame", 754], ["and", 760], ["encoded", 764], ["an", 772], ["extra", 775], ["25", 781], ["amino", 784], ["acids", 790], [",", 795], ["including", 797], ["1", 807], ["cysteine", 809], [".", 817], ["This", 819], ["is", 824], ["the", 827], ["first", 831], ["report", 837], ["of", 844], ["an", 847], ["aberrant", 850], ["splicing", 859], ["event", 868], ["of", 874], ["the", 877], ["NOTCH3", 881], ["gene", 888], ["associated", 893], ["with", 904], ["a", 909], ["mutation", 911], ["far", 920], ["away", 924], ["from", 929], ["the", 934], ["canonical", 938], ["splice", 948], ["site", 955], [".", 959], ["Our", 961], ["finding", 965], ["suggests", 973], ["that", 982], ["the", 987], ["assays", 991], ["used", 998], ["to", 1003], ["evaluate", 1006], ["splicing", 1015], ["should", 1024], ["be", 1031], ["mandatory", 1034], ["in", 1044], ["the", 1047], ["diagnostic", 1051], ["setting", 1062], ["of", 1070], ["genetically", 1073], ["undefined", 1085], ["CADASIL", 1095], ["cases", 1103], [".", 1108]]}
{"context": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). PubMed was searched using the search terms empagliflozin, BI 10773, and BI10773, for entries between January 1, 2000, and December 1, 2014. Reference lists from retrieved articles were searched manually for additional peer-reviewed publications. All publications reporting clinical trials of empagliflozin were eligible for inclusion. Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway. Data from a comprehensive phase III clinical trial program have demonstrated its efficacy as monotherapy, as add-on to other glucose-lowering agents, and in different patient populations. In these studies, empagliflozin resulted in improvements in blood glucose levels as well as reductions in body weight and blood pressure. Empagliflozin was well tolerated and was not associated with an increased risk of hypoglycemia versus placebo. The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "8e4362d962304849af0e9a9cf344f780", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[108, 108], [14, 14]], "char_spans": [[621, 625], [81, 85]]}]}], "context_tokens": [["To", 0], ["review", 3], ["available", 10], ["studies", 20], ["of", 28], ["empagliflozin", 31], [",", 44], ["a", 46], ["sodium", 48], ["glucose", 55], ["co", 63], ["-", 65], ["transporter-2", 66], ["(", 80], ["SGLT2", 81], [")", 86], ["inhibitor", 88], ["approved", 98], ["in", 107], ["2014", 110], ["by", 115], ["the", 118], ["European", 122], ["Commission", 131], ["and", 142], ["the", 146], ["United", 150], ["States", 157], ["Food", 164], ["and", 169], ["Drug", 173], ["Administration", 178], ["for", 193], ["the", 197], ["treatment", 201], ["of", 211], ["type", 214], ["2", 219], ["diabetes", 221], ["mellitus", 230], ["(", 239], ["T2DM", 240], [")", 244], [".", 245], ["PubMed", 247], ["was", 254], ["searched", 258], ["using", 267], ["the", 273], ["search", 277], ["terms", 284], ["empagliflozin", 290], [",", 303], ["BI", 305], ["10773", 308], [",", 313], ["and", 315], ["BI10773", 319], [",", 326], ["for", 328], ["entries", 332], ["between", 340], ["January", 348], ["1", 356], [",", 357], ["2000", 359], [",", 363], ["and", 365], ["December", 369], ["1", 378], [",", 379], ["2014", 381], [".", 385], ["Reference", 387], ["lists", 397], ["from", 403], ["retrieved", 408], ["articles", 418], ["were", 427], ["searched", 432], ["manually", 441], ["for", 450], ["additional", 454], ["peer", 465], ["-", 469], ["reviewed", 470], ["publications", 479], [".", 491], ["All", 493], ["publications", 497], ["reporting", 510], ["clinical", 520], ["trials", 529], ["of", 536], ["empagliflozin", 539], ["were", 553], ["eligible", 558], ["for", 567], ["inclusion", 571], [".", 580], ["Empagliflozin", 582], ["is", 596], ["a", 599], ["new", 601], ["once", 605], ["-", 609], ["daily", 610], ["oral", 616], ["SGLT2", 621], ["inhibitor", 627], ["with", 637], ["a", 642], ["mechanism", 644], ["of", 654], ["action", 657], ["that", 664], ["is", 669], ["independent", 672], ["of", 684], ["\u03b2", 687], ["-", 688], ["cell", 689], ["function", 694], ["and", 703], ["the", 707], ["insulin", 711], ["pathway", 719], [".", 726], ["Data", 728], ["from", 733], ["a", 738], ["comprehensive", 740], ["phase", 754], ["III", 760], ["clinical", 764], ["trial", 773], ["program", 779], ["have", 787], ["demonstrated", 792], ["its", 805], ["efficacy", 809], ["as", 818], ["monotherapy", 821], [",", 832], ["as", 834], ["add", 837], ["-", 840], ["on", 841], ["to", 844], ["other", 847], ["glucose", 853], ["-", 860], ["lowering", 861], ["agents", 870], [",", 876], ["and", 878], ["in", 882], ["different", 885], ["patient", 895], ["populations", 903], [".", 914], ["In", 916], ["these", 919], ["studies", 925], [",", 932], ["empagliflozin", 934], ["resulted", 948], ["in", 957], ["improvements", 960], ["in", 973], ["blood", 976], ["glucose", 982], ["levels", 990], ["as", 997], ["well", 1000], ["as", 1005], ["reductions", 1008], ["in", 1019], ["body", 1022], ["weight", 1027], ["and", 1034], ["blood", 1038], ["pressure", 1044], [".", 1052], ["Empagliflozin", 1054], ["was", 1068], ["well", 1072], ["tolerated", 1077], ["and", 1087], ["was", 1091], ["not", 1095], ["associated", 1099], ["with", 1110], ["an", 1115], ["increased", 1118], ["risk", 1128], ["of", 1133], ["hypoglycemia", 1136], ["versus", 1149], ["placebo", 1156], [".", 1163], ["The", 1165], ["oral", 1169], ["antidiabetes", 1174], ["agent", 1187], [",", 1192], ["empagliflozin", 1194], [",", 1207], ["can", 1209], ["be", 1213], ["used", 1216], ["as", 1221], ["monotherapy", 1224], ["or", 1236], ["alongside", 1239], ["other", 1249], ["glucose", 1255], ["-", 1262], ["lowering", 1263], ["treatments", 1272], [",", 1282], ["including", 1284], ["insulin", 1294], [",", 1301], ["to", 1303], ["treat", 1306], ["T2DM", 1312], [".", 1316]]}
{"context": "While Clostridium difficile epidemiology is well documented in many European countries, data are largely missing for South Eastern European region. Here we report the PCR ribotype distribution of 249 C.\u00a0difficile isolates received for typing from six hospital settings from Croatia, Bosnia and Herzegovina, Republic of Macedonia and Serbia in time period from 2008 to 2015. Twenty-four PCR ribotypes were detected. The majority of strains from Bosnia and Herzegovina and Serbia belonged to PCR ribotype 027 (65.8%). Other three dominating PCR ribotypes were 176 (18 strains; Croatia), 001/072 (15 strains; all countries) and 014/020 (15 strains; all countries).", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "7bfea0506db945dca07567f46a77be7c", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[82, 83]], "char_spans": [[494, 505]]}]}], "context_tokens": [["While", 0], ["Clostridium", 6], ["difficile", 18], ["epidemiology", 28], ["is", 41], ["well", 44], ["documented", 49], ["in", 60], ["many", 63], ["European", 68], ["countries", 77], [",", 86], ["data", 88], ["are", 93], ["largely", 97], ["missing", 105], ["for", 113], ["South", 117], ["Eastern", 123], ["European", 131], ["region", 140], [".", 146], ["Here", 148], ["we", 153], ["report", 156], ["the", 163], ["PCR", 167], ["ribotype", 171], ["distribution", 180], ["of", 193], ["249", 196], ["C.", 200], ["difficile", 203], ["isolates", 213], ["received", 222], ["for", 231], ["typing", 235], ["from", 242], ["six", 247], ["hospital", 251], ["settings", 260], ["from", 269], ["Croatia", 274], [",", 281], ["Bosnia", 283], ["and", 290], ["Herzegovina", 294], [",", 305], ["Republic", 307], ["of", 316], ["Macedonia", 319], ["and", 329], ["Serbia", 333], ["in", 340], ["time", 343], ["period", 348], ["from", 355], ["2008", 360], ["to", 365], ["2015", 368], [".", 372], ["Twenty", 374], ["-", 380], ["four", 381], ["PCR", 386], ["ribotypes", 390], ["were", 400], ["detected", 405], [".", 413], ["The", 415], ["majority", 419], ["of", 428], ["strains", 431], ["from", 439], ["Bosnia", 444], ["and", 451], ["Herzegovina", 455], ["and", 467], ["Serbia", 471], ["belonged", 478], ["to", 487], ["PCR", 490], ["ribotype", 494], ["027", 503], ["(", 507], ["65.8", 508], ["%", 512], [")", 513], [".", 514], ["Other", 516], ["three", 522], ["dominating", 528], ["PCR", 539], ["ribotypes", 543], ["were", 553], ["176", 558], ["(", 562], ["18", 563], ["strains", 566], [";", 573], ["Croatia", 575], [")", 582], [",", 583], ["001/072", 585], ["(", 593], ["15", 594], ["strains", 597], [";", 604], ["all", 606], ["countries", 610], [")", 619], ["and", 621], ["014/020", 625], ["(", 633], ["15", 634], ["strains", 637], [";", 644], ["all", 646], ["countries", 650], [")", 659], [".", 660]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). Mutations at each position were analyzed for their effects on U12-dependent splicing in vivo. Mutations at most positions resulted in a significant reduction of correct U12-dependent splicing. Defects observed included increased unspliced RNA levels, the activation of cryptic U2-dependent 5' and 3' splice sites, and the activation of cryptic U12-dependent branch/3' splice sites. A strong correlation was observed between the predicted thermodynamic stability of the branch site: U12 snRNA interaction and correct U12-dependent splicing. The lack of a polypyrimidine tract between the branch site and 3' splice site of U12-dependent introns and the observed reliance on base-pairing interactions for correct U12-dependent splicing emphasize the importance of RNA/RNA interactions during U12-dependent intron recognition and proper splice site selection.", "qas": [{"question": "Which is the branch site consensus sequence in U12-dependent introns?", "answers": ["UUCCUUAAC"], "qid": "b43e2230834144e38cbeb13c23ffd134", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["branch", 13], ["site", 20], ["consensus", 25], ["sequence", 35], ["in", 44], ["U12-dependent", 47], ["introns", 61], ["?", 68]], "detected_answers": [{"text": "UUCCUUAAC", "token_spans": [[64, 64]], "char_spans": [[391, 399]]}]}], "context_tokens": [["Highly", 0], ["conserved", 7], ["sequences", 17], ["at", 27], ["the", 30], ["5", 34], ["'", 35], ["splice", 37], ["site", 44], ["and", 49], ["branch", 53], ["site", 60], ["of", 65], ["U12-dependent", 68], ["introns", 82], ["are", 90], ["important", 94], ["determinants", 104], ["for", 117], ["splicing", 121], ["by", 130], ["U12-dependent", 133], ["spliceosomes", 147], [".", 159], ["This", 161], ["study", 166], ["investigates", 172], ["the", 185], ["in", 189], ["vivo", 192], ["splicing", 197], ["phenotypes", 206], ["of", 217], ["mutations", 220], ["in", 230], ["the", 233], ["branch", 237], ["site", 244], ["consensus", 249], ["sequence", 259], ["of", 268], ["the", 271], ["U12-dependent", 275], ["intron", 289], ["F", 296], ["from", 298], ["a", 303], ["human", 305], ["NOL1", 311], ["(", 316], ["P120", 317], [")", 321], ["minigene", 323], [".", 331], ["Intron", 333], ["F", 340], ["contains", 342], ["a", 351], ["fully", 353], ["consensus", 359], ["branch", 369], ["site", 376], ["sequence", 381], ["(", 390], ["UUCCUUAAC", 391], [")", 400], [".", 401], ["Mutations", 403], ["at", 413], ["each", 416], ["position", 421], ["were", 430], ["analyzed", 435], ["for", 444], ["their", 448], ["effects", 454], ["on", 462], ["U12-dependent", 465], ["splicing", 479], ["in", 488], ["vivo", 491], [".", 495], ["Mutations", 497], ["at", 507], ["most", 510], ["positions", 515], ["resulted", 525], ["in", 534], ["a", 537], ["significant", 539], ["reduction", 551], ["of", 561], ["correct", 564], ["U12-dependent", 572], ["splicing", 586], [".", 594], ["Defects", 596], ["observed", 604], ["included", 613], ["increased", 622], ["unspliced", 632], ["RNA", 642], ["levels", 646], [",", 652], ["the", 654], ["activation", 658], ["of", 669], ["cryptic", 672], ["U2-dependent", 680], ["5", 693], ["'", 694], ["and", 696], ["3", 700], ["'", 701], ["splice", 703], ["sites", 710], [",", 715], ["and", 717], ["the", 721], ["activation", 725], ["of", 736], ["cryptic", 739], ["U12-dependent", 747], ["branch/3", 761], ["'", 769], ["splice", 771], ["sites", 778], [".", 783], ["A", 785], ["strong", 787], ["correlation", 794], ["was", 806], ["observed", 810], ["between", 819], ["the", 827], ["predicted", 831], ["thermodynamic", 841], ["stability", 855], ["of", 865], ["the", 868], ["branch", 872], ["site", 879], [":", 883], ["U12", 885], ["snRNA", 889], ["interaction", 895], ["and", 907], ["correct", 911], ["U12-dependent", 919], ["splicing", 933], [".", 941], ["The", 943], ["lack", 947], ["of", 952], ["a", 955], ["polypyrimidine", 957], ["tract", 972], ["between", 978], ["the", 986], ["branch", 990], ["site", 997], ["and", 1002], ["3", 1006], ["'", 1007], ["splice", 1009], ["site", 1016], ["of", 1021], ["U12-dependent", 1024], ["introns", 1038], ["and", 1046], ["the", 1050], ["observed", 1054], ["reliance", 1063], ["on", 1072], ["base", 1075], ["-", 1079], ["pairing", 1080], ["interactions", 1088], ["for", 1101], ["correct", 1105], ["U12-dependent", 1113], ["splicing", 1127], ["emphasize", 1136], ["the", 1146], ["importance", 1150], ["of", 1161], ["RNA", 1164], ["/", 1167], ["RNA", 1168], ["interactions", 1172], ["during", 1185], ["U12-dependent", 1192], ["intron", 1206], ["recognition", 1213], ["and", 1225], ["proper", 1229], ["splice", 1236], ["site", 1243], ["selection", 1248], [".", 1257]]}
{"context": "Restless Legs Syndrome (RLS) or Willis-Ekbom Disease (WED) is highly prevalent, but patients and healthcare providers alike know little about it. Furthermore, controversy persists as to the best way of diagnosing this nosological entity. To verify whether the term used to refer to this disease entity (Restless Legs Syndrome or Willis-Ekbom Disease) affects the prevalence of self-diagnosed RLS/WED in a sample of newly graduated physicians. Newly graduated physicians were asked to self-evaluate for the presence of RLS/WED. Briefly, participants were allocated randomly across two groups. One was asked to self-assess for RLS, while the other was asked to self-assess for WED. The evaluation form given to one group asked 'Do you have Restless Legs Syndrome?' whereas the form given to participants in the other group asked 'Do you have Willis-Ekbom Disease?'. Both forms also contained the four criteria for diagnosing RLS proposed by the International Restless Legs Syndrome Study Group (IRLSSG) and instructions for self-diagnosis according to these criteria. The study sample comprised 1413 newly graduated physicians. Of the 708 participants who were given the form that used the term RLS, 87 (12.28%) diagnosed themselves with the condition. Conversely, of 705 physicians given the form with the term WED, 13 (1.84%) diagnosed themselves with the condition (p\u2009<0.0001). A greater proportion of newly graduated physicians diagnosed themselves with RLS/WED when presented with the term Restless Legs Syndrome than when presented with the term Willis-Ekbom Disease. This suggests that the term Restless Legs Syndrome may not be the most appropriate term to denote this nosological entity.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "16a25da84839436a89074d9ddedd979f", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[145, 147], [306, 308], [186, 188], [57, 59], [0, 2], [287, 289]], "char_spans": [[738, 759], [1600, 1621], [957, 978], [303, 324], [0, 21], [1493, 1514]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["or", 29], ["Willis", 32], ["-", 38], ["Ekbom", 39], ["Disease", 45], ["(", 53], ["WED", 54], [")", 57], ["is", 59], ["highly", 62], ["prevalent", 69], [",", 78], ["but", 80], ["patients", 84], ["and", 93], ["healthcare", 97], ["providers", 108], ["alike", 118], ["know", 124], ["little", 129], ["about", 136], ["it", 142], [".", 144], ["Furthermore", 146], [",", 157], ["controversy", 159], ["persists", 171], ["as", 180], ["to", 183], ["the", 186], ["best", 190], ["way", 195], ["of", 199], ["diagnosing", 202], ["this", 213], ["nosological", 218], ["entity", 230], [".", 236], ["To", 238], ["verify", 241], ["whether", 248], ["the", 256], ["term", 260], ["used", 265], ["to", 270], ["refer", 273], ["to", 279], ["this", 282], ["disease", 287], ["entity", 295], ["(", 302], ["Restless", 303], ["Legs", 312], ["Syndrome", 317], ["or", 326], ["Willis", 329], ["-", 335], ["Ekbom", 336], ["Disease", 342], [")", 349], ["affects", 351], ["the", 359], ["prevalence", 363], ["of", 374], ["self", 377], ["-", 381], ["diagnosed", 382], ["RLS", 392], ["/", 395], ["WED", 396], ["in", 400], ["a", 403], ["sample", 405], ["of", 412], ["newly", 415], ["graduated", 421], ["physicians", 431], [".", 441], ["Newly", 443], ["graduated", 449], ["physicians", 459], ["were", 470], ["asked", 475], ["to", 481], ["self", 484], ["-", 488], ["evaluate", 489], ["for", 498], ["the", 502], ["presence", 506], ["of", 515], ["RLS", 518], ["/", 521], ["WED", 522], [".", 525], ["Briefly", 527], [",", 534], ["participants", 536], ["were", 549], ["allocated", 554], ["randomly", 564], ["across", 573], ["two", 580], ["groups", 584], [".", 590], ["One", 592], ["was", 596], ["asked", 600], ["to", 606], ["self", 609], ["-", 613], ["assess", 614], ["for", 621], ["RLS", 625], [",", 628], ["while", 630], ["the", 636], ["other", 640], ["was", 646], ["asked", 650], ["to", 656], ["self", 659], ["-", 663], ["assess", 664], ["for", 671], ["WED", 675], [".", 678], ["The", 680], ["evaluation", 684], ["form", 695], ["given", 700], ["to", 706], ["one", 709], ["group", 713], ["asked", 719], ["'", 725], ["Do", 726], ["you", 729], ["have", 733], ["Restless", 738], ["Legs", 747], ["Syndrome", 752], ["?", 760], ["'", 761], ["whereas", 763], ["the", 771], ["form", 775], ["given", 780], ["to", 786], ["participants", 789], ["in", 802], ["the", 805], ["other", 809], ["group", 815], ["asked", 821], ["'", 827], ["Do", 828], ["you", 831], ["have", 835], ["Willis", 840], ["-", 846], ["Ekbom", 847], ["Disease", 853], ["?", 860], ["'", 861], [".", 862], ["Both", 864], ["forms", 869], ["also", 875], ["contained", 880], ["the", 890], ["four", 894], ["criteria", 899], ["for", 908], ["diagnosing", 912], ["RLS", 923], ["proposed", 927], ["by", 936], ["the", 939], ["International", 943], ["Restless", 957], ["Legs", 966], ["Syndrome", 971], ["Study", 980], ["Group", 986], ["(", 992], ["IRLSSG", 993], [")", 999], ["and", 1001], ["instructions", 1005], ["for", 1018], ["self", 1022], ["-", 1026], ["diagnosis", 1027], ["according", 1037], ["to", 1047], ["these", 1050], ["criteria", 1056], [".", 1064], ["The", 1066], ["study", 1070], ["sample", 1076], ["comprised", 1083], ["1413", 1093], ["newly", 1098], ["graduated", 1104], ["physicians", 1114], [".", 1124], ["Of", 1126], ["the", 1129], ["708", 1133], ["participants", 1137], ["who", 1150], ["were", 1154], ["given", 1159], ["the", 1165], ["form", 1169], ["that", 1174], ["used", 1179], ["the", 1184], ["term", 1188], ["RLS", 1193], [",", 1196], ["87", 1198], ["(", 1201], ["12.28", 1202], ["%", 1207], [")", 1208], ["diagnosed", 1210], ["themselves", 1220], ["with", 1231], ["the", 1236], ["condition", 1240], [".", 1249], ["Conversely", 1251], [",", 1261], ["of", 1263], ["705", 1266], ["physicians", 1270], ["given", 1281], ["the", 1287], ["form", 1291], ["with", 1296], ["the", 1301], ["term", 1305], ["WED", 1310], [",", 1313], ["13", 1315], ["(", 1318], ["1.84", 1319], ["%", 1323], [")", 1324], ["diagnosed", 1326], ["themselves", 1336], ["with", 1347], ["the", 1352], ["condition", 1356], ["(", 1366], ["p", 1367], ["<", 1369], ["0.0001", 1370], [")", 1376], [".", 1377], ["A", 1379], ["greater", 1381], ["proportion", 1389], ["of", 1400], ["newly", 1403], ["graduated", 1409], ["physicians", 1419], ["diagnosed", 1430], ["themselves", 1440], ["with", 1451], ["RLS", 1456], ["/", 1459], ["WED", 1460], ["when", 1464], ["presented", 1469], ["with", 1479], ["the", 1484], ["term", 1488], ["Restless", 1493], ["Legs", 1502], ["Syndrome", 1507], ["than", 1516], ["when", 1521], ["presented", 1526], ["with", 1536], ["the", 1541], ["term", 1545], ["Willis", 1550], ["-", 1556], ["Ekbom", 1557], ["Disease", 1563], [".", 1570], ["This", 1572], ["suggests", 1577], ["that", 1586], ["the", 1591], ["term", 1595], ["Restless", 1600], ["Legs", 1609], ["Syndrome", 1614], ["may", 1623], ["not", 1627], ["be", 1631], ["the", 1634], ["most", 1638], ["appropriate", 1643], ["term", 1655], ["to", 1660], ["denote", 1663], ["this", 1670], ["nosological", 1675], ["entity", 1687], [".", 1693]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is characterised by abnormal sensations in the legs as well as dysaesthesia. Although the aetiology of RLS has not yet been determined, it may be associated with systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a new and simple marker indicating systemic inflammation. The present study aimed to investigate the relationship between systemic inflammation and RLS through the use of the NLR. A total of 75 newly diagnosed patients with RLS and 56 healthy control subjects were included in the study. Baseline NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The NLRs of the two groups were compared. There were no significant differences in gender and age between the two groups. The NLR was 1.96 \u00b1 0.66 in the patient group and 1.67 \u00b1 0.68 in the control group (p = 0.005). Receiver operating characteristic analysis was performed to determine the cut-off value of NLR to predict RLS. The NLR was predictive at 1.58 with a 64% sensitivity and 50% specificity (95% confidence interval 0.55-0.74, area under curve 0.648 \u00b1 0.05). The NLR was found to be statistically higher in patients with RLS and may be used to predict RLS. The aetiology of RLS remains undetermined. The present study showed that systemic inflammation may play a role in RLS. However, RLS could also be associated with systemic inflammatory diseases. This relationship is supported by high NLR values, which are related to chronic systemic inflammation.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "10121cea2cf84ddb98d1d1e853f2f446", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["characterised", 69], ["by", 83], ["abnormal", 86], ["sensations", 95], ["in", 106], ["the", 109], ["legs", 113], ["as", 118], ["well", 121], ["as", 126], ["dysaesthesia", 129], [".", 141], ["Although", 143], ["the", 152], ["aetiology", 156], ["of", 166], ["RLS", 169], ["has", 173], ["not", 177], ["yet", 181], ["been", 185], ["determined", 190], [",", 200], ["it", 202], ["may", 205], ["be", 209], ["associated", 212], ["with", 223], ["systemic", 228], ["inflammation", 237], [".", 249], ["The", 251], ["neutrophil", 255], ["-", 265], ["to", 266], ["-", 268], ["lymphocyte", 269], ["ratio", 280], ["(", 286], ["NLR", 287], [")", 290], ["is", 292], ["a", 295], ["new", 297], ["and", 301], ["simple", 305], ["marker", 312], ["indicating", 319], ["systemic", 330], ["inflammation", 339], [".", 351], ["The", 353], ["present", 357], ["study", 365], ["aimed", 371], ["to", 377], ["investigate", 380], ["the", 392], ["relationship", 396], ["between", 409], ["systemic", 417], ["inflammation", 426], ["and", 439], ["RLS", 443], ["through", 447], ["the", 455], ["use", 459], ["of", 463], ["the", 466], ["NLR", 470], [".", 473], ["A", 475], ["total", 477], ["of", 483], ["75", 486], ["newly", 489], ["diagnosed", 495], ["patients", 505], ["with", 514], ["RLS", 519], ["and", 523], ["56", 527], ["healthy", 530], ["control", 538], ["subjects", 546], ["were", 555], ["included", 560], ["in", 569], ["the", 572], ["study", 576], [".", 581], ["Baseline", 583], ["NLR", 592], ["was", 596], ["calculated", 600], ["by", 611], ["dividing", 614], ["the", 623], ["absolute", 627], ["neutrophil", 636], ["count", 647], ["by", 653], ["the", 656], ["absolute", 660], ["lymphocyte", 669], ["count", 680], [".", 685], ["The", 687], ["NLRs", 691], ["of", 696], ["the", 699], ["two", 703], ["groups", 707], ["were", 714], ["compared", 719], [".", 727], ["There", 729], ["were", 735], ["no", 740], ["significant", 743], ["differences", 755], ["in", 767], ["gender", 770], ["and", 777], ["age", 781], ["between", 785], ["the", 793], ["two", 797], ["groups", 801], [".", 807], ["The", 809], ["NLR", 813], ["was", 817], ["1.96", 821], ["\u00b1", 826], ["0.66", 828], ["in", 833], ["the", 836], ["patient", 840], ["group", 848], ["and", 854], ["1.67", 858], ["\u00b1", 863], ["0.68", 865], ["in", 870], ["the", 873], ["control", 877], ["group", 885], ["(", 891], ["p", 892], ["=", 894], ["0.005", 896], [")", 901], [".", 902], ["Receiver", 904], ["operating", 913], ["characteristic", 923], ["analysis", 938], ["was", 947], ["performed", 951], ["to", 961], ["determine", 964], ["the", 974], ["cut", 978], ["-", 981], ["off", 982], ["value", 986], ["of", 992], ["NLR", 995], ["to", 999], ["predict", 1002], ["RLS", 1010], [".", 1013], ["The", 1015], ["NLR", 1019], ["was", 1023], ["predictive", 1027], ["at", 1038], ["1.58", 1041], ["with", 1046], ["a", 1051], ["64", 1053], ["%", 1055], ["sensitivity", 1057], ["and", 1069], ["50", 1073], ["%", 1075], ["specificity", 1077], ["(", 1089], ["95", 1090], ["%", 1092], ["confidence", 1094], ["interval", 1105], ["0.55", 1114], ["-", 1118], ["0.74", 1119], [",", 1123], ["area", 1125], ["under", 1130], ["curve", 1136], ["0.648", 1142], ["\u00b1", 1148], ["0.05", 1150], [")", 1154], [".", 1155], ["The", 1157], ["NLR", 1161], ["was", 1165], ["found", 1169], ["to", 1175], ["be", 1178], ["statistically", 1181], ["higher", 1195], ["in", 1202], ["patients", 1205], ["with", 1214], ["RLS", 1219], ["and", 1223], ["may", 1227], ["be", 1231], ["used", 1234], ["to", 1239], ["predict", 1242], ["RLS", 1250], [".", 1253], ["The", 1255], ["aetiology", 1259], ["of", 1269], ["RLS", 1272], ["remains", 1276], ["undetermined", 1284], [".", 1296], ["The", 1298], ["present", 1302], ["study", 1310], ["showed", 1316], ["that", 1323], ["systemic", 1328], ["inflammation", 1337], ["may", 1350], ["play", 1354], ["a", 1359], ["role", 1361], ["in", 1366], ["RLS", 1369], [".", 1372], ["However", 1374], [",", 1381], ["RLS", 1383], ["could", 1387], ["also", 1393], ["be", 1398], ["associated", 1401], ["with", 1412], ["systemic", 1417], ["inflammatory", 1426], ["diseases", 1439], [".", 1447], ["This", 1449], ["relationship", 1454], ["is", 1467], ["supported", 1470], ["by", 1480], ["high", 1483], ["NLR", 1488], ["values", 1492], [",", 1498], ["which", 1500], ["are", 1506], ["related", 1510], ["to", 1518], ["chronic", 1521], ["systemic", 1529], ["inflammation", 1538], [".", 1550]]}
{"context": "Peripheral neuropathy (PN) has been reported in idiopathic and hereditary forms of parkinsonism, but the pathogenic mechanisms are unclear and likely heterogeneous. Levodopa-induced vitamin B12 deficiency has been discussed as a causal factor of PN in idiopathic Parkinson's disease, but peripheral nervous system involvement might also be a consequence of the underlying neurodegenerative process. Occurrence of PN with parkinsonism has been associated with a panel of mitochondrial cytopathies, more frequently related to a nuclear gene defect and mainly polymerase gamma (POLG1) gene. Parkin (PARK2) gene mutations are responsible for juvenile parkinsonism, and possible peripheral nervous system involvement has been reported. Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the \u03b2-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations. This article reviews conditions in which PN may coexist with parkinsonism.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "ccaf40e8947045dbb86dafd325b2f626", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[216, 217]], "char_spans": [[1285, 1293]]}]}], "context_tokens": [["Peripheral", 0], ["neuropathy", 11], ["(", 22], ["PN", 23], [")", 25], ["has", 27], ["been", 31], ["reported", 36], ["in", 45], ["idiopathic", 48], ["and", 59], ["hereditary", 63], ["forms", 74], ["of", 80], ["parkinsonism", 83], [",", 95], ["but", 97], ["the", 101], ["pathogenic", 105], ["mechanisms", 116], ["are", 127], ["unclear", 131], ["and", 139], ["likely", 143], ["heterogeneous", 150], [".", 163], ["Levodopa", 165], ["-", 173], ["induced", 174], ["vitamin", 182], ["B12", 190], ["deficiency", 194], ["has", 205], ["been", 209], ["discussed", 214], ["as", 224], ["a", 227], ["causal", 229], ["factor", 236], ["of", 243], ["PN", 246], ["in", 249], ["idiopathic", 252], ["Parkinson", 263], ["'s", 272], ["disease", 275], [",", 282], ["but", 284], ["peripheral", 288], ["nervous", 299], ["system", 307], ["involvement", 314], ["might", 326], ["also", 332], ["be", 337], ["a", 340], ["consequence", 342], ["of", 354], ["the", 357], ["underlying", 361], ["neurodegenerative", 372], ["process", 390], [".", 397], ["Occurrence", 399], ["of", 410], ["PN", 413], ["with", 416], ["parkinsonism", 421], ["has", 434], ["been", 438], ["associated", 443], ["with", 454], ["a", 459], ["panel", 461], ["of", 467], ["mitochondrial", 470], ["cytopathies", 484], [",", 495], ["more", 497], ["frequently", 502], ["related", 513], ["to", 521], ["a", 524], ["nuclear", 526], ["gene", 534], ["defect", 539], ["and", 546], ["mainly", 550], ["polymerase", 557], ["gamma", 568], ["(", 574], ["POLG1", 575], [")", 580], ["gene", 582], [".", 586], ["Parkin", 588], ["(", 595], ["PARK2", 596], [")", 601], ["gene", 603], ["mutations", 608], ["are", 618], ["responsible", 622], ["for", 634], ["juvenile", 638], ["parkinsonism", 647], [",", 659], ["and", 661], ["possible", 665], ["peripheral", 674], ["nervous", 685], ["system", 693], ["involvement", 700], ["has", 712], ["been", 716], ["reported", 721], [".", 729], ["Rarely", 731], [",", 737], ["an", 739], ["association", 742], ["of", 754], ["parkinsonism", 757], ["with", 770], ["PN", 775], ["may", 778], ["be", 782], ["encountered", 785], ["in", 797], ["other", 800], ["neurodegenerative", 806], ["diseases", 824], ["such", 833], ["as", 838], ["fragile", 841], ["X", 849], ["-", 850], ["associated", 851], ["tremor", 862], ["and", 869], ["ataxia", 873], ["syndrome", 880], ["related", 889], ["to", 897], ["premutation", 900], ["CGG", 912], ["repeat", 916], ["expansion", 923], ["in", 933], ["the", 936], ["fragile", 940], ["X", 948], ["mental", 950], ["retardation", 957], ["(", 969], ["FMR1", 970], [")", 974], ["gene", 976], [",", 980], ["Machado", 982], ["-", 989], ["Joseph", 990], ["disease", 997], ["related", 1005], ["to", 1013], ["an", 1016], ["abnormal", 1019], ["CAG", 1028], ["repeat", 1032], ["expansion", 1039], ["in", 1049], ["ataxin-3", 1052], ["(", 1061], ["ATXN3", 1062], [")", 1067], ["gene", 1069], [",", 1073], ["Kufor", 1075], ["-", 1080], ["Rakeb", 1081], ["syndrome", 1087], ["caused", 1096], ["by", 1103], ["mutations", 1106], ["in", 1116], ["ATP13A2", 1119], ["gene", 1127], [",", 1131], ["or", 1133], ["in", 1136], ["hereditary", 1139], ["systemic", 1150], ["disorders", 1159], ["such", 1169], ["as", 1174], ["Gaucher", 1177], ["disease", 1185], ["due", 1193], ["to", 1197], ["mutations", 1200], ["in", 1210], ["the", 1213], ["\u03b2", 1217], ["-", 1218], ["glucocerebrosidase", 1219], ["(", 1238], ["GBA", 1239], [")", 1242], ["gene", 1244], ["and", 1249], ["Chediak", 1253], ["-", 1260], ["Higashi", 1261], ["syndrome", 1269], ["due", 1278], ["to", 1282], ["LYST", 1285], ["gene", 1290], ["mutations", 1295], [".", 1304], ["This", 1306], ["article", 1311], ["reviews", 1319], ["conditions", 1327], ["in", 1338], ["which", 1341], ["PN", 1347], ["may", 1350], ["coexist", 1354], ["with", 1362], ["parkinsonism", 1367], [".", 1379]]}
{"context": "Restless legs syndrome/Willis-Ekbom disease (RLS/WED) is commonly seen in patients with end-stage renal disease (ESRD), but this condition has not been properly recognized. The prevalence of RLS/WED in ESRD shows the ethnic variation (7%-68%), with the similar tendency of primary RLS/WED. Although RLS/WED in ESRD is defined in secondary RLS/WED, the factors of ESRD that are involved in the genesis of RLS/WED remain unknown. Even after renal transplantation, RLS/WED symptoms do not completely disappear, and genetic predisposition to RLS/WED may play an important role in causing RLS/WED. Long-term intervention for RLS/WED and ESRD will be necessary.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "bad640c274d449bc9a202b19f0948118", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["-", 29], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["is", 54], ["commonly", 57], ["seen", 66], ["in", 71], ["patients", 74], ["with", 83], ["end", 88], ["-", 91], ["stage", 92], ["renal", 98], ["disease", 104], ["(", 112], ["ESRD", 113], [")", 117], [",", 118], ["but", 120], ["this", 124], ["condition", 129], ["has", 139], ["not", 143], ["been", 147], ["properly", 152], ["recognized", 161], [".", 171], ["The", 173], ["prevalence", 177], ["of", 188], ["RLS", 191], ["/", 194], ["WED", 195], ["in", 199], ["ESRD", 202], ["shows", 207], ["the", 213], ["ethnic", 217], ["variation", 224], ["(", 234], ["7%-68", 235], ["%", 240], [")", 241], [",", 242], ["with", 244], ["the", 249], ["similar", 253], ["tendency", 261], ["of", 270], ["primary", 273], ["RLS", 281], ["/", 284], ["WED", 285], [".", 288], ["Although", 290], ["RLS", 299], ["/", 302], ["WED", 303], ["in", 307], ["ESRD", 310], ["is", 315], ["defined", 318], ["in", 326], ["secondary", 329], ["RLS", 339], ["/", 342], ["WED", 343], [",", 346], ["the", 348], ["factors", 352], ["of", 360], ["ESRD", 363], ["that", 368], ["are", 373], ["involved", 377], ["in", 386], ["the", 389], ["genesis", 393], ["of", 401], ["RLS", 404], ["/", 407], ["WED", 408], ["remain", 412], ["unknown", 419], [".", 426], ["Even", 428], ["after", 433], ["renal", 439], ["transplantation", 445], [",", 460], ["RLS", 462], ["/", 465], ["WED", 466], ["symptoms", 470], ["do", 479], ["not", 482], ["completely", 486], ["disappear", 497], [",", 506], ["and", 508], ["genetic", 512], ["predisposition", 520], ["to", 535], ["RLS", 538], ["/", 541], ["WED", 542], ["may", 546], ["play", 550], ["an", 555], ["important", 558], ["role", 568], ["in", 573], ["causing", 576], ["RLS", 584], ["/", 587], ["WED", 588], [".", 591], ["Long", 593], ["-", 597], ["term", 598], ["intervention", 603], ["for", 616], ["RLS", 620], ["/", 623], ["WED", 624], ["and", 628], ["ESRD", 632], ["will", 637], ["be", 642], ["necessary", 645], [".", 654]]}
{"context": "Stress-induced mutagenesis describes the accumulation of mutations that occur in nongrowing cells, in contrast to mutagenesis that occurs in actively dividing populations, and has been referred to as stationary-phase or adaptive mutagenesis. The most widely studied system for stress-induced mutagenesis involves monitoring the appearance of Lac(+) revertants of the strain FC40 under starvation conditions in Escherichia coli. The SOS-inducible translesion DNA polymerase DinB plays an important role in this phenomenon. Loss of DinB (DNA pol IV) function results in a severe reduction of Lac(+) revertants. We previously reported that NusA, an essential component of elongating RNA polymerases, interacts with DinB. Here we report our unexpected observation that wild-type NusA function is required for stress-induced mutagenesis. We present evidence that this effect is unlikely to be due to defects in transcription of lac genes but rather is due to an inability to adapt and mutate in response to environmental stress. Furthermore, we extended our analysis to the formation of stress-induced mutants in response to antibiotic treatment, observing the same striking abolition of mutagenesis under entirely different conditions. Our results are the first to implicate NusA as a crucial participant in the phenomenon of stress-induced mutagenesis.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1daf44d1e59d499da16d3746bd6277c2", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[32, 34]], "char_spans": [[200, 215]]}]}], "context_tokens": [["Stress", 0], ["-", 6], ["induced", 7], ["mutagenesis", 15], ["describes", 27], ["the", 37], ["accumulation", 41], ["of", 54], ["mutations", 57], ["that", 67], ["occur", 72], ["in", 78], ["nongrowing", 81], ["cells", 92], [",", 97], ["in", 99], ["contrast", 102], ["to", 111], ["mutagenesis", 114], ["that", 126], ["occurs", 131], ["in", 138], ["actively", 141], ["dividing", 150], ["populations", 159], [",", 170], ["and", 172], ["has", 176], ["been", 180], ["referred", 185], ["to", 194], ["as", 197], ["stationary", 200], ["-", 210], ["phase", 211], ["or", 217], ["adaptive", 220], ["mutagenesis", 229], [".", 240], ["The", 242], ["most", 246], ["widely", 251], ["studied", 258], ["system", 266], ["for", 273], ["stress", 277], ["-", 283], ["induced", 284], ["mutagenesis", 292], ["involves", 304], ["monitoring", 313], ["the", 324], ["appearance", 328], ["of", 339], ["Lac(+", 342], [")", 347], ["revertants", 349], ["of", 360], ["the", 363], ["strain", 367], ["FC40", 374], ["under", 379], ["starvation", 385], ["conditions", 396], ["in", 407], ["Escherichia", 410], ["coli", 422], [".", 426], ["The", 428], ["SOS", 432], ["-", 435], ["inducible", 436], ["translesion", 446], ["DNA", 458], ["polymerase", 462], ["DinB", 473], ["plays", 478], ["an", 484], ["important", 487], ["role", 497], ["in", 502], ["this", 505], ["phenomenon", 510], [".", 520], ["Loss", 522], ["of", 527], ["DinB", 530], ["(", 535], ["DNA", 536], ["pol", 540], ["IV", 544], [")", 546], ["function", 548], ["results", 557], ["in", 565], ["a", 568], ["severe", 570], ["reduction", 577], ["of", 587], ["Lac(+", 590], [")", 595], ["revertants", 597], [".", 607], ["We", 609], ["previously", 612], ["reported", 623], ["that", 632], ["NusA", 637], [",", 641], ["an", 643], ["essential", 646], ["component", 656], ["of", 666], ["elongating", 669], ["RNA", 680], ["polymerases", 684], [",", 695], ["interacts", 697], ["with", 707], ["DinB.", 712], ["Here", 718], ["we", 723], ["report", 726], ["our", 733], ["unexpected", 737], ["observation", 748], ["that", 760], ["wild", 765], ["-", 769], ["type", 770], ["NusA", 775], ["function", 780], ["is", 789], ["required", 792], ["for", 801], ["stress", 805], ["-", 811], ["induced", 812], ["mutagenesis", 820], [".", 831], ["We", 833], ["present", 836], ["evidence", 844], ["that", 853], ["this", 858], ["effect", 863], ["is", 870], ["unlikely", 873], ["to", 882], ["be", 885], ["due", 888], ["to", 892], ["defects", 895], ["in", 903], ["transcription", 906], ["of", 920], ["lac", 923], ["genes", 927], ["but", 933], ["rather", 937], ["is", 944], ["due", 947], ["to", 951], ["an", 954], ["inability", 957], ["to", 967], ["adapt", 970], ["and", 976], ["mutate", 980], ["in", 987], ["response", 990], ["to", 999], ["environmental", 1002], ["stress", 1016], [".", 1022], ["Furthermore", 1024], [",", 1035], ["we", 1037], ["extended", 1040], ["our", 1049], ["analysis", 1053], ["to", 1062], ["the", 1065], ["formation", 1069], ["of", 1079], ["stress", 1082], ["-", 1088], ["induced", 1089], ["mutants", 1097], ["in", 1105], ["response", 1108], ["to", 1117], ["antibiotic", 1120], ["treatment", 1131], [",", 1140], ["observing", 1142], ["the", 1152], ["same", 1156], ["striking", 1161], ["abolition", 1170], ["of", 1180], ["mutagenesis", 1183], ["under", 1195], ["entirely", 1201], ["different", 1210], ["conditions", 1220], [".", 1230], ["Our", 1232], ["results", 1236], ["are", 1244], ["the", 1248], ["first", 1252], ["to", 1258], ["implicate", 1261], ["NusA", 1271], ["as", 1276], ["a", 1279], ["crucial", 1281], ["participant", 1289], ["in", 1301], ["the", 1304], ["phenomenon", 1308], ["of", 1319], ["stress", 1322], ["-", 1328], ["induced", 1329], ["mutagenesis", 1337], [".", 1348]]}
{"context": "A 60-year-old man diagnosed clinically with Becker's muscular dystrophy 20 years ago by another physician presented with gradually progressive proximal muscle weakness since teenage years. Family history revealed a strong paternal familial inheritance pattern of similar distribution of weakness-face, forearm flexion, knee extension and foot dorsiflexion. Work-ups revealed B12 deficiency and allele 1 deletion in fascioscapulohumeral muscular dystrophy (FSHD) DNA testing. FSHD is the third most common muscular dystrophy. Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing. This case strongly demonstrates the importance of a thorough and careful clinical evaluation even in a case with a long standing diagnosis.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "ff8ede38609d4622af0f985023a70e89", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[95, 97]], "char_spans": [[594, 611]]}]}], "context_tokens": [["A", 0], ["60-year", 2], ["-", 9], ["old", 10], ["man", 14], ["diagnosed", 18], ["clinically", 28], ["with", 39], ["Becker", 44], ["'s", 50], ["muscular", 53], ["dystrophy", 62], ["20", 72], ["years", 75], ["ago", 81], ["by", 85], ["another", 88], ["physician", 96], ["presented", 106], ["with", 116], ["gradually", 121], ["progressive", 131], ["proximal", 143], ["muscle", 152], ["weakness", 159], ["since", 168], ["teenage", 174], ["years", 182], [".", 187], ["Family", 189], ["history", 196], ["revealed", 204], ["a", 213], ["strong", 215], ["paternal", 222], ["familial", 231], ["inheritance", 240], ["pattern", 252], ["of", 260], ["similar", 263], ["distribution", 271], ["of", 284], ["weakness", 287], ["-", 295], ["face", 296], [",", 300], ["forearm", 302], ["flexion", 310], [",", 317], ["knee", 319], ["extension", 324], ["and", 334], ["foot", 338], ["dorsiflexion", 343], [".", 355], ["Work", 357], ["-", 361], ["ups", 362], ["revealed", 366], ["B12", 375], ["deficiency", 379], ["and", 390], ["allele", 394], ["1", 401], ["deletion", 403], ["in", 412], ["fascioscapulohumeral", 415], ["muscular", 436], ["dystrophy", 445], ["(", 455], ["FSHD", 456], [")", 460], ["DNA", 462], ["testing", 466], [".", 473], ["FSHD", 475], ["is", 480], ["the", 483], ["third", 487], ["most", 493], ["common", 498], ["muscular", 505], ["dystrophy", 514], [".", 523], ["Clinical", 525], ["diagnosis", 534], ["is", 544], ["made", 547], ["from", 552], ["the", 557], ["distinctive", 561], ["pattern", 573], ["of", 581], ["weakness", 584], [",", 592], ["autosomal", 594], ["-", 603], ["dominant", 604], ["inheritance", 613], [",", 624], ["and", 626], ["confirmed", 630], ["by", 640], ["genetic", 643], ["testing", 651], [".", 658], ["This", 660], ["case", 665], ["strongly", 670], ["demonstrates", 679], ["the", 692], ["importance", 696], ["of", 707], ["a", 710], ["thorough", 712], ["and", 721], ["careful", 725], ["clinical", 733], ["evaluation", 742], ["even", 753], ["in", 758], ["a", 761], ["case", 763], ["with", 768], ["a", 773], ["long", 775], ["standing", 780], ["diagnosis", 789], [".", 798]]}
{"context": "Although alpha-synuclein (alpha-syn) has been implicated as a major component of the abnormal filaments that form glial cytoplasmic inclusions (GCIs) in multiple system atrophy (MSA), it is uncertain if GCIs are homogenous and contain full-length alpha-syn. Since this has implications for hypotheses about the pathogenesis of GCIs, we used a novel panel of antibodies to defined regions throughout alpha-syn in immunohistochemical epitope mapping studies of GCIs in MSA brains. Although the immunostaining profile of GCIs with these antibodies was similar for all MSA brains, there were significant differences in the immunoreactivity of the alpha-syn epitopes detected in GCIs. Notably, carboxy-terminal alpha-syn epitopes were immunodominant in GCIs, but the entire panel of antibodies immunostained cortical Lewy bodies (LBs) in dementia with LBs brain with similar intensity. While the distribution of alpha-syn labeled GCIs paralleled that previously reported using silver stains, antibodies to carboxy-terminal alpha-syn epitopes revealed a previously undescribed burden of GCIs in the MSA hippocampal formation. Finally, Western blots demonstrated detergent insoluble monomeric and high-molecular weight alpha-syn species in GCI rich MSA cerebellar white matter. Collectively, these data indicate that alpha-syn is a prominent component of GCIs in MSA, and that GCIs and LBs may result from cell type specific conformational or post-translational permutations in alpha-syn.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "6bb8ed04d3334d21be1d6007dec1ca83", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[1, 3]], "char_spans": [[9, 23]]}]}], "context_tokens": [["Although", 0], ["alpha", 9], ["-", 14], ["synuclein", 15], ["(", 25], ["alpha", 26], ["-", 31], ["syn", 32], [")", 35], ["has", 37], ["been", 41], ["implicated", 46], ["as", 57], ["a", 60], ["major", 62], ["component", 68], ["of", 78], ["the", 81], ["abnormal", 85], ["filaments", 94], ["that", 104], ["form", 109], ["glial", 114], ["cytoplasmic", 120], ["inclusions", 132], ["(", 143], ["GCIs", 144], [")", 148], ["in", 150], ["multiple", 153], ["system", 162], ["atrophy", 169], ["(", 177], ["MSA", 178], [")", 181], [",", 182], ["it", 184], ["is", 187], ["uncertain", 190], ["if", 200], ["GCIs", 203], ["are", 208], ["homogenous", 212], ["and", 223], ["contain", 227], ["full", 235], ["-", 239], ["length", 240], ["alpha", 247], ["-", 252], ["syn", 253], [".", 256], ["Since", 258], ["this", 264], ["has", 269], ["implications", 273], ["for", 286], ["hypotheses", 290], ["about", 301], ["the", 307], ["pathogenesis", 311], ["of", 324], ["GCIs", 327], [",", 331], ["we", 333], ["used", 336], ["a", 341], ["novel", 343], ["panel", 349], ["of", 355], ["antibodies", 358], ["to", 369], ["defined", 372], ["regions", 380], ["throughout", 388], ["alpha", 399], ["-", 404], ["syn", 405], ["in", 409], ["immunohistochemical", 412], ["epitope", 432], ["mapping", 440], ["studies", 448], ["of", 456], ["GCIs", 459], ["in", 464], ["MSA", 467], ["brains", 471], [".", 477], ["Although", 479], ["the", 488], ["immunostaining", 492], ["profile", 507], ["of", 515], ["GCIs", 518], ["with", 523], ["these", 528], ["antibodies", 534], ["was", 545], ["similar", 549], ["for", 557], ["all", 561], ["MSA", 565], ["brains", 569], [",", 575], ["there", 577], ["were", 583], ["significant", 588], ["differences", 600], ["in", 612], ["the", 615], ["immunoreactivity", 619], ["of", 636], ["the", 639], ["alpha", 643], ["-", 648], ["syn", 649], ["epitopes", 653], ["detected", 662], ["in", 671], ["GCIs", 674], [".", 678], ["Notably", 680], [",", 687], ["carboxy", 689], ["-", 696], ["terminal", 697], ["alpha", 706], ["-", 711], ["syn", 712], ["epitopes", 716], ["were", 725], ["immunodominant", 730], ["in", 745], ["GCIs", 748], [",", 752], ["but", 754], ["the", 758], ["entire", 762], ["panel", 769], ["of", 775], ["antibodies", 778], ["immunostained", 789], ["cortical", 803], ["Lewy", 812], ["bodies", 817], ["(", 824], ["LBs", 825], [")", 828], ["in", 830], ["dementia", 833], ["with", 842], ["LBs", 847], ["brain", 851], ["with", 857], ["similar", 862], ["intensity", 870], [".", 879], ["While", 881], ["the", 887], ["distribution", 891], ["of", 904], ["alpha", 907], ["-", 912], ["syn", 913], ["labeled", 917], ["GCIs", 925], ["paralleled", 930], ["that", 941], ["previously", 946], ["reported", 957], ["using", 966], ["silver", 972], ["stains", 979], [",", 985], ["antibodies", 987], ["to", 998], ["carboxy", 1001], ["-", 1008], ["terminal", 1009], ["alpha", 1018], ["-", 1023], ["syn", 1024], ["epitopes", 1028], ["revealed", 1037], ["a", 1046], ["previously", 1048], ["undescribed", 1059], ["burden", 1071], ["of", 1078], ["GCIs", 1081], ["in", 1086], ["the", 1089], ["MSA", 1093], ["hippocampal", 1097], ["formation", 1109], [".", 1118], ["Finally", 1120], [",", 1127], ["Western", 1129], ["blots", 1137], ["demonstrated", 1143], ["detergent", 1156], ["insoluble", 1166], ["monomeric", 1176], ["and", 1186], ["high", 1190], ["-", 1194], ["molecular", 1195], ["weight", 1205], ["alpha", 1212], ["-", 1217], ["syn", 1218], ["species", 1222], ["in", 1230], ["GCI", 1233], ["rich", 1237], ["MSA", 1242], ["cerebellar", 1246], ["white", 1257], ["matter", 1263], [".", 1269], ["Collectively", 1271], [",", 1283], ["these", 1285], ["data", 1291], ["indicate", 1296], ["that", 1305], ["alpha", 1310], ["-", 1315], ["syn", 1316], ["is", 1320], ["a", 1323], ["prominent", 1325], ["component", 1335], ["of", 1345], ["GCIs", 1348], ["in", 1353], ["MSA", 1356], [",", 1359], ["and", 1361], ["that", 1365], ["GCIs", 1370], ["and", 1375], ["LBs", 1379], ["may", 1383], ["result", 1387], ["from", 1394], ["cell", 1399], ["type", 1404], ["specific", 1409], ["conformational", 1418], ["or", 1433], ["post", 1436], ["-", 1440], ["translational", 1441], ["permutations", 1455], ["in", 1468], ["alpha", 1471], ["-", 1476], ["syn", 1477], [".", 1480]]}
{"context": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy. Eligible patients are 18-85\u00a0years old with hATTR amyloidosis, investigator-estimated survival of \u22652\u00a0years, Neuropathy Impairment Score (NIS) of 5-130, and polyneuropathy disability score\u00a0\u2264IIIb. Patients are randomized 2:1 to receive either intravenous patisiran 0.3\u00a0mg/kg or placebo once every 3\u00a0weeks. The primary objective is to determine the efficacy of patisiran at 18\u00a0months based on the difference in the change in modified NIS+7 (a composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed throughout the study. APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease. This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.", "qas": [{"question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answers": ["Patisiran"], "qid": "f6d7e1841db1466093bc4a2667512ecc", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["RNAi", 24], ["investigational", 29], ["drug", 45], ["being", 50], ["developed", 56], ["against", 66], ["hereditary", 74], ["amyloidosis", 85], ["?", 96]], "detected_answers": [{"text": "Patisiran", "token_spans": [[0, 0], [269, 269], [70, 70], [180, 180], [124, 124], [193, 193], [145, 145]], "char_spans": [[0, 8], [1558, 1566], [400, 408], [1017, 1025], [718, 726], [1098, 1106], [823, 831]]}]}], "context_tokens": [["Patisiran", 0], ["is", 10], ["an", 13], ["investigational", 16], ["RNA", 32], ["interference", 36], ["(", 49], ["RNAi", 50], [")", 54], ["therapeutic", 56], ["in", 68], ["development", 71], ["for", 83], ["the", 87], ["treatment", 91], ["of", 101], ["hereditary", 104], ["ATTR", 115], ["(", 120], ["hATTR", 121], [")", 126], ["amyloidosis", 128], [",", 139], ["a", 141], ["progressive", 143], ["disease", 155], ["associated", 163], ["with", 174], ["significant", 179], ["disability", 191], [",", 201], ["morbidity", 203], [",", 212], ["and", 214], ["mortality", 218], [".", 227], ["Here", 229], ["we", 234], ["describe", 237], ["the", 246], ["rationale", 250], ["and", 260], ["design", 264], ["of", 271], ["the", 274], ["Phase", 278], ["3", 284], ["APOLLO", 286], ["study", 293], [",", 298], ["a", 300], ["randomized", 302], [",", 312], ["double", 314], ["-", 320], ["blind", 321], [",", 326], ["placebo", 328], ["-", 335], ["controlled", 336], [",", 346], ["global", 348], ["study", 355], ["to", 361], ["evaluate", 364], ["the", 373], ["efficacy", 377], ["and", 386], ["safety", 390], ["of", 397], ["patisiran", 400], ["in", 410], ["patients", 413], ["with", 422], ["hATTR", 427], ["amyloidosis", 433], ["with", 445], ["polyneuropathy", 450], [".", 464], ["Eligible", 466], ["patients", 475], ["are", 484], ["18", 488], ["-", 490], ["85", 491], ["years", 494], ["old", 500], ["with", 504], ["hATTR", 509], ["amyloidosis", 515], [",", 526], ["investigator", 528], ["-", 540], ["estimated", 541], ["survival", 551], ["of", 560], ["\u22652", 563], ["years", 566], [",", 571], ["Neuropathy", 573], ["Impairment", 584], ["Score", 595], ["(", 601], ["NIS", 602], [")", 605], ["of", 607], ["5", 610], ["-", 611], ["130", 612], [",", 615], ["and", 617], ["polyneuropathy", 621], ["disability", 636], ["score", 647], ["\u2264IIIb", 653], [".", 658], ["Patients", 660], ["are", 669], ["randomized", 673], ["2:1", 684], ["to", 688], ["receive", 691], ["either", 699], ["intravenous", 706], ["patisiran", 718], ["0.3", 728], ["mg", 732], ["/", 734], ["kg", 735], ["or", 738], ["placebo", 741], ["once", 749], ["every", 754], ["3", 760], ["weeks", 762], [".", 767], ["The", 769], ["primary", 773], ["objective", 781], ["is", 791], ["to", 794], ["determine", 797], ["the", 807], ["efficacy", 811], ["of", 820], ["patisiran", 823], ["at", 833], ["18", 836], ["months", 839], ["based", 846], ["on", 852], ["the", 855], ["difference", 859], ["in", 870], ["the", 873], ["change", 877], ["in", 884], ["modified", 887], ["NIS+7", 896], ["(", 902], ["a", 903], ["composite", 905], ["measure", 915], ["of", 923], ["motor", 926], ["strength", 932], [",", 940], ["sensation", 942], [",", 951], ["reflexes", 953], [",", 961], ["nerve", 963], ["conduction", 969], [",", 979], ["and", 981], ["autonomic", 985], ["function", 995], [")", 1003], ["between", 1005], ["the", 1013], ["patisiran", 1017], ["and", 1027], ["placebo", 1031], ["groups", 1039], [".", 1045], ["Secondary", 1047], ["objectives", 1057], ["are", 1068], ["to", 1072], ["evaluate", 1075], ["the", 1084], ["effect", 1088], ["of", 1095], ["patisiran", 1098], ["on", 1108], ["Norfolk", 1111], ["-", 1118], ["Diabetic", 1119], ["Neuropathy", 1128], ["quality", 1139], ["of", 1147], ["life", 1150], ["questionnaire", 1155], ["score", 1169], [",", 1174], ["nutritional", 1176], ["status", 1188], ["(", 1195], ["as", 1196], ["evaluated", 1199], ["by", 1209], ["modified", 1212], ["body", 1221], ["mass", 1226], ["index", 1231], [")", 1236], [",", 1237], ["motor", 1239], ["function", 1245], ["(", 1254], ["as", 1255], ["measured", 1258], ["by", 1267], ["NIS", 1270], ["-", 1273], ["weakness", 1274], ["and", 1283], ["timed", 1287], ["10-m", 1293], ["walk", 1298], ["test", 1303], [")", 1307], [",", 1308], ["and", 1310], ["autonomic", 1314], ["symptoms", 1324], ["(", 1333], ["as", 1334], ["measured", 1337], ["by", 1346], ["the", 1349], ["Composite", 1353], ["Autonomic", 1363], ["Symptom", 1373], ["Score-31", 1381], ["questionnaire", 1390], [")", 1403], [".", 1404], ["Exploratory", 1406], ["objectives", 1418], ["include", 1429], ["assessment", 1437], ["of", 1448], ["cardiac", 1451], ["function", 1459], ["and", 1468], ["pathologic", 1472], ["evaluation", 1483], ["to", 1494], ["assess", 1497], ["nerve", 1504], ["fiber", 1510], ["innervation", 1516], ["and", 1528], ["amyloid", 1532], ["burden", 1540], [".", 1546], ["Safety", 1548], ["of", 1555], ["patisiran", 1558], ["will", 1568], ["be", 1573], ["assessed", 1576], ["throughout", 1585], ["the", 1596], ["study", 1600], [".", 1605], ["APOLLO", 1607], ["represents", 1614], ["the", 1625], ["largest", 1629], ["randomized", 1637], [",", 1647], ["Phase", 1649], ["3", 1655], ["study", 1657], ["to", 1663], ["date", 1666], ["in", 1671], ["patients", 1674], ["with", 1683], ["hATTR", 1688], ["amyloidosis", 1694], [",", 1705], ["with", 1707], ["endpoints", 1712], ["that", 1722], ["capture", 1727], ["the", 1735], ["multisystemic", 1739], ["nature", 1753], ["of", 1760], ["this", 1763], ["disease", 1768], [".", 1775], ["This", 1777], ["trial", 1782], ["is", 1788], ["registered", 1791], ["at", 1802], ["clinicaltrials.gov", 1805], ["(", 1824], ["NCT01960348", 1826], [")", 1838], [";", 1839], ["October", 1841], ["9", 1849], [",", 1850], ["2013", 1852], [".", 1856]]}
{"context": "The dynamin-related protein Opa1 is localized to the mitochondrial intermembrane space, where it facilitates fusion between mitochondria. Apoptosis causes Opa1 release into the cytosol and causes mitochondria to fragment. Loss of mitochondrial membrane potential also causes mitochondrial fragmentation but not Opa1 release into the cytosol. Both conditions induce the proteolytic cleavage of Opa1, suggesting that mitochondrial fragmentation is triggered by Opa1 inactivation. The opposite effect was observed with knockdown of the mitochondrial intermembrane space protease Yme1. Knockdown of Yme1 prevents the constitutive cleavage of a subset of Opa1 splice variants but does not affect carbonyl cyanide m-chlorophenyl hydrazone or apoptosis-induced cleavage. Knockdown of Yme1 also increases mitochondrial connectivity, but this effect is independent of Opa1 because it also occurs in Opa1 knockdown cells. We conclude that Yme1 constitutively regulates a subset of Opa1 isoforms and an unknown mitochondrial morphology protein, whereas the loss of membrane potential induces the further proteolysis of Opa1.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "06ee6c4a1f9d4cd19afcd49b8dd40d16", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[10, 12], [79, 81]], "char_spans": [[53, 85], [533, 565]]}]}], "context_tokens": [["The", 0], ["dynamin", 4], ["-", 11], ["related", 12], ["protein", 20], ["Opa1", 28], ["is", 33], ["localized", 36], ["to", 46], ["the", 49], ["mitochondrial", 53], ["intermembrane", 67], ["space", 81], [",", 86], ["where", 88], ["it", 94], ["facilitates", 97], ["fusion", 109], ["between", 116], ["mitochondria", 124], [".", 136], ["Apoptosis", 138], ["causes", 148], ["Opa1", 155], ["release", 160], ["into", 168], ["the", 173], ["cytosol", 177], ["and", 185], ["causes", 189], ["mitochondria", 196], ["to", 209], ["fragment", 212], [".", 220], ["Loss", 222], ["of", 227], ["mitochondrial", 230], ["membrane", 244], ["potential", 253], ["also", 263], ["causes", 268], ["mitochondrial", 275], ["fragmentation", 289], ["but", 303], ["not", 307], ["Opa1", 311], ["release", 316], ["into", 324], ["the", 329], ["cytosol", 333], [".", 340], ["Both", 342], ["conditions", 347], ["induce", 358], ["the", 365], ["proteolytic", 369], ["cleavage", 381], ["of", 390], ["Opa1", 393], [",", 397], ["suggesting", 399], ["that", 410], ["mitochondrial", 415], ["fragmentation", 429], ["is", 443], ["triggered", 446], ["by", 456], ["Opa1", 459], ["inactivation", 464], [".", 476], ["The", 478], ["opposite", 482], ["effect", 491], ["was", 498], ["observed", 502], ["with", 511], ["knockdown", 516], ["of", 526], ["the", 529], ["mitochondrial", 533], ["intermembrane", 547], ["space", 561], ["protease", 567], ["Yme1", 576], [".", 580], ["Knockdown", 582], ["of", 592], ["Yme1", 595], ["prevents", 600], ["the", 609], ["constitutive", 613], ["cleavage", 626], ["of", 635], ["a", 638], ["subset", 640], ["of", 647], ["Opa1", 650], ["splice", 655], ["variants", 662], ["but", 671], ["does", 675], ["not", 680], ["affect", 684], ["carbonyl", 691], ["cyanide", 700], ["m", 708], ["-", 709], ["chlorophenyl", 710], ["hydrazone", 723], ["or", 733], ["apoptosis", 736], ["-", 745], ["induced", 746], ["cleavage", 754], [".", 762], ["Knockdown", 764], ["of", 774], ["Yme1", 777], ["also", 782], ["increases", 787], ["mitochondrial", 797], ["connectivity", 811], [",", 823], ["but", 825], ["this", 829], ["effect", 834], ["is", 841], ["independent", 844], ["of", 856], ["Opa1", 859], ["because", 864], ["it", 872], ["also", 875], ["occurs", 880], ["in", 887], ["Opa1", 890], ["knockdown", 895], ["cells", 905], [".", 910], ["We", 912], ["conclude", 915], ["that", 924], ["Yme1", 929], ["constitutively", 934], ["regulates", 949], ["a", 959], ["subset", 961], ["of", 968], ["Opa1", 971], ["isoforms", 976], ["and", 985], ["an", 989], ["unknown", 992], ["mitochondrial", 1000], ["morphology", 1014], ["protein", 1025], [",", 1032], ["whereas", 1034], ["the", 1042], ["loss", 1046], ["of", 1051], ["membrane", 1054], ["potential", 1063], ["induces", 1073], ["the", 1081], ["further", 1085], ["proteolysis", 1093], ["of", 1105], ["Opa1", 1108], [".", 1112]]}
{"context": "Three isoforms of human plasma apolipoprotein E (apoE) are ligands to lipoprotein receptors and influence in different manner the synthesis and catabolism of pro-atherogenic triglyceride-rich lipoproteins. Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). The conformational transitions of beta-amyloid (Abeta) influenced by apoE and serum amyloid P (SAP) component are key events in AD development, the accumulation of intermediate diffusible and soluble oligomers of Abeta being of particular significance. SAP and apoE, in a different manner for the three isoforms, serve as \"pathological\" chaperones during the aggregation of Abeta considered as a conformation-prone process. In turn, apoE consisting of two domains self-associates in solution and intermediate structures differently populated for the three isoforms exist. The different structures of the three isoforms determine their different distribution among various plasma lipoproteins. The structural and metabolic consideration of the common apoE pathway(s) in two pathologies assumes four molecular targets for AD correction: (i) inhibition of the accumulation of diffusible soluble Abeta oligomers; (ii) inhibition of apoE synthesis and secretion by astrocytes, in particular, under lipid-lowering therapy; (iii) inhibition of the binding of apoE and/or SAP to Abeta; (iv) stimulation of the expression of cholesterol transporter ABCA1.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "d2affbf1297d4be7a210c9cbf1cccbba", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[38, 39]], "char_spans": [[232, 244]]}]}], "context_tokens": [["Three", 0], ["isoforms", 6], ["of", 15], ["human", 18], ["plasma", 24], ["apolipoprotein", 31], ["E", 46], ["(", 48], ["apoE", 49], [")", 53], ["are", 55], ["ligands", 59], ["to", 67], ["lipoprotein", 70], ["receptors", 82], ["and", 92], ["influence", 96], ["in", 106], ["different", 109], ["manner", 119], ["the", 126], ["synthesis", 130], ["and", 140], ["catabolism", 144], ["of", 155], ["pro", 158], ["-", 161], ["atherogenic", 162], ["triglyceride", 174], ["-", 186], ["rich", 187], ["lipoproteins", 192], [".", 204], ["Among", 206], ["three", 212], ["isoforms", 218], [",", 226], ["the", 228], ["apoE4", 232], ["isoform", 238], ["is", 246], ["associated", 249], ["with", 260], ["increased", 265], ["frequency", 275], ["of", 285], ["atherosclerosis", 288], ["and", 304], ["Alzheimer", 308], ["'s", 317], ["disease", 320], ["(", 328], ["AD", 329], [")", 331], [".", 332], ["The", 334], ["conformational", 338], ["transitions", 353], ["of", 365], ["beta", 368], ["-", 372], ["amyloid", 373], ["(", 381], ["Abeta", 382], [")", 387], ["influenced", 389], ["by", 400], ["apoE", 403], ["and", 408], ["serum", 412], ["amyloid", 418], ["P", 426], ["(", 428], ["SAP", 429], [")", 432], ["component", 434], ["are", 444], ["key", 448], ["events", 452], ["in", 459], ["AD", 462], ["development", 465], [",", 476], ["the", 478], ["accumulation", 482], ["of", 495], ["intermediate", 498], ["diffusible", 511], ["and", 522], ["soluble", 526], ["oligomers", 534], ["of", 544], ["Abeta", 547], ["being", 553], ["of", 559], ["particular", 562], ["significance", 573], [".", 585], ["SAP", 587], ["and", 591], ["apoE", 595], [",", 599], ["in", 601], ["a", 604], ["different", 606], ["manner", 616], ["for", 623], ["the", 627], ["three", 631], ["isoforms", 637], [",", 645], ["serve", 647], ["as", 653], ["\"", 656], ["pathological", 657], ["\"", 669], ["chaperones", 671], ["during", 682], ["the", 689], ["aggregation", 693], ["of", 705], ["Abeta", 708], ["considered", 714], ["as", 725], ["a", 728], ["conformation", 730], ["-", 742], ["prone", 743], ["process", 749], [".", 756], ["In", 758], ["turn", 761], [",", 765], ["apoE", 767], ["consisting", 772], ["of", 783], ["two", 786], ["domains", 790], ["self", 798], ["-", 802], ["associates", 803], ["in", 814], ["solution", 817], ["and", 826], ["intermediate", 830], ["structures", 843], ["differently", 854], ["populated", 866], ["for", 876], ["the", 880], ["three", 884], ["isoforms", 890], ["exist", 899], [".", 904], ["The", 906], ["different", 910], ["structures", 920], ["of", 931], ["the", 934], ["three", 938], ["isoforms", 944], ["determine", 953], ["their", 963], ["different", 969], ["distribution", 979], ["among", 992], ["various", 998], ["plasma", 1006], ["lipoproteins", 1013], [".", 1025], ["The", 1027], ["structural", 1031], ["and", 1042], ["metabolic", 1046], ["consideration", 1056], ["of", 1070], ["the", 1073], ["common", 1077], ["apoE", 1084], ["pathway(s", 1089], [")", 1098], ["in", 1100], ["two", 1103], ["pathologies", 1107], ["assumes", 1119], ["four", 1127], ["molecular", 1132], ["targets", 1142], ["for", 1150], ["AD", 1154], ["correction", 1157], [":", 1167], ["(", 1169], ["i", 1170], [")", 1171], ["inhibition", 1173], ["of", 1184], ["the", 1187], ["accumulation", 1191], ["of", 1204], ["diffusible", 1207], ["soluble", 1218], ["Abeta", 1226], ["oligomers", 1232], [";", 1241], ["(", 1243], ["ii", 1244], [")", 1246], ["inhibition", 1248], ["of", 1259], ["apoE", 1262], ["synthesis", 1267], ["and", 1277], ["secretion", 1281], ["by", 1291], ["astrocytes", 1294], [",", 1304], ["in", 1306], ["particular", 1309], [",", 1319], ["under", 1321], ["lipid", 1327], ["-", 1332], ["lowering", 1333], ["therapy", 1342], [";", 1349], ["(", 1351], ["iii", 1352], [")", 1355], ["inhibition", 1357], ["of", 1368], ["the", 1371], ["binding", 1375], ["of", 1383], ["apoE", 1386], ["and/or", 1391], ["SAP", 1398], ["to", 1402], ["Abeta", 1405], [";", 1410], ["(", 1412], ["iv", 1413], [")", 1415], ["stimulation", 1417], ["of", 1429], ["the", 1432], ["expression", 1436], ["of", 1447], ["cholesterol", 1450], ["transporter", 1462], ["ABCA1", 1474], [".", 1479]]}
{"context": "The membranous structure of vestibular schwannoma is an important factor in its surgical treatment. Herein, we report intraoperative and microscopic findings relating to an outermost dura-like membrane in cases of vestibular schwannoma and the importance of these findings. Intraoperative findings of 16 cases of vestibular schwannoma treated with an initial surgery were studied with an aim to determine if the cases had a dura-like membrane. Then we studied microscopic findings of the dura-like membrane using hematoxylin and eosin, Masson trichrome, and immunohistochemical staining in 2 cases. The dura-like membrane was observed in 8 out of 16 cases. The average tumor size of the cases that had a dura-like membrane was 30 \u00b1 8.1 mm, and Koos grading 4 was in 7 out of 8 cases, and one was grade 3. In cases without a dura-like membrane, these values were significantly smaller, with an average tumor size of 12.8 \u00b1 5.2 mm, and Koos grading 4 was only in 1 of 8 cases, grade 3 was in 2 cases, and other 5 cases were grade 2. The outermost dura-like membrane enveloped the vestibular schwannoma around the internal acoustic meatus and was continuous with the dura mater. Reactive angiogenesis was observed in the dura mater. Microscopic findings proved its continuity with the dura mater. In one case, the facial nerve was damaged before it was identified during subcapsular dissection. In that case, the dura-like membrane negatively affected our ability to identify the facial nerve. A dura-like membrane sometimes envelops vestibular schwannoma around the internal acoustic meatus. Recognition of this membranous structure is important for the surgical preservation of facial and acoustic nerves.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "49b937d0ed614da79079221407d48ab8", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[49, 50], [289, 290], [4, 5], [212, 213], [34, 35]], "char_spans": [[313, 333], [1531, 1551], [28, 48], [1078, 1098], [214, 234]]}]}], "context_tokens": [["The", 0], ["membranous", 4], ["structure", 15], ["of", 25], ["vestibular", 28], ["schwannoma", 39], ["is", 50], ["an", 53], ["important", 56], ["factor", 66], ["in", 73], ["its", 76], ["surgical", 80], ["treatment", 89], [".", 98], ["Herein", 100], [",", 106], ["we", 108], ["report", 111], ["intraoperative", 118], ["and", 133], ["microscopic", 137], ["findings", 149], ["relating", 158], ["to", 167], ["an", 170], ["outermost", 173], ["dura", 183], ["-", 187], ["like", 188], ["membrane", 193], ["in", 202], ["cases", 205], ["of", 211], ["vestibular", 214], ["schwannoma", 225], ["and", 236], ["the", 240], ["importance", 244], ["of", 255], ["these", 258], ["findings", 264], [".", 272], ["Intraoperative", 274], ["findings", 289], ["of", 298], ["16", 301], ["cases", 304], ["of", 310], ["vestibular", 313], ["schwannoma", 324], ["treated", 335], ["with", 343], ["an", 348], ["initial", 351], ["surgery", 359], ["were", 367], ["studied", 372], ["with", 380], ["an", 385], ["aim", 388], ["to", 392], ["determine", 395], ["if", 405], ["the", 408], ["cases", 412], ["had", 418], ["a", 422], ["dura", 424], ["-", 428], ["like", 429], ["membrane", 434], [".", 442], ["Then", 444], ["we", 449], ["studied", 452], ["microscopic", 460], ["findings", 472], ["of", 481], ["the", 484], ["dura", 488], ["-", 492], ["like", 493], ["membrane", 498], ["using", 507], ["hematoxylin", 513], ["and", 525], ["eosin", 529], [",", 534], ["Masson", 536], ["trichrome", 543], [",", 552], ["and", 554], ["immunohistochemical", 558], ["staining", 578], ["in", 587], ["2", 590], ["cases", 592], [".", 597], ["The", 599], ["dura", 603], ["-", 607], ["like", 608], ["membrane", 613], ["was", 622], ["observed", 626], ["in", 635], ["8", 638], ["out", 640], ["of", 644], ["16", 647], ["cases", 650], [".", 655], ["The", 657], ["average", 661], ["tumor", 669], ["size", 675], ["of", 680], ["the", 683], ["cases", 687], ["that", 693], ["had", 698], ["a", 702], ["dura", 704], ["-", 708], ["like", 709], ["membrane", 714], ["was", 723], ["30", 727], ["\u00b1", 730], ["8.1", 732], ["mm", 736], [",", 738], ["and", 740], ["Koos", 744], ["grading", 749], ["4", 757], ["was", 759], ["in", 763], ["7", 766], ["out", 768], ["of", 772], ["8", 775], ["cases", 777], [",", 782], ["and", 784], ["one", 788], ["was", 792], ["grade", 796], ["3", 802], [".", 803], ["In", 805], ["cases", 808], ["without", 814], ["a", 822], ["dura", 824], ["-", 828], ["like", 829], ["membrane", 834], [",", 842], ["these", 844], ["values", 850], ["were", 857], ["significantly", 862], ["smaller", 876], [",", 883], ["with", 885], ["an", 890], ["average", 893], ["tumor", 901], ["size", 907], ["of", 912], ["12.8", 915], ["\u00b1", 920], ["5.2", 922], ["mm", 926], [",", 928], ["and", 930], ["Koos", 934], ["grading", 939], ["4", 947], ["was", 949], ["only", 953], ["in", 958], ["1", 961], ["of", 963], ["8", 966], ["cases", 968], [",", 973], ["grade", 975], ["3", 981], ["was", 983], ["in", 987], ["2", 990], ["cases", 992], [",", 997], ["and", 999], ["other", 1003], ["5", 1009], ["cases", 1011], ["were", 1017], ["grade", 1022], ["2", 1028], [".", 1029], ["The", 1031], ["outermost", 1035], ["dura", 1045], ["-", 1049], ["like", 1050], ["membrane", 1055], ["enveloped", 1064], ["the", 1074], ["vestibular", 1078], ["schwannoma", 1089], ["around", 1100], ["the", 1107], ["internal", 1111], ["acoustic", 1120], ["meatus", 1129], ["and", 1136], ["was", 1140], ["continuous", 1144], ["with", 1155], ["the", 1160], ["dura", 1164], ["mater", 1169], [".", 1174], ["Reactive", 1176], ["angiogenesis", 1185], ["was", 1198], ["observed", 1202], ["in", 1211], ["the", 1214], ["dura", 1218], ["mater", 1223], [".", 1228], ["Microscopic", 1230], ["findings", 1242], ["proved", 1251], ["its", 1258], ["continuity", 1262], ["with", 1273], ["the", 1278], ["dura", 1282], ["mater", 1287], [".", 1292], ["In", 1294], ["one", 1297], ["case", 1301], [",", 1305], ["the", 1307], ["facial", 1311], ["nerve", 1318], ["was", 1324], ["damaged", 1328], ["before", 1336], ["it", 1343], ["was", 1346], ["identified", 1350], ["during", 1361], ["subcapsular", 1368], ["dissection", 1380], [".", 1390], ["In", 1392], ["that", 1395], ["case", 1400], [",", 1404], ["the", 1406], ["dura", 1410], ["-", 1414], ["like", 1415], ["membrane", 1420], ["negatively", 1429], ["affected", 1440], ["our", 1449], ["ability", 1453], ["to", 1461], ["identify", 1464], ["the", 1473], ["facial", 1477], ["nerve", 1484], [".", 1489], ["A", 1491], ["dura", 1493], ["-", 1497], ["like", 1498], ["membrane", 1503], ["sometimes", 1512], ["envelops", 1522], ["vestibular", 1531], ["schwannoma", 1542], ["around", 1553], ["the", 1560], ["internal", 1564], ["acoustic", 1573], ["meatus", 1582], [".", 1588], ["Recognition", 1590], ["of", 1602], ["this", 1605], ["membranous", 1610], ["structure", 1621], ["is", 1631], ["important", 1634], ["for", 1644], ["the", 1648], ["surgical", 1652], ["preservation", 1661], ["of", 1674], ["facial", 1677], ["and", 1684], ["acoustic", 1688], ["nerves", 1697], [".", 1703]]}
{"context": "In recent years, we have seen remarkable progress in our understanding of the disease mechanism underlying facioscapulohumeral muscular dystrophy (FSHD). The purpose of this review is to provide a comprehensive overview of our current understanding of the disease mechanism and to discuss the observations supporting the possibility of a developmental defect in this disorder. In the majority of cases, FSHD is caused by contraction of the D4Z4 repeat array (FSHD1). This results in local chromatin relaxation and stable expression of the DUX4 retrogene in skeletal muscle, but only when a polymorphic DUX4 polyadenylation signal is present. In some cases (FSHD2), D4Z4 chromatin relaxation and stable DUX4 expression occur in the absence of D4Z4 array contraction. DUX4 is a germline transcription factor and its expression in skeletal muscle leads to activation of early stem cell and germline programs and transcriptional activation of retroelements. Recent studies have provided a plausible disease mechanism for FSHD in which FSHD results from inappropriate expression of the germline transcription factor DUX4. The genes regulated by DUX4 suggest several mechanisms of muscle damage, and provide potential biomarkers and therapeutic targets that should be investigated in future studies.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "942b79bc7d384edd901fe2769f46512d", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[65, 65], [167, 167], [21, 21], [170, 170]], "char_spans": [[403, 406], [1017, 1020], [147, 150], [1031, 1034]]}]}], "context_tokens": [["In", 0], ["recent", 3], ["years", 10], [",", 15], ["we", 17], ["have", 20], ["seen", 25], ["remarkable", 30], ["progress", 41], ["in", 50], ["our", 53], ["understanding", 57], ["of", 71], ["the", 74], ["disease", 78], ["mechanism", 86], ["underlying", 96], ["facioscapulohumeral", 107], ["muscular", 127], ["dystrophy", 136], ["(", 146], ["FSHD", 147], [")", 151], [".", 152], ["The", 154], ["purpose", 158], ["of", 166], ["this", 169], ["review", 174], ["is", 181], ["to", 184], ["provide", 187], ["a", 195], ["comprehensive", 197], ["overview", 211], ["of", 220], ["our", 223], ["current", 227], ["understanding", 235], ["of", 249], ["the", 252], ["disease", 256], ["mechanism", 264], ["and", 274], ["to", 278], ["discuss", 281], ["the", 289], ["observations", 293], ["supporting", 306], ["the", 317], ["possibility", 321], ["of", 333], ["a", 336], ["developmental", 338], ["defect", 352], ["in", 359], ["this", 362], ["disorder", 367], [".", 375], ["In", 377], ["the", 380], ["majority", 384], ["of", 393], ["cases", 396], [",", 401], ["FSHD", 403], ["is", 408], ["caused", 411], ["by", 418], ["contraction", 421], ["of", 433], ["the", 436], ["D4Z4", 440], ["repeat", 445], ["array", 452], ["(", 458], ["FSHD1", 459], [")", 464], [".", 465], ["This", 467], ["results", 472], ["in", 480], ["local", 483], ["chromatin", 489], ["relaxation", 499], ["and", 510], ["stable", 514], ["expression", 521], ["of", 532], ["the", 535], ["DUX4", 539], ["retrogene", 544], ["in", 554], ["skeletal", 557], ["muscle", 566], [",", 572], ["but", 574], ["only", 578], ["when", 583], ["a", 588], ["polymorphic", 590], ["DUX4", 602], ["polyadenylation", 607], ["signal", 623], ["is", 630], ["present", 633], [".", 640], ["In", 642], ["some", 645], ["cases", 650], ["(", 656], ["FSHD2", 657], [")", 662], [",", 663], ["D4Z4", 665], ["chromatin", 670], ["relaxation", 680], ["and", 691], ["stable", 695], ["DUX4", 702], ["expression", 707], ["occur", 718], ["in", 724], ["the", 727], ["absence", 731], ["of", 739], ["D4Z4", 742], ["array", 747], ["contraction", 753], [".", 764], ["DUX4", 766], ["is", 771], ["a", 774], ["germline", 776], ["transcription", 785], ["factor", 799], ["and", 806], ["its", 810], ["expression", 814], ["in", 825], ["skeletal", 828], ["muscle", 837], ["leads", 844], ["to", 850], ["activation", 853], ["of", 864], ["early", 867], ["stem", 873], ["cell", 878], ["and", 883], ["germline", 887], ["programs", 896], ["and", 905], ["transcriptional", 909], ["activation", 925], ["of", 936], ["retroelements", 939], [".", 952], ["Recent", 954], ["studies", 961], ["have", 969], ["provided", 974], ["a", 983], ["plausible", 985], ["disease", 995], ["mechanism", 1003], ["for", 1013], ["FSHD", 1017], ["in", 1022], ["which", 1025], ["FSHD", 1031], ["results", 1036], ["from", 1044], ["inappropriate", 1049], ["expression", 1063], ["of", 1074], ["the", 1077], ["germline", 1081], ["transcription", 1090], ["factor", 1104], ["DUX4", 1111], [".", 1115], ["The", 1117], ["genes", 1121], ["regulated", 1127], ["by", 1137], ["DUX4", 1140], ["suggest", 1145], ["several", 1153], ["mechanisms", 1161], ["of", 1172], ["muscle", 1175], ["damage", 1182], [",", 1188], ["and", 1190], ["provide", 1194], ["potential", 1202], ["biomarkers", 1212], ["and", 1223], ["therapeutic", 1227], ["targets", 1239], ["that", 1247], ["should", 1252], ["be", 1259], ["investigated", 1262], ["in", 1275], ["future", 1278], ["studies", 1285], [".", 1292]]}
{"context": "A study was carried out on 200 patients of ages 20-40 years suffering from acute viral hepatitis. Sera were tested for markers of hepatitis B (HBsAg, and IgM anti-HBc) and hepatitis A (IgM-anti-HAV) by the ELISA technique. Sera negative for the markers of both viruses: Hepatitis A (HAV) and Hepatitis B (HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (CMV) infection. Non-A, non-B hepatitis (NANB) was diagnosed by exclusion. The results of the study showed that 133 (66.5%) patients had evidence of HBV infection, while only 9(4.5%) were diagnosed as HAV infection. EBV and CMV were the possible etiological agents of acute viral hepatitis in (3.5%) and 1%) respectively. Accordingly the Non-A, non-B hepatitis in this study amounts to (24.5%) of the acute viral hepatitis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "c5f3d85f9a094b98b72b423fbde816d2", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[80, 83]], "char_spans": [[373, 390]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["carried", 12], ["out", 20], ["on", 24], ["200", 27], ["patients", 31], ["of", 40], ["ages", 43], ["20", 48], ["-", 50], ["40", 51], ["years", 54], ["suffering", 60], ["from", 70], ["acute", 75], ["viral", 81], ["hepatitis", 87], [".", 96], ["Sera", 98], ["were", 103], ["tested", 108], ["for", 115], ["markers", 119], ["of", 127], ["hepatitis", 130], ["B", 140], ["(", 142], ["HBsAg", 143], [",", 148], ["and", 150], ["IgM", 154], ["anti", 158], ["-", 162], ["HBc", 163], [")", 166], ["and", 168], ["hepatitis", 172], ["A", 182], ["(", 184], ["IgM", 185], ["-", 188], ["anti", 189], ["-", 193], ["HAV", 194], [")", 197], ["by", 199], ["the", 202], ["ELISA", 206], ["technique", 212], [".", 221], ["Sera", 223], ["negative", 228], ["for", 237], ["the", 241], ["markers", 245], ["of", 253], ["both", 256], ["viruses", 261], [":", 268], ["Hepatitis", 270], ["A", 280], ["(", 282], ["HAV", 283], [")", 286], ["and", 288], ["Hepatitis", 292], ["B", 302], ["(", 304], ["HBV", 305], [")", 308], ["were", 310], ["subsequently", 315], ["tested", 328], ["for", 335], ["IGM", 339], ["Heterophil", 343], ["antibodies", 354], ["against", 365], ["Epstein", 373], ["-", 380], ["Barr", 381], ["virus", 386], ["(", 392], ["EBV", 393], [")", 396], ["by", 398], ["the", 401], ["Monospot", 405], ["slide", 414], ["test", 420], ["to", 425], ["diagnose", 428], ["acute", 437], ["infectious", 443], ["mononucleosis", 454], ["and", 468], ["tested", 472], ["for", 479], ["anti", 483], ["-", 487], ["CMV", 488], ["(", 492], ["IgM", 493], [")", 496], ["by", 498], ["ELISA", 501], ["technique", 507], ["for", 517], ["the", 521], ["diagnosis", 525], ["of", 535], ["acute", 538], ["Cytomegalovirus", 544], ["(", 560], ["CMV", 561], [")", 564], ["infection", 566], [".", 575], ["Non", 577], ["-", 580], ["A", 581], [",", 582], ["non", 584], ["-", 587], ["B", 588], ["hepatitis", 590], ["(", 600], ["NANB", 601], [")", 605], ["was", 607], ["diagnosed", 611], ["by", 621], ["exclusion", 624], [".", 633], ["The", 635], ["results", 639], ["of", 647], ["the", 650], ["study", 654], ["showed", 660], ["that", 667], ["133", 672], ["(", 676], ["66.5", 677], ["%", 681], [")", 682], ["patients", 684], ["had", 693], ["evidence", 697], ["of", 706], ["HBV", 709], ["infection", 713], [",", 722], ["while", 724], ["only", 730], ["9(4.5", 735], ["%", 740], [")", 741], ["were", 743], ["diagnosed", 748], ["as", 758], ["HAV", 761], ["infection", 765], [".", 774], ["EBV", 776], ["and", 780], ["CMV", 784], ["were", 788], ["the", 793], ["possible", 797], ["etiological", 806], ["agents", 818], ["of", 825], ["acute", 828], ["viral", 834], ["hepatitis", 840], ["in", 850], ["(", 853], ["3.5", 854], ["%", 857], [")", 858], ["and", 860], ["1", 864], ["%", 865], [")", 866], ["respectively", 868], [".", 880], ["Accordingly", 882], ["the", 894], ["Non", 898], ["-", 901], ["A", 902], [",", 903], ["non", 905], ["-", 908], ["B", 909], ["hepatitis", 911], ["in", 921], ["this", 924], ["study", 929], ["amounts", 935], ["to", 943], ["(", 946], ["24.5", 947], ["%", 951], [")", 952], ["of", 954], ["the", 957], ["acute", 961], ["viral", 967], ["hepatitis", 973], [".", 982]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells [Ohta et al., 2002: J. Cell Biol. 156:87-99]. To identify Cep135-interacting molecules, we screened yeast two-hybrid libraries. One clone encoded dynamitin, a p50 dynactin subunit, which localized at the centrosome and has been shown to be involved in anchoring microtubules to centrosomes. The central domain of p50 binds to the C-terminal sequence of Cep135; this was further confirmed by immunoprecipitation and immunostaining of CHO cells co-expressing the binding domains for Cep135 and p50. Exogenous p50 lacking the Cep 135-binding domain failed to locate at the centrosome, suggesting that Cep135 is required for initial targeting of the centrosome. Altered levels of Cep135 and p50 by RNAi and protein overexpression caused the release of endogenous partner molecules from centrosomes. This also resulted in dislocation of other centrosomal molecules, such as gamma-tubulin and pericentrin, ultimately leading to disorganization of microtubule patterns. These results suggest that Cep135 and p50 play an important role in assembly and maintenance of functional microtubule-organizing centers.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "08c3aa54125445ca90f9fe4a6632bcf7", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[134, 134], [8, 8], [59, 59], [122, 122]], "char_spans": [[756, 765], [33, 42], [314, 323], [680, 689]]}]}], "context_tokens": [["Cep135", 0], ["is", 7], ["a", 10], ["135-kDa", 12], [",", 19], ["coiled", 21], ["-", 27], ["coil", 28], ["centrosome", 33], ["protein", 44], ["important", 52], ["for", 62], ["microtubule", 66], ["organization", 78], ["in", 91], ["mammalian", 94], ["cells", 104], ["[", 110], ["Ohta", 111], ["et", 116], ["al", 119], [".", 121], [",", 122], ["2002", 124], [":", 128], ["J.", 130], ["Cell", 133], ["Biol", 138], [".", 142], ["156:87", 144], ["-", 150], ["99].", 151], ["To", 156], ["identify", 159], ["Cep135-interacting", 168], ["molecules", 187], [",", 196], ["we", 198], ["screened", 201], ["yeast", 210], ["two", 216], ["-", 219], ["hybrid", 220], ["libraries", 227], [".", 236], ["One", 238], ["clone", 242], ["encoded", 248], ["dynamitin", 256], [",", 265], ["a", 267], ["p50", 269], ["dynactin", 273], ["subunit", 282], [",", 289], ["which", 291], ["localized", 297], ["at", 307], ["the", 310], ["centrosome", 314], ["and", 325], ["has", 329], ["been", 333], ["shown", 338], ["to", 344], ["be", 347], ["involved", 350], ["in", 359], ["anchoring", 362], ["microtubules", 372], ["to", 385], ["centrosomes", 388], [".", 399], ["The", 401], ["central", 405], ["domain", 413], ["of", 420], ["p50", 423], ["binds", 427], ["to", 433], ["the", 436], ["C", 440], ["-", 441], ["terminal", 442], ["sequence", 451], ["of", 460], ["Cep135", 463], [";", 469], ["this", 471], ["was", 476], ["further", 480], ["confirmed", 488], ["by", 498], ["immunoprecipitation", 501], ["and", 521], ["immunostaining", 525], ["of", 540], ["CHO", 543], ["cells", 547], ["co", 553], ["-", 555], ["expressing", 556], ["the", 567], ["binding", 571], ["domains", 579], ["for", 587], ["Cep135", 591], ["and", 598], ["p50", 602], [".", 605], ["Exogenous", 607], ["p50", 617], ["lacking", 621], ["the", 629], ["Cep", 633], ["135-binding", 637], ["domain", 649], ["failed", 656], ["to", 663], ["locate", 666], ["at", 673], ["the", 676], ["centrosome", 680], [",", 690], ["suggesting", 692], ["that", 703], ["Cep135", 708], ["is", 715], ["required", 718], ["for", 727], ["initial", 731], ["targeting", 739], ["of", 749], ["the", 752], ["centrosome", 756], [".", 766], ["Altered", 768], ["levels", 776], ["of", 783], ["Cep135", 786], ["and", 793], ["p50", 797], ["by", 801], ["RNAi", 804], ["and", 809], ["protein", 813], ["overexpression", 821], ["caused", 836], ["the", 843], ["release", 847], ["of", 855], ["endogenous", 858], ["partner", 869], ["molecules", 877], ["from", 887], ["centrosomes", 892], [".", 903], ["This", 905], ["also", 910], ["resulted", 915], ["in", 924], ["dislocation", 927], ["of", 939], ["other", 942], ["centrosomal", 948], ["molecules", 960], [",", 969], ["such", 971], ["as", 976], ["gamma", 979], ["-", 984], ["tubulin", 985], ["and", 993], ["pericentrin", 997], [",", 1008], ["ultimately", 1010], ["leading", 1021], ["to", 1029], ["disorganization", 1032], ["of", 1048], ["microtubule", 1051], ["patterns", 1063], [".", 1071], ["These", 1073], ["results", 1079], ["suggest", 1087], ["that", 1095], ["Cep135", 1100], ["and", 1107], ["p50", 1111], ["play", 1115], ["an", 1120], ["important", 1123], ["role", 1133], ["in", 1138], ["assembly", 1141], ["and", 1150], ["maintenance", 1154], ["of", 1166], ["functional", 1169], ["microtubule", 1180], ["-", 1191], ["organizing", 1192], ["centers", 1203], [".", 1210]]}
{"context": "Small supernumerary marker chromosomes (sSMC) can be present in numerically abnormal karyotypes like in a 'Turner-syndrome karyotype' mos 45,X/46,X,+mar. Here we report the first case of an sSMC found in Turner syndrome karyotypes (sSMCT) derived from chromosome 14 in a Turner syndrome patient. According to cytogenetic and molecular cytogenetic characterization the karyotype was 46,X,+del(14)(q11.1). The present case is the third Turner syndrome case with an sSMCT not derived from the X- or the Y-chromosome. More comprehensive characterization of such sSMCT might identify them to be more frequent than only ~0.6% in Turner syndrome cases according to available data.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "d691510d9c1e401ebf6364b876537b48", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[82, 82]], "char_spans": [[490, 491]]}]}], "context_tokens": [["Small", 0], ["supernumerary", 6], ["marker", 20], ["chromosomes", 27], ["(", 39], ["sSMC", 40], [")", 44], ["can", 46], ["be", 50], ["present", 53], ["in", 61], ["numerically", 64], ["abnormal", 76], ["karyotypes", 85], ["like", 96], ["in", 101], ["a", 104], ["'", 106], ["Turner", 107], ["-", 113], ["syndrome", 114], ["karyotype", 123], ["'", 132], ["mos", 134], ["45,X/46,X,+mar", 138], [".", 152], ["Here", 154], ["we", 159], ["report", 162], ["the", 169], ["first", 173], ["case", 179], ["of", 184], ["an", 187], ["sSMC", 190], ["found", 195], ["in", 201], ["Turner", 204], ["syndrome", 211], ["karyotypes", 220], ["(", 231], ["sSMCT", 232], [")", 237], ["derived", 239], ["from", 247], ["chromosome", 252], ["14", 263], ["in", 266], ["a", 269], ["Turner", 271], ["syndrome", 278], ["patient", 287], [".", 294], ["According", 296], ["to", 306], ["cytogenetic", 309], ["and", 321], ["molecular", 325], ["cytogenetic", 335], ["characterization", 347], ["the", 364], ["karyotype", 368], ["was", 378], ["46,X,+del(14)(q11.1", 382], [")", 401], [".", 402], ["The", 404], ["present", 408], ["case", 416], ["is", 421], ["the", 424], ["third", 428], ["Turner", 434], ["syndrome", 441], ["case", 450], ["with", 455], ["an", 460], ["sSMCT", 463], ["not", 469], ["derived", 473], ["from", 481], ["the", 486], ["X-", 490], ["or", 493], ["the", 496], ["Y", 500], ["-", 501], ["chromosome", 502], [".", 512], ["More", 514], ["comprehensive", 519], ["characterization", 533], ["of", 550], ["such", 553], ["sSMCT", 558], ["might", 564], ["identify", 570], ["them", 579], ["to", 584], ["be", 587], ["more", 590], ["frequent", 595], ["than", 604], ["only", 609], ["~0.6", 614], ["%", 618], ["in", 620], ["Turner", 623], ["syndrome", 630], ["cases", 639], ["according", 645], ["to", 655], ["available", 658], ["data", 668], [".", 672]]}
{"context": "Deubiquitinating enzymes (DUbs) play important roles in many ubiquitin-dependent pathways, yet how DUbs themselves are regulated is not well understood. Here, we provide insight into the mechanism by which ubiquitination directly enhances the activity of ataxin-3, a DUb implicated in protein quality control and the disease protein in the polyglutamine neurodegenerative disorder, Spinocerebellar Ataxia Type 3. We identify Lys-117, which resides near the catalytic triad, as the primary site of ubiquitination in wild type and pathogenic ataxin-3. Further studies indicate that ubiquitin-dependent activation of ataxin-3 at Lys-117 is important for its ability to reduce high molecular weight ubiquitinated species in cells. Ubiquitination at Lys-117 also facilitates the ability of ataxin-3 to induce aggresome formation in cells. Finally, structure-function studies support a model of activation whereby ubiquitination at Lys-117 enhances ataxin-3 activity independent of the known ubiquitin-binding sites in ataxin-3, most likely through a direct conformational change in or near the catalytic domain.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "76df6ea078eb43ef838474f8a30b5d15", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[160, 160], [149, 149], [99, 99], [125, 125], [42, 42], [88, 88]], "char_spans": [[1013, 1020], [943, 950], [614, 621], [785, 792], [255, 262], [540, 547]]}]}], "context_tokens": [["Deubiquitinating", 0], ["enzymes", 17], ["(", 25], ["DUbs", 26], [")", 30], ["play", 32], ["important", 37], ["roles", 47], ["in", 53], ["many", 56], ["ubiquitin", 61], ["-", 70], ["dependent", 71], ["pathways", 81], [",", 89], ["yet", 91], ["how", 95], ["DUbs", 99], ["themselves", 104], ["are", 115], ["regulated", 119], ["is", 129], ["not", 132], ["well", 136], ["understood", 141], [".", 151], ["Here", 153], [",", 157], ["we", 159], ["provide", 162], ["insight", 170], ["into", 178], ["the", 183], ["mechanism", 187], ["by", 197], ["which", 200], ["ubiquitination", 206], ["directly", 221], ["enhances", 230], ["the", 239], ["activity", 243], ["of", 252], ["ataxin-3", 255], [",", 263], ["a", 265], ["DUb", 267], ["implicated", 271], ["in", 282], ["protein", 285], ["quality", 293], ["control", 301], ["and", 309], ["the", 313], ["disease", 317], ["protein", 325], ["in", 333], ["the", 336], ["polyglutamine", 340], ["neurodegenerative", 354], ["disorder", 372], [",", 380], ["Spinocerebellar", 382], ["Ataxia", 398], ["Type", 405], ["3", 410], [".", 411], ["We", 413], ["identify", 416], ["Lys-117", 425], [",", 432], ["which", 434], ["resides", 440], ["near", 448], ["the", 453], ["catalytic", 457], ["triad", 467], [",", 472], ["as", 474], ["the", 477], ["primary", 481], ["site", 489], ["of", 494], ["ubiquitination", 497], ["in", 512], ["wild", 515], ["type", 520], ["and", 525], ["pathogenic", 529], ["ataxin-3", 540], [".", 548], ["Further", 550], ["studies", 558], ["indicate", 566], ["that", 575], ["ubiquitin", 580], ["-", 589], ["dependent", 590], ["activation", 600], ["of", 611], ["ataxin-3", 614], ["at", 623], ["Lys-117", 626], ["is", 634], ["important", 637], ["for", 647], ["its", 651], ["ability", 655], ["to", 663], ["reduce", 666], ["high", 673], ["molecular", 678], ["weight", 688], ["ubiquitinated", 695], ["species", 709], ["in", 717], ["cells", 720], [".", 725], ["Ubiquitination", 727], ["at", 742], ["Lys-117", 745], ["also", 753], ["facilitates", 758], ["the", 770], ["ability", 774], ["of", 782], ["ataxin-3", 785], ["to", 794], ["induce", 797], ["aggresome", 804], ["formation", 814], ["in", 824], ["cells", 827], [".", 832], ["Finally", 834], [",", 841], ["structure", 843], ["-", 852], ["function", 853], ["studies", 862], ["support", 870], ["a", 878], ["model", 880], ["of", 886], ["activation", 889], ["whereby", 900], ["ubiquitination", 908], ["at", 923], ["Lys-117", 926], ["enhances", 934], ["ataxin-3", 943], ["activity", 952], ["independent", 961], ["of", 973], ["the", 976], ["known", 980], ["ubiquitin", 986], ["-", 995], ["binding", 996], ["sites", 1004], ["in", 1010], ["ataxin-3", 1013], [",", 1021], ["most", 1023], ["likely", 1028], ["through", 1035], ["a", 1043], ["direct", 1045], ["conformational", 1052], ["change", 1067], ["in", 1074], ["or", 1077], ["near", 1080], ["the", 1085], ["catalytic", 1089], ["domain", 1099], [".", 1105]]}
{"context": "Both non-Group A streptococcal (non-GAS) pharyngitis and Group A streptococcal (GAS) pharyngitis are commonly found in patients with sore throat. It is not known whether or not they present with similar signs and symptoms compared to patients with non-streptococcal pharyngitis. MEDLINE was searched for prospective studies that reported throat culture for both GAS and non-GAS as a reference standard, and reported at least one sign, symptom, or the Centor score. Summary estimates of sensitivity, specificity, likelihood ratios (LR+ and LR-), and diagnostic odds ratios (DOR) were calculated using a bivariate random effects model. Summary receiver operating characteristic (ROC) curves were created for key signs and symptoms. Eight studies met our inclusion criteria. Tonsillar exudate had the highest LR+ for both GAS and non-GAS pharyngitis (1.53 versus 1.71). The confidence intervals of sensitivity, LR+, LR-, and DOR for all signs, symptoms, and the Centor score between two groups overlapped, with the relative difference between sensitivities within 15% for arthralgia or myalgia, fever, injected throat, tonsillar enlargement, and tonsillar exudate. Larger differences in sensitivities were observed for sore throat, cervical adenopathy, and lack of a cough, although the difference for lack of a cough largely due to a single outlier. Signs and symptoms of patients with GAS and non-GAS pharyngitis are generally similar. No signs or symptoms clearly distinguish GAS from non-GAS infection. Further work is needed to determine whether Group C streptococcus is a pathogen that should be treated.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "6952c83e31114a20b979dc5962329901", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[49, 50]], "char_spans": [[252, 276]]}]}], "context_tokens": [["Both", 0], ["non", 5], ["-", 8], ["Group", 9], ["A", 15], ["streptococcal", 17], ["(", 31], ["non", 32], ["-", 35], ["GAS", 36], [")", 39], ["pharyngitis", 41], ["and", 53], ["Group", 57], ["A", 63], ["streptococcal", 65], ["(", 79], ["GAS", 80], [")", 83], ["pharyngitis", 85], ["are", 97], ["commonly", 101], ["found", 110], ["in", 116], ["patients", 119], ["with", 128], ["sore", 133], ["throat", 138], [".", 144], ["It", 146], ["is", 149], ["not", 152], ["known", 156], ["whether", 162], ["or", 170], ["not", 173], ["they", 177], ["present", 182], ["with", 190], ["similar", 195], ["signs", 203], ["and", 209], ["symptoms", 213], ["compared", 222], ["to", 231], ["patients", 234], ["with", 243], ["non", 248], ["-", 251], ["streptococcal", 252], ["pharyngitis", 266], [".", 277], ["MEDLINE", 279], ["was", 287], ["searched", 291], ["for", 300], ["prospective", 304], ["studies", 316], ["that", 324], ["reported", 329], ["throat", 338], ["culture", 345], ["for", 353], ["both", 357], ["GAS", 362], ["and", 366], ["non", 370], ["-", 373], ["GAS", 374], ["as", 378], ["a", 381], ["reference", 383], ["standard", 393], [",", 401], ["and", 403], ["reported", 407], ["at", 416], ["least", 419], ["one", 425], ["sign", 429], [",", 433], ["symptom", 435], [",", 442], ["or", 444], ["the", 447], ["Centor", 451], ["score", 458], [".", 463], ["Summary", 465], ["estimates", 473], ["of", 483], ["sensitivity", 486], [",", 497], ["specificity", 499], [",", 510], ["likelihood", 512], ["ratios", 523], ["(", 530], ["LR+", 531], ["and", 535], ["LR-", 539], [")", 542], [",", 543], ["and", 545], ["diagnostic", 549], ["odds", 560], ["ratios", 565], ["(", 572], ["DOR", 573], [")", 576], ["were", 578], ["calculated", 583], ["using", 594], ["a", 600], ["bivariate", 602], ["random", 612], ["effects", 619], ["model", 627], [".", 632], ["Summary", 634], ["receiver", 642], ["operating", 651], ["characteristic", 661], ["(", 676], ["ROC", 677], [")", 680], ["curves", 682], ["were", 689], ["created", 694], ["for", 702], ["key", 706], ["signs", 710], ["and", 716], ["symptoms", 720], [".", 728], ["Eight", 730], ["studies", 736], ["met", 744], ["our", 748], ["inclusion", 752], ["criteria", 762], [".", 770], ["Tonsillar", 772], ["exudate", 782], ["had", 790], ["the", 794], ["highest", 798], ["LR+", 806], ["for", 810], ["both", 814], ["GAS", 819], ["and", 823], ["non", 827], ["-", 830], ["GAS", 831], ["pharyngitis", 835], ["(", 847], ["1.53", 848], ["versus", 853], ["1.71", 860], [")", 864], [".", 865], ["The", 867], ["confidence", 871], ["intervals", 882], ["of", 892], ["sensitivity", 895], [",", 906], ["LR+", 908], [",", 911], ["LR-", 913], [",", 916], ["and", 918], ["DOR", 922], ["for", 926], ["all", 930], ["signs", 934], [",", 939], ["symptoms", 941], [",", 949], ["and", 951], ["the", 955], ["Centor", 959], ["score", 966], ["between", 972], ["two", 980], ["groups", 984], ["overlapped", 991], [",", 1001], ["with", 1003], ["the", 1008], ["relative", 1012], ["difference", 1021], ["between", 1032], ["sensitivities", 1040], ["within", 1054], ["15", 1061], ["%", 1063], ["for", 1065], ["arthralgia", 1069], ["or", 1080], ["myalgia", 1083], [",", 1090], ["fever", 1092], [",", 1097], ["injected", 1099], ["throat", 1108], [",", 1114], ["tonsillar", 1116], ["enlargement", 1126], [",", 1137], ["and", 1139], ["tonsillar", 1143], ["exudate", 1153], [".", 1160], ["Larger", 1162], ["differences", 1169], ["in", 1181], ["sensitivities", 1184], ["were", 1198], ["observed", 1203], ["for", 1212], ["sore", 1216], ["throat", 1221], [",", 1227], ["cervical", 1229], ["adenopathy", 1238], [",", 1248], ["and", 1250], ["lack", 1254], ["of", 1259], ["a", 1262], ["cough", 1264], [",", 1269], ["although", 1271], ["the", 1280], ["difference", 1284], ["for", 1295], ["lack", 1299], ["of", 1304], ["a", 1307], ["cough", 1309], ["largely", 1315], ["due", 1323], ["to", 1327], ["a", 1330], ["single", 1332], ["outlier", 1339], [".", 1346], ["Signs", 1348], ["and", 1354], ["symptoms", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["GAS", 1384], ["and", 1388], ["non", 1392], ["-", 1395], ["GAS", 1396], ["pharyngitis", 1400], ["are", 1412], ["generally", 1416], ["similar", 1426], [".", 1433], ["No", 1435], ["signs", 1438], ["or", 1444], ["symptoms", 1447], ["clearly", 1456], ["distinguish", 1464], ["GAS", 1476], ["from", 1480], ["non", 1485], ["-", 1488], ["GAS", 1489], ["infection", 1493], [".", 1502], ["Further", 1504], ["work", 1512], ["is", 1517], ["needed", 1520], ["to", 1527], ["determine", 1530], ["whether", 1540], ["Group", 1548], ["C", 1554], ["streptococcus", 1556], ["is", 1570], ["a", 1573], ["pathogen", 1575], ["that", 1584], ["should", 1589], ["be", 1596], ["treated", 1599], [".", 1606]]}
{"context": "Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) has an unusual pathogenic mechanism. FSHD is caused by deletion of a subset of D4Z4 macrosatellite repeat units in the subtelomere of chromosome 4q. Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. In FSHD, the combination of inefficient chromatin silencing of the D4Z4 repeat and polymorphisms on the FSHD-permissive alleles that stabilize the DUX4 mRNAs emanating from the repeat result in inappropriate DUX4 protein expression in muscle cells. FSHD is thereby the first example of a human disease caused by the inefficient repression of a retrogene in a macrosatellite repeat array.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "fb6050311b794585986ab4a8b17b564e", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[6, 6], [65, 65], [104, 104], [14, 14], [81, 81]], "char_spans": [[59, 62], [402, 405], [648, 651], [102, 105], [503, 506]]}]}], "context_tokens": [["Autosomal", 0], ["dominant", 10], ["facioscapulohumeral", 19], ["muscular", 39], ["dystrophy", 48], ["(", 58], ["FSHD", 59], [")", 63], ["has", 65], ["an", 69], ["unusual", 72], ["pathogenic", 80], ["mechanism", 91], [".", 100], ["FSHD", 102], ["is", 107], ["caused", 110], ["by", 117], ["deletion", 120], ["of", 129], ["a", 132], ["subset", 134], ["of", 141], ["D4Z4", 144], ["macrosatellite", 149], ["repeat", 164], ["units", 171], ["in", 177], ["the", 180], ["subtelomere", 184], ["of", 196], ["chromosome", 199], ["4q", 210], [".", 212], ["Recent", 214], ["studies", 221], ["provide", 229], ["compelling", 237], ["evidence", 248], ["that", 257], ["a", 262], ["retrotransposed", 264], ["gene", 280], ["in", 285], ["the", 288], ["D4Z4", 292], ["repeat", 297], [",", 303], ["DUX4", 305], [",", 309], ["is", 311], ["expressed", 314], ["in", 324], ["the", 327], ["human", 331], ["germline", 337], ["and", 346], ["then", 350], ["epigenetically", 355], ["silenced", 370], ["in", 379], ["somatic", 382], ["tissues", 390], [".", 397], ["In", 399], ["FSHD", 402], [",", 406], ["the", 408], ["combination", 412], ["of", 424], ["inefficient", 427], ["chromatin", 439], ["silencing", 449], ["of", 459], ["the", 462], ["D4Z4", 466], ["repeat", 471], ["and", 478], ["polymorphisms", 482], ["on", 496], ["the", 499], ["FSHD", 503], ["-", 507], ["permissive", 508], ["alleles", 519], ["that", 527], ["stabilize", 532], ["the", 542], ["DUX4", 546], ["mRNAs", 551], ["emanating", 557], ["from", 567], ["the", 572], ["repeat", 576], ["result", 583], ["in", 590], ["inappropriate", 593], ["DUX4", 607], ["protein", 612], ["expression", 620], ["in", 631], ["muscle", 634], ["cells", 641], [".", 646], ["FSHD", 648], ["is", 653], ["thereby", 656], ["the", 664], ["first", 668], ["example", 674], ["of", 682], ["a", 685], ["human", 687], ["disease", 693], ["caused", 701], ["by", 708], ["the", 711], ["inefficient", 715], ["repression", 727], ["of", 738], ["a", 741], ["retrogene", 743], ["in", 753], ["a", 756], ["macrosatellite", 758], ["repeat", 773], ["array", 780], [".", 785]]}
{"context": "Understanding the pathogenesis of CLL has uncovered a plethora of novel targets for human application of monoclonal antibodies, engineered T cells, or inhibitors of signal transduction pathways. The B-cell receptor signaling pathway is being actively explored as a therapeutic target in CLL. Ibrutinib, an inhibitor of Bruton's tyrosine kinase is showing impressive responses in heavily pre-treated high-risk CLL, whether alone or in combination with MoAbs or chemotherapy. Other key components of the BCR pathway, namely PI3K-\u03b4, are also being targeted with novel therapies with promising results as well. Future trials would likely evaluate ibrutinib in the front-line setting. Moreover, improvements in allogeneic HCT mostly by continuing to reduce associated toxicity as well as incorporating cellular therapies such as autologous CLL tumor vaccines, among others, will continue to expand. This is also the case for the next generation of chimeric antigen receptor therapy for CLL once genetically modified T cells are available at broad scale and with improved efficacy. As our ability to further refine and integrate these therapies continues to improve, and we gain further knowledge from gene sequencing, we anticipate that treatment algorithms will continue to be revised to a more personalized approach to treat this disease with improved efficacy and devoid of unnecessary toxicity.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "e34cd287534b4fd788442be110013bba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[48, 48], [112, 112]], "char_spans": [[292, 300], [643, 651]]}]}], "context_tokens": [["Understanding", 0], ["the", 14], ["pathogenesis", 18], ["of", 31], ["CLL", 34], ["has", 38], ["uncovered", 42], ["a", 52], ["plethora", 54], ["of", 63], ["novel", 66], ["targets", 72], ["for", 80], ["human", 84], ["application", 90], ["of", 102], ["monoclonal", 105], ["antibodies", 116], [",", 126], ["engineered", 128], ["T", 139], ["cells", 141], [",", 146], ["or", 148], ["inhibitors", 151], ["of", 162], ["signal", 165], ["transduction", 172], ["pathways", 185], [".", 193], ["The", 195], ["B", 199], ["-", 200], ["cell", 201], ["receptor", 206], ["signaling", 215], ["pathway", 225], ["is", 233], ["being", 236], ["actively", 242], ["explored", 251], ["as", 260], ["a", 263], ["therapeutic", 265], ["target", 277], ["in", 284], ["CLL", 287], [".", 290], ["Ibrutinib", 292], [",", 301], ["an", 303], ["inhibitor", 306], ["of", 316], ["Bruton", 319], ["'s", 325], ["tyrosine", 328], ["kinase", 337], ["is", 344], ["showing", 347], ["impressive", 355], ["responses", 366], ["in", 376], ["heavily", 379], ["pre", 387], ["-", 390], ["treated", 391], ["high", 399], ["-", 403], ["risk", 404], ["CLL", 409], [",", 412], ["whether", 414], ["alone", 422], ["or", 428], ["in", 431], ["combination", 434], ["with", 446], ["MoAbs", 451], ["or", 457], ["chemotherapy", 460], [".", 472], ["Other", 474], ["key", 480], ["components", 484], ["of", 495], ["the", 498], ["BCR", 502], ["pathway", 506], [",", 513], ["namely", 515], ["PI3K", 522], ["-", 526], ["\u03b4", 527], [",", 528], ["are", 530], ["also", 534], ["being", 539], ["targeted", 545], ["with", 554], ["novel", 559], ["therapies", 565], ["with", 575], ["promising", 580], ["results", 590], ["as", 598], ["well", 601], [".", 605], ["Future", 607], ["trials", 614], ["would", 621], ["likely", 627], ["evaluate", 634], ["ibrutinib", 643], ["in", 653], ["the", 656], ["front", 660], ["-", 665], ["line", 666], ["setting", 671], [".", 678], ["Moreover", 680], [",", 688], ["improvements", 690], ["in", 703], ["allogeneic", 706], ["HCT", 717], ["mostly", 721], ["by", 728], ["continuing", 731], ["to", 742], ["reduce", 745], ["associated", 752], ["toxicity", 763], ["as", 772], ["well", 775], ["as", 780], ["incorporating", 783], ["cellular", 797], ["therapies", 806], ["such", 816], ["as", 821], ["autologous", 824], ["CLL", 835], ["tumor", 839], ["vaccines", 845], [",", 853], ["among", 855], ["others", 861], [",", 867], ["will", 869], ["continue", 874], ["to", 883], ["expand", 886], [".", 892], ["This", 894], ["is", 899], ["also", 902], ["the", 907], ["case", 911], ["for", 916], ["the", 920], ["next", 924], ["generation", 929], ["of", 940], ["chimeric", 943], ["antigen", 952], ["receptor", 960], ["therapy", 969], ["for", 977], ["CLL", 981], ["once", 985], ["genetically", 990], ["modified", 1002], ["T", 1011], ["cells", 1013], ["are", 1019], ["available", 1023], ["at", 1033], ["broad", 1036], ["scale", 1042], ["and", 1048], ["with", 1052], ["improved", 1057], ["efficacy", 1066], [".", 1074], ["As", 1076], ["our", 1079], ["ability", 1083], ["to", 1091], ["further", 1094], ["refine", 1102], ["and", 1109], ["integrate", 1113], ["these", 1123], ["therapies", 1129], ["continues", 1139], ["to", 1149], ["improve", 1152], [",", 1159], ["and", 1161], ["we", 1165], ["gain", 1168], ["further", 1173], ["knowledge", 1181], ["from", 1191], ["gene", 1196], ["sequencing", 1201], [",", 1211], ["we", 1213], ["anticipate", 1216], ["that", 1227], ["treatment", 1232], ["algorithms", 1242], ["will", 1253], ["continue", 1258], ["to", 1267], ["be", 1270], ["revised", 1273], ["to", 1281], ["a", 1284], ["more", 1286], ["personalized", 1291], ["approach", 1304], ["to", 1313], ["treat", 1316], ["this", 1322], ["disease", 1327], ["with", 1335], ["improved", 1340], ["efficacy", 1349], ["and", 1358], ["devoid", 1362], ["of", 1369], ["unnecessary", 1372], ["toxicity", 1384], [".", 1392]]}
{"context": "Chronic lymphocytic leukemia (CLL) is characterized by constitutive activation of the B-cell receptor (BCR) signaling pathway, but variable responsiveness of the BCR to antigen ligation. Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL. Early clinical results in CLL with other reversible and irreversible BTK inhibitors have been less promising, however, raising the question of whether BTK kinase activity is an important target of ibrutinib and also in CLL. To determine the role of BTK in CLL, we used patient samples and the E\u03bc-TCL1 (TCL1) transgenic mouse model of CLL, which results in spontaneous leukemia development. Inhibition of BTK in primary human CLL cells by small interfering RNA promotes apoptosis. Inhibition of BTK kinase activity through either targeted genetic inactivation or ibrutinib in the TCL1 mouse significantly delays the development of CLL, demonstrating that BTK is a critical kinase for CLL development and expansion and thus an important target of ibrutinib. Collectively, our data confirm the importance of kinase-functional BTK in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "6696f9c425644649871fb87ff9a6ff0d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[196, 196], [100, 100], [53, 53], [166, 166]], "char_spans": [[1141, 1149], [593, 601], [301, 309], [958, 966]]}]}], "context_tokens": [["Chronic", 0], ["lymphocytic", 8], ["leukemia", 20], ["(", 29], ["CLL", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["constitutive", 55], ["activation", 68], ["of", 79], ["the", 82], ["B", 86], ["-", 87], ["cell", 88], ["receptor", 93], ["(", 102], ["BCR", 103], [")", 106], ["signaling", 108], ["pathway", 118], [",", 125], ["but", 127], ["variable", 131], ["responsiveness", 140], ["of", 155], ["the", 158], ["BCR", 162], ["to", 166], ["antigen", 169], ["ligation", 177], [".", 185], ["Bruton", 187], ["'s", 193], ["tyrosine", 196], ["kinase", 205], ["(", 212], ["BTK", 213], [")", 216], ["shows", 218], ["constitutive", 224], ["activity", 237], ["in", 246], ["CLL", 249], ["and", 253], ["is", 257], ["the", 260], ["target", 264], ["of", 271], ["irreversible", 274], ["inhibition", 287], ["by", 298], ["ibrutinib", 301], [",", 310], ["an", 312], ["orally", 315], ["bioavailable", 322], ["kinase", 335], ["inhibitor", 342], ["that", 352], ["has", 357], ["shown", 361], ["outstanding", 367], ["activity", 379], ["in", 388], ["CLL", 391], [".", 394], ["Early", 396], ["clinical", 402], ["results", 411], ["in", 419], ["CLL", 422], ["with", 426], ["other", 431], ["reversible", 437], ["and", 448], ["irreversible", 452], ["BTK", 465], ["inhibitors", 469], ["have", 480], ["been", 485], ["less", 490], ["promising", 495], [",", 504], ["however", 506], [",", 513], ["raising", 515], ["the", 523], ["question", 527], ["of", 536], ["whether", 539], ["BTK", 547], ["kinase", 551], ["activity", 558], ["is", 567], ["an", 570], ["important", 573], ["target", 583], ["of", 590], ["ibrutinib", 593], ["and", 603], ["also", 607], ["in", 612], ["CLL", 615], [".", 618], ["To", 620], ["determine", 623], ["the", 633], ["role", 637], ["of", 642], ["BTK", 645], ["in", 649], ["CLL", 652], [",", 655], ["we", 657], ["used", 660], ["patient", 665], ["samples", 673], ["and", 681], ["the", 685], ["E\u03bc", 689], ["-", 691], ["TCL1", 692], ["(", 697], ["TCL1", 698], [")", 702], ["transgenic", 704], ["mouse", 715], ["model", 721], ["of", 727], ["CLL", 730], [",", 733], ["which", 735], ["results", 741], ["in", 749], ["spontaneous", 752], ["leukemia", 764], ["development", 773], [".", 784], ["Inhibition", 786], ["of", 797], ["BTK", 800], ["in", 804], ["primary", 807], ["human", 815], ["CLL", 821], ["cells", 825], ["by", 831], ["small", 834], ["interfering", 840], ["RNA", 852], ["promotes", 856], ["apoptosis", 865], [".", 874], ["Inhibition", 876], ["of", 887], ["BTK", 890], ["kinase", 894], ["activity", 901], ["through", 910], ["either", 918], ["targeted", 925], ["genetic", 934], ["inactivation", 942], ["or", 955], ["ibrutinib", 958], ["in", 968], ["the", 971], ["TCL1", 975], ["mouse", 980], ["significantly", 986], ["delays", 1000], ["the", 1007], ["development", 1011], ["of", 1023], ["CLL", 1026], [",", 1029], ["demonstrating", 1031], ["that", 1045], ["BTK", 1050], ["is", 1054], ["a", 1057], ["critical", 1059], ["kinase", 1068], ["for", 1075], ["CLL", 1079], ["development", 1083], ["and", 1095], ["expansion", 1099], ["and", 1109], ["thus", 1113], ["an", 1118], ["important", 1121], ["target", 1131], ["of", 1138], ["ibrutinib", 1141], [".", 1150], ["Collectively", 1152], [",", 1164], ["our", 1166], ["data", 1170], ["confirm", 1175], ["the", 1183], ["importance", 1187], ["of", 1198], ["kinase", 1201], ["-", 1207], ["functional", 1208], ["BTK", 1219], ["in", 1223], ["CLL", 1226], [".", 1229]]}
{"context": "Mutations in the ribosomal protein (RP)S19 gene have been found in about 25% of the cases of Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia that includes variable physical malformations. Various mutations have been identified in the RPS19 gene, but no investigations regarding the effect of these alterations on RPS19 mRNA levels have been performed. It is well established that mutated mRNA containing a premature stop codon (PTC) or lacking a stop codon can be rapidly degraded by specific mechanisms called nonsense mediated decay (NMD) and nonstop decay. To study the involvement of such mechanisms in DBA, we analyzed immortalized lymphoblastoid cells and primary fibroblasts from patients presenting different kinds of mutations in the RPS19 gene, generating allelic deletion, missense, nonsense, and nonstop messengers. We found that RPS19 mRNA levels are decreased in the cells with allelic deletion and, to a variable extent, also in all the cell lines with PTC or nonstop mutations. Further analysis showed that translation inhibition causes a stabilization of the mutated RPS19 mRNA. Our findings indicate that NMD and nonstop decay affect the expression of mutated RPS19 genes; this may help to clarify genotype-phenotype correlations in DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "141cca4558cd4f99b00b0fe5066754ca", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[19, 22]], "char_spans": [[93, 115]]}, {"text": "DBA", "token_spans": [[219, 219], [24, 24], [111, 111]], "char_spans": [[1271, 1273], [118, 120], [627, 629]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["ribosomal", 17], ["protein", 27], ["(", 35], ["RP)S19", 36], ["gene", 43], ["have", 48], ["been", 53], ["found", 58], ["in", 64], ["about", 67], ["25", 73], ["%", 75], ["of", 77], ["the", 80], ["cases", 84], ["of", 90], ["Diamond", 93], ["-", 100], ["Blackfan", 101], ["anemia", 110], ["(", 117], ["DBA", 118], [")", 121], [",", 122], ["a", 124], ["rare", 126], ["congenital", 131], ["hypoplastic", 142], ["anemia", 154], ["that", 161], ["includes", 166], ["variable", 175], ["physical", 184], ["malformations", 193], [".", 206], ["Various", 208], ["mutations", 216], ["have", 226], ["been", 231], ["identified", 236], ["in", 247], ["the", 250], ["RPS19", 254], ["gene", 260], [",", 264], ["but", 266], ["no", 270], ["investigations", 273], ["regarding", 288], ["the", 298], ["effect", 302], ["of", 309], ["these", 312], ["alterations", 318], ["on", 330], ["RPS19", 333], ["mRNA", 339], ["levels", 344], ["have", 351], ["been", 356], ["performed", 361], [".", 370], ["It", 372], ["is", 375], ["well", 378], ["established", 383], ["that", 395], ["mutated", 400], ["mRNA", 408], ["containing", 413], ["a", 424], ["premature", 426], ["stop", 436], ["codon", 441], ["(", 447], ["PTC", 448], [")", 451], ["or", 453], ["lacking", 456], ["a", 464], ["stop", 466], ["codon", 471], ["can", 477], ["be", 481], ["rapidly", 484], ["degraded", 492], ["by", 501], ["specific", 504], ["mechanisms", 513], ["called", 524], ["nonsense", 531], ["mediated", 540], ["decay", 549], ["(", 555], ["NMD", 556], [")", 559], ["and", 561], ["nonstop", 565], ["decay", 573], [".", 578], ["To", 580], ["study", 583], ["the", 589], ["involvement", 593], ["of", 605], ["such", 608], ["mechanisms", 613], ["in", 624], ["DBA", 627], [",", 630], ["we", 632], ["analyzed", 635], ["immortalized", 644], ["lymphoblastoid", 657], ["cells", 672], ["and", 678], ["primary", 682], ["fibroblasts", 690], ["from", 702], ["patients", 707], ["presenting", 716], ["different", 727], ["kinds", 737], ["of", 743], ["mutations", 746], ["in", 756], ["the", 759], ["RPS19", 763], ["gene", 769], [",", 773], ["generating", 775], ["allelic", 786], ["deletion", 794], [",", 802], ["missense", 804], [",", 812], ["nonsense", 814], [",", 822], ["and", 824], ["nonstop", 828], ["messengers", 836], [".", 846], ["We", 848], ["found", 851], ["that", 857], ["RPS19", 862], ["mRNA", 868], ["levels", 873], ["are", 880], ["decreased", 884], ["in", 894], ["the", 897], ["cells", 901], ["with", 907], ["allelic", 912], ["deletion", 920], ["and", 929], [",", 932], ["to", 934], ["a", 937], ["variable", 939], ["extent", 948], [",", 954], ["also", 956], ["in", 961], ["all", 964], ["the", 968], ["cell", 972], ["lines", 977], ["with", 983], ["PTC", 988], ["or", 992], ["nonstop", 995], ["mutations", 1003], [".", 1012], ["Further", 1014], ["analysis", 1022], ["showed", 1031], ["that", 1038], ["translation", 1043], ["inhibition", 1055], ["causes", 1066], ["a", 1073], ["stabilization", 1075], ["of", 1089], ["the", 1092], ["mutated", 1096], ["RPS19", 1104], ["mRNA", 1110], [".", 1114], ["Our", 1116], ["findings", 1120], ["indicate", 1129], ["that", 1138], ["NMD", 1143], ["and", 1147], ["nonstop", 1151], ["decay", 1159], ["affect", 1165], ["the", 1172], ["expression", 1176], ["of", 1187], ["mutated", 1190], ["RPS19", 1198], ["genes", 1204], [";", 1209], ["this", 1211], ["may", 1216], ["help", 1220], ["to", 1225], ["clarify", 1228], ["genotype", 1236], ["-", 1244], ["phenotype", 1245], ["correlations", 1255], ["in", 1268], ["DBA", 1271], [".", 1274]]}
{"context": "Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease progression may be mediated by other mechanisms that render tumor cells independent of BCR-ABL. To demonstrate this potential, IM-resistant cells were found in chronic myelogenous leukemia patients with continuous BCR-ABL gene expression but undetectable BCR-ABL protein expression. These cells were unresponsive to IM and acquired BCR-ABL-independent signaling characteristics. IM resistance in some patients may be mediated through loss of kinase target dependence.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7887f12a541643aebe9893f82a5f0c28", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[86, 88], [36, 38], [100, 102], [8, 10], [57, 59], [79, 81]], "char_spans": [[505, 511], [213, 219], [582, 588], [36, 42], [337, 343], [464, 470]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["IM", 19], [")", 21], ["binds", 23], ["to", 29], ["the", 32], ["BCR", 36], ["-", 39], ["ABL", 40], ["protein", 44], [",", 51], ["inhibiting", 53], ["its", 64], ["kinase", 68], ["activity", 75], ["and", 84], ["effectively", 88], ["controlling", 100], ["diseases", 112], ["driven", 121], ["by", 128], ["this", 131], ["kinase", 136], [".", 142], ["IM", 144], ["resistance", 147], ["has", 158], ["been", 162], ["associated", 167], ["with", 178], ["kinase", 183], ["mutations", 190], ["or", 200], ["increased", 203], ["BCR", 213], ["-", 216], ["ABL", 217], ["expression", 221], [".", 231], ["However", 233], [",", 240], ["disease", 242], ["progression", 250], ["may", 262], ["be", 266], ["mediated", 269], ["by", 278], ["other", 281], ["mechanisms", 287], ["that", 298], ["render", 303], ["tumor", 310], ["cells", 316], ["independent", 322], ["of", 334], ["BCR", 337], ["-", 340], ["ABL", 341], [".", 344], ["To", 346], ["demonstrate", 349], ["this", 361], ["potential", 366], [",", 375], ["IM", 377], ["-", 379], ["resistant", 380], ["cells", 390], ["were", 396], ["found", 401], ["in", 407], ["chronic", 410], ["myelogenous", 418], ["leukemia", 430], ["patients", 439], ["with", 448], ["continuous", 453], ["BCR", 464], ["-", 467], ["ABL", 468], ["gene", 472], ["expression", 477], ["but", 488], ["undetectable", 492], ["BCR", 505], ["-", 508], ["ABL", 509], ["protein", 513], ["expression", 521], [".", 531], ["These", 533], ["cells", 539], ["were", 545], ["unresponsive", 550], ["to", 563], ["IM", 566], ["and", 569], ["acquired", 573], ["BCR", 582], ["-", 585], ["ABL", 586], ["-", 589], ["independent", 590], ["signaling", 602], ["characteristics", 612], [".", 627], ["IM", 629], ["resistance", 632], ["in", 643], ["some", 646], ["patients", 651], ["may", 660], ["be", 664], ["mediated", 667], ["through", 676], ["loss", 684], ["of", 689], ["kinase", 692], ["target", 699], ["dependence", 706], [".", 716]]}
{"context": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease. Here we define the role of phosphorylation of Ser129 in alpha-synuclein toxicity and inclusion formation using a Drosophila model of Parkinson disease. Mutation of Ser129 to alanine to prevent phosphorylation completely suppresses dopaminergic neuronal loss produced by expression of human alpha-synuclein. In contrast, altering Ser129 to the negatively charged residue aspartate, to mimic phosphorylation, significantly enhances alpha-synuclein toxicity. The G protein-coupled receptor kinase 2 (Gprk2) phosphorylates Ser129 in vivo and enhances alpha-synuclein toxicity. Blocking phosphorylation at Ser129 substantially increases aggregate formation. Thus Ser129 phosphorylation status is crucial in mediating alpha-synuclein neurotoxicity and inclusion formation. Because increased number of inclusion bodies correlates with reduced toxicity, inclusion bodies may protect neurons from alpha-synuclein toxicity.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "7161d325e39f4f4884391fb5e3adb5db", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[6, 7]], "char_spans": [[37, 46]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["phosphorylated", 19], ["at", 34], ["serine", 37], ["129", 44], ["(", 48], ["Ser129", 49], [")", 55], ["in", 57], ["intracellular", 60], ["protein", 74], ["aggregates", 82], ["called", 93], ["Lewy", 100], ["bodies", 105], [".", 111], ["These", 113], ["inclusion", 119], ["bodies", 129], ["are", 136], ["the", 140], ["characteristic", 144], ["pathologic", 159], ["lesions", 170], ["of", 178], ["Parkinson", 181], ["disease", 191], [".", 198], ["Here", 200], ["we", 205], ["define", 208], ["the", 215], ["role", 219], ["of", 224], ["phosphorylation", 227], ["of", 243], ["Ser129", 246], ["in", 253], ["alpha", 256], ["-", 261], ["synuclein", 262], ["toxicity", 272], ["and", 281], ["inclusion", 285], ["formation", 295], ["using", 305], ["a", 311], ["Drosophila", 313], ["model", 324], ["of", 330], ["Parkinson", 333], ["disease", 343], [".", 350], ["Mutation", 352], ["of", 361], ["Ser129", 364], ["to", 371], ["alanine", 374], ["to", 382], ["prevent", 385], ["phosphorylation", 393], ["completely", 409], ["suppresses", 420], ["dopaminergic", 431], ["neuronal", 444], ["loss", 453], ["produced", 458], ["by", 467], ["expression", 470], ["of", 481], ["human", 484], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["In", 507], ["contrast", 510], [",", 518], ["altering", 520], ["Ser129", 529], ["to", 536], ["the", 539], ["negatively", 543], ["charged", 554], ["residue", 562], ["aspartate", 570], [",", 579], ["to", 581], ["mimic", 584], ["phosphorylation", 590], [",", 605], ["significantly", 607], ["enhances", 621], ["alpha", 630], ["-", 635], ["synuclein", 636], ["toxicity", 646], [".", 654], ["The", 656], ["G", 660], ["protein", 662], ["-", 669], ["coupled", 670], ["receptor", 678], ["kinase", 687], ["2", 694], ["(", 696], ["Gprk2", 697], [")", 702], ["phosphorylates", 704], ["Ser129", 719], ["in", 726], ["vivo", 729], ["and", 734], ["enhances", 738], ["alpha", 747], ["-", 752], ["synuclein", 753], ["toxicity", 763], [".", 771], ["Blocking", 773], ["phosphorylation", 782], ["at", 798], ["Ser129", 801], ["substantially", 808], ["increases", 822], ["aggregate", 832], ["formation", 842], [".", 851], ["Thus", 853], ["Ser129", 858], ["phosphorylation", 865], ["status", 881], ["is", 888], ["crucial", 891], ["in", 899], ["mediating", 902], ["alpha", 912], ["-", 917], ["synuclein", 918], ["neurotoxicity", 928], ["and", 942], ["inclusion", 946], ["formation", 956], [".", 965], ["Because", 967], ["increased", 975], ["number", 985], ["of", 992], ["inclusion", 995], ["bodies", 1005], ["correlates", 1012], ["with", 1023], ["reduced", 1028], ["toxicity", 1036], [",", 1044], ["inclusion", 1046], ["bodies", 1056], ["may", 1063], ["protect", 1067], ["neurons", 1075], ["from", 1083], ["alpha", 1088], ["-", 1093], ["synuclein", 1094], ["toxicity", 1104], [".", 1112]]}
{"context": "Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. To provide an evidence-based update of new treatments published since 2005 for the management of RLS. First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "de513d59252e439c8c943b250eba9f14", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23]], "char_spans": [[128, 149]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["publication", 10], ["of", 22], ["the", 25], ["first", 29], ["European", 35], ["Federation", 44], ["of", 55], ["Neurological", 58], ["Societies", 71], ["(", 81], ["EFNS", 82], [")", 86], ["guidelines", 88], ["in", 99], ["2005", 102], ["on", 107], ["the", 110], ["management", 114], ["of", 125], ["restless", 128], ["legs", 137], ["syndrome", 142], ["(", 151], ["RLS", 152], [";", 155], ["also", 157], ["known", 162], ["as", 168], ["Willis", 171], ["-", 177], ["Ekbom", 178], ["disease", 184], [")", 191], [",", 192], ["there", 194], ["have", 200], ["been", 205], ["major", 210], ["therapeutic", 216], ["advances", 228], ["in", 237], ["the", 240], ["field", 244], [".", 249], ["Furthermore", 251], [",", 262], ["the", 264], ["management", 268], ["of", 279], ["RLS", 282], ["is", 286], ["now", 289], ["a", 293], ["part", 295], ["of", 300], ["routine", 303], ["neurological", 311], ["practice", 324], ["in", 333], ["Europe", 336], [".", 342], ["New", 344], ["drugs", 348], ["have", 354], ["also", 359], ["become", 364], ["available", 371], [",", 380], ["and", 382], ["further", 386], ["randomized", 394], ["controlled", 405], ["trials", 416], ["have", 423], ["been", 428], ["undertaken", 433], [".", 443], ["These", 445], ["guidelines", 451], ["were", 462], ["undertaken", 467], ["by", 478], ["the", 481], ["EFNS", 485], ["in", 490], ["collaboration", 493], ["with", 507], ["the", 512], ["European", 516], ["Neurological", 525], ["Society", 538], ["and", 546], ["the", 550], ["European", 554], ["Sleep", 563], ["Research", 569], ["Society", 578], [".", 585], ["To", 587], ["provide", 590], ["an", 598], ["evidence", 601], ["-", 609], ["based", 610], ["update", 616], ["of", 623], ["new", 626], ["treatments", 630], ["published", 641], ["since", 651], ["2005", 657], ["for", 662], ["the", 666], ["management", 670], ["of", 681], ["RLS", 684], [".", 687], ["First", 689], [",", 694], ["we", 696], ["determined", 699], ["what", 710], ["the", 715], ["objectives", 719], ["of", 730], ["management", 733], ["of", 744], ["primary", 747], ["and", 755], ["secondary", 759], ["RLS", 769], ["should", 773], ["be", 780], [".", 782], ["We", 784], ["developed", 787], ["the", 797], ["search", 801], ["strategy", 808], ["and", 817], ["conducted", 821], ["a", 831], ["review", 833], ["of", 840], ["the", 843], ["scientific", 847], ["literature", 858], ["up", 869], ["to", 872], ["31", 875], ["December", 878], ["2011", 887], ["(", 892], ["print", 893], ["and", 899], ["electronic", 903], ["publications", 914], [")", 926], ["for", 928], ["the", 932], ["drug", 936], ["classes", 941], ["and", 949], ["interventions", 953], ["employed", 967], ["in", 976], ["RLS", 979], ["treatment", 983], [".", 992], ["Previous", 994], ["guidelines", 1003], ["were", 1014], ["consulted", 1019], [".", 1028], ["All", 1030], ["trials", 1034], ["were", 1041], ["analysed", 1046], ["according", 1055], ["to", 1065], ["class", 1068], ["of", 1074], ["evidence", 1077], [",", 1085], ["and", 1087], ["recommendations", 1091], ["made", 1107], ["according", 1112], ["to", 1122], ["the", 1125], ["2004", 1129], ["EFNS", 1134], ["criteria", 1139], ["for", 1148], ["rating", 1152], [".", 1158], ["Level", 1160], ["A", 1166], ["recommendations", 1168], ["can", 1184], ["be", 1188], ["made", 1191], ["for", 1196], ["rotigotine", 1200], [",", 1210], ["ropinirole", 1212], [",", 1222], ["pramipexole", 1224], [",", 1235], ["gabapentin", 1237], ["enacarbil", 1248], [",", 1257], ["gabapentin", 1259], ["and", 1270], ["pregabalin", 1274], [",", 1284], ["which", 1286], ["are", 1292], ["all", 1296], ["considered", 1300], ["effective", 1311], ["for", 1321], ["the", 1325], ["short", 1329], ["-", 1334], ["term", 1335], ["treatment", 1340], ["for", 1350], ["RLS", 1354], [".", 1357], ["However", 1359], [",", 1366], ["for", 1368], ["the", 1372], ["long", 1376], ["-", 1380], ["term", 1381], ["treatment", 1386], ["for", 1396], ["RLS", 1400], [",", 1403], ["rotigotine", 1405], ["is", 1416], ["considered", 1419], ["effective", 1430], [",", 1439], ["gabapentin", 1441], ["enacarbil", 1452], ["is", 1462], ["probably", 1465], ["effective", 1474], [",", 1483], ["and", 1485], ["ropinirole", 1489], [",", 1499], ["pramipexole", 1501], ["and", 1513], ["gabapentin", 1517], ["are", 1528], ["considered", 1532], ["possibly", 1543], ["effective", 1552], [".", 1561], ["Cabergoline", 1563], ["has", 1575], ["according", 1579], ["to", 1589], ["our", 1592], ["criteria", 1596], ["a", 1605], ["level", 1607], ["A", 1613], ["recommendation", 1615], [",", 1629], ["but", 1631], ["the", 1635], ["taskforce", 1639], ["can", 1649], ["not", 1652], ["recommend", 1656], ["this", 1666], ["drug", 1671], ["because", 1676], ["of", 1684], ["its", 1687], ["serious", 1691], ["adverse", 1699], ["events", 1707], [".", 1713]]}
{"context": "A dedicated excision repair pathway, termed transcription-coupled repair (TCR), targets the removal of DNA lesions from transcribed strands of expressed genes. Transcription arrest at the site of the lesion has been proposed as the first step for initiation of TCR. In support of this model, a strong correlation between arrest of transcription by a lesion in vitro and TCR of that lesion in vivo has been found in most cases analyzed. TCR has been reported for oxidative DNA damage; however, very little is known about how frequently occurring and spontaneous DNA damage, such as depurination and base deamination, affects progression of the transcription complex. We have previously determined that the oxidative lesion, thymine glycol, is a significant block to transcription by T7 RNA polymerase (T7 RNAP) but has no detectable effect on transcription by RNA polymerase II (RNAP II) in a reconstituted system with all of the required factors. Another oxidative lesion, 8-oxoguanine, only slightly blocked T7 RNAP and caused RNAP II to briefly pause at the lesion before bypassing it. Because an abasic site is an intermediate in the repair of oxidative damage, it was of interest to learn whether it arrested transcription. Using in vitro transcription assays and substrates containing a specifically positioned lesion, we found that an abasic site in the transcribed strand is a 60% block to transcription by T7 RNAP but nearly a complete block to transcription by mammalian RNAP II. An abasic site in the nontranscribed strand did not block either polymerase. Our results clearly indicate that an abasic site is a much stronger block to transcription than either a thymine glycol or an 8-oxoguanine. Because the predominant model for TCR postulates that only lesions that block RNAP will be subject to TCR, our findings suggest that the abasic site may be sufficient to initiate TCR in vivo.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "6960bdbb74c3432a83bd3a3c0a6c30f1", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[242, 243]], "char_spans": [[1360, 1377]]}]}], "context_tokens": [["A", 0], ["dedicated", 2], ["excision", 12], ["repair", 21], ["pathway", 28], [",", 35], ["termed", 37], ["transcription", 44], ["-", 57], ["coupled", 58], ["repair", 66], ["(", 73], ["TCR", 74], [")", 77], [",", 78], ["targets", 80], ["the", 88], ["removal", 92], ["of", 100], ["DNA", 103], ["lesions", 107], ["from", 115], ["transcribed", 120], ["strands", 132], ["of", 140], ["expressed", 143], ["genes", 153], [".", 158], ["Transcription", 160], ["arrest", 174], ["at", 181], ["the", 184], ["site", 188], ["of", 193], ["the", 196], ["lesion", 200], ["has", 207], ["been", 211], ["proposed", 216], ["as", 225], ["the", 228], ["first", 232], ["step", 238], ["for", 243], ["initiation", 247], ["of", 258], ["TCR", 261], [".", 264], ["In", 266], ["support", 269], ["of", 277], ["this", 280], ["model", 285], [",", 290], ["a", 292], ["strong", 294], ["correlation", 301], ["between", 313], ["arrest", 321], ["of", 328], ["transcription", 331], ["by", 345], ["a", 348], ["lesion", 350], ["in", 357], ["vitro", 360], ["and", 366], ["TCR", 370], ["of", 374], ["that", 377], ["lesion", 382], ["in", 389], ["vivo", 392], ["has", 397], ["been", 401], ["found", 406], ["in", 412], ["most", 415], ["cases", 420], ["analyzed", 426], [".", 434], ["TCR", 436], ["has", 440], ["been", 444], ["reported", 449], ["for", 458], ["oxidative", 462], ["DNA", 472], ["damage", 476], [";", 482], ["however", 484], [",", 491], ["very", 493], ["little", 498], ["is", 505], ["known", 508], ["about", 514], ["how", 520], ["frequently", 524], ["occurring", 535], ["and", 545], ["spontaneous", 549], ["DNA", 561], ["damage", 565], [",", 571], ["such", 573], ["as", 578], ["depurination", 581], ["and", 594], ["base", 598], ["deamination", 603], [",", 614], ["affects", 616], ["progression", 624], ["of", 636], ["the", 639], ["transcription", 643], ["complex", 657], [".", 664], ["We", 666], ["have", 669], ["previously", 674], ["determined", 685], ["that", 696], ["the", 701], ["oxidative", 705], ["lesion", 715], [",", 721], ["thymine", 723], ["glycol", 731], [",", 737], ["is", 739], ["a", 742], ["significant", 744], ["block", 756], ["to", 762], ["transcription", 765], ["by", 779], ["T7", 782], ["RNA", 785], ["polymerase", 789], ["(", 800], ["T7", 801], ["RNAP", 804], [")", 808], ["but", 810], ["has", 814], ["no", 818], ["detectable", 821], ["effect", 832], ["on", 839], ["transcription", 842], ["by", 856], ["RNA", 859], ["polymerase", 863], ["II", 874], ["(", 877], ["RNAP", 878], ["II", 883], [")", 885], ["in", 887], ["a", 890], ["reconstituted", 892], ["system", 906], ["with", 913], ["all", 918], ["of", 922], ["the", 925], ["required", 929], ["factors", 938], [".", 945], ["Another", 947], ["oxidative", 955], ["lesion", 965], [",", 971], ["8-oxoguanine", 973], [",", 985], ["only", 987], ["slightly", 992], ["blocked", 1001], ["T7", 1009], ["RNAP", 1012], ["and", 1017], ["caused", 1021], ["RNAP", 1028], ["II", 1033], ["to", 1036], ["briefly", 1039], ["pause", 1047], ["at", 1053], ["the", 1056], ["lesion", 1060], ["before", 1067], ["bypassing", 1074], ["it", 1084], [".", 1086], ["Because", 1088], ["an", 1096], ["abasic", 1099], ["site", 1106], ["is", 1111], ["an", 1114], ["intermediate", 1117], ["in", 1130], ["the", 1133], ["repair", 1137], ["of", 1144], ["oxidative", 1147], ["damage", 1157], [",", 1163], ["it", 1165], ["was", 1168], ["of", 1172], ["interest", 1175], ["to", 1184], ["learn", 1187], ["whether", 1193], ["it", 1201], ["arrested", 1204], ["transcription", 1213], [".", 1226], ["Using", 1228], ["in", 1234], ["vitro", 1237], ["transcription", 1243], ["assays", 1257], ["and", 1264], ["substrates", 1268], ["containing", 1279], ["a", 1290], ["specifically", 1292], ["positioned", 1305], ["lesion", 1316], [",", 1322], ["we", 1324], ["found", 1327], ["that", 1333], ["an", 1338], ["abasic", 1341], ["site", 1348], ["in", 1353], ["the", 1356], ["transcribed", 1360], ["strand", 1372], ["is", 1379], ["a", 1382], ["60", 1384], ["%", 1386], ["block", 1388], ["to", 1394], ["transcription", 1397], ["by", 1411], ["T7", 1414], ["RNAP", 1417], ["but", 1422], ["nearly", 1426], ["a", 1433], ["complete", 1435], ["block", 1444], ["to", 1450], ["transcription", 1453], ["by", 1467], ["mammalian", 1470], ["RNAP", 1480], ["II", 1485], [".", 1487], ["An", 1489], ["abasic", 1492], ["site", 1499], ["in", 1504], ["the", 1507], ["nontranscribed", 1511], ["strand", 1526], ["did", 1533], ["not", 1537], ["block", 1541], ["either", 1547], ["polymerase", 1554], [".", 1564], ["Our", 1566], ["results", 1570], ["clearly", 1578], ["indicate", 1586], ["that", 1595], ["an", 1600], ["abasic", 1603], ["site", 1610], ["is", 1615], ["a", 1618], ["much", 1620], ["stronger", 1625], ["block", 1634], ["to", 1640], ["transcription", 1643], ["than", 1657], ["either", 1662], ["a", 1669], ["thymine", 1671], ["glycol", 1679], ["or", 1686], ["an", 1689], ["8-oxoguanine", 1692], [".", 1704], ["Because", 1706], ["the", 1714], ["predominant", 1718], ["model", 1730], ["for", 1736], ["TCR", 1740], ["postulates", 1744], ["that", 1755], ["only", 1760], ["lesions", 1765], ["that", 1773], ["block", 1778], ["RNAP", 1784], ["will", 1789], ["be", 1794], ["subject", 1797], ["to", 1805], ["TCR", 1808], [",", 1811], ["our", 1813], ["findings", 1817], ["suggest", 1826], ["that", 1834], ["the", 1839], ["abasic", 1843], ["site", 1850], ["may", 1855], ["be", 1859], ["sufficient", 1862], ["to", 1873], ["initiate", 1876], ["TCR", 1885], ["in", 1889], ["vivo", 1892], [".", 1896]]}
{"context": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types. Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation. This disease involves a col 3A1 gene mutation. We report the case of a 44 year-old woman with type IV Ehlers-Danlos syndrome. The medical history of our patient included bowel necrosis and two vascular ruptures. We indicate data required to establish Ehlers-Danlos syndrome diagnosis and guidelines for patient management.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "549476d728754e0e979168d1b056eae7", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[9, 10]], "char_spans": [[52, 68]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["denotes", 23], ["a", 31], ["group", 33], ["of", 39], ["inherited", 42], ["connective", 52], ["tissue", 63], ["diseases", 70], ["comprising", 79], ["nine", 90], ["types", 95], [".", 100], ["Type", 102], ["IV", 107], ["Ehlers", 110], ["-", 116], ["Danlos", 117], ["syndrome", 124], ["is", 133], ["the", 136], ["most", 140], ["life", 145], ["-", 149], ["threatening", 150], ["form", 162], [".", 166], ["It", 168], ["is", 171], ["characterized", 174], ["by", 188], ["a", 191], ["type", 193], ["III", 198], ["collagen", 202], ["deficiency", 211], ["resulting", 222], ["in", 232], ["arterial", 235], ["fragility", 244], ["and", 254], ["death", 258], ["from", 264], ["vascular", 269], ["rupture", 278], ["or", 286], ["bowel", 289], ["perforation", 295], [".", 306], ["This", 308], ["disease", 313], ["involves", 321], ["a", 330], ["col", 332], ["3A1", 336], ["gene", 340], ["mutation", 345], [".", 353], ["We", 355], ["report", 358], ["the", 365], ["case", 369], ["of", 374], ["a", 377], ["44", 379], ["year", 382], ["-", 386], ["old", 387], ["woman", 391], ["with", 397], ["type", 402], ["IV", 407], ["Ehlers", 410], ["-", 416], ["Danlos", 417], ["syndrome", 424], [".", 432], ["The", 434], ["medical", 438], ["history", 446], ["of", 454], ["our", 457], ["patient", 461], ["included", 469], ["bowel", 478], ["necrosis", 484], ["and", 493], ["two", 497], ["vascular", 501], ["ruptures", 510], [".", 518], ["We", 520], ["indicate", 523], ["data", 532], ["required", 537], ["to", 546], ["establish", 549], ["Ehlers", 559], ["-", 565], ["Danlos", 566], ["syndrome", 573], ["diagnosis", 582], ["and", 592], ["guidelines", 596], ["for", 607], ["patient", 611], ["management", 619], [".", 629]]}
{"context": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. The prevalence of Mowat-Wilson syndrome is currently unknown, but it seems that Mowat-Wilson syndrome is underdiagnosed, particularly in patients without Hirschsprung disease. We report here the first Egyptian case of Mowat-Wilson syndrome who was conceived by intracytoplasmic sperm injection. The patient manifested bilateral sensorineural hearing loss--a new feature not previously reported in cases of Mowat-Wilson syndrome. This report describes the first Egyptian patient of Mowat-Wilson syndrome who was conceived after intracytoplasmic sperm injection, and provides a new evidence for the inclusion of deafness among the congenital defects of the syndrome.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c3272be6bdea40c9ac22dfe5337dc311", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[26, 26]], "char_spans": [[134, 137]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["disease", 35], ["caused", 43], ["by", 50], ["heterozygous", 53], ["mutations", 66], ["or", 76], ["deletions", 79], ["of", 89], ["the", 92], ["zinc", 96], ["finger", 101], ["E", 108], ["-", 109], ["box", 110], ["-", 113], ["binding", 114], ["homeobox", 122], ["2", 131], ["(", 133], ["ZEB2", 134], [")", 138], ["gene", 140], [".", 144], ["The", 146], ["syndrome", 150], ["is", 159], ["characterized", 162], ["by", 176], ["typical", 179], ["facial", 187], ["features", 194], [",", 202], ["moderate", 204], ["-", 212], ["to", 213], ["-", 215], ["severe", 216], ["mental", 223], ["retardation", 230], [",", 241], ["epilepsy", 243], ["and", 252], ["variable", 256], ["congenital", 265], ["malformations", 276], [",", 289], ["including", 291], ["Hirschsprung", 301], ["disease", 314], [",", 321], ["genital", 323], ["anomalies", 331], [",", 340], ["congenital", 342], ["heart", 353], ["disease", 359], [",", 366], ["agenesis", 368], ["of", 377], ["the", 380], ["corpus", 384], ["callosum", 391], [",", 399], ["and", 401], ["eye", 405], ["defects", 409], [".", 416], ["The", 418], ["prevalence", 422], ["of", 433], ["Mowat", 436], ["-", 441], ["Wilson", 442], ["syndrome", 449], ["is", 458], ["currently", 461], ["unknown", 471], [",", 478], ["but", 480], ["it", 484], ["seems", 487], ["that", 493], ["Mowat", 498], ["-", 503], ["Wilson", 504], ["syndrome", 511], ["is", 520], ["underdiagnosed", 523], [",", 537], ["particularly", 539], ["in", 552], ["patients", 555], ["without", 564], ["Hirschsprung", 572], ["disease", 585], [".", 592], ["We", 594], ["report", 597], ["here", 604], ["the", 609], ["first", 613], ["Egyptian", 619], ["case", 628], ["of", 633], ["Mowat", 636], ["-", 641], ["Wilson", 642], ["syndrome", 649], ["who", 658], ["was", 662], ["conceived", 666], ["by", 676], ["intracytoplasmic", 679], ["sperm", 696], ["injection", 702], [".", 711], ["The", 713], ["patient", 717], ["manifested", 725], ["bilateral", 736], ["sensorineural", 746], ["hearing", 760], ["loss", 768], ["--", 772], ["a", 774], ["new", 776], ["feature", 780], ["not", 788], ["previously", 792], ["reported", 803], ["in", 812], ["cases", 815], ["of", 821], ["Mowat", 824], ["-", 829], ["Wilson", 830], ["syndrome", 837], [".", 845], ["This", 847], ["report", 852], ["describes", 859], ["the", 869], ["first", 873], ["Egyptian", 879], ["patient", 888], ["of", 896], ["Mowat", 899], ["-", 904], ["Wilson", 905], ["syndrome", 912], ["who", 921], ["was", 925], ["conceived", 929], ["after", 939], ["intracytoplasmic", 945], ["sperm", 962], ["injection", 968], [",", 977], ["and", 979], ["provides", 983], ["a", 992], ["new", 994], ["evidence", 998], ["for", 1007], ["the", 1011], ["inclusion", 1015], ["of", 1025], ["deafness", 1028], ["among", 1037], ["the", 1043], ["congenital", 1047], ["defects", 1058], ["of", 1066], ["the", 1069], ["syndrome", 1073], [".", 1081]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Many of the ~17,000 examined genes were differentially expressed (>2-fold, p<0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis-specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. Other classes of genes, including those encoding extracellular matrix or pro-inflammatory proteins, were upregulated in FSHD myogenic cells independent of an inverse myogenesis association. Importantly, the disease-linked DUX4 RNA isoform was detected by RT-PCR in FSHD myoblast and myotube preparations only at extremely low levels. Unique insights into myogenesis-specific gene expression were also obtained. For example, all four Argonaute genes involved in RNA-silencing were significantly upregulated during normal (but not FSHD) myogenesis relative to non-muscle cell types. DUX4's pathogenic effect in FSHD may occur transiently at or before the stage of myoblast formation to establish a cascade of gene dysregulation. This contrasts with the current emphasis on toxic effects of experimentally upregulated DUX4 expression at the myoblast or myotube stages. Our model could explain why DUX4's inappropriate expression was barely detectable in myoblasts and myotubes but nonetheless linked to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7d7dfb5ece1846bc8fab1c8af7bcce92", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[256, 256], [115, 115], [325, 325], [282, 282], [341, 341], [196, 196], [4, 4], [174, 174], [402, 402], [94, 94]], "char_spans": [[1517, 1520], [695, 698], [1926, 1929], [1662, 1665], [2006, 2009], [1147, 1150], [40, 43], [1011, 1014], [2397, 2400], [553, 556]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["dominant", 51], ["disease", 60], ["linked", 68], ["to", 75], ["contraction", 78], ["of", 90], ["an", 93], ["array", 96], ["of", 102], ["tandem", 105], ["3.3-kb", 112], ["repeats", 119], ["(", 127], ["D4Z4", 128], [")", 132], ["at", 134], ["4q35", 137], [".", 141], ["Within", 143], ["each", 150], ["repeat", 155], ["unit", 162], ["is", 167], ["a", 170], ["gene", 172], [",", 176], ["DUX4", 178], [",", 182], ["that", 184], ["can", 189], ["encode", 193], ["a", 200], ["protein", 202], ["containing", 210], ["two", 221], ["homeodomains", 225], [".", 237], ["A", 239], ["DUX4", 241], ["transcript", 246], ["derived", 257], ["from", 265], ["the", 270], ["last", 274], ["repeat", 279], ["unit", 286], ["in", 291], ["a", 294], ["contracted", 296], ["array", 307], ["is", 313], ["associated", 316], ["with", 327], ["pathogenesis", 332], ["but", 345], ["it", 349], ["is", 352], ["unclear", 355], ["how", 363], [".", 366], ["Using", 368], ["exon", 374], ["-", 378], ["based", 379], ["microarrays", 385], [",", 396], ["the", 398], ["expression", 402], ["profiles", 413], ["of", 422], ["myogenic", 425], ["precursor", 434], ["cells", 444], ["were", 450], ["determined", 455], [".", 465], ["Both", 467], ["undifferentiated", 472], ["myoblasts", 489], ["and", 499], ["myoblasts", 503], ["differentiated", 513], ["to", 528], ["myotubes", 531], ["derived", 540], ["from", 548], ["FSHD", 553], ["patients", 558], ["and", 567], ["controls", 571], ["were", 580], ["studied", 585], ["after", 593], ["immunocytochemical", 599], ["verification", 618], ["of", 631], ["the", 634], ["quality", 638], ["of", 646], ["the", 649], ["cultures", 653], [".", 661], ["To", 663], ["further", 666], ["our", 674], ["understanding", 678], ["of", 692], ["FSHD", 695], ["and", 700], ["normal", 704], ["myogenesis", 711], [",", 721], ["the", 723], ["expression", 727], ["profiles", 738], ["obtained", 747], ["were", 756], ["compared", 761], ["to", 770], ["those", 773], ["of", 779], ["19", 782], ["non", 785], ["-", 788], ["muscle", 789], ["cell", 796], ["types", 801], ["analyzed", 807], ["by", 816], ["identical", 819], ["methods", 829], [".", 836], ["Many", 838], ["of", 843], ["the", 846], ["~17,000", 850], ["examined", 858], ["genes", 867], ["were", 873], ["differentially", 878], ["expressed", 893], ["(", 903], [">", 904], ["2-fold", 905], [",", 911], ["p<0.01", 913], [")", 919], ["in", 921], ["control", 924], ["myoblasts", 932], ["or", 942], ["myotubes", 945], ["vs.", 954], ["non", 958], ["-", 961], ["muscle", 962], ["cells", 969], ["(", 975], ["2185", 976], ["and", 981], ["3006", 985], [",", 989], ["respectively", 991], [")", 1003], ["or", 1005], ["in", 1008], ["FSHD", 1011], ["vs.", 1016], ["control", 1020], ["myoblasts", 1028], ["or", 1038], ["myotubes", 1041], ["(", 1050], ["295", 1051], ["and", 1055], ["797", 1059], [",", 1062], ["respectively", 1064], [")", 1076], [".", 1077], ["Surprisingly", 1079], [",", 1091], ["despite", 1093], ["the", 1101], ["morphologically", 1105], ["normal", 1121], ["differentiation", 1128], ["of", 1144], ["FSHD", 1147], ["myoblasts", 1152], ["to", 1162], ["myotubes", 1165], [",", 1173], ["most", 1175], ["of", 1180], ["the", 1183], ["disease", 1187], ["-", 1194], ["related", 1195], ["dysregulation", 1203], ["was", 1217], ["seen", 1221], ["as", 1226], ["dampening", 1229], ["of", 1239], ["normal", 1242], ["myogenesis", 1249], ["-", 1259], ["specific", 1260], ["expression", 1269], ["changes", 1280], [",", 1287], ["including", 1289], ["in", 1299], ["genes", 1302], ["for", 1308], ["muscle", 1312], ["structure", 1319], [",", 1328], ["mitochondrial", 1330], ["function", 1344], [",", 1352], ["stress", 1354], ["responses", 1361], [",", 1370], ["and", 1372], ["signal", 1376], ["transduction", 1383], [".", 1395], ["Other", 1397], ["classes", 1403], ["of", 1411], ["genes", 1414], [",", 1419], ["including", 1421], ["those", 1431], ["encoding", 1437], ["extracellular", 1446], ["matrix", 1460], ["or", 1467], ["pro", 1470], ["-", 1473], ["inflammatory", 1474], ["proteins", 1487], [",", 1495], ["were", 1497], ["upregulated", 1502], ["in", 1514], ["FSHD", 1517], ["myogenic", 1522], ["cells", 1531], ["independent", 1537], ["of", 1549], ["an", 1552], ["inverse", 1555], ["myogenesis", 1563], ["association", 1574], [".", 1585], ["Importantly", 1587], [",", 1598], ["the", 1600], ["disease", 1604], ["-", 1611], ["linked", 1612], ["DUX4", 1619], ["RNA", 1624], ["isoform", 1628], ["was", 1636], ["detected", 1640], ["by", 1649], ["RT", 1652], ["-", 1654], ["PCR", 1655], ["in", 1659], ["FSHD", 1662], ["myoblast", 1667], ["and", 1676], ["myotube", 1680], ["preparations", 1688], ["only", 1701], ["at", 1706], ["extremely", 1709], ["low", 1719], ["levels", 1723], [".", 1729], ["Unique", 1731], ["insights", 1738], ["into", 1747], ["myogenesis", 1752], ["-", 1762], ["specific", 1763], ["gene", 1772], ["expression", 1777], ["were", 1788], ["also", 1793], ["obtained", 1798], [".", 1806], ["For", 1808], ["example", 1812], [",", 1819], ["all", 1821], ["four", 1825], ["Argonaute", 1830], ["genes", 1840], ["involved", 1846], ["in", 1855], ["RNA", 1858], ["-", 1861], ["silencing", 1862], ["were", 1872], ["significantly", 1877], ["upregulated", 1891], ["during", 1903], ["normal", 1910], ["(", 1917], ["but", 1918], ["not", 1922], ["FSHD", 1926], [")", 1930], ["myogenesis", 1932], ["relative", 1943], ["to", 1952], ["non", 1955], ["-", 1958], ["muscle", 1959], ["cell", 1966], ["types", 1971], [".", 1976], ["DUX4", 1978], ["'s", 1982], ["pathogenic", 1985], ["effect", 1996], ["in", 2003], ["FSHD", 2006], ["may", 2011], ["occur", 2015], ["transiently", 2021], ["at", 2033], ["or", 2036], ["before", 2039], ["the", 2046], ["stage", 2050], ["of", 2056], ["myoblast", 2059], ["formation", 2068], ["to", 2078], ["establish", 2081], ["a", 2091], ["cascade", 2093], ["of", 2101], ["gene", 2104], ["dysregulation", 2109], [".", 2122], ["This", 2124], ["contrasts", 2129], ["with", 2139], ["the", 2144], ["current", 2148], ["emphasis", 2156], ["on", 2165], ["toxic", 2168], ["effects", 2174], ["of", 2182], ["experimentally", 2185], ["upregulated", 2200], ["DUX4", 2212], ["expression", 2217], ["at", 2228], ["the", 2231], ["myoblast", 2235], ["or", 2244], ["myotube", 2247], ["stages", 2255], [".", 2261], ["Our", 2263], ["model", 2267], ["could", 2273], ["explain", 2279], ["why", 2287], ["DUX4", 2291], ["'s", 2295], ["inappropriate", 2298], ["expression", 2312], ["was", 2323], ["barely", 2327], ["detectable", 2334], ["in", 2345], ["myoblasts", 2348], ["and", 2358], ["myotubes", 2362], ["but", 2371], ["nonetheless", 2375], ["linked", 2387], ["to", 2394], ["FSHD", 2397], [".", 2401]]}
{"context": "{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) is the main metabolite of the selective prostacyclin (PGI(2)) receptor (IP receptor) agonist selexipag. The goal of this study was to determine the influence of IP receptor selectivity on the vasorelaxant efficacy of ACT-333679 and the PGI(2) analog treprostinil in pulmonary artery under conditions associated with pulmonary arterial hypertension (PAH). Selexipag and ACT-333679 evoked full relaxation of pulmonary artery from control and monocrotaline (MCT)-PAH rats, and ACT-333679 relaxed normal pulmonary artery contracted with either endothelin-1 (ET-1) or phenylephrine. In contrast, treprostinil evoked weaker relaxation than ACT-333679 of control pulmonary artery and failed to induce relaxation of pulmonary artery from MCT-PAH rats. Treprostinil did not evoke relaxation of normal pulmonary artery contracted with either ET-1 or phenylephrine. Expression of prostaglandin E(3) (EP(3)) receptor mRNA was increased in pulmonary artery from MCT-PAH rats. In contraction experiments, the selective EP(3) receptor agonist sulprostone evoked significantly greater contraction of pulmonary artery from MCT-PAH rats compared with control rats. The presence of a threshold concentration of ET-1 significantly augmented the contractile response to sulprostone in normal pulmonary artery. ACT-333679 did not evoke direct contraction of rat pulmonary artery, whereas treprostinil evoked concentration-dependent contraction that was inhibited by the EP(3) receptor antagonist (2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide. Antagonism of EP(3) receptors also revealed a relaxant response to treprostinil in normal pulmonary artery contracted with ET-1. These data demonstrate that the relaxant efficacy of the selective IP receptor agonist selexipag and its metabolite ACT-333679 is not modified under conditions associated with PAH, whereas relaxation to treprostinil may be limited in the presence of mediators of disease.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "69acbdb73b2c414cb48a711bb6da31f1", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[59, 61]], "char_spans": [[395, 425]]}]}], "context_tokens": [["{", 0], ["4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic", 1], ["acid", 61], ["(", 66], ["ACT-333679", 67], [")", 77], ["is", 79], ["the", 82], ["main", 86], ["metabolite", 91], ["of", 102], ["the", 105], ["selective", 109], ["prostacyclin", 119], ["(", 132], ["PGI(2", 133], [")", 138], [")", 139], ["receptor", 141], ["(", 150], ["IP", 151], ["receptor", 154], [")", 162], ["agonist", 164], ["selexipag", 172], [".", 181], ["The", 183], ["goal", 187], ["of", 192], ["this", 195], ["study", 200], ["was", 206], ["to", 210], ["determine", 213], ["the", 223], ["influence", 227], ["of", 237], ["IP", 240], ["receptor", 243], ["selectivity", 252], ["on", 264], ["the", 267], ["vasorelaxant", 271], ["efficacy", 284], ["of", 293], ["ACT-333679", 296], ["and", 307], ["the", 311], ["PGI(2", 315], [")", 320], ["analog", 322], ["treprostinil", 329], ["in", 342], ["pulmonary", 345], ["artery", 355], ["under", 362], ["conditions", 368], ["associated", 379], ["with", 390], ["pulmonary", 395], ["arterial", 405], ["hypertension", 414], ["(", 427], ["PAH", 428], [")", 431], [".", 432], ["Selexipag", 434], ["and", 444], ["ACT-333679", 448], ["evoked", 459], ["full", 466], ["relaxation", 471], ["of", 482], ["pulmonary", 485], ["artery", 495], ["from", 502], ["control", 507], ["and", 515], ["monocrotaline", 519], ["(", 533], ["MCT)-PAH", 534], ["rats", 543], [",", 547], ["and", 549], ["ACT-333679", 553], ["relaxed", 564], ["normal", 572], ["pulmonary", 579], ["artery", 589], ["contracted", 596], ["with", 607], ["either", 612], ["endothelin-1", 619], ["(", 632], ["ET-1", 633], [")", 637], ["or", 639], ["phenylephrine", 642], [".", 655], ["In", 657], ["contrast", 660], [",", 668], ["treprostinil", 670], ["evoked", 683], ["weaker", 690], ["relaxation", 697], ["than", 708], ["ACT-333679", 713], ["of", 724], ["control", 727], ["pulmonary", 735], ["artery", 745], ["and", 752], ["failed", 756], ["to", 763], ["induce", 766], ["relaxation", 773], ["of", 784], ["pulmonary", 787], ["artery", 797], ["from", 804], ["MCT", 809], ["-", 812], ["PAH", 813], ["rats", 817], [".", 821], ["Treprostinil", 823], ["did", 836], ["not", 840], ["evoke", 844], ["relaxation", 850], ["of", 861], ["normal", 864], ["pulmonary", 871], ["artery", 881], ["contracted", 888], ["with", 899], ["either", 904], ["ET-1", 911], ["or", 916], ["phenylephrine", 919], [".", 932], ["Expression", 934], ["of", 945], ["prostaglandin", 948], ["E(3", 962], [")", 965], ["(", 967], ["EP(3", 968], [")", 972], [")", 973], ["receptor", 975], ["mRNA", 984], ["was", 989], ["increased", 993], ["in", 1003], ["pulmonary", 1006], ["artery", 1016], ["from", 1023], ["MCT", 1028], ["-", 1031], ["PAH", 1032], ["rats", 1036], [".", 1040], ["In", 1042], ["contraction", 1045], ["experiments", 1057], [",", 1068], ["the", 1070], ["selective", 1074], ["EP(3", 1084], [")", 1088], ["receptor", 1090], ["agonist", 1099], ["sulprostone", 1107], ["evoked", 1119], ["significantly", 1126], ["greater", 1140], ["contraction", 1148], ["of", 1160], ["pulmonary", 1163], ["artery", 1173], ["from", 1180], ["MCT", 1185], ["-", 1188], ["PAH", 1189], ["rats", 1193], ["compared", 1198], ["with", 1207], ["control", 1212], ["rats", 1220], [".", 1224], ["The", 1226], ["presence", 1230], ["of", 1239], ["a", 1242], ["threshold", 1244], ["concentration", 1254], ["of", 1268], ["ET-1", 1271], ["significantly", 1276], ["augmented", 1290], ["the", 1300], ["contractile", 1304], ["response", 1316], ["to", 1325], ["sulprostone", 1328], ["in", 1340], ["normal", 1343], ["pulmonary", 1350], ["artery", 1360], [".", 1366], ["ACT-333679", 1368], ["did", 1379], ["not", 1383], ["evoke", 1387], ["direct", 1393], ["contraction", 1400], ["of", 1412], ["rat", 1415], ["pulmonary", 1419], ["artery", 1429], [",", 1435], ["whereas", 1437], ["treprostinil", 1445], ["evoked", 1458], ["concentration", 1465], ["-", 1478], ["dependent", 1479], ["contraction", 1489], ["that", 1501], ["was", 1506], ["inhibited", 1510], ["by", 1520], ["the", 1523], ["EP(3", 1527], [")", 1531], ["receptor", 1533], ["antagonist", 1542], ["(", 1553], ["2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide", 1554], [".", 1621], ["Antagonism", 1623], ["of", 1634], ["EP(3", 1637], [")", 1641], ["receptors", 1643], ["also", 1653], ["revealed", 1658], ["a", 1667], ["relaxant", 1669], ["response", 1678], ["to", 1687], ["treprostinil", 1690], ["in", 1703], ["normal", 1706], ["pulmonary", 1713], ["artery", 1723], ["contracted", 1730], ["with", 1741], ["ET-1", 1746], [".", 1750], ["These", 1752], ["data", 1758], ["demonstrate", 1763], ["that", 1775], ["the", 1780], ["relaxant", 1784], ["efficacy", 1793], ["of", 1802], ["the", 1805], ["selective", 1809], ["IP", 1819], ["receptor", 1822], ["agonist", 1831], ["selexipag", 1839], ["and", 1849], ["its", 1853], ["metabolite", 1857], ["ACT-333679", 1868], ["is", 1879], ["not", 1882], ["modified", 1886], ["under", 1895], ["conditions", 1901], ["associated", 1912], ["with", 1923], ["PAH", 1928], [",", 1931], ["whereas", 1933], ["relaxation", 1941], ["to", 1952], ["treprostinil", 1955], ["may", 1968], ["be", 1972], ["limited", 1975], ["in", 1983], ["the", 1986], ["presence", 1990], ["of", 1999], ["mediators", 2002], ["of", 2012], ["disease", 2015], [".", 2022]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "Spectrins comprise \u03b1- and \u03b2-subunits made up predominantly of a series of homologous repeating units of about 106 amino acids; the \u03b1- and \u03b2-chains form antiparallel dimers by lateral association, and tetramers through head-to-head contacts between the dimers. Here we consider the first of these interactions. (1) We confirm earlier observations, showing that the first two paired repeats (\u03b2IR1 with \u03b1IR21, and \u03b2IR2 with \u03b1RI20) at one end of the erythroid spectrin (\u03b1I\u03b2I) dimer are necessary and sufficient to unite the chains; (2) we resolve a conflict in published reports by showing that the strength of the interaction is considerably increased on adding the adjoining pair of repeats (\u03b2IR3-\u03b1IR19); (3) in brain (\u03b1II\u03b2II) spectrin the first two pairs of repeats are similarly essential and sufficient for heterodimer formation; (4) this interaction is ~60-fold stronger than that in the erythroid counterpart, but no enhancement can be detected on addition of three further pairs of repeats; (5) formation of a tight \u03b1I\u03b2I dimer probably depends on structural coupling of the first two repeats in each chain; (6) an analysis of the sequences of the strongly interacting repeats, \u03b2IR1, \u03b2IIR1, \u03b1IR21 and \u03b1IIR20 and repeats in \u03b1-actinin, which also interact very strongly in forming an antiparallel dimer, affords a possible explanation for the different properties of the two spectrin isoforms in respect of the stability of the inter-chain interactions, and also suggests the evolutionary path by which the erythroid and non-erythroid sequences diverged.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "0cf3e09ca48743ab8afcd531f7b306e9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[248, 248], [30, 30]], "char_spans": [[1285, 1296], [152, 163]]}]}], "context_tokens": [["Spectrins", 0], ["comprise", 10], ["\u03b1-", 19], ["and", 22], ["\u03b2", 26], ["-", 27], ["subunits", 28], ["made", 37], ["up", 42], ["predominantly", 45], ["of", 59], ["a", 62], ["series", 64], ["of", 71], ["homologous", 74], ["repeating", 85], ["units", 95], ["of", 101], ["about", 104], ["106", 110], ["amino", 114], ["acids", 120], [";", 125], ["the", 127], ["\u03b1-", 131], ["and", 134], ["\u03b2", 138], ["-", 139], ["chains", 140], ["form", 147], ["antiparallel", 152], ["dimers", 165], ["by", 172], ["lateral", 175], ["association", 183], [",", 194], ["and", 196], ["tetramers", 200], ["through", 210], ["head", 218], ["-", 222], ["to", 223], ["-", 225], ["head", 226], ["contacts", 231], ["between", 240], ["the", 248], ["dimers", 252], [".", 258], ["Here", 260], ["we", 265], ["consider", 268], ["the", 277], ["first", 281], ["of", 287], ["these", 290], ["interactions", 296], [".", 308], ["(", 310], ["1", 311], [")", 312], ["We", 314], ["confirm", 317], ["earlier", 325], ["observations", 333], [",", 345], ["showing", 347], ["that", 355], ["the", 360], ["first", 364], ["two", 370], ["paired", 374], ["repeats", 381], ["(", 389], ["\u03b2IR1", 390], ["with", 395], ["\u03b1IR21", 400], [",", 405], ["and", 407], ["\u03b2IR2", 411], ["with", 416], ["\u03b1RI20", 421], [")", 426], ["at", 428], ["one", 431], ["end", 435], ["of", 439], ["the", 442], ["erythroid", 446], ["spectrin", 456], ["(", 465], ["\u03b1I\u03b2I", 466], [")", 470], ["dimer", 472], ["are", 478], ["necessary", 482], ["and", 492], ["sufficient", 496], ["to", 507], ["unite", 510], ["the", 516], ["chains", 520], [";", 526], ["(", 528], ["2", 529], [")", 530], ["we", 532], ["resolve", 535], ["a", 543], ["conflict", 545], ["in", 554], ["published", 557], ["reports", 567], ["by", 575], ["showing", 578], ["that", 586], ["the", 591], ["strength", 595], ["of", 604], ["the", 607], ["interaction", 611], ["is", 623], ["considerably", 626], ["increased", 639], ["on", 649], ["adding", 652], ["the", 659], ["adjoining", 663], ["pair", 673], ["of", 678], ["repeats", 681], ["(", 689], ["\u03b2IR3-\u03b1IR19", 690], [")", 700], [";", 701], ["(", 703], ["3", 704], [")", 705], ["in", 707], ["brain", 710], ["(", 716], ["\u03b1II\u03b2II", 717], [")", 723], ["spectrin", 725], ["the", 734], ["first", 738], ["two", 744], ["pairs", 748], ["of", 754], ["repeats", 757], ["are", 765], ["similarly", 769], ["essential", 779], ["and", 789], ["sufficient", 793], ["for", 804], ["heterodimer", 808], ["formation", 820], [";", 829], ["(", 831], ["4", 832], [")", 833], ["this", 835], ["interaction", 840], ["is", 852], ["~60-fold", 855], ["stronger", 864], ["than", 873], ["that", 878], ["in", 883], ["the", 886], ["erythroid", 890], ["counterpart", 900], [",", 911], ["but", 913], ["no", 917], ["enhancement", 920], ["can", 932], ["be", 936], ["detected", 939], ["on", 948], ["addition", 951], ["of", 960], ["three", 963], ["further", 969], ["pairs", 977], ["of", 983], ["repeats", 986], [";", 993], ["(", 995], ["5", 996], [")", 997], ["formation", 999], ["of", 1009], ["a", 1012], ["tight", 1014], ["\u03b1I\u03b2I", 1020], ["dimer", 1025], ["probably", 1031], ["depends", 1040], ["on", 1048], ["structural", 1051], ["coupling", 1062], ["of", 1071], ["the", 1074], ["first", 1078], ["two", 1084], ["repeats", 1088], ["in", 1096], ["each", 1099], ["chain", 1104], [";", 1109], ["(", 1111], ["6", 1112], [")", 1113], ["an", 1115], ["analysis", 1118], ["of", 1127], ["the", 1130], ["sequences", 1134], ["of", 1144], ["the", 1147], ["strongly", 1151], ["interacting", 1160], ["repeats", 1172], [",", 1179], ["\u03b2IR1", 1181], [",", 1185], ["\u03b2IIR1", 1187], [",", 1192], ["\u03b1IR21", 1194], ["and", 1200], ["\u03b1IIR20", 1204], ["and", 1211], ["repeats", 1215], ["in", 1223], ["\u03b1", 1226], ["-", 1227], ["actinin", 1228], [",", 1235], ["which", 1237], ["also", 1243], ["interact", 1248], ["very", 1257], ["strongly", 1262], ["in", 1271], ["forming", 1274], ["an", 1282], ["antiparallel", 1285], ["dimer", 1298], [",", 1303], ["affords", 1305], ["a", 1313], ["possible", 1315], ["explanation", 1324], ["for", 1336], ["the", 1340], ["different", 1344], ["properties", 1354], ["of", 1365], ["the", 1368], ["two", 1372], ["spectrin", 1376], ["isoforms", 1385], ["in", 1394], ["respect", 1397], ["of", 1405], ["the", 1408], ["stability", 1412], ["of", 1422], ["the", 1425], ["inter", 1429], ["-", 1434], ["chain", 1435], ["interactions", 1441], [",", 1453], ["and", 1455], ["also", 1459], ["suggests", 1464], ["the", 1473], ["evolutionary", 1477], ["path", 1490], ["by", 1495], ["which", 1498], ["the", 1504], ["erythroid", 1508], ["and", 1518], ["non", 1522], ["-", 1525], ["erythroid", 1526], ["sequences", 1536], ["diverged", 1546], [".", 1554]]}
{"context": "Two forms of neurofibromatosis, type 1 (NF1) and type 2 (NF2) are connected with genes localized on chromosomes 17 and 22, respectively. The genes that are inactivated in neurofibromatosis code for the proteins neurofibromine and merline, respectively. Since inactivation leads to neoplasia, they are called tumour suppressor genes. Neurofibromine shows resemblances to proteins that serve to inactivate oncogenes. Merline has a relationship with proteins that connect the cytoskeleton and the cell membrane. The precise function of the proteins is still unknown. The NF1 gene is characterized by extraordinarily high sensitivity to mutation; half the NF1 patients have not inherited the disease. In the familial form of neurofibromatosis, a mutated gene is inherited and the normal allele in the tumour is inactivated, making tumour growth possible. In the sporadic form of neurofibromatosis, both normal alleles are inactivated locally in the tissue so that a tumour develops in that place.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "02a0b88b776d4b2d90874b4cebd2bc40", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[8, 8], [96, 96], [109, 109]], "char_spans": [[40, 42], [568, 570], [652, 654]]}]}], "context_tokens": [["Two", 0], ["forms", 4], ["of", 10], ["neurofibromatosis", 13], [",", 30], ["type", 32], ["1", 37], ["(", 39], ["NF1", 40], [")", 43], ["and", 45], ["type", 49], ["2", 54], ["(", 56], ["NF2", 57], [")", 60], ["are", 62], ["connected", 66], ["with", 76], ["genes", 81], ["localized", 87], ["on", 97], ["chromosomes", 100], ["17", 112], ["and", 115], ["22", 119], [",", 121], ["respectively", 123], [".", 135], ["The", 137], ["genes", 141], ["that", 147], ["are", 152], ["inactivated", 156], ["in", 168], ["neurofibromatosis", 171], ["code", 189], ["for", 194], ["the", 198], ["proteins", 202], ["neurofibromine", 211], ["and", 226], ["merline", 230], [",", 237], ["respectively", 239], [".", 251], ["Since", 253], ["inactivation", 259], ["leads", 272], ["to", 278], ["neoplasia", 281], [",", 290], ["they", 292], ["are", 297], ["called", 301], ["tumour", 308], ["suppressor", 315], ["genes", 326], [".", 331], ["Neurofibromine", 333], ["shows", 348], ["resemblances", 354], ["to", 367], ["proteins", 370], ["that", 379], ["serve", 384], ["to", 390], ["inactivate", 393], ["oncogenes", 404], [".", 413], ["Merline", 415], ["has", 423], ["a", 427], ["relationship", 429], ["with", 442], ["proteins", 447], ["that", 456], ["connect", 461], ["the", 469], ["cytoskeleton", 473], ["and", 486], ["the", 490], ["cell", 494], ["membrane", 499], [".", 507], ["The", 509], ["precise", 513], ["function", 521], ["of", 530], ["the", 533], ["proteins", 537], ["is", 546], ["still", 549], ["unknown", 555], [".", 562], ["The", 564], ["NF1", 568], ["gene", 572], ["is", 577], ["characterized", 580], ["by", 594], ["extraordinarily", 597], ["high", 613], ["sensitivity", 618], ["to", 630], ["mutation", 633], [";", 641], ["half", 643], ["the", 648], ["NF1", 652], ["patients", 656], ["have", 665], ["not", 670], ["inherited", 674], ["the", 684], ["disease", 688], [".", 695], ["In", 697], ["the", 700], ["familial", 704], ["form", 713], ["of", 718], ["neurofibromatosis", 721], [",", 738], ["a", 740], ["mutated", 742], ["gene", 750], ["is", 755], ["inherited", 758], ["and", 768], ["the", 772], ["normal", 776], ["allele", 783], ["in", 790], ["the", 793], ["tumour", 797], ["is", 804], ["inactivated", 807], [",", 818], ["making", 820], ["tumour", 827], ["growth", 834], ["possible", 841], [".", 849], ["In", 851], ["the", 854], ["sporadic", 858], ["form", 867], ["of", 872], ["neurofibromatosis", 875], [",", 892], ["both", 894], ["normal", 899], ["alleles", 906], ["are", 914], ["inactivated", 918], ["locally", 930], ["in", 938], ["the", 941], ["tissue", 945], ["so", 952], ["that", 955], ["a", 960], ["tumour", 962], ["develops", 969], ["in", 978], ["that", 981], ["place", 986], [".", 991]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies are common disorders of the aging population and characterized by the progressive accumulation of \u03b1-synuclein (\u03b1-syn) in the central nervous system. Aggregation of \u03b1-syn into oligomers with a ring-like appearance has been proposed to play a role in toxicity. However, the molecular mechanisms and the potential sequence of events involved in the formation of pore-like structures are unclear. We utilized computer modeling and cell-based studies to investigate the process of oligomerization of wild-type and A53T mutant \u03b1-syn in membranes. The studies suggest that \u03b1-syn penetrates the membrane rapidly, changing its conformation from \u03b1-helical towards a coiled structure. This penetration facilitates the incorporation of additional \u03b1-syn monomers in the complex, and the subsequent displacement of phospholipids and the formation of oligomers in the membrane. This process occurred more rapidly, and with a more favorable energy of interaction, for mutant A53T compared with wild-type \u03b1-syn. After 4 ns of simulation of the protein-membrane model, \u03b1-syn had penetrated through two-thirds of the membrane. By 9 ns, the penetration of the annular \u03b1-syn oligomers can result in the formation of pore-like structures that fully perforate the lipid bilayer. Experimental incubation of recombinant \u03b1-syn in synthetic membranes resulted in the formation of similar pore-like complexes. Moreover, mutant (A53T) \u03b1-syn had a greater tendency to accumulate in neuronal membrane fractions in cell cultures, resulting in greater neuronal permeability, as demonstrated with the calcein efflux assay. These studies provide a sequential molecular explanation for the process of \u03b1-syn oligomerization in the membrane, and support the role of formation of pore-like structures in the pathogenesis of the neurodegenerative process in PD.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "c042537f3aac4a97a4633fcf4c88fc5b", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["are", 55], ["common", 59], ["disorders", 66], ["of", 76], ["the", 79], ["aging", 83], ["population", 89], ["and", 100], ["characterized", 104], ["by", 118], ["the", 121], ["progressive", 125], ["accumulation", 137], ["of", 150], ["\u03b1", 153], ["-", 154], ["synuclein", 155], ["(", 165], ["\u03b1", 166], ["-", 167], ["syn", 168], [")", 171], ["in", 173], ["the", 176], ["central", 180], ["nervous", 188], ["system", 196], [".", 202], ["Aggregation", 204], ["of", 216], ["\u03b1", 219], ["-", 220], ["syn", 221], ["into", 225], ["oligomers", 230], ["with", 240], ["a", 245], ["ring", 247], ["-", 251], ["like", 252], ["appearance", 257], ["has", 268], ["been", 272], ["proposed", 277], ["to", 286], ["play", 289], ["a", 294], ["role", 296], ["in", 301], ["toxicity", 304], [".", 312], ["However", 314], [",", 321], ["the", 323], ["molecular", 327], ["mechanisms", 337], ["and", 348], ["the", 352], ["potential", 356], ["sequence", 366], ["of", 375], ["events", 378], ["involved", 385], ["in", 394], ["the", 397], ["formation", 401], ["of", 411], ["pore", 414], ["-", 418], ["like", 419], ["structures", 424], ["are", 435], ["unclear", 439], [".", 446], ["We", 448], ["utilized", 451], ["computer", 460], ["modeling", 469], ["and", 478], ["cell", 482], ["-", 486], ["based", 487], ["studies", 493], ["to", 501], ["investigate", 504], ["the", 516], ["process", 520], ["of", 528], ["oligomerization", 531], ["of", 547], ["wild", 550], ["-", 554], ["type", 555], ["and", 560], ["A53", 564], ["T", 567], ["mutant", 569], ["\u03b1", 576], ["-", 577], ["syn", 578], ["in", 582], ["membranes", 585], [".", 594], ["The", 596], ["studies", 600], ["suggest", 608], ["that", 616], ["\u03b1", 621], ["-", 622], ["syn", 623], ["penetrates", 627], ["the", 638], ["membrane", 642], ["rapidly", 651], [",", 658], ["changing", 660], ["its", 669], ["conformation", 673], ["from", 686], ["\u03b1", 691], ["-", 692], ["helical", 693], ["towards", 701], ["a", 709], ["coiled", 711], ["structure", 718], [".", 727], ["This", 729], ["penetration", 734], ["facilitates", 746], ["the", 758], ["incorporation", 762], ["of", 776], ["additional", 779], ["\u03b1", 790], ["-", 791], ["syn", 792], ["monomers", 796], ["in", 805], ["the", 808], ["complex", 812], [",", 819], ["and", 821], ["the", 825], ["subsequent", 829], ["displacement", 840], ["of", 853], ["phospholipids", 856], ["and", 870], ["the", 874], ["formation", 878], ["of", 888], ["oligomers", 891], ["in", 901], ["the", 904], ["membrane", 908], [".", 916], ["This", 918], ["process", 923], ["occurred", 931], ["more", 940], ["rapidly", 945], [",", 952], ["and", 954], ["with", 958], ["a", 963], ["more", 965], ["favorable", 970], ["energy", 980], ["of", 987], ["interaction", 990], [",", 1001], ["for", 1003], ["mutant", 1007], ["A53", 1014], ["T", 1017], ["compared", 1019], ["with", 1028], ["wild", 1033], ["-", 1037], ["type", 1038], ["\u03b1", 1043], ["-", 1044], ["syn", 1045], [".", 1048], ["After", 1050], ["4", 1056], ["ns", 1058], ["of", 1061], ["simulation", 1064], ["of", 1075], ["the", 1078], ["protein", 1082], ["-", 1089], ["membrane", 1090], ["model", 1099], [",", 1104], ["\u03b1", 1106], ["-", 1107], ["syn", 1108], ["had", 1112], ["penetrated", 1116], ["through", 1127], ["two", 1135], ["-", 1138], ["thirds", 1139], ["of", 1146], ["the", 1149], ["membrane", 1153], [".", 1161], ["By", 1163], ["9", 1166], ["ns", 1168], [",", 1170], ["the", 1172], ["penetration", 1176], ["of", 1188], ["the", 1191], ["annular", 1195], ["\u03b1", 1203], ["-", 1204], ["syn", 1205], ["oligomers", 1209], ["can", 1219], ["result", 1223], ["in", 1230], ["the", 1233], ["formation", 1237], ["of", 1247], ["pore", 1250], ["-", 1254], ["like", 1255], ["structures", 1260], ["that", 1271], ["fully", 1276], ["perforate", 1282], ["the", 1292], ["lipid", 1296], ["bilayer", 1302], [".", 1309], ["Experimental", 1311], ["incubation", 1324], ["of", 1335], ["recombinant", 1338], ["\u03b1", 1350], ["-", 1351], ["syn", 1352], ["in", 1356], ["synthetic", 1359], ["membranes", 1369], ["resulted", 1379], ["in", 1388], ["the", 1391], ["formation", 1395], ["of", 1405], ["similar", 1408], ["pore", 1416], ["-", 1420], ["like", 1421], ["complexes", 1426], [".", 1435], ["Moreover", 1437], [",", 1445], ["mutant", 1447], ["(", 1454], ["A53", 1455], ["T", 1458], [")", 1459], ["\u03b1", 1461], ["-", 1462], ["syn", 1463], ["had", 1467], ["a", 1471], ["greater", 1473], ["tendency", 1481], ["to", 1490], ["accumulate", 1493], ["in", 1504], ["neuronal", 1507], ["membrane", 1516], ["fractions", 1525], ["in", 1535], ["cell", 1538], ["cultures", 1543], [",", 1551], ["resulting", 1553], ["in", 1563], ["greater", 1566], ["neuronal", 1574], ["permeability", 1583], [",", 1595], ["as", 1597], ["demonstrated", 1600], ["with", 1613], ["the", 1618], ["calcein", 1622], ["efflux", 1630], ["assay", 1637], [".", 1642], ["These", 1644], ["studies", 1650], ["provide", 1658], ["a", 1666], ["sequential", 1668], ["molecular", 1679], ["explanation", 1689], ["for", 1701], ["the", 1705], ["process", 1709], ["of", 1717], ["\u03b1", 1720], ["-", 1721], ["syn", 1722], ["oligomerization", 1726], ["in", 1742], ["the", 1745], ["membrane", 1749], [",", 1757], ["and", 1759], ["support", 1763], ["the", 1771], ["role", 1775], ["of", 1780], ["formation", 1783], ["of", 1793], ["pore", 1796], ["-", 1800], ["like", 1801], ["structures", 1806], ["in", 1817], ["the", 1820], ["pathogenesis", 1824], ["of", 1837], ["the", 1840], ["neurodegenerative", 1844], ["process", 1862], ["in", 1870], ["PD", 1873], [".", 1875]]}
{"context": "To develop a clinical prediction rule to identify patients who can be safely discharged one hour after the administration of naloxone for presumed opioid overdose. Patients who received naloxone for known or presumed opioid overdose were formally evaluated one hour later for multiple potential predictor variables. Patients were classified into two groups: those with adverse events within 24 hours and those without. Using classification and regression tree methodology, a decision rule was developed to predict safe discharge. Clinical findings from 573 patients allowed us to develop a clinical prediction rule with a sensitivity of 99% (95% CI = 96% to 100%) and a specificity of 40% (95% CI = 36% to 45%). Patients with presumed opioid overdose can be safely discharged one hour after naloxone administration if they: 1) can mobilize as usual; 2) have oxygen saturation on room air of >92%; 3) have a respiratory rate >10 breaths/min and <20 breaths/min; 4) have a temperature of >35.0 degrees C and <37.5 degrees C; 5) have a heart rate >50 beats/min and <100 beats/min; and 6) have a Glasgow Coma Scale score of 15. This prediction rule for safe early discharge of patients with presumed opioid overdose performs well in this derivation set but requires validation followed by confirmation of safe implementation.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "70d7878277804532b313a72e5e20e286", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[20, 20], [29, 29], [143, 143]], "char_spans": [[125, 132], [186, 193], [791, 798]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["a", 11], ["clinical", 13], ["prediction", 22], ["rule", 33], ["to", 38], ["identify", 41], ["patients", 50], ["who", 59], ["can", 63], ["be", 67], ["safely", 70], ["discharged", 77], ["one", 88], ["hour", 92], ["after", 97], ["the", 103], ["administration", 107], ["of", 122], ["naloxone", 125], ["for", 134], ["presumed", 138], ["opioid", 147], ["overdose", 154], [".", 162], ["Patients", 164], ["who", 173], ["received", 177], ["naloxone", 186], ["for", 195], ["known", 199], ["or", 205], ["presumed", 208], ["opioid", 217], ["overdose", 224], ["were", 233], ["formally", 238], ["evaluated", 247], ["one", 257], ["hour", 261], ["later", 266], ["for", 272], ["multiple", 276], ["potential", 285], ["predictor", 295], ["variables", 305], [".", 314], ["Patients", 316], ["were", 325], ["classified", 330], ["into", 341], ["two", 346], ["groups", 350], [":", 356], ["those", 358], ["with", 364], ["adverse", 369], ["events", 377], ["within", 384], ["24", 391], ["hours", 394], ["and", 400], ["those", 404], ["without", 410], [".", 417], ["Using", 419], ["classification", 425], ["and", 440], ["regression", 444], ["tree", 455], ["methodology", 460], [",", 471], ["a", 473], ["decision", 475], ["rule", 484], ["was", 489], ["developed", 493], ["to", 503], ["predict", 506], ["safe", 514], ["discharge", 519], [".", 528], ["Clinical", 530], ["findings", 539], ["from", 548], ["573", 553], ["patients", 557], ["allowed", 566], ["us", 574], ["to", 577], ["develop", 580], ["a", 588], ["clinical", 590], ["prediction", 599], ["rule", 610], ["with", 615], ["a", 620], ["sensitivity", 622], ["of", 634], ["99", 637], ["%", 639], ["(", 641], ["95", 642], ["%", 644], ["CI", 646], ["=", 649], ["96", 651], ["%", 653], ["to", 655], ["100", 658], ["%", 661], [")", 662], ["and", 664], ["a", 668], ["specificity", 670], ["of", 682], ["40", 685], ["%", 687], ["(", 689], ["95", 690], ["%", 692], ["CI", 694], ["=", 697], ["36", 699], ["%", 701], ["to", 703], ["45", 706], ["%", 708], [")", 709], [".", 710], ["Patients", 712], ["with", 721], ["presumed", 726], ["opioid", 735], ["overdose", 742], ["can", 751], ["be", 755], ["safely", 758], ["discharged", 765], ["one", 776], ["hour", 780], ["after", 785], ["naloxone", 791], ["administration", 800], ["if", 815], ["they", 818], [":", 822], ["1", 824], [")", 825], ["can", 827], ["mobilize", 831], ["as", 840], ["usual", 843], [";", 848], ["2", 850], [")", 851], ["have", 853], ["oxygen", 858], ["saturation", 865], ["on", 876], ["room", 879], ["air", 884], ["of", 888], [">", 891], ["92", 892], ["%", 894], [";", 895], ["3", 897], [")", 898], ["have", 900], ["a", 905], ["respiratory", 907], ["rate", 919], [">", 924], ["10", 925], ["breaths", 928], ["/", 935], ["min", 936], ["and", 940], ["<", 944], ["20", 945], ["breaths", 948], ["/", 955], ["min", 956], [";", 959], ["4", 961], [")", 962], ["have", 964], ["a", 969], ["temperature", 971], ["of", 983], [">", 986], ["35.0", 987], ["degrees", 992], ["C", 1000], ["and", 1002], ["<", 1006], ["37.5", 1007], ["degrees", 1012], ["C", 1020], [";", 1021], ["5", 1023], [")", 1024], ["have", 1026], ["a", 1031], ["heart", 1033], ["rate", 1039], [">", 1044], ["50", 1045], ["beats", 1048], ["/", 1053], ["min", 1054], ["and", 1058], ["<", 1062], ["100", 1063], ["beats", 1067], ["/", 1072], ["min", 1073], [";", 1076], ["and", 1078], ["6", 1082], [")", 1083], ["have", 1085], ["a", 1090], ["Glasgow", 1092], ["Coma", 1100], ["Scale", 1105], ["score", 1111], ["of", 1117], ["15", 1120], [".", 1122], ["This", 1124], ["prediction", 1129], ["rule", 1140], ["for", 1145], ["safe", 1149], ["early", 1154], ["discharge", 1160], ["of", 1170], ["patients", 1173], ["with", 1182], ["presumed", 1187], ["opioid", 1196], ["overdose", 1203], ["performs", 1212], ["well", 1221], ["in", 1226], ["this", 1229], ["derivation", 1234], ["set", 1245], ["but", 1249], ["requires", 1253], ["validation", 1262], ["followed", 1273], ["by", 1282], ["confirmation", 1285], ["of", 1298], ["safe", 1301], ["implementation", 1306], [".", 1320]]}
{"context": "The carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved. Its presentation is characteristic in females about 40 years of age. The diagnosis is mainly based on clinical features and is confirmed by electrical criteria. In the anamnesis it is important to consider systemic diseases as causing the abnormality. Treatment depends on the etiology. It may be medical or surgical. In the present article we report three cases with different etiology and treatment. We also review the syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "944fef283f4a45c0b0e909cc2f35bb32", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[29, 29]], "char_spans": [[138, 143]]}]}], "context_tokens": [["The", 0], ["carpal", 4], ["tunnel", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["neuropathy", 32], ["due", 43], ["to", 47], ["trapping", 50], ["(", 59], ["focal", 60], ["lesion", 66], ["of", 73], ["the", 76], ["peripheral", 80], ["nerve", 91], ["due", 97], ["to", 101], ["a", 104], ["local", 106], ["cause", 112], [")", 117], [";", 118], ["in", 120], ["this", 123], ["case", 128], [",", 132], ["the", 134], ["median", 138], ["nerve", 145], ["is", 151], ["the", 154], ["most", 158], ["commonly", 163], ["involved", 172], [".", 180], ["Its", 182], ["presentation", 186], ["is", 199], ["characteristic", 202], ["in", 217], ["females", 220], ["about", 228], ["40", 234], ["years", 237], ["of", 243], ["age", 246], [".", 249], ["The", 251], ["diagnosis", 255], ["is", 265], ["mainly", 268], ["based", 275], ["on", 281], ["clinical", 284], ["features", 293], ["and", 302], ["is", 306], ["confirmed", 309], ["by", 319], ["electrical", 322], ["criteria", 333], [".", 341], ["In", 343], ["the", 346], ["anamnesis", 350], ["it", 360], ["is", 363], ["important", 366], ["to", 376], ["consider", 379], ["systemic", 388], ["diseases", 397], ["as", 406], ["causing", 409], ["the", 417], ["abnormality", 421], [".", 432], ["Treatment", 434], ["depends", 444], ["on", 452], ["the", 455], ["etiology", 459], [".", 467], ["It", 469], ["may", 472], ["be", 476], ["medical", 479], ["or", 487], ["surgical", 490], [".", 498], ["In", 500], ["the", 503], ["present", 507], ["article", 515], ["we", 523], ["report", 526], ["three", 533], ["cases", 539], ["with", 545], ["different", 550], ["etiology", 560], ["and", 569], ["treatment", 573], [".", 582], ["We", 584], ["also", 587], ["review", 592], ["the", 599], ["syndrome", 603], [".", 611]]}
{"context": "We have recently shown that the Na(+)/Ca(2+) exchanger (NCX) is involved in nitric oxide (NO)-induced cytotoxicity in cultured astrocytes and neurons. However, there is no in vivo evidence suggesting the role of NCX in neurodegenerative disorders associated with NO. NO is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. This study examined the effect of SEA0400, the specific NCX inhibitor, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a model of Parkinson's disease, in C57BL/6J mice. MPTP treatment (10 mg/kg, four times at 2-h intervals) decreased dopamine levels in the midbrain and impaired motor coordination, and these effects were counteracted by S-methylthiocitrulline, a selective neuronal NO synthase inhibitor. SEA0400 protected against the dopaminergic neurotoxicity (determined by dopamine levels in the midbrain and striatum, tyrosine hydroxylase immunoreactivity in the substantia nigra and striatum, striatal dopamine release, and motor deficits) in MPTP-treated mice. SEA0400 had no radical-scavenging activity. SEA0400 did not affect MPTP metabolism and MPTP-induced NO production and microglial activation, while it attenuated MPTP-induced increases in extracellular signal-regulated kinase (ERK) phosphorylation and lipid peroxidation product, thiobarbituric acid reactive substance. These findings suggest that SEA0400 protects against MPTP-induced neurotoxicity probably by blocking ERK phosphorylation and lipid peroxidation which are downstream of NCX-mediated Ca(2+) influx.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "da32f12980d845719c03c2c03494afe1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[6, 9]], "char_spans": [[32, 53]]}, {"text": "NCX", "token_spans": [[72, 72], [39, 39], [11, 11], [250, 250]], "char_spans": [[420, 422], [212, 214], [56, 58], [1563, 1565]]}]}], "context_tokens": [["We", 0], ["have", 3], ["recently", 8], ["shown", 17], ["that", 23], ["the", 28], ["Na(+)/Ca(2", 32], ["+", 42], [")", 43], ["exchanger", 45], ["(", 55], ["NCX", 56], [")", 59], ["is", 61], ["involved", 64], ["in", 73], ["nitric", 76], ["oxide", 83], ["(", 89], ["NO)-induced", 90], ["cytotoxicity", 102], ["in", 115], ["cultured", 118], ["astrocytes", 127], ["and", 138], ["neurons", 142], [".", 149], ["However", 151], [",", 158], ["there", 160], ["is", 166], ["no", 169], ["in", 172], ["vivo", 175], ["evidence", 180], ["suggesting", 189], ["the", 200], ["role", 204], ["of", 209], ["NCX", 212], ["in", 216], ["neurodegenerative", 219], ["disorders", 237], ["associated", 247], ["with", 258], ["NO", 263], [".", 265], ["NO", 267], ["is", 270], ["implicated", 273], ["in", 284], ["the", 287], ["pathogenesis", 291], ["of", 304], ["neurodegenerative", 307], ["disorders", 325], ["such", 335], ["as", 340], ["Parkinson", 343], ["'s", 352], ["disease", 355], [".", 362], ["This", 364], ["study", 369], ["examined", 375], ["the", 384], ["effect", 388], ["of", 395], ["SEA0400", 398], [",", 405], ["the", 407], ["specific", 411], ["NCX", 420], ["inhibitor", 424], [",", 433], ["on", 435], ["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", 438], ["(", 483], ["MPTP)-induced", 484], ["dopaminergic", 498], ["neurotoxicity", 511], [",", 524], ["a", 526], ["model", 528], ["of", 534], ["Parkinson", 537], ["'s", 546], ["disease", 549], [",", 556], ["in", 558], ["C57BL/6J", 561], ["mice", 570], [".", 574], ["MPTP", 576], ["treatment", 581], ["(", 591], ["10", 592], ["mg", 595], ["/", 597], ["kg", 598], [",", 600], ["four", 602], ["times", 607], ["at", 613], ["2-h", 616], ["intervals", 620], [")", 629], ["decreased", 631], ["dopamine", 641], ["levels", 650], ["in", 657], ["the", 660], ["midbrain", 664], ["and", 673], ["impaired", 677], ["motor", 686], ["coordination", 692], [",", 704], ["and", 706], ["these", 710], ["effects", 716], ["were", 724], ["counteracted", 729], ["by", 742], ["S", 745], ["-", 746], ["methylthiocitrulline", 747], [",", 767], ["a", 769], ["selective", 771], ["neuronal", 781], ["NO", 790], ["synthase", 793], ["inhibitor", 802], [".", 811], ["SEA0400", 813], ["protected", 821], ["against", 831], ["the", 839], ["dopaminergic", 843], ["neurotoxicity", 856], ["(", 870], ["determined", 871], ["by", 882], ["dopamine", 885], ["levels", 894], ["in", 901], ["the", 904], ["midbrain", 908], ["and", 917], ["striatum", 921], [",", 929], ["tyrosine", 931], ["hydroxylase", 940], ["immunoreactivity", 952], ["in", 969], ["the", 972], ["substantia", 976], ["nigra", 987], ["and", 993], ["striatum", 997], [",", 1005], ["striatal", 1007], ["dopamine", 1016], ["release", 1025], [",", 1032], ["and", 1034], ["motor", 1038], ["deficits", 1044], [")", 1052], ["in", 1054], ["MPTP", 1057], ["-", 1061], ["treated", 1062], ["mice", 1070], [".", 1074], ["SEA0400", 1076], ["had", 1084], ["no", 1088], ["radical", 1091], ["-", 1098], ["scavenging", 1099], ["activity", 1110], [".", 1118], ["SEA0400", 1120], ["did", 1128], ["not", 1132], ["affect", 1136], ["MPTP", 1143], ["metabolism", 1148], ["and", 1159], ["MPTP", 1163], ["-", 1167], ["induced", 1168], ["NO", 1176], ["production", 1179], ["and", 1190], ["microglial", 1194], ["activation", 1205], [",", 1215], ["while", 1217], ["it", 1223], ["attenuated", 1226], ["MPTP", 1237], ["-", 1241], ["induced", 1242], ["increases", 1250], ["in", 1260], ["extracellular", 1263], ["signal", 1277], ["-", 1283], ["regulated", 1284], ["kinase", 1294], ["(", 1301], ["ERK", 1302], [")", 1305], ["phosphorylation", 1307], ["and", 1323], ["lipid", 1327], ["peroxidation", 1333], ["product", 1346], [",", 1353], ["thiobarbituric", 1355], ["acid", 1370], ["reactive", 1375], ["substance", 1384], [".", 1393], ["These", 1395], ["findings", 1401], ["suggest", 1410], ["that", 1418], ["SEA0400", 1423], ["protects", 1431], ["against", 1440], ["MPTP", 1448], ["-", 1452], ["induced", 1453], ["neurotoxicity", 1461], ["probably", 1475], ["by", 1484], ["blocking", 1487], ["ERK", 1496], ["phosphorylation", 1500], ["and", 1516], ["lipid", 1520], ["peroxidation", 1526], ["which", 1539], ["are", 1545], ["downstream", 1549], ["of", 1560], ["NCX", 1563], ["-", 1566], ["mediated", 1567], ["Ca(2", 1576], ["+", 1580], [")", 1581], ["influx", 1583], [".", 1589]]}
{"context": "Previous X-ray crystal structures have shown that linkers of five amino acid residues connecting pairs of chicken brain alpha-spectrin and human erythroid beta-spectrin repeats can undergo bending without losing their alpha-helical structure. To test whether bending at one linker can influence bending at an adjacent linker, the structures of two and three repeat fragments of chicken brain alpha-spectrin have been determined by X-ray crystallography. The structure of the three-repeat fragment clearly shows that bending at one linker can occur independently of bending at an adjacent linker. This observation increases the possible trajectories of modeled chains of spectrin repeats. Furthermore, the three-repeat molecule crystallized as an antiparallel dimer with a significantly smaller buried interfacial area than that of alpha-actinin, a spectrin-related molecule, but large enough and of a type indicating biological specificity. Comparison of the structures of the spectrin and alpha-actinin dimers supports weak association of the former, which could not be detected by analytical ultracentrifugation, versus strong association of the latter, which has been observed by others. To correlate features of the structure with solution properties and to test a previous model of stable spectrin and dystrophin repeats, the number of inter-helical interactions in each repeat of several spectrin structures were counted and compared to their thermal stabilities. Inter-helical interactions, but not all interactions, increased in parallel with measured thermal stabilities of each repeat and in agreement with the thermal stabilities of two and three repeats and also partial repeats of spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "159e2ef1d3ca4a3b889fd3fd5ef2acb9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[127, 127]], "char_spans": [[746, 757]]}]}], "context_tokens": [["Previous", 0], ["X", 9], ["-", 10], ["ray", 11], ["crystal", 15], ["structures", 23], ["have", 34], ["shown", 39], ["that", 45], ["linkers", 50], ["of", 58], ["five", 61], ["amino", 66], ["acid", 72], ["residues", 77], ["connecting", 86], ["pairs", 97], ["of", 103], ["chicken", 106], ["brain", 114], ["alpha", 120], ["-", 125], ["spectrin", 126], ["and", 135], ["human", 139], ["erythroid", 145], ["beta", 155], ["-", 159], ["spectrin", 160], ["repeats", 169], ["can", 177], ["undergo", 181], ["bending", 189], ["without", 197], ["losing", 205], ["their", 212], ["alpha", 218], ["-", 223], ["helical", 224], ["structure", 232], [".", 241], ["To", 243], ["test", 246], ["whether", 251], ["bending", 259], ["at", 267], ["one", 270], ["linker", 274], ["can", 281], ["influence", 285], ["bending", 295], ["at", 303], ["an", 306], ["adjacent", 309], ["linker", 318], [",", 324], ["the", 326], ["structures", 330], ["of", 341], ["two", 344], ["and", 348], ["three", 352], ["repeat", 358], ["fragments", 365], ["of", 375], ["chicken", 378], ["brain", 386], ["alpha", 392], ["-", 397], ["spectrin", 398], ["have", 407], ["been", 412], ["determined", 417], ["by", 428], ["X", 431], ["-", 432], ["ray", 433], ["crystallography", 437], [".", 452], ["The", 454], ["structure", 458], ["of", 468], ["the", 471], ["three", 475], ["-", 480], ["repeat", 481], ["fragment", 488], ["clearly", 497], ["shows", 505], ["that", 511], ["bending", 516], ["at", 524], ["one", 527], ["linker", 531], ["can", 538], ["occur", 542], ["independently", 548], ["of", 562], ["bending", 565], ["at", 573], ["an", 576], ["adjacent", 579], ["linker", 588], [".", 594], ["This", 596], ["observation", 601], ["increases", 613], ["the", 623], ["possible", 627], ["trajectories", 636], ["of", 649], ["modeled", 652], ["chains", 660], ["of", 667], ["spectrin", 670], ["repeats", 679], [".", 686], ["Furthermore", 688], [",", 699], ["the", 701], ["three", 705], ["-", 710], ["repeat", 711], ["molecule", 718], ["crystallized", 727], ["as", 740], ["an", 743], ["antiparallel", 746], ["dimer", 759], ["with", 765], ["a", 770], ["significantly", 772], ["smaller", 786], ["buried", 794], ["interfacial", 801], ["area", 813], ["than", 818], ["that", 823], ["of", 828], ["alpha", 831], ["-", 836], ["actinin", 837], [",", 844], ["a", 846], ["spectrin", 848], ["-", 856], ["related", 857], ["molecule", 865], [",", 873], ["but", 875], ["large", 879], ["enough", 885], ["and", 892], ["of", 896], ["a", 899], ["type", 901], ["indicating", 906], ["biological", 917], ["specificity", 928], [".", 939], ["Comparison", 941], ["of", 952], ["the", 955], ["structures", 959], ["of", 970], ["the", 973], ["spectrin", 977], ["and", 986], ["alpha", 990], ["-", 995], ["actinin", 996], ["dimers", 1004], ["supports", 1011], ["weak", 1020], ["association", 1025], ["of", 1037], ["the", 1040], ["former", 1044], [",", 1050], ["which", 1052], ["could", 1058], ["not", 1064], ["be", 1068], ["detected", 1071], ["by", 1080], ["analytical", 1083], ["ultracentrifugation", 1094], [",", 1113], ["versus", 1115], ["strong", 1122], ["association", 1129], ["of", 1141], ["the", 1144], ["latter", 1148], [",", 1154], ["which", 1156], ["has", 1162], ["been", 1166], ["observed", 1171], ["by", 1180], ["others", 1183], [".", 1189], ["To", 1191], ["correlate", 1194], ["features", 1204], ["of", 1213], ["the", 1216], ["structure", 1220], ["with", 1230], ["solution", 1235], ["properties", 1244], ["and", 1255], ["to", 1259], ["test", 1262], ["a", 1267], ["previous", 1269], ["model", 1278], ["of", 1284], ["stable", 1287], ["spectrin", 1294], ["and", 1303], ["dystrophin", 1307], ["repeats", 1318], [",", 1325], ["the", 1327], ["number", 1331], ["of", 1338], ["inter", 1341], ["-", 1346], ["helical", 1347], ["interactions", 1355], ["in", 1368], ["each", 1371], ["repeat", 1376], ["of", 1383], ["several", 1386], ["spectrin", 1394], ["structures", 1403], ["were", 1414], ["counted", 1419], ["and", 1427], ["compared", 1431], ["to", 1440], ["their", 1443], ["thermal", 1449], ["stabilities", 1457], [".", 1468], ["Inter", 1470], ["-", 1475], ["helical", 1476], ["interactions", 1484], [",", 1496], ["but", 1498], ["not", 1502], ["all", 1506], ["interactions", 1510], [",", 1522], ["increased", 1524], ["in", 1534], ["parallel", 1537], ["with", 1546], ["measured", 1551], ["thermal", 1560], ["stabilities", 1568], ["of", 1580], ["each", 1583], ["repeat", 1588], ["and", 1595], ["in", 1599], ["agreement", 1602], ["with", 1612], ["the", 1617], ["thermal", 1621], ["stabilities", 1629], ["of", 1641], ["two", 1644], ["and", 1648], ["three", 1652], ["repeats", 1658], ["and", 1666], ["also", 1670], ["partial", 1675], ["repeats", 1683], ["of", 1691], ["spectrin", 1694], [".", 1702]]}
{"context": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to develop or optimize therapies for TD, and to develop new APDs with lower indices of motor side effects, the pathology underlying TD must first be understood. The use of animal models has been used to further this objective. Here, we review different preparations that have been used to model TD and discuss the contribution of neuroimaging studies conducted in these models. Studies in animal models have lead to several hypotheses of TD pathology, although none has yet emerged as the ultimate underlying cause of this syndrome. We discuss alterations in functional indices, neuron and synapse morphology and changes in specific neurotransmitter systems that have been described in animal models of TD, and outline how these findings have contributed to our understanding of antipsychotic-induced dyskinesias. We conclude that several non-mutually exclusive theories of TD are supported by animal studies, including increases in oxidative stress leading to structural and functional changes in specific neurotransmitter systems. Elucidating the mechanisms underlying TD neuropathology partly through the use of animal models will lead to the development of APDs with superior side effect profiles or more effective therapies for TD.", "qas": [{"question": "What is the cause of Tardive dyskinesia?", "answers": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "qid": "b0f3562cb2574620ba46ae33c88d65b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Tardive", 21], ["dyskinesia", 29], ["?", 39]], "detected_answers": [{"text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "token_spans": [[0, 22]], "char_spans": [[0, 168]]}]}], "context_tokens": [["Tardive", 0], ["dyskinesia", 8], ["(", 19], ["TD", 20], [")", 22], ["is", 24], ["a", 27], ["movement", 29], ["disorder", 38], ["characterized", 47], ["by", 61], ["abnormal", 64], ["involuntary", 73], ["facial", 85], ["movements", 92], ["induced", 102], ["by", 110], ["chronic", 113], ["therapy", 121], ["with", 129], ["classical", 134], ["antipsychotic", 144], ["medications", 158], [".", 169], ["Currently", 171], [",", 180], ["there", 182], ["is", 188], ["no", 191], ["satisfactory", 194], ["pharmacotherapy", 207], ["for", 223], ["TD", 227], [",", 229], ["which", 231], ["represents", 237], ["a", 248], ["major", 250], ["limitation", 256], ["to", 267], ["therapy", 270], ["with", 278], ["classical", 283], ["antipsychotics", 293], [".", 307], ["In", 309], ["order", 312], ["to", 318], ["develop", 321], ["or", 329], ["optimize", 332], ["therapies", 341], ["for", 351], ["TD", 355], [",", 357], ["and", 359], ["to", 363], ["develop", 366], ["new", 374], ["APDs", 378], ["with", 383], ["lower", 388], ["indices", 394], ["of", 402], ["motor", 405], ["side", 411], ["effects", 416], [",", 423], ["the", 425], ["pathology", 429], ["underlying", 439], ["TD", 450], ["must", 453], ["first", 458], ["be", 464], ["understood", 467], [".", 477], ["The", 479], ["use", 483], ["of", 487], ["animal", 490], ["models", 497], ["has", 504], ["been", 508], ["used", 513], ["to", 518], ["further", 521], ["this", 529], ["objective", 534], [".", 543], ["Here", 545], [",", 549], ["we", 551], ["review", 554], ["different", 561], ["preparations", 571], ["that", 584], ["have", 589], ["been", 594], ["used", 599], ["to", 604], ["model", 607], ["TD", 613], ["and", 616], ["discuss", 620], ["the", 628], ["contribution", 632], ["of", 645], ["neuroimaging", 648], ["studies", 661], ["conducted", 669], ["in", 679], ["these", 682], ["models", 688], [".", 694], ["Studies", 696], ["in", 704], ["animal", 707], ["models", 714], ["have", 721], ["lead", 726], ["to", 731], ["several", 734], ["hypotheses", 742], ["of", 753], ["TD", 756], ["pathology", 759], [",", 768], ["although", 770], ["none", 779], ["has", 784], ["yet", 788], ["emerged", 792], ["as", 800], ["the", 803], ["ultimate", 807], ["underlying", 816], ["cause", 827], ["of", 833], ["this", 836], ["syndrome", 841], [".", 849], ["We", 851], ["discuss", 854], ["alterations", 862], ["in", 874], ["functional", 877], ["indices", 888], [",", 895], ["neuron", 897], ["and", 904], ["synapse", 908], ["morphology", 916], ["and", 927], ["changes", 931], ["in", 939], ["specific", 942], ["neurotransmitter", 951], ["systems", 968], ["that", 976], ["have", 981], ["been", 986], ["described", 991], ["in", 1001], ["animal", 1004], ["models", 1011], ["of", 1018], ["TD", 1021], [",", 1023], ["and", 1025], ["outline", 1029], ["how", 1037], ["these", 1041], ["findings", 1047], ["have", 1056], ["contributed", 1061], ["to", 1073], ["our", 1076], ["understanding", 1080], ["of", 1094], ["antipsychotic", 1097], ["-", 1110], ["induced", 1111], ["dyskinesias", 1119], [".", 1130], ["We", 1132], ["conclude", 1135], ["that", 1144], ["several", 1149], ["non", 1157], ["-", 1160], ["mutually", 1161], ["exclusive", 1170], ["theories", 1180], ["of", 1189], ["TD", 1192], ["are", 1195], ["supported", 1199], ["by", 1209], ["animal", 1212], ["studies", 1219], [",", 1226], ["including", 1228], ["increases", 1238], ["in", 1248], ["oxidative", 1251], ["stress", 1261], ["leading", 1268], ["to", 1276], ["structural", 1279], ["and", 1290], ["functional", 1294], ["changes", 1305], ["in", 1313], ["specific", 1316], ["neurotransmitter", 1325], ["systems", 1342], [".", 1349], ["Elucidating", 1351], ["the", 1363], ["mechanisms", 1367], ["underlying", 1378], ["TD", 1389], ["neuropathology", 1392], ["partly", 1407], ["through", 1414], ["the", 1422], ["use", 1426], ["of", 1430], ["animal", 1433], ["models", 1440], ["will", 1447], ["lead", 1452], ["to", 1457], ["the", 1460], ["development", 1464], ["of", 1476], ["APDs", 1479], ["with", 1484], ["superior", 1489], ["side", 1498], ["effect", 1503], ["profiles", 1510], ["or", 1519], ["more", 1522], ["effective", 1527], ["therapies", 1537], ["for", 1547], ["TD", 1551], [".", 1553]]}
{"context": "Kx is lacking in the RBCs of patients with the McLeod syndrome. This condition is sometimes associated with chronic granulomatous disease (CGD). If given allogeneic RBCs, CGD patients with the McLeod phenotype may produce anti-Kx and anti-Km, and only phenotypically matched McLeod blood would be compatible. McLeod phenotype persons without CGD have made anti-Km but not anti-Kx (2 examples), and thus both McLeod and K(O) blood would be compatible. RBCs from a transfused patient with the McLeod phenotype but not with CGD (non-CGD McLeod) were typed for the Kell blood group antigens, and the plasma was analyzed for the presence of antibody by agglutination. The molecular basis was determined by analyzing for XK protein on RBC membranes by Western immunoblotting, by sequencing the XK gene, and by RFLP. The RBCs did not react with anti-Kx + anti-Km and showed weakening of Kell system antigens. The patient's plasma reacted moderately (2+) with RBCs of common Kell type and strongly (4+) with K(O) RBCs and RBCs of common Kell type treated with dithiothreitol, and did not react with McLeod RBCs. XK protein was absent from the RBC membranes. The XK gene had a point mutation in the donor splice site of intron 1 (G>C). This is the first report describing the molecular alteration in a non-CGD McLeod patient who has made anti-Kx. The immune response of people with the McLeod phenotype can vary, and K(O) blood may not always be compatible.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "ae5bb34ab378486298ab61b3973ece7b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[232, 232], [150, 150], [222, 222], [138, 138]], "char_spans": [[1154, 1155], [788, 789], [1104, 1105], [715, 716]]}]}], "context_tokens": [["Kx", 0], ["is", 3], ["lacking", 6], ["in", 14], ["the", 17], ["RBCs", 21], ["of", 26], ["patients", 29], ["with", 38], ["the", 43], ["McLeod", 47], ["syndrome", 54], [".", 62], ["This", 64], ["condition", 69], ["is", 79], ["sometimes", 82], ["associated", 92], ["with", 103], ["chronic", 108], ["granulomatous", 116], ["disease", 130], ["(", 138], ["CGD", 139], [")", 142], [".", 143], ["If", 145], ["given", 148], ["allogeneic", 154], ["RBCs", 165], [",", 169], ["CGD", 171], ["patients", 175], ["with", 184], ["the", 189], ["McLeod", 193], ["phenotype", 200], ["may", 210], ["produce", 214], ["anti", 222], ["-", 226], ["Kx", 227], ["and", 230], ["anti", 234], ["-", 238], ["Km", 239], [",", 241], ["and", 243], ["only", 247], ["phenotypically", 252], ["matched", 267], ["McLeod", 275], ["blood", 282], ["would", 288], ["be", 294], ["compatible", 297], [".", 307], ["McLeod", 309], ["phenotype", 316], ["persons", 326], ["without", 334], ["CGD", 342], ["have", 346], ["made", 351], ["anti", 356], ["-", 360], ["Km", 361], ["but", 364], ["not", 368], ["anti", 372], ["-", 376], ["Kx", 377], ["(", 380], ["2", 381], ["examples", 383], [")", 391], [",", 392], ["and", 394], ["thus", 398], ["both", 403], ["McLeod", 408], ["and", 415], ["K(O", 419], [")", 422], ["blood", 424], ["would", 430], ["be", 436], ["compatible", 439], [".", 449], ["RBCs", 451], ["from", 456], ["a", 461], ["transfused", 463], ["patient", 474], ["with", 482], ["the", 487], ["McLeod", 491], ["phenotype", 498], ["but", 508], ["not", 512], ["with", 516], ["CGD", 521], ["(", 525], ["non", 526], ["-", 529], ["CGD", 530], ["McLeod", 534], [")", 540], ["were", 542], ["typed", 547], ["for", 553], ["the", 557], ["Kell", 561], ["blood", 566], ["group", 572], ["antigens", 578], [",", 586], ["and", 588], ["the", 592], ["plasma", 596], ["was", 603], ["analyzed", 607], ["for", 616], ["the", 620], ["presence", 624], ["of", 633], ["antibody", 636], ["by", 645], ["agglutination", 648], [".", 661], ["The", 663], ["molecular", 667], ["basis", 677], ["was", 683], ["determined", 687], ["by", 698], ["analyzing", 701], ["for", 711], ["XK", 715], ["protein", 718], ["on", 726], ["RBC", 729], ["membranes", 733], ["by", 743], ["Western", 746], ["immunoblotting", 754], [",", 768], ["by", 770], ["sequencing", 773], ["the", 784], ["XK", 788], ["gene", 791], [",", 795], ["and", 797], ["by", 801], ["RFLP", 804], [".", 808], ["The", 810], ["RBCs", 814], ["did", 819], ["not", 823], ["react", 827], ["with", 833], ["anti", 838], ["-", 842], ["Kx", 843], ["+", 846], ["anti", 848], ["-", 852], ["Km", 853], ["and", 856], ["showed", 860], ["weakening", 867], ["of", 877], ["Kell", 880], ["system", 885], ["antigens", 892], [".", 900], ["The", 902], ["patient", 906], ["'s", 913], ["plasma", 916], ["reacted", 923], ["moderately", 931], ["(", 942], ["2", 943], ["+", 944], [")", 945], ["with", 947], ["RBCs", 952], ["of", 957], ["common", 960], ["Kell", 967], ["type", 972], ["and", 977], ["strongly", 981], ["(", 990], ["4", 991], ["+", 992], [")", 993], ["with", 995], ["K(O", 1000], [")", 1003], ["RBCs", 1005], ["and", 1010], ["RBCs", 1014], ["of", 1019], ["common", 1022], ["Kell", 1029], ["type", 1034], ["treated", 1039], ["with", 1047], ["dithiothreitol", 1052], [",", 1066], ["and", 1068], ["did", 1072], ["not", 1076], ["react", 1080], ["with", 1086], ["McLeod", 1091], ["RBCs", 1098], [".", 1102], ["XK", 1104], ["protein", 1107], ["was", 1115], ["absent", 1119], ["from", 1126], ["the", 1131], ["RBC", 1135], ["membranes", 1139], [".", 1148], ["The", 1150], ["XK", 1154], ["gene", 1157], ["had", 1162], ["a", 1166], ["point", 1168], ["mutation", 1174], ["in", 1183], ["the", 1186], ["donor", 1190], ["splice", 1196], ["site", 1203], ["of", 1208], ["intron", 1211], ["1", 1218], ["(", 1220], ["G", 1221], [">", 1222], ["C", 1223], [")", 1224], [".", 1225], ["This", 1227], ["is", 1232], ["the", 1235], ["first", 1239], ["report", 1245], ["describing", 1252], ["the", 1263], ["molecular", 1267], ["alteration", 1277], ["in", 1288], ["a", 1291], ["non", 1293], ["-", 1296], ["CGD", 1297], ["McLeod", 1301], ["patient", 1308], ["who", 1316], ["has", 1320], ["made", 1324], ["anti", 1329], ["-", 1333], ["Kx", 1334], [".", 1336], ["The", 1338], ["immune", 1342], ["response", 1349], ["of", 1358], ["people", 1361], ["with", 1368], ["the", 1373], ["McLeod", 1377], ["phenotype", 1384], ["can", 1394], ["vary", 1398], [",", 1402], ["and", 1404], ["K(O", 1408], [")", 1411], ["blood", 1413], ["may", 1419], ["not", 1423], ["always", 1427], ["be", 1434], ["compatible", 1437], [".", 1447]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disorder characterized by the appearance of intracytoplasmic inclusions called Lewy bodies (LB) in dopamine neurons in the substantia nigra and the progressive loss of these neurons. Recently, mutations in the alpha-synuclein gene have been identified in early-onset familial PD, and alpha-synuclein has been shown to be a major component of LB in all patients. Yet, the pathophysiological function of alpha-synuclein remains unknown. In this report, we have investigated the toxic effects of adenovirus-mediated alpha-synuclein overexpression on dopamine neurons in rat primary mesencephalic cultures and in a rat dopaminergic cell line - the large T-antigen immortalized, mesencephalon-derived 1RB3AN27 (N27). Adenovirus-transduced cultures showed high-level expression of alpha-synuclein within the cells. Overexpression of human mutant alpha-synuclein (Ala(53)Thr) selectively induced apoptotic programmed cell death of primary dopamine neurons as well as N27 cells. The mutant protein also potentiated the neurotoxicity of 6-hydroxydopamine (6-OHDA). By contrast, overexpression of wild-type human alpha-synuclein was not directly neurotoxic but did increase cell death after 6-OHDA. Overexpression of wild-type rat alpha-synuclein had no effect on dopamine cell survival or 6-OHDA neurotoxicity. These results indicate that overexpression of human mutant alpha-synuclein directly leads to dopamine neuron death, and overexpression of either human mutant or human wild-type alpha-synuclein renders dopamine neurons more vulnerable to neurotoxic insults.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d46479c4ece34bc181a6026e994a86e9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[81, 83], [222, 224], [244, 246], [101, 103], [157, 159], [58, 60], [201, 203], [265, 267], [146, 148], [43, 45]], "char_spans": [[450, 464], [1269, 1283], [1409, 1423], [561, 575], [888, 902], [332, 346], [1151, 1165], [1527, 1541], [823, 837], [258, 272]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disorder", 48], ["characterized", 57], ["by", 71], ["the", 74], ["appearance", 78], ["of", 89], ["intracytoplasmic", 92], ["inclusions", 109], ["called", 120], ["Lewy", 127], ["bodies", 132], ["(", 139], ["LB", 140], [")", 142], ["in", 144], ["dopamine", 147], ["neurons", 156], ["in", 164], ["the", 167], ["substantia", 171], ["nigra", 182], ["and", 188], ["the", 192], ["progressive", 196], ["loss", 208], ["of", 213], ["these", 216], ["neurons", 222], [".", 229], ["Recently", 231], [",", 239], ["mutations", 241], ["in", 251], ["the", 254], ["alpha", 258], ["-", 263], ["synuclein", 264], ["gene", 274], ["have", 279], ["been", 284], ["identified", 289], ["in", 300], ["early", 303], ["-", 308], ["onset", 309], ["familial", 315], ["PD", 324], [",", 326], ["and", 328], ["alpha", 332], ["-", 337], ["synuclein", 338], ["has", 348], ["been", 352], ["shown", 357], ["to", 363], ["be", 366], ["a", 369], ["major", 371], ["component", 377], ["of", 387], ["LB", 390], ["in", 393], ["all", 396], ["patients", 400], [".", 408], ["Yet", 410], [",", 413], ["the", 415], ["pathophysiological", 419], ["function", 438], ["of", 447], ["alpha", 450], ["-", 455], ["synuclein", 456], ["remains", 466], ["unknown", 474], [".", 481], ["In", 483], ["this", 486], ["report", 491], [",", 497], ["we", 499], ["have", 502], ["investigated", 507], ["the", 520], ["toxic", 524], ["effects", 530], ["of", 538], ["adenovirus", 541], ["-", 551], ["mediated", 552], ["alpha", 561], ["-", 566], ["synuclein", 567], ["overexpression", 577], ["on", 592], ["dopamine", 595], ["neurons", 604], ["in", 612], ["rat", 615], ["primary", 619], ["mesencephalic", 627], ["cultures", 641], ["and", 650], ["in", 654], ["a", 657], ["rat", 659], ["dopaminergic", 663], ["cell", 676], ["line", 681], ["-", 686], ["the", 688], ["large", 692], ["T", 698], ["-", 699], ["antigen", 700], ["immortalized", 708], [",", 720], ["mesencephalon", 722], ["-", 735], ["derived", 736], ["1RB3AN27", 744], ["(", 753], ["N27", 754], [")", 757], [".", 758], ["Adenovirus", 760], ["-", 770], ["transduced", 771], ["cultures", 782], ["showed", 791], ["high", 798], ["-", 802], ["level", 803], ["expression", 809], ["of", 820], ["alpha", 823], ["-", 828], ["synuclein", 829], ["within", 839], ["the", 846], ["cells", 850], [".", 855], ["Overexpression", 857], ["of", 872], ["human", 875], ["mutant", 881], ["alpha", 888], ["-", 893], ["synuclein", 894], ["(", 904], ["Ala(53)Thr", 905], [")", 915], ["selectively", 917], ["induced", 929], ["apoptotic", 937], ["programmed", 947], ["cell", 958], ["death", 963], ["of", 969], ["primary", 972], ["dopamine", 980], ["neurons", 989], ["as", 997], ["well", 1000], ["as", 1005], ["N27", 1008], ["cells", 1012], [".", 1017], ["The", 1019], ["mutant", 1023], ["protein", 1030], ["also", 1038], ["potentiated", 1043], ["the", 1055], ["neurotoxicity", 1059], ["of", 1073], ["6-hydroxydopamine", 1076], ["(", 1094], ["6-OHDA", 1095], [")", 1101], [".", 1102], ["By", 1104], ["contrast", 1107], [",", 1115], ["overexpression", 1117], ["of", 1132], ["wild", 1135], ["-", 1139], ["type", 1140], ["human", 1145], ["alpha", 1151], ["-", 1156], ["synuclein", 1157], ["was", 1167], ["not", 1171], ["directly", 1175], ["neurotoxic", 1184], ["but", 1195], ["did", 1199], ["increase", 1203], ["cell", 1212], ["death", 1217], ["after", 1223], ["6-OHDA", 1229], [".", 1235], ["Overexpression", 1237], ["of", 1252], ["wild", 1255], ["-", 1259], ["type", 1260], ["rat", 1265], ["alpha", 1269], ["-", 1274], ["synuclein", 1275], ["had", 1285], ["no", 1289], ["effect", 1292], ["on", 1299], ["dopamine", 1302], ["cell", 1311], ["survival", 1316], ["or", 1325], ["6-OHDA", 1328], ["neurotoxicity", 1335], [".", 1348], ["These", 1350], ["results", 1356], ["indicate", 1364], ["that", 1373], ["overexpression", 1378], ["of", 1393], ["human", 1396], ["mutant", 1402], ["alpha", 1409], ["-", 1414], ["synuclein", 1415], ["directly", 1425], ["leads", 1434], ["to", 1440], ["dopamine", 1443], ["neuron", 1452], ["death", 1459], [",", 1464], ["and", 1466], ["overexpression", 1470], ["of", 1485], ["either", 1488], ["human", 1495], ["mutant", 1501], ["or", 1508], ["human", 1511], ["wild", 1517], ["-", 1521], ["type", 1522], ["alpha", 1527], ["-", 1532], ["synuclein", 1533], ["renders", 1543], ["dopamine", 1551], ["neurons", 1560], ["more", 1568], ["vulnerable", 1573], ["to", 1584], ["neurotoxic", 1587], ["insults", 1598], [".", 1605]]}
{"context": "Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. It is indicated in the management of benzodiazepine overdose, but its role in the routine reversal of endoscopic conscious sedation has not been defined. Patients undergoing diagnostic upper endoscopy who received sedation with either diazepam or midazolam alone were given flumazenil 0.2 mg incrementally immediately following the procedure until awake. They were then asked to repeat three psychomotor tests measuring cognitive and motor skills, with their baseline scores compared with postprocedure scores over a 3-hour period. Full psychomotor function was restored to baseline values within 30 minutes after flumazenil in 79% of patients, with no differences in the reversal of psychomotor skill impairment observed between diazepam and midazolam sedation. There was no evidence of rebound sedation seen for up to 3 hours. No significant anterograde amnesia was evident in 78% of individuals. These results demonstrate that flumazenil's effects on reversing psychomotor impairment are similar when midazolam or diazepam are used for conscious sedation. However, the potential usefulness of routine flumazenil reversal of conscious sedation will require further evaluation of specific psychomotor performance skills (such as driving a car) before we lift the admonition against leaving the endoscopic suite unattended, driving a vehicle, or operating complicated machinery for several hours.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "8c08be9367e44a248f7e98941e6d911d", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [163, 163], [189, 189], [109, 109], [58, 58]], "char_spans": [[0, 9], [1042, 1051], [1216, 1225], [726, 735], [386, 395]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["competitive", 16], ["benzodiazepine", 28], ["antagonist", 43], ["that", 54], ["acts", 59], ["to", 64], ["reverse", 67], ["their", 75], ["sedative", 81], ["and", 90], ["hypnotic", 94], ["effects", 103], [".", 110], ["It", 112], ["is", 115], ["indicated", 118], ["in", 128], ["the", 131], ["management", 135], ["of", 146], ["benzodiazepine", 149], ["overdose", 164], [",", 172], ["but", 174], ["its", 178], ["role", 182], ["in", 187], ["the", 190], ["routine", 194], ["reversal", 202], ["of", 211], ["endoscopic", 214], ["conscious", 225], ["sedation", 235], ["has", 244], ["not", 248], ["been", 252], ["defined", 257], [".", 264], ["Patients", 266], ["undergoing", 275], ["diagnostic", 286], ["upper", 297], ["endoscopy", 303], ["who", 313], ["received", 317], ["sedation", 326], ["with", 335], ["either", 340], ["diazepam", 347], ["or", 356], ["midazolam", 359], ["alone", 369], ["were", 375], ["given", 380], ["flumazenil", 386], ["0.2", 397], ["mg", 401], ["incrementally", 404], ["immediately", 418], ["following", 430], ["the", 440], ["procedure", 444], ["until", 454], ["awake", 460], [".", 465], ["They", 467], ["were", 472], ["then", 477], ["asked", 482], ["to", 488], ["repeat", 491], ["three", 498], ["psychomotor", 504], ["tests", 516], ["measuring", 522], ["cognitive", 532], ["and", 542], ["motor", 546], ["skills", 552], [",", 558], ["with", 560], ["their", 565], ["baseline", 571], ["scores", 580], ["compared", 587], ["with", 596], ["postprocedure", 601], ["scores", 615], ["over", 622], ["a", 627], ["3-hour", 629], ["period", 636], [".", 642], ["Full", 644], ["psychomotor", 649], ["function", 661], ["was", 670], ["restored", 674], ["to", 683], ["baseline", 686], ["values", 695], ["within", 702], ["30", 709], ["minutes", 712], ["after", 720], ["flumazenil", 726], ["in", 737], ["79", 740], ["%", 742], ["of", 744], ["patients", 747], [",", 755], ["with", 757], ["no", 762], ["differences", 765], ["in", 777], ["the", 780], ["reversal", 784], ["of", 793], ["psychomotor", 796], ["skill", 808], ["impairment", 814], ["observed", 825], ["between", 834], ["diazepam", 842], ["and", 851], ["midazolam", 855], ["sedation", 865], [".", 873], ["There", 875], ["was", 881], ["no", 885], ["evidence", 888], ["of", 897], ["rebound", 900], ["sedation", 908], ["seen", 917], ["for", 922], ["up", 926], ["to", 929], ["3", 932], ["hours", 934], [".", 939], ["No", 941], ["significant", 944], ["anterograde", 956], ["amnesia", 968], ["was", 976], ["evident", 980], ["in", 988], ["78", 991], ["%", 993], ["of", 995], ["individuals", 998], [".", 1009], ["These", 1011], ["results", 1017], ["demonstrate", 1025], ["that", 1037], ["flumazenil", 1042], ["'s", 1052], ["effects", 1055], ["on", 1063], ["reversing", 1066], ["psychomotor", 1076], ["impairment", 1088], ["are", 1099], ["similar", 1103], ["when", 1111], ["midazolam", 1116], ["or", 1126], ["diazepam", 1129], ["are", 1138], ["used", 1142], ["for", 1147], ["conscious", 1151], ["sedation", 1161], [".", 1169], ["However", 1171], [",", 1178], ["the", 1180], ["potential", 1184], ["usefulness", 1194], ["of", 1205], ["routine", 1208], ["flumazenil", 1216], ["reversal", 1227], ["of", 1236], ["conscious", 1239], ["sedation", 1249], ["will", 1258], ["require", 1263], ["further", 1271], ["evaluation", 1279], ["of", 1290], ["specific", 1293], ["psychomotor", 1302], ["performance", 1314], ["skills", 1326], ["(", 1333], ["such", 1334], ["as", 1339], ["driving", 1342], ["a", 1350], ["car", 1352], [")", 1355], ["before", 1357], ["we", 1364], ["lift", 1367], ["the", 1372], ["admonition", 1376], ["against", 1387], ["leaving", 1395], ["the", 1403], ["endoscopic", 1407], ["suite", 1418], ["unattended", 1424], [",", 1434], ["driving", 1436], ["a", 1444], ["vehicle", 1446], [",", 1453], ["or", 1455], ["operating", 1458], ["complicated", 1468], ["machinery", 1480], ["for", 1490], ["several", 1494], ["hours", 1502], [".", 1507]]}
{"context": "Inherited ventricular arrhythmias such as the long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), idiopathic ventricular fibrillation (VF), and arrhythmogenic right ventricular cardiomyopathy (ARVC) account for a relevant proportion of sudden cardiac death cases in young patients cohorts. The detailed pathogenetic mechanisms of inherited ventricular arrhythmias are still poorly understood because systematic investigations are difficult to perform due to low patient numbers and the lack of appropriate experimental models. However, recent advances in research and science have identified a genetic background for many of these diseases. In LQTS, various mutations in different genes encoding for cardiac potassium and sodium channel proteins have been identified (\"channelopathy\"), and initial progress in genotype-phenotype correlation is made. Mutations in the cardiac sodium channel gene have also been identified in a subset of patients with Brugada syndrome, whereas a genetic background has not yet been demonstrated in idiopathic VF and right ventricular outflow-tract tachycardia (RVO-VT). Very recently, mutations in the cardiac ryanodine receptor gene have been identified in CPVT and in a subgroup of patients with ARVC. Although several chromosomal loci were suggested, no other responsible genes or mutations have been found in autosomal dominant forms of ARVC. However, in Naxos disease, a recessive form of ARVC with coexpression of palmoplantar keratoderma and woolly hair, a mutation in the plakoglobin gene has recently been discovered, thus underscoring the potential role of genetic alterations in cytoskeletal proteins in ARVC. In the next years, significant progress in the genetic diagnosis pathophysiologic understanding of disease mechanisms, genotype-phenotype correlation, and the development of gene- or target-directed treatment strategies can be expected in the field of inherited ventricular arrhythmias. This review summarizes the current knowledge of the molecular mechanisms, including aspects of pathoanatomy, autonomic innervation, genetics, and genotype-phenotype correlations with their potential implications for diagnosis and treatment of inherited ventricular arrhythmias.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "82cb45ef0dce4731bfd7549461b332ab", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[257, 258]], "char_spans": [[1565, 1580]]}]}], "context_tokens": [["Inherited", 0], ["ventricular", 10], ["arrhythmias", 22], ["such", 34], ["as", 39], ["the", 42], ["long", 46], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], [",", 69], ["Brugada", 71], ["syndrome", 79], [",", 87], ["catecholaminergic", 89], ["polymorphic", 107], ["ventricular", 119], ["tachycardia", 131], ["(", 143], ["CPVT", 144], [")", 148], [",", 149], ["idiopathic", 151], ["ventricular", 162], ["fibrillation", 174], ["(", 187], ["VF", 188], [")", 190], [",", 191], ["and", 193], ["arrhythmogenic", 197], ["right", 212], ["ventricular", 218], ["cardiomyopathy", 230], ["(", 245], ["ARVC", 246], [")", 250], ["account", 252], ["for", 260], ["a", 264], ["relevant", 266], ["proportion", 275], ["of", 286], ["sudden", 289], ["cardiac", 296], ["death", 304], ["cases", 310], ["in", 316], ["young", 319], ["patients", 325], ["cohorts", 334], [".", 341], ["The", 343], ["detailed", 347], ["pathogenetic", 356], ["mechanisms", 369], ["of", 380], ["inherited", 383], ["ventricular", 393], ["arrhythmias", 405], ["are", 417], ["still", 421], ["poorly", 427], ["understood", 434], ["because", 445], ["systematic", 453], ["investigations", 464], ["are", 479], ["difficult", 483], ["to", 493], ["perform", 496], ["due", 504], ["to", 508], ["low", 511], ["patient", 515], ["numbers", 523], ["and", 531], ["the", 535], ["lack", 539], ["of", 544], ["appropriate", 547], ["experimental", 559], ["models", 572], [".", 578], ["However", 580], [",", 587], ["recent", 589], ["advances", 596], ["in", 605], ["research", 608], ["and", 617], ["science", 621], ["have", 629], ["identified", 634], ["a", 645], ["genetic", 647], ["background", 655], ["for", 666], ["many", 670], ["of", 675], ["these", 678], ["diseases", 684], [".", 692], ["In", 694], ["LQTS", 697], [",", 701], ["various", 703], ["mutations", 711], ["in", 721], ["different", 724], ["genes", 734], ["encoding", 740], ["for", 749], ["cardiac", 753], ["potassium", 761], ["and", 771], ["sodium", 775], ["channel", 782], ["proteins", 790], ["have", 799], ["been", 804], ["identified", 809], ["(", 820], ["\"", 821], ["channelopathy", 822], ["\"", 835], [")", 836], [",", 837], ["and", 839], ["initial", 843], ["progress", 851], ["in", 860], ["genotype", 863], ["-", 871], ["phenotype", 872], ["correlation", 882], ["is", 894], ["made", 897], [".", 901], ["Mutations", 903], ["in", 913], ["the", 916], ["cardiac", 920], ["sodium", 928], ["channel", 935], ["gene", 943], ["have", 948], ["also", 953], ["been", 958], ["identified", 963], ["in", 974], ["a", 977], ["subset", 979], ["of", 986], ["patients", 989], ["with", 998], ["Brugada", 1003], ["syndrome", 1011], [",", 1019], ["whereas", 1021], ["a", 1029], ["genetic", 1031], ["background", 1039], ["has", 1050], ["not", 1054], ["yet", 1058], ["been", 1062], ["demonstrated", 1067], ["in", 1080], ["idiopathic", 1083], ["VF", 1094], ["and", 1097], ["right", 1101], ["ventricular", 1107], ["outflow", 1119], ["-", 1126], ["tract", 1127], ["tachycardia", 1133], ["(", 1145], ["RVO", 1146], ["-", 1149], ["VT", 1150], [")", 1152], [".", 1153], ["Very", 1155], ["recently", 1160], [",", 1168], ["mutations", 1170], ["in", 1180], ["the", 1183], ["cardiac", 1187], ["ryanodine", 1195], ["receptor", 1205], ["gene", 1214], ["have", 1219], ["been", 1224], ["identified", 1229], ["in", 1240], ["CPVT", 1243], ["and", 1248], ["in", 1252], ["a", 1255], ["subgroup", 1257], ["of", 1266], ["patients", 1269], ["with", 1278], ["ARVC", 1283], [".", 1287], ["Although", 1289], ["several", 1298], ["chromosomal", 1306], ["loci", 1318], ["were", 1323], ["suggested", 1328], [",", 1337], ["no", 1339], ["other", 1342], ["responsible", 1348], ["genes", 1360], ["or", 1366], ["mutations", 1369], ["have", 1379], ["been", 1384], ["found", 1389], ["in", 1395], ["autosomal", 1398], ["dominant", 1408], ["forms", 1417], ["of", 1423], ["ARVC", 1426], [".", 1430], ["However", 1432], [",", 1439], ["in", 1441], ["Naxos", 1444], ["disease", 1450], [",", 1457], ["a", 1459], ["recessive", 1461], ["form", 1471], ["of", 1476], ["ARVC", 1479], ["with", 1484], ["coexpression", 1489], ["of", 1502], ["palmoplantar", 1505], ["keratoderma", 1518], ["and", 1530], ["woolly", 1534], ["hair", 1541], [",", 1545], ["a", 1547], ["mutation", 1549], ["in", 1558], ["the", 1561], ["plakoglobin", 1565], ["gene", 1577], ["has", 1582], ["recently", 1586], ["been", 1595], ["discovered", 1600], [",", 1610], ["thus", 1612], ["underscoring", 1617], ["the", 1630], ["potential", 1634], ["role", 1644], ["of", 1649], ["genetic", 1652], ["alterations", 1660], ["in", 1672], ["cytoskeletal", 1675], ["proteins", 1688], ["in", 1697], ["ARVC", 1700], [".", 1704], ["In", 1706], ["the", 1709], ["next", 1713], ["years", 1718], [",", 1723], ["significant", 1725], ["progress", 1737], ["in", 1746], ["the", 1749], ["genetic", 1753], ["diagnosis", 1761], ["pathophysiologic", 1771], ["understanding", 1788], ["of", 1802], ["disease", 1805], ["mechanisms", 1813], [",", 1823], ["genotype", 1825], ["-", 1833], ["phenotype", 1834], ["correlation", 1844], [",", 1855], ["and", 1857], ["the", 1861], ["development", 1865], ["of", 1877], ["gene-", 1880], ["or", 1886], ["target", 1889], ["-", 1895], ["directed", 1896], ["treatment", 1905], ["strategies", 1915], ["can", 1926], ["be", 1930], ["expected", 1933], ["in", 1942], ["the", 1945], ["field", 1949], ["of", 1955], ["inherited", 1958], ["ventricular", 1968], ["arrhythmias", 1980], [".", 1991], ["This", 1993], ["review", 1998], ["summarizes", 2005], ["the", 2016], ["current", 2020], ["knowledge", 2028], ["of", 2038], ["the", 2041], ["molecular", 2045], ["mechanisms", 2055], [",", 2065], ["including", 2067], ["aspects", 2077], ["of", 2085], ["pathoanatomy", 2088], [",", 2100], ["autonomic", 2102], ["innervation", 2112], [",", 2123], ["genetics", 2125], [",", 2133], ["and", 2135], ["genotype", 2139], ["-", 2147], ["phenotype", 2148], ["correlations", 2158], ["with", 2171], ["their", 2176], ["potential", 2182], ["implications", 2192], ["for", 2205], ["diagnosis", 2209], ["and", 2219], ["treatment", 2223], ["of", 2233], ["inherited", 2236], ["ventricular", 2246], ["arrhythmias", 2258], [".", 2269]]}
{"context": "Delamanid (Deltyba(\u00ae)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for use as part of an appropriate combination regimen in adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. In a robust phase\u00a0II trial in adult patients with MDR-TB, oral delamanid 100\u00a0mg twice daily for 2\u00a0months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. In a 6-month extension study, long-term (\u22648\u00a0months) treatment with delamanid was associated with a higher incidence of favourable outcomes (i.e. cured or completed all treatment) than short-term (\u22642\u00a0months) treatment, with an accompanying reduction inunfavourable outcomes as defined by the WHO (i.e. pre-specified proportion of TB-positive sputum cultures, death or treatment discontinuation for \u22652\u00a0months without medical approval). Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly. Although the incidence of QT interval prolongation was higher with delamanid-based therapy, it was not associated with clinical symptoms such as syncope and arrhythmia. In conclusion, delamanid is a useful addition to the treatment options currently available for patients with MDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "cffa38bb217641c08713c8debdecf88f", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[75, 75], [19, 19], [43, 43]], "char_spans": [[405, 416], [73, 84], [228, 239]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["Deltyba", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["a", 24], ["nitroimidazo", 26], ["-", 38], ["oxazole", 39], ["derivative", 47], [",", 57], ["is", 59], ["a", 62], ["new", 64], ["anti", 68], ["-", 72], ["tuberculosis", 73], ["(", 86], ["TB", 87], [")", 89], ["drug", 91], ["which", 96], ["exhibits", 102], ["potent", 111], ["in", 118], ["vitro", 121], ["and", 127], ["in", 131], ["vivo", 134], ["antitubercular", 139], ["activity", 154], ["against", 163], ["drug", 171], ["-", 175], ["susceptible", 176], ["and", 188], ["-resistant", 192], ["strains", 203], ["of", 211], ["Mycobacterium", 214], ["tuberculosis", 228], [".", 240], ["It", 242], ["is", 245], ["approved", 248], ["in", 257], ["several", 260], ["countries", 268], [",", 277], ["including", 279], ["Japan", 289], ["and", 295], ["those", 299], ["of", 305], ["the", 308], ["EU", 312], [",", 314], ["for", 316], ["use", 320], ["as", 324], ["part", 327], ["of", 332], ["an", 335], ["appropriate", 338], ["combination", 350], ["regimen", 362], ["in", 370], ["adults", 373], ["with", 380], ["multidrug", 385], ["-", 394], ["resistant", 395], ["tuberculosis", 405], ["(", 418], ["MDR", 419], ["-", 422], ["TB", 423], [")", 425], ["when", 427], ["an", 432], ["effective", 435], ["treatment", 445], ["regimen", 455], ["can", 463], ["not", 466], ["otherwise", 470], ["be", 480], ["composed", 483], ["due", 492], ["to", 496], ["resistance", 499], ["or", 510], ["tolerability", 513], [".", 525], ["In", 527], ["a", 530], ["robust", 532], ["phase", 539], ["II", 545], ["trial", 548], ["in", 554], ["adult", 557], ["patients", 563], ["with", 572], ["MDR", 577], ["-", 580], ["TB", 581], [",", 583], ["oral", 585], ["delamanid", 590], ["100", 600], ["mg", 604], ["twice", 607], ["daily", 613], ["for", 619], ["2", 623], ["months", 625], ["plus", 632], ["an", 637], ["optimized", 640], ["background", 650], ["regimen", 661], ["improved", 669], ["sputum", 678], ["culture", 685], ["conversion", 693], ["rates", 704], ["to", 710], ["a", 713], ["significantly", 715], ["greater", 729], ["extent", 737], ["than", 744], ["placebo", 749], [".", 756], ["In", 758], ["a", 761], ["6-month", 763], ["extension", 771], ["study", 781], [",", 786], ["long", 788], ["-", 792], ["term", 793], ["(", 798], ["\u22648", 799], ["months", 802], [")", 808], ["treatment", 810], ["with", 820], ["delamanid", 825], ["was", 835], ["associated", 839], ["with", 850], ["a", 855], ["higher", 857], ["incidence", 864], ["of", 874], ["favourable", 877], ["outcomes", 888], ["(", 897], ["i.e.", 898], ["cured", 903], ["or", 909], ["completed", 912], ["all", 922], ["treatment", 926], [")", 935], ["than", 937], ["short", 942], ["-", 947], ["term", 948], ["(", 953], ["\u22642", 954], ["months", 957], [")", 963], ["treatment", 965], [",", 974], ["with", 976], ["an", 981], ["accompanying", 984], ["reduction", 997], ["inunfavourable", 1007], ["outcomes", 1022], ["as", 1031], ["defined", 1034], ["by", 1042], ["the", 1045], ["WHO", 1049], ["(", 1053], ["i.e.", 1054], ["pre", 1059], ["-", 1062], ["specified", 1063], ["proportion", 1073], ["of", 1084], ["TB", 1087], ["-", 1089], ["positive", 1090], ["sputum", 1099], ["cultures", 1106], [",", 1114], ["death", 1116], ["or", 1122], ["treatment", 1125], ["discontinuation", 1135], ["for", 1151], ["\u22652", 1155], ["months", 1158], ["without", 1165], ["medical", 1173], ["approval", 1181], [")", 1189], [".", 1190], ["Delamanid", 1192], ["was", 1202], ["not", 1206], ["associated", 1210], ["with", 1221], ["clinically", 1226], ["relevant", 1237], ["drug", 1246], ["-", 1250], ["drug", 1251], ["interactions", 1256], [",", 1268], ["including", 1270], ["with", 1280], ["antiretroviral", 1285], ["drugs", 1300], ["and", 1306], ["those", 1310], ["commonly", 1316], ["used", 1325], ["in", 1330], ["treating", 1333], ["TB", 1342], [".", 1344], ["Delamanid", 1346], ["was", 1356], ["generally", 1360], ["well", 1370], ["tolerated", 1375], ["in", 1385], ["patients", 1388], ["with", 1397], ["MDR", 1402], ["-", 1405], ["TB", 1406], [",", 1408], ["with", 1410], ["gastrointestinal", 1415], ["adverse", 1432], ["events", 1440], ["and", 1447], ["insomnia", 1451], ["reported", 1460], ["most", 1469], ["commonly", 1474], [".", 1482], ["Although", 1484], ["the", 1493], ["incidence", 1497], ["of", 1507], ["QT", 1510], ["interval", 1513], ["prolongation", 1522], ["was", 1535], ["higher", 1539], ["with", 1546], ["delamanid", 1551], ["-", 1560], ["based", 1561], ["therapy", 1567], [",", 1574], ["it", 1576], ["was", 1579], ["not", 1583], ["associated", 1587], ["with", 1598], ["clinical", 1603], ["symptoms", 1612], ["such", 1621], ["as", 1626], ["syncope", 1629], ["and", 1637], ["arrhythmia", 1641], [".", 1651], ["In", 1653], ["conclusion", 1656], [",", 1666], ["delamanid", 1668], ["is", 1678], ["a", 1681], ["useful", 1683], ["addition", 1690], ["to", 1699], ["the", 1702], ["treatment", 1706], ["options", 1716], ["currently", 1724], ["available", 1734], ["for", 1744], ["patients", 1748], ["with", 1757], ["MDR", 1762], ["-", 1765], ["TB", 1766], [".", 1768]]}
{"context": "To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies. A total of 219 patients with active RA in whom treatment with biologic agents had failed were enrolled in a 3-month multicenter, randomized, double-blind, placebo-controlled trial of R788. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at month 3. Secondary end points included changes in inflammation and damage, as assessed by magnetic resonance imaging (MRI), and changes in the Disease Activity Score. The ACR20 response in the R788 100 mg twice daily group was 38%, versus 37% in the placebo group, at month 3. No significant differences were achieved in the ACR20, ACR50, or ACR70 response levels at 3 months. There were differences between the groups from baseline to month 3 in the secondary end points C-reactive protein (CRP) level and synovitis score on MRI. There were baseline differences in steroid use, prior biologic use, and synovitis score on MRI between the R788 group and the placebo group that may have affected the outcomes. A high placebo response rate was seen in this trial, and exploratory analysis suggested that this may in part have been driven by patients who entered the trial with an elevated erythrocyte sedimentation rate but normal CRP level. Our findings indicate that there were no differences in the primary end point between the R788 and placebo groups. Differences were observed between the R788 and placebo groups in secondary end points, particularly in those patients who entered the study with an elevated CRP level.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "da2a8dc6772a49fb956f810030d12b53", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[16, 18]], "char_spans": [[83, 104]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], ["and", 23], ["safety", 27], ["of", 34], ["R788", 37], ["(", 42], ["fostamatinib", 43], ["disodium", 56], [")", 64], [",", 65], ["an", 67], ["inhibitor", 70], ["of", 80], ["spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], [",", 111], ["in", 113], ["patients", 116], ["with", 125], ["active", 130], ["rheumatoid", 137], ["arthritis", 148], ["(", 158], ["RA", 159], [")", 161], ["that", 163], ["did", 168], ["not", 172], ["respond", 176], ["to", 184], ["biologic", 187], ["therapies", 196], [".", 205], ["A", 207], ["total", 209], ["of", 215], ["219", 218], ["patients", 222], ["with", 231], ["active", 236], ["RA", 243], ["in", 246], ["whom", 249], ["treatment", 254], ["with", 264], ["biologic", 269], ["agents", 278], ["had", 285], ["failed", 289], ["were", 296], ["enrolled", 301], ["in", 310], ["a", 313], ["3-month", 315], ["multicenter", 323], [",", 334], ["randomized", 336], [",", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["placebo", 362], ["-", 369], ["controlled", 370], ["trial", 381], ["of", 387], ["R788", 390], [".", 394], ["The", 396], ["primary", 400], ["end", 408], ["point", 412], ["was", 418], ["the", 422], ["percentage", 426], ["of", 437], ["patients", 440], ["who", 449], ["met", 453], ["the", 457], ["American", 461], ["College", 470], ["of", 478], ["Rheumatology", 481], ["20", 494], ["%", 496], ["improvement", 498], ["criteria", 510], ["(", 519], ["achieved", 520], ["an", 529], ["ACR20", 532], ["response", 538], [")", 546], ["at", 548], ["month", 551], ["3", 557], [".", 558], ["Secondary", 560], ["end", 570], ["points", 574], ["included", 581], ["changes", 590], ["in", 598], ["inflammation", 601], ["and", 614], ["damage", 618], [",", 624], ["as", 626], ["assessed", 629], ["by", 638], ["magnetic", 641], ["resonance", 650], ["imaging", 660], ["(", 668], ["MRI", 669], [")", 672], [",", 673], ["and", 675], ["changes", 679], ["in", 687], ["the", 690], ["Disease", 694], ["Activity", 702], ["Score", 711], [".", 716], ["The", 718], ["ACR20", 722], ["response", 728], ["in", 737], ["the", 740], ["R788", 744], ["100", 749], ["mg", 753], ["twice", 756], ["daily", 762], ["group", 768], ["was", 774], ["38", 778], ["%", 780], [",", 781], ["versus", 783], ["37", 790], ["%", 792], ["in", 794], ["the", 797], ["placebo", 801], ["group", 809], [",", 814], ["at", 816], ["month", 819], ["3", 825], [".", 826], ["No", 828], ["significant", 831], ["differences", 843], ["were", 855], ["achieved", 860], ["in", 869], ["the", 872], ["ACR20", 876], [",", 881], ["ACR50", 883], [",", 888], ["or", 890], ["ACR70", 893], ["response", 899], ["levels", 908], ["at", 915], ["3", 918], ["months", 920], [".", 926], ["There", 928], ["were", 934], ["differences", 939], ["between", 951], ["the", 959], ["groups", 963], ["from", 970], ["baseline", 975], ["to", 984], ["month", 987], ["3", 993], ["in", 995], ["the", 998], ["secondary", 1002], ["end", 1012], ["points", 1016], ["C", 1023], ["-", 1024], ["reactive", 1025], ["protein", 1034], ["(", 1042], ["CRP", 1043], [")", 1046], ["level", 1048], ["and", 1054], ["synovitis", 1058], ["score", 1068], ["on", 1074], ["MRI", 1077], [".", 1080], ["There", 1082], ["were", 1088], ["baseline", 1093], ["differences", 1102], ["in", 1114], ["steroid", 1117], ["use", 1125], [",", 1128], ["prior", 1130], ["biologic", 1136], ["use", 1145], [",", 1148], ["and", 1150], ["synovitis", 1154], ["score", 1164], ["on", 1170], ["MRI", 1173], ["between", 1177], ["the", 1185], ["R788", 1189], ["group", 1194], ["and", 1200], ["the", 1204], ["placebo", 1208], ["group", 1216], ["that", 1222], ["may", 1227], ["have", 1231], ["affected", 1236], ["the", 1245], ["outcomes", 1249], [".", 1257], ["A", 1259], ["high", 1261], ["placebo", 1266], ["response", 1274], ["rate", 1283], ["was", 1288], ["seen", 1292], ["in", 1297], ["this", 1300], ["trial", 1305], [",", 1310], ["and", 1312], ["exploratory", 1316], ["analysis", 1328], ["suggested", 1337], ["that", 1347], ["this", 1352], ["may", 1357], ["in", 1361], ["part", 1364], ["have", 1369], ["been", 1374], ["driven", 1379], ["by", 1386], ["patients", 1389], ["who", 1398], ["entered", 1402], ["the", 1410], ["trial", 1414], ["with", 1420], ["an", 1425], ["elevated", 1428], ["erythrocyte", 1437], ["sedimentation", 1449], ["rate", 1463], ["but", 1468], ["normal", 1472], ["CRP", 1479], ["level", 1483], [".", 1488], ["Our", 1490], ["findings", 1494], ["indicate", 1503], ["that", 1512], ["there", 1517], ["were", 1523], ["no", 1528], ["differences", 1531], ["in", 1543], ["the", 1546], ["primary", 1550], ["end", 1558], ["point", 1562], ["between", 1568], ["the", 1576], ["R788", 1580], ["and", 1585], ["placebo", 1589], ["groups", 1597], [".", 1603], ["Differences", 1605], ["were", 1617], ["observed", 1622], ["between", 1631], ["the", 1639], ["R788", 1643], ["and", 1648], ["placebo", 1652], ["groups", 1660], ["in", 1667], ["secondary", 1670], ["end", 1680], ["points", 1684], [",", 1690], ["particularly", 1692], ["in", 1705], ["those", 1708], ["patients", 1714], ["who", 1723], ["entered", 1727], ["the", 1735], ["study", 1739], ["with", 1745], ["an", 1750], ["elevated", 1753], ["CRP", 1762], ["level", 1766], [".", 1771]]}
{"context": "Mutations in FOXP2 cause developmental verbal dyspraxia (DVD), but only a few cases have been described. We characterize 13 patients with DVD--5 with hemizygous paternal deletions spanning the FOXP2 gene, 1 with a translocation interrupting FOXP2, and the remaining 7 with maternal uniparental disomy of chromosome 7 (UPD7), who were also given a diagnosis of Silver-Russell Syndrome (SRS). Of these individuals with DVD, all 12 for whom parental DNA was available showed absence of a paternal copy of FOXP2. Five other individuals with deletions of paternally inherited FOXP2 but with incomplete clinical information or phenotypes too complex to properly assess are also described. Four of the patients with DVD also meet criteria for autism spectrum disorder. Individuals with paternal UPD7 or with partial maternal UPD7 or deletion starting downstream of FOXP2 do not have DVD. Using quantitative real-time polymerase chain reaction, we show the maternally inherited FOXP2 to be comparatively underexpressed. Our results indicate that absence of paternal FOXP2 is the cause of DVD in patients with SRS with maternal UPD7. The data also point to a role for differential parent-of-origin expression of FOXP2 in human speech development.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "a5597097671740739398b8d4cab19549", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[32, 32], [93, 93], [181, 181], [211, 211], [148, 148], [103, 103], [40, 40], [168, 168], [2, 2]], "char_spans": [[193, 197], [502, 506], [1058, 1062], [1203, 1207], [858, 862], [571, 575], [241, 245], [970, 974], [13, 17]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["FOXP2", 13], ["cause", 19], ["developmental", 25], ["verbal", 39], ["dyspraxia", 46], ["(", 56], ["DVD", 57], [")", 60], [",", 61], ["but", 63], ["only", 67], ["a", 72], ["few", 74], ["cases", 78], ["have", 84], ["been", 89], ["described", 94], [".", 103], ["We", 105], ["characterize", 108], ["13", 121], ["patients", 124], ["with", 133], ["DVD--5", 138], ["with", 145], ["hemizygous", 150], ["paternal", 161], ["deletions", 170], ["spanning", 180], ["the", 189], ["FOXP2", 193], ["gene", 199], [",", 203], ["1", 205], ["with", 207], ["a", 212], ["translocation", 214], ["interrupting", 228], ["FOXP2", 241], [",", 246], ["and", 248], ["the", 252], ["remaining", 256], ["7", 266], ["with", 268], ["maternal", 273], ["uniparental", 282], ["disomy", 294], ["of", 301], ["chromosome", 304], ["7", 315], ["(", 317], ["UPD7", 318], [")", 322], [",", 323], ["who", 325], ["were", 329], ["also", 334], ["given", 339], ["a", 345], ["diagnosis", 347], ["of", 357], ["Silver", 360], ["-", 366], ["Russell", 367], ["Syndrome", 375], ["(", 384], ["SRS", 385], [")", 388], [".", 389], ["Of", 391], ["these", 394], ["individuals", 400], ["with", 412], ["DVD", 417], [",", 420], ["all", 422], ["12", 426], ["for", 429], ["whom", 433], ["parental", 438], ["DNA", 447], ["was", 451], ["available", 455], ["showed", 465], ["absence", 472], ["of", 480], ["a", 483], ["paternal", 485], ["copy", 494], ["of", 499], ["FOXP2", 502], [".", 507], ["Five", 509], ["other", 514], ["individuals", 520], ["with", 532], ["deletions", 537], ["of", 547], ["paternally", 550], ["inherited", 561], ["FOXP2", 571], ["but", 577], ["with", 581], ["incomplete", 586], ["clinical", 597], ["information", 606], ["or", 618], ["phenotypes", 621], ["too", 632], ["complex", 636], ["to", 644], ["properly", 647], ["assess", 656], ["are", 663], ["also", 667], ["described", 672], [".", 681], ["Four", 683], ["of", 688], ["the", 691], ["patients", 695], ["with", 704], ["DVD", 709], ["also", 713], ["meet", 718], ["criteria", 723], ["for", 732], ["autism", 736], ["spectrum", 743], ["disorder", 752], [".", 760], ["Individuals", 762], ["with", 774], ["paternal", 779], ["UPD7", 788], ["or", 793], ["with", 796], ["partial", 801], ["maternal", 809], ["UPD7", 818], ["or", 823], ["deletion", 826], ["starting", 835], ["downstream", 844], ["of", 855], ["FOXP2", 858], ["do", 864], ["not", 867], ["have", 871], ["DVD", 876], [".", 879], ["Using", 881], ["quantitative", 887], ["real", 900], ["-", 904], ["time", 905], ["polymerase", 910], ["chain", 921], ["reaction", 927], [",", 935], ["we", 937], ["show", 940], ["the", 945], ["maternally", 949], ["inherited", 960], ["FOXP2", 970], ["to", 976], ["be", 979], ["comparatively", 982], ["underexpressed", 996], [".", 1010], ["Our", 1012], ["results", 1016], ["indicate", 1024], ["that", 1033], ["absence", 1038], ["of", 1046], ["paternal", 1049], ["FOXP2", 1058], ["is", 1064], ["the", 1067], ["cause", 1071], ["of", 1077], ["DVD", 1080], ["in", 1084], ["patients", 1087], ["with", 1096], ["SRS", 1101], ["with", 1105], ["maternal", 1110], ["UPD7", 1119], [".", 1123], ["The", 1125], ["data", 1129], ["also", 1134], ["point", 1139], ["to", 1145], ["a", 1148], ["role", 1150], ["for", 1155], ["differential", 1159], ["parent", 1172], ["-", 1178], ["of", 1179], ["-", 1181], ["origin", 1182], ["expression", 1189], ["of", 1200], ["FOXP2", 1203], ["in", 1209], ["human", 1212], ["speech", 1218], ["development", 1225], [".", 1236]]}
{"context": "Atrial fibrillation (AF), a common cardiac arrhythmia associated with increased risk of heart failure, thromboembolic phenomena and death, is a leading cause of hospitalization of adults. A major complication of AF is an increased risk of ischemic stroke leading to long-term disability and in severe cases, death. Historically, Coumadin has been the drug of choice for chronic anticoagulation and stroke prevention in AF patients however, given the need for constant monitoring and multiple drug interactions, newer anticoagulants have been developed. One such drug is dabigatran, with the promise of less frequent monitoring and decreased bleeding tendencies as compared to Coumadin. The main disadvantage of dabigatran has been the lack of a reversal agent in case of severe bleeding or emergent surgical intervention. This was until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran. In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d6e9cee2def349948db2eae4577d1aaa", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[158, 158], [120, 120], [180, 180], [98, 98]], "char_spans": [[938, 947], [711, 720], [1077, 1086], [570, 579]]}]}], "context_tokens": [["Atrial", 0], ["fibrillation", 7], ["(", 20], ["AF", 21], [")", 23], [",", 24], ["a", 26], ["common", 28], ["cardiac", 35], ["arrhythmia", 43], ["associated", 54], ["with", 65], ["increased", 70], ["risk", 80], ["of", 85], ["heart", 88], ["failure", 94], [",", 101], ["thromboembolic", 103], ["phenomena", 118], ["and", 128], ["death", 132], [",", 137], ["is", 139], ["a", 142], ["leading", 144], ["cause", 152], ["of", 158], ["hospitalization", 161], ["of", 177], ["adults", 180], [".", 186], ["A", 188], ["major", 190], ["complication", 196], ["of", 209], ["AF", 212], ["is", 215], ["an", 218], ["increased", 221], ["risk", 231], ["of", 236], ["ischemic", 239], ["stroke", 248], ["leading", 255], ["to", 263], ["long", 266], ["-", 270], ["term", 271], ["disability", 276], ["and", 287], ["in", 291], ["severe", 294], ["cases", 301], [",", 306], ["death", 308], [".", 313], ["Historically", 315], [",", 327], ["Coumadin", 329], ["has", 338], ["been", 342], ["the", 347], ["drug", 351], ["of", 356], ["choice", 359], ["for", 366], ["chronic", 370], ["anticoagulation", 378], ["and", 394], ["stroke", 398], ["prevention", 405], ["in", 416], ["AF", 419], ["patients", 422], ["however", 431], [",", 438], ["given", 440], ["the", 446], ["need", 450], ["for", 455], ["constant", 459], ["monitoring", 468], ["and", 479], ["multiple", 483], ["drug", 492], ["interactions", 497], [",", 509], ["newer", 511], ["anticoagulants", 517], ["have", 532], ["been", 537], ["developed", 542], [".", 551], ["One", 553], ["such", 557], ["drug", 562], ["is", 567], ["dabigatran", 570], [",", 580], ["with", 582], ["the", 587], ["promise", 591], ["of", 599], ["less", 602], ["frequent", 607], ["monitoring", 616], ["and", 627], ["decreased", 631], ["bleeding", 641], ["tendencies", 650], ["as", 661], ["compared", 664], ["to", 673], ["Coumadin", 676], [".", 684], ["The", 686], ["main", 690], ["disadvantage", 695], ["of", 708], ["dabigatran", 711], ["has", 722], ["been", 726], ["the", 731], ["lack", 735], ["of", 740], ["a", 743], ["reversal", 745], ["agent", 754], ["in", 760], ["case", 763], ["of", 768], ["severe", 771], ["bleeding", 778], ["or", 787], ["emergent", 790], ["surgical", 799], ["intervention", 808], [".", 820], ["This", 822], ["was", 827], ["until", 831], ["the", 837], ["recent", 841], ["The", 848], ["Food", 852], ["and", 857], ["Drug", 861], ["Administration", 866], ["approval", 881], ["of", 890], ["idarucizumab", 893], [",", 905], ["a", 907], ["potential", 909], ["reversal", 919], ["agent", 928], ["for", 934], ["dabigatran", 938], [".", 948], ["In", 950], ["this", 953], ["article", 958], [",", 965], ["we", 967], ["discuss", 970], ["the", 978], ["evidence", 982], ["addressing", 991], ["idarucizumab", 1002], ["safety", 1015], [",", 1021], ["tolerability", 1023], ["and", 1036], ["its", 1040], ["efficacy", 1044], ["for", 1053], ["reversing", 1057], ["effect", 1067], ["of", 1074], ["dabigatran", 1077], [".", 1087]]}
{"context": "The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36). To date, the intrinsic properties of NSD1 that determine its nucleosomal substrate selectivity and dimethyl H3K36 product specificity remain unknown. The 1.7 \u00c5 structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine. Molecular dynamics simulation and computational docking revealed that this normally inhibitory loop can adopt an active conformation, allowing H3K36 access to the active site, and that the nucleosome may stabilize the active conformation of the regulatory loop. Hence, our study reveals an autoregulatory mechanism of NSD1 and provides insight into the molecular mechanism of the nucleosomal substrate selectivity of this disease-related H3K36 methyltransferase.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d8dc6dcb02604df98e1a216e74a229fa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[10, 11]], "char_spans": [[44, 53]]}]}], "context_tokens": [["The", 0], ["Sotos", 4], ["syndrome", 10], ["gene", 19], ["product", 24], [",", 31], ["NSD1", 33], [",", 37], ["is", 39], ["a", 42], ["SET", 44], ["domain", 48], ["histone", 55], ["methyltransferase", 63], ["that", 81], ["primarily", 86], ["dimethylates", 96], ["nucleosomal", 109], ["histone", 121], ["H3", 129], ["lysine", 132], ["36", 139], ["(", 142], ["H3K36", 143], [")", 148], [".", 149], ["To", 151], ["date", 154], [",", 158], ["the", 160], ["intrinsic", 164], ["properties", 174], ["of", 185], ["NSD1", 188], ["that", 193], ["determine", 198], ["its", 208], ["nucleosomal", 212], ["substrate", 224], ["selectivity", 234], ["and", 246], ["dimethyl", 250], ["H3K36", 259], ["product", 265], ["specificity", 273], ["remain", 285], ["unknown", 292], [".", 299], ["The", 301], ["1.7", 305], ["\u00c5", 309], ["structure", 311], ["of", 321], ["the", 324], ["catalytic", 328], ["domain", 338], ["of", 345], ["NSD1", 348], ["presented", 353], ["here", 363], ["shows", 368], ["that", 374], ["a", 379], ["regulatory", 381], ["loop", 392], ["adopts", 397], ["a", 404], ["conformation", 406], ["that", 419], ["prevents", 424], ["free", 433], ["access", 438], ["of", 445], ["H3K36", 448], ["to", 454], ["the", 457], ["bound", 461], ["S", 467], ["-", 468], ["adenosyl", 469], ["-", 477], ["L", 478], ["-", 479], ["methionine", 480], [".", 490], ["Molecular", 492], ["dynamics", 502], ["simulation", 511], ["and", 522], ["computational", 526], ["docking", 540], ["revealed", 548], ["that", 557], ["this", 562], ["normally", 567], ["inhibitory", 576], ["loop", 587], ["can", 592], ["adopt", 596], ["an", 602], ["active", 605], ["conformation", 612], [",", 624], ["allowing", 626], ["H3K36", 635], ["access", 641], ["to", 648], ["the", 651], ["active", 655], ["site", 662], [",", 666], ["and", 668], ["that", 672], ["the", 677], ["nucleosome", 681], ["may", 692], ["stabilize", 696], ["the", 706], ["active", 710], ["conformation", 717], ["of", 730], ["the", 733], ["regulatory", 737], ["loop", 748], [".", 752], ["Hence", 754], [",", 759], ["our", 761], ["study", 765], ["reveals", 771], ["an", 779], ["autoregulatory", 782], ["mechanism", 797], ["of", 807], ["NSD1", 810], ["and", 815], ["provides", 819], ["insight", 828], ["into", 836], ["the", 841], ["molecular", 845], ["mechanism", 855], ["of", 865], ["the", 868], ["nucleosomal", 872], ["substrate", 884], ["selectivity", 894], ["of", 906], ["this", 909], ["disease", 914], ["-", 921], ["related", 922], ["H3K36", 930], ["methyltransferase", 936], [".", 953]]}
{"context": "We have investigated the contribution of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC). NE enhanced release of AA via activation of cytosolic phospholipase A2 (cPLA2) but not secretory PLA2 in VSMC prelabeled with [3H]AA. NE (10 microM) enhanced CaM kinase II and MAP kinase activity. In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2. NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity. Phosphorylation of MAP kinase and CaM kinase II by NE, studied by 32P incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA2 to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase. Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA2 to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes. Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA2 and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "4c1e2ae7b3044ebdbc54ebb2645c4732", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[247, 249], [305, 307], [220, 222], [101, 103], [13, 15], [210, 212], [280, 282], [79, 81], [361, 363], [176, 178], [167, 169]], "char_spans": [[1369, 1381], [1704, 1716], [1223, 1235], [581, 593], [86, 98], [1165, 1177], [1550, 1562], [424, 436], [2001, 2013], [968, 980], [928, 940]]}]}], "context_tokens": [["We", 0], ["have", 3], ["investigated", 8], ["the", 21], ["contribution", 25], ["of", 38], ["Ca2+/calmodulin", 41], ["-", 56], ["dependent", 57], ["protein", 67], ["kinase", 75], ["II", 82], ["(", 85], ["CaM", 86], ["kinase", 90], ["II", 97], [")", 99], ["and", 101], ["mitogen", 105], ["-", 112], ["activated", 113], ["protein", 123], ["kinase", 131], ["(", 138], ["MAP", 139], ["kinase", 143], [")", 149], ["in", 151], ["norepinephrine", 154], ["(", 169], ["NE)-induced", 170], ["arachidonic", 182], ["acid", 194], ["(", 199], ["AA", 200], [")", 202], ["release", 204], ["in", 212], ["rabbit", 215], ["aortic", 222], ["vascular", 229], ["smooth", 238], ["muscle", 245], ["cells", 252], ["(", 258], ["VSMC", 259], [")", 263], [".", 264], ["NE", 266], ["enhanced", 269], ["release", 278], ["of", 286], ["AA", 289], ["via", 292], ["activation", 296], ["of", 307], ["cytosolic", 310], ["phospholipase", 320], ["A2", 334], ["(", 337], ["cPLA2", 338], [")", 343], ["but", 345], ["not", 349], ["secretory", 353], ["PLA2", 363], ["in", 368], ["VSMC", 371], ["prelabeled", 376], ["with", 387], ["[", 392], ["3H]AA", 393], [".", 398], ["NE", 400], ["(", 403], ["10", 404], ["microM", 407], [")", 413], ["enhanced", 415], ["CaM", 424], ["kinase", 428], ["II", 435], ["and", 438], ["MAP", 442], ["kinase", 446], ["activity", 453], [".", 461], ["In", 463], ["cells", 466], ["transiently", 472], ["transfected", 484], ["with", 496], ["antisense", 501], ["oligonucleotides", 511], ["complementary", 528], ["to", 542], ["the", 545], ["translation", 549], ["initiation", 561], ["sites", 572], ["of", 578], ["CaM", 581], ["kinase", 585], ["II", 592], ["and", 595], ["MAP", 599], ["kinase", 603], [",", 609], ["NE", 611], ["-", 613], ["induced", 614], ["AA", 622], ["release", 625], ["was", 633], ["inhibited", 637], ["by", 647], ["100", 650], ["and", 654], ["35", 658], ["%", 660], ["respectively", 662], [".", 674], ["Treatment", 676], ["of", 686], ["cells", 689], ["with", 695], ["PD-098059", 700], [",", 709], ["a", 711], ["MAP", 713], ["kinase", 717], ["kinase", 724], ["inhibitor", 731], [",", 740], ["or", 742], ["with", 745], ["MAP", 750], ["kinase", 754], ["antisense", 761], ["oligonucleotide", 771], ["reduced", 787], ["NE", 795], ["-", 797], ["induced", 798], ["activation", 806], ["of", 817], ["MAP", 820], ["kinase", 824], ["and", 831], ["cPLA2", 835], [".", 840], ["NE", 842], ["-", 844], ["induced", 845], ["MAP", 853], ["kinase", 857], ["and", 864], ["cPLA2", 868], ["activation", 874], ["was", 885], ["also", 889], ["inhibited", 894], ["in", 904], ["cells", 907], ["treated", 913], ["with", 921], ["a", 926], ["CaM", 928], ["kinase", 932], ["II", 939], ["inhibitor", 942], [",", 951], ["KN-93", 953], [",", 958], ["or", 960], ["with", 963], ["CaM", 968], ["kinase", 972], ["II", 979], ["antisense", 982], ["oligonucleotide", 992], [".", 1007], ["On", 1009], ["the", 1012], ["other", 1016], ["hand", 1022], [",", 1026], ["inhibition", 1028], ["of", 1039], ["MAP", 1042], ["kinase", 1046], ["kinase", 1053], ["with", 1060], ["PD-098059", 1065], ["or", 1075], ["of", 1078], ["MAP", 1081], ["kinase", 1085], ["with", 1092], ["antisense", 1097], ["oligonucleotides", 1107], ["did", 1124], ["not", 1128], ["alter", 1132], ["the", 1138], ["NE", 1142], ["-", 1144], ["induced", 1145], ["increase", 1153], ["in", 1162], ["CaM", 1165], ["kinase", 1169], ["II", 1176], ["activity", 1179], [".", 1187], ["Phosphorylation", 1189], ["of", 1205], ["MAP", 1208], ["kinase", 1212], ["and", 1219], ["CaM", 1223], ["kinase", 1227], ["II", 1234], ["by", 1237], ["NE", 1240], [",", 1242], ["studied", 1244], ["by", 1252], ["32P", 1255], ["incorporation", 1259], ["and", 1273], ["immune", 1277], ["complex", 1284], ["kinase", 1292], ["assays", 1299], [",", 1305], ["was", 1307], ["inhibited", 1311], ["by", 1321], ["KN-93", 1324], [".", 1329], ["Collectively", 1331], [",", 1343], ["these", 1345], ["data", 1351], ["suggest", 1356], ["that", 1364], ["CaM", 1369], ["kinase", 1373], ["II", 1380], ["can", 1383], ["activate", 1387], ["MAP", 1396], ["kinase", 1400], [",", 1406], ["which", 1408], ["in", 1414], ["turn", 1417], ["activates", 1422], ["cPLA2", 1432], ["to", 1438], ["release", 1441], ["AA", 1449], ["for", 1452], ["prostacyclin", 1456], ["synthesis", 1469], ["in", 1479], ["the", 1482], ["rabbit", 1486], ["VSMC", 1493], [".", 1497], ["This", 1499], ["novel", 1504], ["pathway", 1510], ["for", 1518], ["activation", 1522], ["of", 1533], ["MAP", 1536], ["kinase", 1540], ["by", 1547], ["CaM", 1550], ["kinase", 1554], ["II", 1561], ["appears", 1564], ["to", 1572], ["be", 1575], ["mediated", 1578], ["through", 1587], ["stimulation", 1595], ["of", 1607], ["MAP", 1610], ["kinase", 1614], ["kinase", 1621], [".", 1627], ["Activation", 1629], ["of", 1640], ["adrenergic", 1643], ["receptors", 1654], ["with", 1664], ["NE", 1669], ["in", 1672], ["VSMC", 1675], ["caused", 1680], ["translocation", 1687], ["of", 1701], ["CaM", 1704], ["kinase", 1708], ["II", 1715], [",", 1717], ["MAP", 1719], ["kinase", 1723], [",", 1729], ["and", 1731], ["cPLA2", 1735], ["to", 1741], ["the", 1744], ["nuclear", 1748], ["envelope", 1756], ["only", 1765], ["in", 1770], ["the", 1773], ["presence", 1777], ["of", 1786], ["extracellular", 1789], ["Ca2", 1803], ["+", 1806], [".", 1807], ["Okadaic", 1809], ["acid", 1817], [",", 1821], ["which", 1823], ["increased", 1829], ["phosphorylation", 1839], ["and", 1855], ["activity", 1859], [",", 1867], ["did", 1869], ["not", 1873], ["translocate", 1877], ["these", 1889], ["enzymes", 1895], [".", 1902], ["Therefore", 1904], [",", 1913], ["it", 1915], ["appears", 1918], ["that", 1926], ["in", 1931], ["rabbit", 1934], ["VSMC", 1941], [",", 1945], ["NE", 1947], [",", 1949], ["by", 1951], ["promoting", 1954], ["extracellular", 1964], ["Ca2", 1978], ["+", 1981], ["influx", 1983], [",", 1989], ["increases", 1991], ["CaM", 2001], ["kinase", 2005], ["II", 2012], ["activity", 2015], [",", 2023], ["leading", 2025], ["to", 2033], ["activation", 2036], ["of", 2047], ["MAP", 2050], ["kinase", 2054], ["and", 2061], ["cPLA2", 2065], ["and", 2071], ["translocation", 2075], ["to", 2089], ["the", 2092], ["nuclear", 2096], ["envelope", 2104], [",", 2112], ["resulting", 2114], ["in", 2124], ["release", 2127], ["of", 2135], ["AA", 2138], ["from", 2141], ["the", 2146], ["nuclear", 2150], ["envelope", 2158], ["for", 2167], ["prostacyclin", 2171], ["synthesis", 2184], [".", 2193]]}
{"context": "Long QT and short QT syndromes (LQTS and SQTS) are cardiac repolarization abnormalities that are characterized by length perturbations of the QT interval as measured on electrocardiogram (ECG). Prolonged QT interval and a propensity for ventricular tachycardia of the torsades de pointes (TdP) type are characteristic of LQTS, while SQTS is characterized by shortened QT interval with tall peaked T-waves and a propensity for atrial fibrillation. Both syndromes represent a high risk for syncope and sudden death. LQTS exists as a congenital genetic disease (cLQTS) with more than 700 mutations described in 12 genes (LQT1-12), but can also be acquired (aLQTS). The genetic forms of LQTS include Romano-Ward syndrome (RWS), which is characterized by isolated LQTS and an autosomal dominant pattern of inheritance, and syndromes with LQTS in association with other conditions. The latter includes Jervell and Lange-Nielsen syndrome (JLNS), Andersen syndrome (AS), and Timothy syndrome (TS). The genetics are further complicated by the occurrence of double and triple heterozygotes in LQTS and a considerable number of nonpathogenic rare polymorphisms in the involved genes. SQTS is a very rare condition, caused by mutations in five genes (SQTS1-5). The present mutation update is a comprehensive description of all known LQTS- and SQTS-associated mutations.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "857f5bd2ba3140ffa45bbf468805dfa3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[145, 146]], "char_spans": [[771, 788]]}]}], "context_tokens": [["Long", 0], ["QT", 5], ["and", 8], ["short", 12], ["QT", 18], ["syndromes", 21], ["(", 31], ["LQTS", 32], ["and", 37], ["SQTS", 41], [")", 45], ["are", 47], ["cardiac", 51], ["repolarization", 59], ["abnormalities", 74], ["that", 88], ["are", 93], ["characterized", 97], ["by", 111], ["length", 114], ["perturbations", 121], ["of", 135], ["the", 138], ["QT", 142], ["interval", 145], ["as", 154], ["measured", 157], ["on", 166], ["electrocardiogram", 169], ["(", 187], ["ECG", 188], [")", 191], [".", 192], ["Prolonged", 194], ["QT", 204], ["interval", 207], ["and", 216], ["a", 220], ["propensity", 222], ["for", 233], ["ventricular", 237], ["tachycardia", 249], ["of", 261], ["the", 264], ["torsades", 268], ["de", 277], ["pointes", 280], ["(", 288], ["TdP", 289], [")", 292], ["type", 294], ["are", 299], ["characteristic", 303], ["of", 318], ["LQTS", 321], [",", 325], ["while", 327], ["SQTS", 333], ["is", 338], ["characterized", 341], ["by", 355], ["shortened", 358], ["QT", 368], ["interval", 371], ["with", 380], ["tall", 385], ["peaked", 390], ["T", 397], ["-", 398], ["waves", 399], ["and", 405], ["a", 409], ["propensity", 411], ["for", 422], ["atrial", 426], ["fibrillation", 433], [".", 445], ["Both", 447], ["syndromes", 452], ["represent", 462], ["a", 472], ["high", 474], ["risk", 479], ["for", 484], ["syncope", 488], ["and", 496], ["sudden", 500], ["death", 507], [".", 512], ["LQTS", 514], ["exists", 519], ["as", 526], ["a", 529], ["congenital", 531], ["genetic", 542], ["disease", 550], ["(", 558], ["cLQTS", 559], [")", 564], ["with", 566], ["more", 571], ["than", 576], ["700", 581], ["mutations", 585], ["described", 595], ["in", 605], ["12", 608], ["genes", 611], ["(", 617], ["LQT1", 618], ["-", 622], ["12", 623], [")", 625], [",", 626], ["but", 628], ["can", 632], ["also", 636], ["be", 641], ["acquired", 644], ["(", 653], ["aLQTS", 654], [")", 659], [".", 660], ["The", 662], ["genetic", 666], ["forms", 674], ["of", 680], ["LQTS", 683], ["include", 688], ["Romano", 696], ["-", 702], ["Ward", 703], ["syndrome", 708], ["(", 717], ["RWS", 718], [")", 721], [",", 722], ["which", 724], ["is", 730], ["characterized", 733], ["by", 747], ["isolated", 750], ["LQTS", 759], ["and", 764], ["an", 768], ["autosomal", 771], ["dominant", 781], ["pattern", 790], ["of", 798], ["inheritance", 801], [",", 812], ["and", 814], ["syndromes", 818], ["with", 828], ["LQTS", 833], ["in", 838], ["association", 841], ["with", 853], ["other", 858], ["conditions", 864], [".", 874], ["The", 876], ["latter", 880], ["includes", 887], ["Jervell", 896], ["and", 904], ["Lange", 908], ["-", 913], ["Nielsen", 914], ["syndrome", 922], ["(", 931], ["JLNS", 932], [")", 936], [",", 937], ["Andersen", 939], ["syndrome", 948], ["(", 957], ["AS", 958], [")", 960], [",", 961], ["and", 963], ["Timothy", 967], ["syndrome", 975], ["(", 984], ["TS", 985], [")", 987], [".", 988], ["The", 990], ["genetics", 994], ["are", 1003], ["further", 1007], ["complicated", 1015], ["by", 1027], ["the", 1030], ["occurrence", 1034], ["of", 1045], ["double", 1048], ["and", 1055], ["triple", 1059], ["heterozygotes", 1066], ["in", 1080], ["LQTS", 1083], ["and", 1088], ["a", 1092], ["considerable", 1094], ["number", 1107], ["of", 1114], ["nonpathogenic", 1117], ["rare", 1131], ["polymorphisms", 1136], ["in", 1150], ["the", 1153], ["involved", 1157], ["genes", 1166], [".", 1171], ["SQTS", 1173], ["is", 1178], ["a", 1181], ["very", 1183], ["rare", 1188], ["condition", 1193], [",", 1202], ["caused", 1204], ["by", 1211], ["mutations", 1214], ["in", 1224], ["five", 1227], ["genes", 1232], ["(", 1238], ["SQTS1", 1239], ["-", 1244], ["5", 1245], [")", 1246], [".", 1247], ["The", 1249], ["present", 1253], ["mutation", 1261], ["update", 1270], ["is", 1277], ["a", 1280], ["comprehensive", 1282], ["description", 1296], ["of", 1308], ["all", 1311], ["known", 1315], ["LQTS-", 1321], ["and", 1327], ["SQTS", 1331], ["-", 1335], ["associated", 1336], ["mutations", 1347], [".", 1356]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "For dozens of years, a variety of pathological findings have been revealed through previous observations on surgically resected lesions from patients with intractable epilepsy, including excessive number of neurons in the molecular layer of cortices, unexpected existence of white matter neurons, and persistent columnar structure. These findings have sometimes been referred to as microdysgenesis (MD) or mild malformation of cortical development (mMCD), which is defined as microscopic abnormalities of brain formations with no macroscopical and neuroradiological findings. Taylor et al. (1971) described surgical cases with giant neurons and bizarre, grotesque cells as \"focal dysplasia of the cerebral cortices with epilepsy.\" Since 1997, such malformations have subsequently been referred to as focal cortical dysplasia (FCD), in Greenfield's Neuropathology. Since early 2000, the definition of FCD has gradually been given a broader interpretation than the case described by Taylor et al., as shown in Palmini's classification (2004) or the newest classification (2011) proposed by the Neuropathology Task Force of the International League Against Epilepsy (ILAE). The ILAE classification describes 3 types of disease: Type I, Type II, and Type III. Type I is equivalent to some, but not all, pathological phenotypes of MD or mMCD. Type II is Taylor's FCD alone. Type III, which was not included in Palmini's classification, merges brain malformation and other pathological findings. However, the reproducibility of pathological diagnosis by using the ILAE classification was low, except for Type IIb. Hence, future studies are necessary to provide further reliable criteria for the pathological diagnosis of epilepsy patients.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "71df3d8251d84f0f8c452651b470a6ec", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[129, 131]], "char_spans": [[800, 823]]}]}], "context_tokens": [["For", 0], ["dozens", 4], ["of", 11], ["years", 14], [",", 19], ["a", 21], ["variety", 23], ["of", 31], ["pathological", 34], ["findings", 47], ["have", 56], ["been", 61], ["revealed", 66], ["through", 75], ["previous", 83], ["observations", 92], ["on", 105], ["surgically", 108], ["resected", 119], ["lesions", 128], ["from", 136], ["patients", 141], ["with", 150], ["intractable", 155], ["epilepsy", 167], [",", 175], ["including", 177], ["excessive", 187], ["number", 197], ["of", 204], ["neurons", 207], ["in", 215], ["the", 218], ["molecular", 222], ["layer", 232], ["of", 238], ["cortices", 241], [",", 249], ["unexpected", 251], ["existence", 262], ["of", 272], ["white", 275], ["matter", 281], ["neurons", 288], [",", 295], ["and", 297], ["persistent", 301], ["columnar", 312], ["structure", 321], [".", 330], ["These", 332], ["findings", 338], ["have", 347], ["sometimes", 352], ["been", 362], ["referred", 367], ["to", 376], ["as", 379], ["microdysgenesis", 382], ["(", 398], ["MD", 399], [")", 401], ["or", 403], ["mild", 406], ["malformation", 411], ["of", 424], ["cortical", 427], ["development", 436], ["(", 448], ["mMCD", 449], [")", 453], [",", 454], ["which", 456], ["is", 462], ["defined", 465], ["as", 473], ["microscopic", 476], ["abnormalities", 488], ["of", 502], ["brain", 505], ["formations", 511], ["with", 522], ["no", 527], ["macroscopical", 530], ["and", 544], ["neuroradiological", 548], ["findings", 566], [".", 574], ["Taylor", 576], ["et", 583], ["al", 586], [".", 588], ["(", 590], ["1971", 591], [")", 595], ["described", 597], ["surgical", 607], ["cases", 616], ["with", 622], ["giant", 627], ["neurons", 633], ["and", 641], ["bizarre", 645], [",", 652], ["grotesque", 654], ["cells", 664], ["as", 670], ["\"", 673], ["focal", 674], ["dysplasia", 680], ["of", 690], ["the", 693], ["cerebral", 697], ["cortices", 706], ["with", 715], ["epilepsy", 720], [".", 728], ["\"", 729], ["Since", 731], ["1997", 737], [",", 741], ["such", 743], ["malformations", 748], ["have", 762], ["subsequently", 767], ["been", 780], ["referred", 785], ["to", 794], ["as", 797], ["focal", 800], ["cortical", 806], ["dysplasia", 815], ["(", 825], ["FCD", 826], [")", 829], [",", 830], ["in", 832], ["Greenfield", 835], ["'s", 845], ["Neuropathology", 848], [".", 862], ["Since", 864], ["early", 870], ["2000", 876], [",", 880], ["the", 882], ["definition", 886], ["of", 897], ["FCD", 900], ["has", 904], ["gradually", 908], ["been", 918], ["given", 923], ["a", 929], ["broader", 931], ["interpretation", 939], ["than", 954], ["the", 959], ["case", 963], ["described", 968], ["by", 978], ["Taylor", 981], ["et", 988], ["al", 991], [".", 993], [",", 994], ["as", 996], ["shown", 999], ["in", 1005], ["Palmini", 1008], ["'s", 1015], ["classification", 1018], ["(", 1033], ["2004", 1034], [")", 1038], ["or", 1040], ["the", 1043], ["newest", 1047], ["classification", 1054], ["(", 1069], ["2011", 1070], [")", 1074], ["proposed", 1076], ["by", 1085], ["the", 1088], ["Neuropathology", 1092], ["Task", 1107], ["Force", 1112], ["of", 1118], ["the", 1121], ["International", 1125], ["League", 1139], ["Against", 1146], ["Epilepsy", 1154], ["(", 1163], ["ILAE", 1164], [")", 1168], [".", 1169], ["The", 1171], ["ILAE", 1175], ["classification", 1180], ["describes", 1195], ["3", 1205], ["types", 1207], ["of", 1213], ["disease", 1216], [":", 1223], ["Type", 1225], ["I", 1230], [",", 1231], ["Type", 1233], ["II", 1238], [",", 1240], ["and", 1242], ["Type", 1246], ["III", 1251], [".", 1254], ["Type", 1256], ["I", 1261], ["is", 1263], ["equivalent", 1266], ["to", 1277], ["some", 1280], [",", 1284], ["but", 1286], ["not", 1290], ["all", 1294], [",", 1297], ["pathological", 1299], ["phenotypes", 1312], ["of", 1323], ["MD", 1326], ["or", 1329], ["mMCD", 1332], [".", 1336], ["Type", 1338], ["II", 1343], ["is", 1346], ["Taylor", 1349], ["'s", 1355], ["FCD", 1358], ["alone", 1362], [".", 1367], ["Type", 1369], ["III", 1374], [",", 1377], ["which", 1379], ["was", 1385], ["not", 1389], ["included", 1393], ["in", 1402], ["Palmini", 1405], ["'s", 1412], ["classification", 1415], [",", 1429], ["merges", 1431], ["brain", 1438], ["malformation", 1444], ["and", 1457], ["other", 1461], ["pathological", 1467], ["findings", 1480], [".", 1488], ["However", 1490], [",", 1497], ["the", 1499], ["reproducibility", 1503], ["of", 1519], ["pathological", 1522], ["diagnosis", 1535], ["by", 1545], ["using", 1548], ["the", 1554], ["ILAE", 1558], ["classification", 1563], ["was", 1578], ["low", 1582], [",", 1585], ["except", 1587], ["for", 1594], ["Type", 1598], ["IIb", 1603], [".", 1606], ["Hence", 1608], [",", 1613], ["future", 1615], ["studies", 1622], ["are", 1630], ["necessary", 1634], ["to", 1644], ["provide", 1647], ["further", 1655], ["reliable", 1663], ["criteria", 1672], ["for", 1681], ["the", 1685], ["pathological", 1689], ["diagnosis", 1702], ["of", 1712], ["epilepsy", 1715], ["patients", 1724], [".", 1732]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance. BORSA strains show low, borderline resistance to penicillinase-resistant penicillins (PRPs), with oxacillin MICs typically equal to 1-8\u2009\u00b5g\u2009ml", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6bf60ce1cd73408f93464f39ccdb6be4", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["represents", 61], ["a", 72], ["quite", 74], ["poorly", 80], ["understood", 87], ["and", 98], ["inadequately", 102], ["defined", 115], ["phenotype", 123], ["of", 133], ["methicillin", 136], ["resistance", 148], [".", 158], ["BORSA", 160], ["strains", 166], ["show", 174], ["low", 179], [",", 182], ["borderline", 184], ["resistance", 195], ["to", 206], ["penicillinase", 209], ["-", 222], ["resistant", 223], ["penicillins", 233], ["(", 245], ["PRPs", 246], [")", 250], [",", 251], ["with", 253], ["oxacillin", 258], ["MICs", 268], ["typically", 273], ["equal", 283], ["to", 289], ["1", 292], ["-", 293], ["8", 294], ["\u00b5g", 296], ["ml", 299]]}
{"context": "The authors discuss the clinical and molecular genetic aspects of genetically determined neuromuscular disorders of some Roma families living in Hungary. Among the autosomal recessively inherited spinal muscular atrophic (SMA) group, 8 Caucasian children had the typical 7-8 exonal deletions of the SMA gene, but only 2 patients belonged to the Roma population. There was no difference in the molecular genetic findings among the Caucasian and the Roma SMA patients. All of them had 7-8 exonal deletions of the SMA gene. We wanted to call attention to the founder mutation of the Roma population in 7 patients suffering from congenital myasthenia (CMS) from 3 Roma families. The 1267G deletion for CMS was detected by molecular genetic method. Clinical onset was pubertal and relatively slow progression of specific and phenotypic features for this founder mutation of acetyl-cholin receptor epsylon gene. In 2 patients (sister and brother) the sarcoglycanopathy 2C type C283Q mutation was proven in one Roma family suffering from limb-girdle muscular dystrophy (LGMD). Two out of the three facioscapular-humeral dystrophy (FSHD) Roma families carried 21.8 kb and 18.5 kb alleles in FSHD A1 gene (D4S139). In one family together with prenatal diagnosis founder mutation in FSHD A1 gene was detected, according to the autosomal dominant (AD) inheritance. In (F2) prenatal diagnosis was carried out, 18.5 kb/18.5 kb homozygosity was proven in the fetus, so the pregnancy was interrupted. In the CMS, LGMD and FSHD Roma patients ancient typical Roma founder mutations were found.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "0219464e052f47129d0aa71da3738b73", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[238, 239]], "char_spans": [[1317, 1334]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["discuss", 12], ["the", 20], ["clinical", 24], ["and", 33], ["molecular", 37], ["genetic", 47], ["aspects", 55], ["of", 63], ["genetically", 66], ["determined", 78], ["neuromuscular", 89], ["disorders", 103], ["of", 113], ["some", 116], ["Roma", 121], ["families", 126], ["living", 135], ["in", 142], ["Hungary", 145], [".", 152], ["Among", 154], ["the", 160], ["autosomal", 164], ["recessively", 174], ["inherited", 186], ["spinal", 196], ["muscular", 203], ["atrophic", 212], ["(", 221], ["SMA", 222], [")", 225], ["group", 227], [",", 232], ["8", 234], ["Caucasian", 236], ["children", 246], ["had", 255], ["the", 259], ["typical", 263], ["7", 271], ["-", 272], ["8", 273], ["exonal", 275], ["deletions", 282], ["of", 292], ["the", 295], ["SMA", 299], ["gene", 303], [",", 307], ["but", 309], ["only", 313], ["2", 318], ["patients", 320], ["belonged", 329], ["to", 338], ["the", 341], ["Roma", 345], ["population", 350], [".", 360], ["There", 362], ["was", 368], ["no", 372], ["difference", 375], ["in", 386], ["the", 389], ["molecular", 393], ["genetic", 403], ["findings", 411], ["among", 420], ["the", 426], ["Caucasian", 430], ["and", 440], ["the", 444], ["Roma", 448], ["SMA", 453], ["patients", 457], [".", 465], ["All", 467], ["of", 471], ["them", 474], ["had", 479], ["7", 483], ["-", 484], ["8", 485], ["exonal", 487], ["deletions", 494], ["of", 504], ["the", 507], ["SMA", 511], ["gene", 515], [".", 519], ["We", 521], ["wanted", 524], ["to", 531], ["call", 534], ["attention", 539], ["to", 549], ["the", 552], ["founder", 556], ["mutation", 564], ["of", 573], ["the", 576], ["Roma", 580], ["population", 585], ["in", 596], ["7", 599], ["patients", 601], ["suffering", 610], ["from", 620], ["congenital", 625], ["myasthenia", 636], ["(", 647], ["CMS", 648], [")", 651], ["from", 653], ["3", 658], ["Roma", 660], ["families", 665], [".", 673], ["The", 675], ["1267", 679], ["G", 683], ["deletion", 685], ["for", 694], ["CMS", 698], ["was", 702], ["detected", 706], ["by", 715], ["molecular", 718], ["genetic", 728], ["method", 736], [".", 742], ["Clinical", 744], ["onset", 753], ["was", 759], ["pubertal", 763], ["and", 772], ["relatively", 776], ["slow", 787], ["progression", 792], ["of", 804], ["specific", 807], ["and", 816], ["phenotypic", 820], ["features", 831], ["for", 840], ["this", 844], ["founder", 849], ["mutation", 857], ["of", 866], ["acetyl", 869], ["-", 875], ["cholin", 876], ["receptor", 883], ["epsylon", 892], ["gene", 900], [".", 904], ["In", 906], ["2", 909], ["patients", 911], ["(", 920], ["sister", 921], ["and", 928], ["brother", 932], [")", 939], ["the", 941], ["sarcoglycanopathy", 945], ["2C", 963], ["type", 966], ["C283Q", 971], ["mutation", 977], ["was", 986], ["proven", 990], ["in", 997], ["one", 1000], ["Roma", 1004], ["family", 1009], ["suffering", 1016], ["from", 1026], ["limb", 1031], ["-", 1035], ["girdle", 1036], ["muscular", 1043], ["dystrophy", 1052], ["(", 1062], ["LGMD", 1063], [")", 1067], [".", 1068], ["Two", 1070], ["out", 1074], ["of", 1078], ["the", 1081], ["three", 1085], ["facioscapular", 1091], ["-", 1104], ["humeral", 1105], ["dystrophy", 1113], ["(", 1123], ["FSHD", 1124], [")", 1128], ["Roma", 1130], ["families", 1135], ["carried", 1144], ["21.8", 1152], ["kb", 1157], ["and", 1160], ["18.5", 1164], ["kb", 1169], ["alleles", 1172], ["in", 1180], ["FSHD", 1183], ["A1", 1188], ["gene", 1191], ["(", 1196], ["D4S139", 1197], [")", 1203], [".", 1204], ["In", 1206], ["one", 1209], ["family", 1213], ["together", 1220], ["with", 1229], ["prenatal", 1234], ["diagnosis", 1243], ["founder", 1253], ["mutation", 1261], ["in", 1270], ["FSHD", 1273], ["A1", 1278], ["gene", 1281], ["was", 1286], ["detected", 1290], [",", 1298], ["according", 1300], ["to", 1310], ["the", 1313], ["autosomal", 1317], ["dominant", 1327], ["(", 1336], ["AD", 1337], [")", 1339], ["inheritance", 1341], [".", 1352], ["In", 1354], ["(", 1357], ["F2", 1358], [")", 1360], ["prenatal", 1362], ["diagnosis", 1371], ["was", 1381], ["carried", 1385], ["out", 1393], [",", 1396], ["18.5", 1398], ["kb/18.5", 1403], ["kb", 1411], ["homozygosity", 1414], ["was", 1427], ["proven", 1431], ["in", 1438], ["the", 1441], ["fetus", 1445], [",", 1450], ["so", 1452], ["the", 1455], ["pregnancy", 1459], ["was", 1469], ["interrupted", 1473], [".", 1484], ["In", 1486], ["the", 1489], ["CMS", 1493], [",", 1496], ["LGMD", 1498], ["and", 1503], ["FSHD", 1507], ["Roma", 1512], ["patients", 1517], ["ancient", 1526], ["typical", 1534], ["Roma", 1542], ["founder", 1547], ["mutations", 1555], ["were", 1565], ["found", 1570], [".", 1575]]}
{"context": "Alpha-synuclein (\u03b1-Syn) is the principal protein component of Lewy bodies, a pathological hallmark of Parkinson's disease (PD). This protein may regulate protein phosphatase 2A (PP2A) activity, although the molecular mechanisms for \u03b1-Syn-mediated regulation of PP2A and the potential neuroprotective actions of PP2A against PD-associated pathology remain largely unexplored. We found that \u03b1-Syn gene overexpression in SK-N-SH cells and primary neurons led to PP2A/C phosphorylation at Y307, a known target of Src kinase, and consequent phosphatase inhibition. In addition, phospho-activated Src (p-Y416 Src, pSrc) was higher in SK-N-SH cells and primary neurons overexpressing \u03b1-Syn. Thus, \u03b1-Syn may promote Src activation and PP2A inactivation, leading to hyperphosphorylation of proteins. Immunoprecipitation revealed higher calmodulin/Src complex formation in \u03b1-Syn-overexpressing cells and \u03b1-Syn transgenic mice. A TUNEL apoptosis assay and an MTT cell viability assay demonstrated that the PP2A activator C2-ceramide protected neurons against \u03b1-Syn-induced cell injury. Buffering the Ca(2+) elevations induced by \u03b1-Syn overexpression ameliorated the cytotoxicity of \u03b1-Syn. Our findings define a potential molecular mechanism for \u03b1-Syn-mediated regulation of PP2A through formation of the calmodulin/Src complex, activation of Src, and Src-mediated phospho-inhibition of PP2A. Overexpression of \u03b1-Syn may lead to neurodegeneration in PD in part by suppressing the endogenous neuroprotective activity of PP2A.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "cf97c5fcf3d94305a47f705ecb7271f5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["\u03b1", 17], ["-", 18], ["Syn", 19], [")", 22], ["is", 24], ["the", 27], ["principal", 31], ["protein", 41], ["component", 49], ["of", 59], ["Lewy", 62], ["bodies", 67], [",", 73], ["a", 75], ["pathological", 77], ["hallmark", 90], ["of", 99], ["Parkinson", 102], ["'s", 111], ["disease", 114], ["(", 122], ["PD", 123], [")", 125], [".", 126], ["This", 128], ["protein", 133], ["may", 141], ["regulate", 145], ["protein", 154], ["phosphatase", 162], ["2A", 174], ["(", 177], ["PP2A", 178], [")", 182], ["activity", 184], [",", 192], ["although", 194], ["the", 203], ["molecular", 207], ["mechanisms", 217], ["for", 228], ["\u03b1", 232], ["-", 233], ["Syn", 234], ["-", 237], ["mediated", 238], ["regulation", 247], ["of", 258], ["PP2A", 261], ["and", 266], ["the", 270], ["potential", 274], ["neuroprotective", 284], ["actions", 300], ["of", 308], ["PP2A", 311], ["against", 316], ["PD", 324], ["-", 326], ["associated", 327], ["pathology", 338], ["remain", 348], ["largely", 355], ["unexplored", 363], [".", 373], ["We", 375], ["found", 378], ["that", 384], ["\u03b1", 389], ["-", 390], ["Syn", 391], ["gene", 395], ["overexpression", 400], ["in", 415], ["SK", 418], ["-", 420], ["N", 421], ["-", 422], ["SH", 423], ["cells", 426], ["and", 432], ["primary", 436], ["neurons", 444], ["led", 452], ["to", 456], ["PP2A", 459], ["/", 463], ["C", 464], ["phosphorylation", 466], ["at", 482], ["Y307", 485], [",", 489], ["a", 491], ["known", 493], ["target", 499], ["of", 506], ["Src", 509], ["kinase", 513], [",", 519], ["and", 521], ["consequent", 525], ["phosphatase", 536], ["inhibition", 548], [".", 558], ["In", 560], ["addition", 563], [",", 571], ["phospho", 573], ["-", 580], ["activated", 581], ["Src", 591], ["(", 595], ["p", 596], ["-", 597], ["Y416", 598], ["Src", 603], [",", 606], ["pSrc", 608], [")", 612], ["was", 614], ["higher", 618], ["in", 625], ["SK", 628], ["-", 630], ["N", 631], ["-", 632], ["SH", 633], ["cells", 636], ["and", 642], ["primary", 646], ["neurons", 654], ["overexpressing", 662], ["\u03b1", 677], ["-", 678], ["Syn", 679], [".", 682], ["Thus", 684], [",", 688], ["\u03b1", 690], ["-", 691], ["Syn", 692], ["may", 696], ["promote", 700], ["Src", 708], ["activation", 712], ["and", 723], ["PP2A", 727], ["inactivation", 732], [",", 744], ["leading", 746], ["to", 754], ["hyperphosphorylation", 757], ["of", 778], ["proteins", 781], [".", 789], ["Immunoprecipitation", 791], ["revealed", 811], ["higher", 820], ["calmodulin", 827], ["/", 837], ["Src", 838], ["complex", 842], ["formation", 850], ["in", 860], ["\u03b1", 863], ["-", 864], ["Syn", 865], ["-", 868], ["overexpressing", 869], ["cells", 884], ["and", 890], ["\u03b1", 894], ["-", 895], ["Syn", 896], ["transgenic", 900], ["mice", 911], [".", 915], ["A", 917], ["TUNEL", 919], ["apoptosis", 925], ["assay", 935], ["and", 941], ["an", 945], ["MTT", 948], ["cell", 952], ["viability", 957], ["assay", 967], ["demonstrated", 973], ["that", 986], ["the", 991], ["PP2A", 995], ["activator", 1000], ["C2-ceramide", 1010], ["protected", 1022], ["neurons", 1032], ["against", 1040], ["\u03b1", 1048], ["-", 1049], ["Syn", 1050], ["-", 1053], ["induced", 1054], ["cell", 1062], ["injury", 1067], [".", 1073], ["Buffering", 1075], ["the", 1085], ["Ca(2", 1089], ["+", 1093], [")", 1094], ["elevations", 1096], ["induced", 1107], ["by", 1115], ["\u03b1", 1118], ["-", 1119], ["Syn", 1120], ["overexpression", 1124], ["ameliorated", 1139], ["the", 1151], ["cytotoxicity", 1155], ["of", 1168], ["\u03b1", 1171], ["-", 1172], ["Syn", 1173], [".", 1176], ["Our", 1178], ["findings", 1182], ["define", 1191], ["a", 1198], ["potential", 1200], ["molecular", 1210], ["mechanism", 1220], ["for", 1230], ["\u03b1", 1234], ["-", 1235], ["Syn", 1236], ["-", 1239], ["mediated", 1240], ["regulation", 1249], ["of", 1260], ["PP2A", 1263], ["through", 1268], ["formation", 1276], ["of", 1286], ["the", 1289], ["calmodulin", 1293], ["/", 1303], ["Src", 1304], ["complex", 1308], [",", 1315], ["activation", 1317], ["of", 1328], ["Src", 1331], [",", 1334], ["and", 1336], ["Src", 1340], ["-", 1343], ["mediated", 1344], ["phospho", 1353], ["-", 1360], ["inhibition", 1361], ["of", 1372], ["PP2A.", 1375], ["Overexpression", 1381], ["of", 1396], ["\u03b1", 1399], ["-", 1400], ["Syn", 1401], ["may", 1405], ["lead", 1409], ["to", 1414], ["neurodegeneration", 1417], ["in", 1435], ["PD", 1438], ["in", 1441], ["part", 1444], ["by", 1449], ["suppressing", 1452], ["the", 1464], ["endogenous", 1468], ["neuroprotective", 1479], ["activity", 1495], ["of", 1504], ["PP2A.", 1507]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease characterized by variable degrees of oculocutaneous albinism, recurrent infections, and a mild bleeding tendency, with late neurologic dysfunction. Most patients also undergo an accelerated phase of lymphohistiocytosis and die at an early age unless they receive an allogeneic hematopoietic stem cell transplant (SCT). Mutations in the CHS1 (LYST) gene result in CHS. Here, we describe an adopted infant who is compound heterozygous for two novel CHS1 gene mutations, both of which are predicted to result in truncated proteins. The two mutations are a nonsense mutation (c.1540 C>T, CGA>TGA, R514X) in exon 5 and a one base pair deletion (del c.9893T, F3298fsX3304) in exon 43, coding for part of the CHS1 protein's BEACH domain. These two newly described mutations are expected to give rise to a severe phenotype and, indeed, the patient had absolutely no cytotoxicity by natural killer cells or cytotoxic lymphocytes prior to his allogeneic SCT.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "08de58bba59d48acbc705a1f43e25d57", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disease", 61], ["characterized", 69], ["by", 83], ["variable", 86], ["degrees", 95], ["of", 103], ["oculocutaneous", 106], ["albinism", 121], [",", 129], ["recurrent", 131], ["infections", 141], [",", 151], ["and", 153], ["a", 157], ["mild", 159], ["bleeding", 164], ["tendency", 173], [",", 181], ["with", 183], ["late", 188], ["neurologic", 193], ["dysfunction", 204], [".", 215], ["Most", 217], ["patients", 222], ["also", 231], ["undergo", 236], ["an", 244], ["accelerated", 247], ["phase", 259], ["of", 265], ["lymphohistiocytosis", 268], ["and", 288], ["die", 292], ["at", 296], ["an", 299], ["early", 302], ["age", 308], ["unless", 312], ["they", 319], ["receive", 324], ["an", 332], ["allogeneic", 335], ["hematopoietic", 346], ["stem", 360], ["cell", 365], ["transplant", 370], ["(", 381], ["SCT", 382], [")", 385], [".", 386], ["Mutations", 388], ["in", 398], ["the", 401], ["CHS1", 405], ["(", 410], ["LYST", 411], [")", 415], ["gene", 417], ["result", 422], ["in", 429], ["CHS", 432], [".", 435], ["Here", 437], [",", 441], ["we", 443], ["describe", 446], ["an", 455], ["adopted", 458], ["infant", 466], ["who", 473], ["is", 477], ["compound", 480], ["heterozygous", 489], ["for", 502], ["two", 506], ["novel", 510], ["CHS1", 516], ["gene", 521], ["mutations", 526], [",", 535], ["both", 537], ["of", 542], ["which", 545], ["are", 551], ["predicted", 555], ["to", 565], ["result", 568], ["in", 575], ["truncated", 578], ["proteins", 588], [".", 596], ["The", 598], ["two", 602], ["mutations", 606], ["are", 616], ["a", 620], ["nonsense", 622], ["mutation", 631], ["(", 640], ["c.1540", 641], ["C", 648], [">", 649], ["T", 650], [",", 651], ["CGA", 653], [">", 656], ["TGA", 657], [",", 660], ["R514X", 662], [")", 667], ["in", 669], ["exon", 672], ["5", 677], ["and", 679], ["a", 683], ["one", 685], ["base", 689], ["pair", 694], ["deletion", 699], ["(", 708], ["del", 709], ["c.9893", 713], ["T", 719], [",", 720], ["F3298fsX3304", 722], [")", 734], ["in", 736], ["exon", 739], ["43", 744], [",", 746], ["coding", 748], ["for", 755], ["part", 759], ["of", 764], ["the", 767], ["CHS1", 771], ["protein", 776], ["'s", 783], ["BEACH", 786], ["domain", 792], [".", 798], ["These", 800], ["two", 806], ["newly", 810], ["described", 816], ["mutations", 826], ["are", 836], ["expected", 840], ["to", 849], ["give", 852], ["rise", 857], ["to", 862], ["a", 865], ["severe", 867], ["phenotype", 874], ["and", 884], [",", 887], ["indeed", 889], [",", 895], ["the", 897], ["patient", 901], ["had", 909], ["absolutely", 913], ["no", 924], ["cytotoxicity", 927], ["by", 940], ["natural", 943], ["killer", 951], ["cells", 958], ["or", 964], ["cytotoxic", 967], ["lymphocytes", 977], ["prior", 989], ["to", 995], ["his", 998], ["allogeneic", 1002], ["SCT", 1013], [".", 1016]]}
{"context": "We describe the clinical characteristics and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in children with cystic fibrosis (CF) from the U.S. CF center with the highest MRSA prevalence. Medical records of children with CF were retrospectively reviewed from 1997-2009. MRSA clinical isolates from 2007-2009 were analyzed by polymerase chain reaction and pulsed field gel electrophoresis. The prevalence of MRSA was 1% in 1997 and 49% in 2009. Fifty-five children (26%) had persistent MRSA infection. Sixty-eight percent of MRSA isolates were hospital-associated (HA) MRSA, of which 52% were pulsed-field type USA 100. Ninety-three percent of HA MRSA isolates were clindamycin resistant. Twelve children acquired MRSA before 1 year of age, 83% of whom were hospitalized prior to acquisition of MRSA. Ten of 11 sibling pairs carried indistinguishable MRSA strains. Children with persistent MRSA were hospitalized more often (P\u2009=\u2009.01), required inhaled medications more frequently (P\u2009=\u2009.01), and had higher rates of Pseudomonas aeruginosa coinfection (P\u2009<\u2009.001). MRSA prevalence in children with CF is increasing, and most children are infected with HA MRSA. Exposure to health care facilities and gastrointestinal surgeries may facilitate early acquisition of MRSA. Siblings carry indistinguishable MRSA strains, indicating household transmission of MRSA. Children with persistent MRSA had worse pulmonary morbidity. Coinfection with MRSA and P aeruginosa is likely associated with further increased pulmonary morbidity.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4e1c49bbf28c4f2e9198848bf13a61dc", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[32, 32], [139, 139], [171, 171], [243, 243], [250, 250], [71, 71], [263, 263], [14, 14], [130, 130], [255, 255], [207, 207], [49, 49], [110, 110], [93, 93], [101, 101], [165, 165], [156, 156], [238, 238], [223, 223]], "char_spans": [[191, 194], [733, 736], [909, 912], [1318, 1321], [1369, 1372], [427, 430], [1453, 1456], [106, 109], [666, 669], [1400, 1403], [1081, 1084], [290, 293], [588, 591], [505, 508], [544, 547], [870, 873], [814, 817], [1279, 1282], [1171, 1174]]}]}], "context_tokens": [["We", 0], ["describe", 3], ["the", 12], ["clinical", 16], ["characteristics", 25], ["and", 41], ["epidemiology", 45], ["of", 58], ["methicillin", 61], ["-", 72], ["resistant", 73], ["Staphylococcus", 83], ["aureus", 98], ["(", 105], ["MRSA", 106], [")", 110], ["in", 112], ["children", 115], ["with", 124], ["cystic", 129], ["fibrosis", 136], ["(", 145], ["CF", 146], [")", 148], ["from", 150], ["the", 155], ["U.S.", 159], ["CF", 164], ["center", 167], ["with", 174], ["the", 179], ["highest", 183], ["MRSA", 191], ["prevalence", 196], [".", 206], ["Medical", 208], ["records", 216], ["of", 224], ["children", 227], ["with", 236], ["CF", 241], ["were", 244], ["retrospectively", 249], ["reviewed", 265], ["from", 274], ["1997", 279], ["-", 283], ["2009", 284], [".", 288], ["MRSA", 290], ["clinical", 295], ["isolates", 304], ["from", 313], ["2007", 318], ["-", 322], ["2009", 323], ["were", 328], ["analyzed", 333], ["by", 342], ["polymerase", 345], ["chain", 356], ["reaction", 362], ["and", 371], ["pulsed", 375], ["field", 382], ["gel", 388], ["electrophoresis", 392], [".", 407], ["The", 409], ["prevalence", 413], ["of", 424], ["MRSA", 427], ["was", 432], ["1", 436], ["%", 437], ["in", 439], ["1997", 442], ["and", 447], ["49", 451], ["%", 453], ["in", 455], ["2009", 458], [".", 462], ["Fifty", 464], ["-", 469], ["five", 470], ["children", 475], ["(", 484], ["26", 485], ["%", 487], [")", 488], ["had", 490], ["persistent", 494], ["MRSA", 505], ["infection", 510], [".", 519], ["Sixty", 521], ["-", 526], ["eight", 527], ["percent", 533], ["of", 541], ["MRSA", 544], ["isolates", 549], ["were", 558], ["hospital", 563], ["-", 571], ["associated", 572], ["(", 583], ["HA", 584], [")", 586], ["MRSA", 588], [",", 592], ["of", 594], ["which", 597], ["52", 603], ["%", 605], ["were", 607], ["pulsed", 612], ["-", 618], ["field", 619], ["type", 625], ["USA", 630], ["100", 634], [".", 637], ["Ninety", 639], ["-", 645], ["three", 646], ["percent", 652], ["of", 660], ["HA", 663], ["MRSA", 666], ["isolates", 671], ["were", 680], ["clindamycin", 685], ["resistant", 697], [".", 706], ["Twelve", 708], ["children", 715], ["acquired", 724], ["MRSA", 733], ["before", 738], ["1", 745], ["year", 747], ["of", 752], ["age", 755], [",", 758], ["83", 760], ["%", 762], ["of", 764], ["whom", 767], ["were", 772], ["hospitalized", 777], ["prior", 790], ["to", 796], ["acquisition", 799], ["of", 811], ["MRSA", 814], [".", 818], ["Ten", 820], ["of", 824], ["11", 827], ["sibling", 830], ["pairs", 838], ["carried", 844], ["indistinguishable", 852], ["MRSA", 870], ["strains", 875], [".", 882], ["Children", 884], ["with", 893], ["persistent", 898], ["MRSA", 909], ["were", 914], ["hospitalized", 919], ["more", 932], ["often", 937], ["(", 943], ["P", 944], ["=", 946], [".01", 948], [")", 951], [",", 952], ["required", 954], ["inhaled", 963], ["medications", 971], ["more", 983], ["frequently", 988], ["(", 999], ["P", 1000], ["=", 1002], [".01", 1004], [")", 1007], [",", 1008], ["and", 1010], ["had", 1014], ["higher", 1018], ["rates", 1025], ["of", 1031], ["Pseudomonas", 1034], ["aeruginosa", 1046], ["coinfection", 1057], ["(", 1069], ["P", 1070], ["<", 1072], [".001", 1074], [")", 1078], [".", 1079], ["MRSA", 1081], ["prevalence", 1086], ["in", 1097], ["children", 1100], ["with", 1109], ["CF", 1114], ["is", 1117], ["increasing", 1120], [",", 1130], ["and", 1132], ["most", 1136], ["children", 1141], ["are", 1150], ["infected", 1154], ["with", 1163], ["HA", 1168], ["MRSA", 1171], [".", 1175], ["Exposure", 1177], ["to", 1186], ["health", 1189], ["care", 1196], ["facilities", 1201], ["and", 1212], ["gastrointestinal", 1216], ["surgeries", 1233], ["may", 1243], ["facilitate", 1247], ["early", 1258], ["acquisition", 1264], ["of", 1276], ["MRSA", 1279], [".", 1283], ["Siblings", 1285], ["carry", 1294], ["indistinguishable", 1300], ["MRSA", 1318], ["strains", 1323], [",", 1330], ["indicating", 1332], ["household", 1343], ["transmission", 1353], ["of", 1366], ["MRSA", 1369], [".", 1373], ["Children", 1375], ["with", 1384], ["persistent", 1389], ["MRSA", 1400], ["had", 1405], ["worse", 1409], ["pulmonary", 1415], ["morbidity", 1425], [".", 1434], ["Coinfection", 1436], ["with", 1448], ["MRSA", 1453], ["and", 1458], ["P", 1462], ["aeruginosa", 1464], ["is", 1475], ["likely", 1478], ["associated", 1485], ["with", 1496], ["further", 1501], ["increased", 1509], ["pulmonary", 1519], ["morbidity", 1529], [".", 1538]]}
{"context": "McLeod syndrome and chorea-acanthocytosis are classified with the so-called neuroacanthocytosis group of syndromes. Both lead to progressive basal ganglia degeneration and were not easily distinguished in the past. With the discovery of their molecular bases, mutations of the X-linked gene XK and autosomal recessive mutations of the gene coding for chorein, respectively, the two phenotypes can now be differentiated and extend the diagnostic spectrum in patients presenting with chorea. The present review compares the two conditions and proposes a practical approach to diagnosis and treatment. Better-defined disease concepts should eventually replace the umbrella term of \"neuroacanthocytosis.\" Animal models are needed to understand the underlying mechanisms. A final common pathway is likely for the pathogenesis of these conditions and is most probably shared with Huntington's disease.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "4678fd2baf4f4fc2a3d6a5f6d70178ed", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[49, 49]], "char_spans": [[291, 292]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["and", 16], ["chorea", 20], ["-", 26], ["acanthocytosis", 27], ["are", 42], ["classified", 46], ["with", 57], ["the", 62], ["so", 66], ["-", 68], ["called", 69], ["neuroacanthocytosis", 76], ["group", 96], ["of", 102], ["syndromes", 105], [".", 114], ["Both", 116], ["lead", 121], ["to", 126], ["progressive", 129], ["basal", 141], ["ganglia", 147], ["degeneration", 155], ["and", 168], ["were", 172], ["not", 177], ["easily", 181], ["distinguished", 188], ["in", 202], ["the", 205], ["past", 209], [".", 213], ["With", 215], ["the", 220], ["discovery", 224], ["of", 234], ["their", 237], ["molecular", 243], ["bases", 253], [",", 258], ["mutations", 260], ["of", 270], ["the", 273], ["X", 277], ["-", 278], ["linked", 279], ["gene", 286], ["XK", 291], ["and", 294], ["autosomal", 298], ["recessive", 308], ["mutations", 318], ["of", 328], ["the", 331], ["gene", 335], ["coding", 340], ["for", 347], ["chorein", 351], [",", 358], ["respectively", 360], [",", 372], ["the", 374], ["two", 378], ["phenotypes", 382], ["can", 393], ["now", 397], ["be", 401], ["differentiated", 404], ["and", 419], ["extend", 423], ["the", 430], ["diagnostic", 434], ["spectrum", 445], ["in", 454], ["patients", 457], ["presenting", 466], ["with", 477], ["chorea", 482], [".", 488], ["The", 490], ["present", 494], ["review", 502], ["compares", 509], ["the", 518], ["two", 522], ["conditions", 526], ["and", 537], ["proposes", 541], ["a", 550], ["practical", 552], ["approach", 562], ["to", 571], ["diagnosis", 574], ["and", 584], ["treatment", 588], [".", 597], ["Better", 599], ["-", 605], ["defined", 606], ["disease", 614], ["concepts", 622], ["should", 631], ["eventually", 638], ["replace", 649], ["the", 657], ["umbrella", 661], ["term", 670], ["of", 675], ["\"", 678], ["neuroacanthocytosis", 679], [".", 698], ["\"", 699], ["Animal", 701], ["models", 708], ["are", 715], ["needed", 719], ["to", 726], ["understand", 729], ["the", 740], ["underlying", 744], ["mechanisms", 755], [".", 765], ["A", 767], ["final", 769], ["common", 775], ["pathway", 782], ["is", 790], ["likely", 793], ["for", 800], ["the", 804], ["pathogenesis", 808], ["of", 821], ["these", 824], ["conditions", 830], ["and", 841], ["is", 845], ["most", 848], ["probably", 853], ["shared", 862], ["with", 869], ["Huntington", 874], ["'s", 884], ["disease", 887], [".", 894]]}
{"context": "We previously identified a mammalian Set1A complex analogous to the yeast Set1/COMPASS histone H3-Lys4 methyltransferase complex (Lee, J.-H., and Skalnik, D. G. (2005) J. Biol. Chem. 280, 41725-41731). Data base analysis indicates that human Set1A protein shares 39% identity with an uncharacterized SET domain protein, KIAA1076, hereafter denoted Set1B. Immunoprecipitation and mass spectrometry reveal that Set1B associates with a approximately 450 kDa complex that contains all five non-catalytic components of the Set1A complex, including CFP1, Rbbp5, Ash2, Wdr5, and Wdr82. These data reveal two human protein complexes that differ only in the identity of the catalytic histone methyltransferase. In vitro assays demonstrate that the Set1B complex is a histone methyltransferase that produces trimethylated histone H3 at Lys(4). Both Set1A and Set1B are widely expressed. Inducible expression of the carboxyl terminus of either Set1A or Set1B decreases steady-state levels of both endogenous Set1A and Set1B protein, but does not alter the expression of the non-catalytic components of the Set1 complexes. A 123-amino acid fragment upstream of the Set1A SET domain is necessary for interaction with CFP1, Ash2, Rbbp5, and Wdr5. This protein domain is also required to mediate feedback inhibition of Set1A and Set1B expression, which is a consequence of reduced Set1A and Set1B stability when not associated with the methyltransferase complex. Confocal microscopy reveals that Set1A and Set1B each localize to a largely non-overlapping set of euchromatic nuclear speckles, suggesting that Set1A and Set1B each bind to a unique set of target genes and thus make non-redundant contributions to the epigenetic control of chromatin structure and gene expression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "7b483c4cbcd8422c8a975ae0c76fa06c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[56, 57], [201, 202]], "char_spans": [[300, 309], [1159, 1168]]}]}], "context_tokens": [["We", 0], ["previously", 3], ["identified", 14], ["a", 25], ["mammalian", 27], ["Set1A", 37], ["complex", 43], ["analogous", 51], ["to", 61], ["the", 64], ["yeast", 68], ["Set1/COMPASS", 74], ["histone", 87], ["H3-Lys4", 95], ["methyltransferase", 103], ["complex", 121], ["(", 129], ["Lee", 130], [",", 133], ["J.-H.", 135], [",", 140], ["and", 142], ["Skalnik", 146], [",", 153], ["D.", 155], ["G.", 158], ["(", 161], ["2005", 162], [")", 166], ["J.", 168], ["Biol", 171], [".", 175], ["Chem", 177], [".", 181], ["280", 183], [",", 186], ["41725", 188], ["-", 193], ["41731", 194], [")", 199], [".", 200], ["Data", 202], ["base", 207], ["analysis", 212], ["indicates", 221], ["that", 231], ["human", 236], ["Set1A", 242], ["protein", 248], ["shares", 256], ["39", 263], ["%", 265], ["identity", 267], ["with", 276], ["an", 281], ["uncharacterized", 284], ["SET", 300], ["domain", 304], ["protein", 311], [",", 318], ["KIAA1076", 320], [",", 328], ["hereafter", 330], ["denoted", 340], ["Set1B.", 348], ["Immunoprecipitation", 355], ["and", 375], ["mass", 379], ["spectrometry", 384], ["reveal", 397], ["that", 404], ["Set1B", 409], ["associates", 415], ["with", 426], ["a", 431], ["approximately", 433], ["450", 447], ["kDa", 451], ["complex", 455], ["that", 463], ["contains", 468], ["all", 477], ["five", 481], ["non", 486], ["-", 489], ["catalytic", 490], ["components", 500], ["of", 511], ["the", 514], ["Set1A", 518], ["complex", 524], [",", 531], ["including", 533], ["CFP1", 543], [",", 547], ["Rbbp5", 549], [",", 554], ["Ash2", 556], [",", 560], ["Wdr5", 562], [",", 566], ["and", 568], ["Wdr82", 572], [".", 577], ["These", 579], ["data", 585], ["reveal", 590], ["two", 597], ["human", 601], ["protein", 607], ["complexes", 615], ["that", 625], ["differ", 630], ["only", 637], ["in", 642], ["the", 645], ["identity", 649], ["of", 658], ["the", 661], ["catalytic", 665], ["histone", 675], ["methyltransferase", 683], [".", 700], ["In", 702], ["vitro", 705], ["assays", 711], ["demonstrate", 718], ["that", 730], ["the", 735], ["Set1B", 739], ["complex", 745], ["is", 753], ["a", 756], ["histone", 758], ["methyltransferase", 766], ["that", 784], ["produces", 789], ["trimethylated", 798], ["histone", 812], ["H3", 820], ["at", 823], ["Lys(4", 826], [")", 831], [".", 832], ["Both", 834], ["Set1A", 839], ["and", 845], ["Set1B", 849], ["are", 855], ["widely", 859], ["expressed", 866], [".", 875], ["Inducible", 877], ["expression", 887], ["of", 898], ["the", 901], ["carboxyl", 905], ["terminus", 914], ["of", 923], ["either", 926], ["Set1A", 933], ["or", 939], ["Set1B", 942], ["decreases", 948], ["steady", 958], ["-", 964], ["state", 965], ["levels", 971], ["of", 978], ["both", 981], ["endogenous", 986], ["Set1A", 997], ["and", 1003], ["Set1B", 1007], ["protein", 1013], [",", 1020], ["but", 1022], ["does", 1026], ["not", 1031], ["alter", 1035], ["the", 1041], ["expression", 1045], ["of", 1056], ["the", 1059], ["non", 1063], ["-", 1066], ["catalytic", 1067], ["components", 1077], ["of", 1088], ["the", 1091], ["Set1", 1095], ["complexes", 1100], [".", 1109], ["A", 1111], ["123-amino", 1113], ["acid", 1123], ["fragment", 1128], ["upstream", 1137], ["of", 1146], ["the", 1149], ["Set1A", 1153], ["SET", 1159], ["domain", 1163], ["is", 1170], ["necessary", 1173], ["for", 1183], ["interaction", 1187], ["with", 1199], ["CFP1", 1204], [",", 1208], ["Ash2", 1210], [",", 1214], ["Rbbp5", 1216], [",", 1221], ["and", 1223], ["Wdr5", 1227], [".", 1231], ["This", 1233], ["protein", 1238], ["domain", 1246], ["is", 1253], ["also", 1256], ["required", 1261], ["to", 1270], ["mediate", 1273], ["feedback", 1281], ["inhibition", 1290], ["of", 1301], ["Set1A", 1304], ["and", 1310], ["Set1B", 1314], ["expression", 1320], [",", 1330], ["which", 1332], ["is", 1338], ["a", 1341], ["consequence", 1343], ["of", 1355], ["reduced", 1358], ["Set1A", 1366], ["and", 1372], ["Set1B", 1376], ["stability", 1382], ["when", 1392], ["not", 1397], ["associated", 1401], ["with", 1412], ["the", 1417], ["methyltransferase", 1421], ["complex", 1439], [".", 1446], ["Confocal", 1448], ["microscopy", 1457], ["reveals", 1468], ["that", 1476], ["Set1A", 1481], ["and", 1487], ["Set1B", 1491], ["each", 1497], ["localize", 1502], ["to", 1511], ["a", 1514], ["largely", 1516], ["non", 1524], ["-", 1527], ["overlapping", 1528], ["set", 1540], ["of", 1544], ["euchromatic", 1547], ["nuclear", 1559], ["speckles", 1567], [",", 1575], ["suggesting", 1577], ["that", 1588], ["Set1A", 1593], ["and", 1599], ["Set1B", 1603], ["each", 1609], ["bind", 1614], ["to", 1619], ["a", 1622], ["unique", 1624], ["set", 1631], ["of", 1635], ["target", 1638], ["genes", 1645], ["and", 1651], ["thus", 1655], ["make", 1660], ["non", 1665], ["-", 1668], ["redundant", 1669], ["contributions", 1679], ["to", 1693], ["the", 1696], ["epigenetic", 1700], ["control", 1711], ["of", 1719], ["chromatin", 1722], ["structure", 1732], ["and", 1742], ["gene", 1746], ["expression", 1751], [".", 1761]]}
{"context": "To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5-13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFN(high) individuals converted to arthritis, compared with 29 out of 90 IFN(low) individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFN(high) at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["IFN-signature", "Interferon signature", "IFN signature"], "qid": "78f9bca0ee664b74b0be699e63138b9b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[307, 309]], "char_spans": [[1644, 1656]]}]}], "context_tokens": [["To", 0], ["validate", 3], ["the", 12], ["presence", 16], ["and", 25], ["demonstrate", 29], ["the", 41], ["clinical", 45], ["value", 54], ["of", 60], ["the", 63], ["type", 67], ["I", 72], ["interferon", 74], ["(", 85], ["IFN)-signature", 86], ["during", 101], ["arthritis", 108], ["development", 118], [".", 129], ["In", 131], ["115", 134], ["seropositive", 138], ["arthralgia", 151], ["patients", 162], ["who", 171], ["were", 175], ["followed", 180], ["for", 189], ["the", 193], ["development", 197], ["of", 209], ["arthritis", 212], ["(", 222], ["Amsterdam", 223], ["Reade", 233], ["cohort", 239], [")", 245], [",", 246], ["and", 248], ["25", 252], ["presymptomatic", 255], ["individuals", 270], ["who", 282], ["developed", 286], ["rheumatoid", 296], ["arthritis", 307], ["(", 317], ["RA", 318], [")", 320], ["later", 322], [",", 327], ["and", 329], ["45", 333], ["population", 336], ["-", 346], ["based", 347], ["controls", 353], ["(", 362], ["Northern", 363], ["Sweden", 372], ["cohort", 379], [")", 385], [",", 386], ["the", 388], ["expression", 392], ["levels", 403], ["of", 410], ["7", 413], ["type", 415], ["I", 420], ["IFN", 422], ["response", 426], ["genes", 435], ["were", 441], ["determined", 446], ["with", 457], ["multiplex", 462], ["qPCR", 472], ["and", 477], ["an", 481], ["IFN", 484], ["-", 487], ["score", 488], ["was", 494], ["calculated", 498], [".", 508], ["The", 510], ["diagnostic", 514], ["performance", 525], ["of", 537], ["the", 540], ["IFN", 544], ["-", 547], ["score", 548], ["was", 554], ["evaluated", 558], ["using", 568], ["Cox", 574], ["regression", 578], ["and", 589], ["Receiver", 593], ["Operating", 602], ["Characteristics", 612], ["(", 628], ["ROC)-curve", 629], ["analysis", 640], [".", 648], ["In", 650], ["44", 653], ["of", 656], ["the", 659], ["115", 663], ["at", 667], ["-", 669], ["risk", 670], ["individuals", 675], ["(", 687], ["38", 688], ["%", 690], [")", 691], ["from", 693], ["the", 698], ["Amsterdam", 702], ["Reade", 712], ["cohort", 718], [",", 724], ["arthritis", 726], ["developed", 736], ["after", 746], ["a", 752], ["median", 754], ["period", 761], ["of", 768], ["8", 771], ["months", 773], ["(", 780], ["IQR", 781], ["5", 785], ["-", 786], ["13", 787], [")", 789], [".", 790], ["Stratification", 792], ["of", 807], ["these", 810], ["individuals", 816], ["based", 828], ["on", 834], ["the", 837], ["IFN", 841], ["-", 844], ["score", 845], ["revealed", 851], ["that", 860], ["15", 865], ["out", 868], ["of", 872], ["25", 875], ["IFN(high", 878], [")", 886], ["individuals", 888], ["converted", 900], ["to", 910], ["arthritis", 913], [",", 922], ["compared", 924], ["with", 933], ["29", 938], ["out", 941], ["of", 945], ["90", 948], ["IFN(low", 951], [")", 958], ["individuals", 960], ["(", 972], ["p=0.011", 973], [")", 980], [".", 981], ["In", 983], ["the", 986], ["Northern", 990], ["Sweden", 999], ["cohort", 1006], [",", 1012], ["the", 1014], ["level", 1018], ["of", 1024], ["the", 1027], ["IFN", 1031], ["-", 1034], ["score", 1035], ["was", 1041], ["also", 1045], ["significantly", 1050], ["increased", 1064], ["in", 1074], ["presymptomatic", 1077], ["individuals", 1092], ["who", 1104], ["developed", 1108], ["RA", 1118], ["compared", 1121], ["with", 1130], ["population", 1135], ["-", 1145], ["based", 1146], ["controls", 1152], ["(", 1161], ["p=0.002", 1162], [")", 1169], [".", 1170], ["Cox", 1172], ["regression", 1176], ["analysis", 1187], ["of", 1196], ["the", 1199], ["Amsterdam", 1203], ["Reade", 1213], ["cohort", 1219], ["showed", 1226], ["that", 1233], ["the", 1238], ["hazard", 1242], ["ratio", 1249], ["(", 1255], ["HR", 1256], [")", 1258], ["for", 1260], ["development", 1264], ["of", 1276], ["arthritis", 1279], ["was", 1289], ["2.38", 1293], ["(", 1298], ["p=0.008", 1299], [")", 1306], ["for", 1308], ["IFN(high", 1312], [")", 1320], ["at", 1322], ["-", 1324], ["risk", 1325], ["individuals", 1330], ["after", 1342], ["correction", 1348], ["for", 1359], ["anticitrullinated", 1363], ["protein", 1381], ["antibodies", 1389], ["(", 1400], ["ACPA", 1401], [")", 1405], ["and", 1407], ["rheumatoid", 1411], ["factor", 1422], ["(", 1429], ["RF", 1430], [")", 1432], [".", 1433], ["The", 1435], ["ROC", 1439], ["-", 1442], ["curve", 1443], ["area", 1449], ["under", 1454], ["the", 1460], ["curve", 1464], ["(", 1470], ["AUC", 1471], [")", 1474], ["for", 1476], ["the", 1480], ["IFN", 1484], ["-", 1487], ["score", 1488], ["combined", 1494], ["with", 1503], ["ACPA", 1508], ["and", 1513], ["RF", 1517], ["in", 1520], ["the", 1523], ["prediction", 1527], ["of", 1538], ["arthritis", 1541], ["was", 1551], ["78.5", 1555], ["%", 1559], ["(", 1561], ["p=0.0001", 1562], [",", 1570], ["95", 1572], ["%", 1574], ["CI", 1576], ["0.70", 1579], ["to", 1584], ["0.87", 1587], [")", 1591], [".", 1592], ["The", 1594], ["results", 1598], ["demonstrated", 1606], ["clinical", 1619], ["utility", 1628], ["for", 1636], ["the", 1640], ["IFN", 1644], ["-", 1647], ["signature", 1648], ["as", 1658], ["a", 1661], ["biomarker", 1663], ["in", 1673], ["the", 1676], ["prediction", 1680], ["of", 1691], ["arthritis", 1694], ["development", 1704], [".", 1715]]}
{"context": "Ehlers-Danlos syndrome is an inherited connective tissue disorder. Clinical manifestations of this syndrome are due to fragile connective tissue. Though many cardiovascular disorders in association with it have been reported, myocardial infarction is quite rare. In this report, two cases with type 4 Ehlers-Danlos syndrome and myocardial infarction are described. Patient 1 was a 30-year-old woman. She was diagnosed as having myocardial infarction on the basis of typical changes in electrocardiograms and serum enzymes (CPK, SGOT and LDH). The diagnosis of type 4 Ehlers-Danlos syndrome was made by the microscopic examination of her connective tissue. Patient 2 was a 32-year-old man. He was also diagnosed as having acute myocardial infarction. His fibroblasts were cultured and they could not synthesize type 3 collagen. Type 4 Ehlers-Danlos syndrome was diagnosed. It was likely that myocardial infarction might have resulted from the fragility of their coronary arteries in type 4 Ehlers-Danlos syndrome.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "2400eadb605d444e87f69ff530a1856c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[20, 21], [7, 8], [112, 113]], "char_spans": [[127, 143], [39, 55], [637, 653]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["an", 26], ["inherited", 29], ["connective", 39], ["tissue", 50], ["disorder", 57], [".", 65], ["Clinical", 67], ["manifestations", 76], ["of", 91], ["this", 94], ["syndrome", 99], ["are", 108], ["due", 112], ["to", 116], ["fragile", 119], ["connective", 127], ["tissue", 138], [".", 144], ["Though", 146], ["many", 153], ["cardiovascular", 158], ["disorders", 173], ["in", 183], ["association", 186], ["with", 198], ["it", 203], ["have", 206], ["been", 211], ["reported", 216], [",", 224], ["myocardial", 226], ["infarction", 237], ["is", 248], ["quite", 251], ["rare", 257], [".", 261], ["In", 263], ["this", 266], ["report", 271], [",", 277], ["two", 279], ["cases", 283], ["with", 289], ["type", 294], ["4", 299], ["Ehlers", 301], ["-", 307], ["Danlos", 308], ["syndrome", 315], ["and", 324], ["myocardial", 328], ["infarction", 339], ["are", 350], ["described", 354], [".", 363], ["Patient", 365], ["1", 373], ["was", 375], ["a", 379], ["30-year", 381], ["-", 388], ["old", 389], ["woman", 393], [".", 398], ["She", 400], ["was", 404], ["diagnosed", 408], ["as", 418], ["having", 421], ["myocardial", 428], ["infarction", 439], ["on", 450], ["the", 453], ["basis", 457], ["of", 463], ["typical", 466], ["changes", 474], ["in", 482], ["electrocardiograms", 485], ["and", 504], ["serum", 508], ["enzymes", 514], ["(", 522], ["CPK", 523], [",", 526], ["SGOT", 528], ["and", 533], ["LDH", 537], [")", 540], [".", 541], ["The", 543], ["diagnosis", 547], ["of", 557], ["type", 560], ["4", 565], ["Ehlers", 567], ["-", 573], ["Danlos", 574], ["syndrome", 581], ["was", 590], ["made", 594], ["by", 599], ["the", 602], ["microscopic", 606], ["examination", 618], ["of", 630], ["her", 633], ["connective", 637], ["tissue", 648], [".", 654], ["Patient", 656], ["2", 664], ["was", 666], ["a", 670], ["32-year", 672], ["-", 679], ["old", 680], ["man", 684], [".", 687], ["He", 689], ["was", 692], ["also", 696], ["diagnosed", 701], ["as", 711], ["having", 714], ["acute", 721], ["myocardial", 727], ["infarction", 738], [".", 748], ["His", 750], ["fibroblasts", 754], ["were", 766], ["cultured", 771], ["and", 780], ["they", 784], ["could", 789], ["not", 795], ["synthesize", 799], ["type", 810], ["3", 815], ["collagen", 817], [".", 825], ["Type", 827], ["4", 832], ["Ehlers", 834], ["-", 840], ["Danlos", 841], ["syndrome", 848], ["was", 857], ["diagnosed", 861], [".", 870], ["It", 872], ["was", 875], ["likely", 879], ["that", 886], ["myocardial", 891], ["infarction", 902], ["might", 913], ["have", 919], ["resulted", 924], ["from", 933], ["the", 938], ["fragility", 942], ["of", 952], ["their", 955], ["coronary", 961], ["arteries", 970], ["in", 979], ["type", 982], ["4", 987], ["Ehlers", 989], ["-", 995], ["Danlos", 996], ["syndrome", 1003], [".", 1011]]}
{"context": "Suppression subtractive hybridization performed on Down syndrome (DS) versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis. The under-expression of PRDX2 observed in DS samples was confirmed by real-time PCR (0.73-fold). To test whether decreased expression is associated with enhanced sensitivity of DS neurons to reactive oxygen species, we down-regulated PRDX2 through stable transfections of SH-SY5Y neuroblastoma cells with antisense contructs of the complete PRDX2 coding sequence. In addition, we over-expressed SOD1 and compared the effects of the two genes on cell viability. Cells transfected with either construct showed similar sensitivity to oxidative stress in addition to increased apoptosis under basal conditions and after treatment with oxidative cytotoxic agents. This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "733e977ad4f14caf9148b8dbb151fd8c", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[30, 30]], "char_spans": [[195, 205]]}]}], "context_tokens": [["Suppression", 0], ["subtractive", 12], ["hybridization", 24], ["performed", 38], ["on", 48], ["Down", 51], ["syndrome", 56], ["(", 65], ["DS", 66], [")", 68], ["versus", 70], ["control", 77], ["fetal", 85], ["brains", 91], ["revealed", 98], ["differential", 107], ["expression", 120], ["of", 131], ["peroxiredoxin", 134], ["2", 148], ["(", 150], ["PRDX2", 151], [")", 156], [",", 157], ["mapped", 159], ["at", 166], ["13q12", 169], [".", 174], ["Peroxiredoxins", 176], ["are", 191], ["antioxidant", 195], ["enzymes", 207], ["involved", 215], ["in", 224], ["protein", 227], ["and", 235], ["lipid", 239], ["protection", 245], ["against", 256], ["oxidative", 264], ["injury", 274], ["and", 281], ["in", 285], ["cellular", 288], ["signalling", 297], ["pathways", 308], ["regulating", 317], ["apoptosis", 328], [".", 337], ["The", 339], ["under", 343], ["-", 348], ["expression", 349], ["of", 360], ["PRDX2", 363], ["observed", 369], ["in", 378], ["DS", 381], ["samples", 384], ["was", 392], ["confirmed", 396], ["by", 406], ["real", 409], ["-", 413], ["time", 414], ["PCR", 419], ["(", 423], ["0.73-fold", 424], [")", 433], [".", 434], ["To", 436], ["test", 439], ["whether", 444], ["decreased", 452], ["expression", 462], ["is", 473], ["associated", 476], ["with", 487], ["enhanced", 492], ["sensitivity", 501], ["of", 513], ["DS", 516], ["neurons", 519], ["to", 527], ["reactive", 530], ["oxygen", 539], ["species", 546], [",", 553], ["we", 555], ["down", 558], ["-", 562], ["regulated", 563], ["PRDX2", 573], ["through", 579], ["stable", 587], ["transfections", 594], ["of", 608], ["SH", 611], ["-", 613], ["SY5Y", 614], ["neuroblastoma", 619], ["cells", 633], ["with", 639], ["antisense", 644], ["contructs", 654], ["of", 664], ["the", 667], ["complete", 671], ["PRDX2", 680], ["coding", 686], ["sequence", 693], [".", 701], ["In", 703], ["addition", 706], [",", 714], ["we", 716], ["over", 719], ["-", 723], ["expressed", 724], ["SOD1", 734], ["and", 739], ["compared", 743], ["the", 752], ["effects", 756], ["of", 764], ["the", 767], ["two", 771], ["genes", 775], ["on", 781], ["cell", 784], ["viability", 789], [".", 798], ["Cells", 800], ["transfected", 806], ["with", 818], ["either", 823], ["construct", 830], ["showed", 840], ["similar", 847], ["sensitivity", 855], ["to", 867], ["oxidative", 870], ["stress", 880], ["in", 887], ["addition", 890], ["to", 899], ["increased", 902], ["apoptosis", 912], ["under", 922], ["basal", 928], ["conditions", 934], ["and", 945], ["after", 949], ["treatment", 955], ["with", 965], ["oxidative", 970], ["cytotoxic", 980], ["agents", 990], [".", 996], ["This", 998], ["suggests", 1003], ["that", 1012], ["the", 1017], ["decreased", 1021], ["expression", 1031], ["of", 1042], ["PRDX2", 1045], ["may", 1051], ["contribute", 1055], ["to", 1066], ["the", 1069], ["altered", 1073], ["redox", 1081], ["state", 1087], ["in", 1093], ["DS", 1096], ["at", 1099], ["levels", 1102], ["comparable", 1109], ["to", 1120], ["that", 1123], ["of", 1128], ["the", 1131], ["increased", 1135], ["expression", 1145], ["of", 1156], ["SOD1", 1159], [".", 1163]]}
{"context": "Systemic autoinflammatory diseases are caused by mutations in genes that function in innate immunity. Here, we report an autoinflammatory disease caused by loss-of-function mutations in OTULIN (FAM105B), encoding a deubiquitinase with linear linkage specificity. We identified two missense and one frameshift mutations in one Pakistani and two Turkish families with four affected patients. Patients presented with neonatal-onset fever, neutrophilic dermatitis/panniculitis, and failure to thrive, but without obvious primary immunodeficiency. HEK293 cells transfected with mutated OTULIN had decreased enzyme activity relative to cells transfected with WT OTULIN, and showed a substantial defect in the linear deubiquitination of target molecules. Stimulated patients' fibroblasts and peripheral blood mononuclear cells showed evidence for increased signaling in the canonical NF-\u03baB pathway and accumulated linear ubiquitin aggregates. Levels of proinflammatory cytokines were significantly increased in the supernatants of stimulated primary cells and serum samples. This discovery adds to the emerging spectrum of human diseases caused by defects in the ubiquitin pathway and suggests a role for targeted cytokine therapies.", "qas": [{"question": "Which is the enzymatic activity of OTULIN?", "answers": ["deubiquitination"], "qid": "f85c2449871b49c598f41e1f233256be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["OTULIN", 35], ["?", 41]], "detected_answers": [{"text": "deubiquitination", "token_spans": [[114, 114]], "char_spans": [[710, 725]]}]}], "context_tokens": [["Systemic", 0], ["autoinflammatory", 9], ["diseases", 26], ["are", 35], ["caused", 39], ["by", 46], ["mutations", 49], ["in", 59], ["genes", 62], ["that", 68], ["function", 73], ["in", 82], ["innate", 85], ["immunity", 92], [".", 100], ["Here", 102], [",", 106], ["we", 108], ["report", 111], ["an", 118], ["autoinflammatory", 121], ["disease", 138], ["caused", 146], ["by", 153], ["loss", 156], ["-", 160], ["of", 161], ["-", 163], ["function", 164], ["mutations", 173], ["in", 183], ["OTULIN", 186], ["(", 193], ["FAM105B", 194], [")", 201], [",", 202], ["encoding", 204], ["a", 213], ["deubiquitinase", 215], ["with", 230], ["linear", 235], ["linkage", 242], ["specificity", 250], [".", 261], ["We", 263], ["identified", 266], ["two", 277], ["missense", 281], ["and", 290], ["one", 294], ["frameshift", 298], ["mutations", 309], ["in", 319], ["one", 322], ["Pakistani", 326], ["and", 336], ["two", 340], ["Turkish", 344], ["families", 352], ["with", 361], ["four", 366], ["affected", 371], ["patients", 380], [".", 388], ["Patients", 390], ["presented", 399], ["with", 409], ["neonatal", 414], ["-", 422], ["onset", 423], ["fever", 429], [",", 434], ["neutrophilic", 436], ["dermatitis", 449], ["/", 459], ["panniculitis", 460], [",", 472], ["and", 474], ["failure", 478], ["to", 486], ["thrive", 489], [",", 495], ["but", 497], ["without", 501], ["obvious", 509], ["primary", 517], ["immunodeficiency", 525], [".", 541], ["HEK293", 543], ["cells", 550], ["transfected", 556], ["with", 568], ["mutated", 573], ["OTULIN", 581], ["had", 588], ["decreased", 592], ["enzyme", 602], ["activity", 609], ["relative", 618], ["to", 627], ["cells", 630], ["transfected", 636], ["with", 648], ["WT", 653], ["OTULIN", 656], [",", 662], ["and", 664], ["showed", 668], ["a", 675], ["substantial", 677], ["defect", 689], ["in", 696], ["the", 699], ["linear", 703], ["deubiquitination", 710], ["of", 727], ["target", 730], ["molecules", 737], [".", 746], ["Stimulated", 748], ["patients", 759], ["'", 767], ["fibroblasts", 769], ["and", 781], ["peripheral", 785], ["blood", 796], ["mononuclear", 802], ["cells", 814], ["showed", 820], ["evidence", 827], ["for", 836], ["increased", 840], ["signaling", 850], ["in", 860], ["the", 863], ["canonical", 867], ["NF", 877], ["-", 879], ["\u03baB", 880], ["pathway", 883], ["and", 891], ["accumulated", 895], ["linear", 907], ["ubiquitin", 914], ["aggregates", 924], [".", 934], ["Levels", 936], ["of", 943], ["proinflammatory", 946], ["cytokines", 962], ["were", 972], ["significantly", 977], ["increased", 991], ["in", 1001], ["the", 1004], ["supernatants", 1008], ["of", 1021], ["stimulated", 1024], ["primary", 1035], ["cells", 1043], ["and", 1049], ["serum", 1053], ["samples", 1059], [".", 1066], ["This", 1068], ["discovery", 1073], ["adds", 1083], ["to", 1088], ["the", 1091], ["emerging", 1095], ["spectrum", 1104], ["of", 1113], ["human", 1116], ["diseases", 1122], ["caused", 1131], ["by", 1138], ["defects", 1141], ["in", 1149], ["the", 1152], ["ubiquitin", 1156], ["pathway", 1166], ["and", 1174], ["suggests", 1178], ["a", 1187], ["role", 1189], ["for", 1194], ["targeted", 1198], ["cytokine", 1207], ["therapies", 1216], [".", 1225]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "37ea67d513cc47e680a8cad150662beb", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Lewy bodies and coarse Lewy neurites are the pathological hallmarks of degenerating neurons in the brains of patients suffering from Parkinson's disease (PD). Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites. This study demonstrates for the first time that extensive and thin alpha-synuclein-immunoreactive inclusions are present in the axonal processes of neurons.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "62d0c93b45ca401ca522395ff2d09c8b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[60, 62], [32, 34]], "char_spans": [[344, 358], [193, 207]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], ["and", 12], ["coarse", 16], ["Lewy", 23], ["neurites", 28], ["are", 37], ["the", 41], ["pathological", 45], ["hallmarks", 58], ["of", 68], ["degenerating", 71], ["neurons", 84], ["in", 92], ["the", 95], ["brains", 99], ["of", 106], ["patients", 109], ["suffering", 118], ["from", 128], ["Parkinson", 133], ["'s", 142], ["disease", 145], ["(", 153], ["PD", 154], [")", 156], [".", 157], ["Recently", 159], [",", 167], ["the", 169], ["presynaptic", 173], ["protein", 185], ["alpha", 193], ["-", 198], ["synuclein", 199], ["was", 209], ["shown", 213], ["to", 219], ["be", 222], ["a", 225], ["major", 227], ["component", 233], ["of", 243], ["Lewy", 246], ["bodies", 251], ["and", 258], ["Lewy", 262], ["neurites", 267], [".", 275], ["This", 277], ["study", 282], ["demonstrates", 288], ["for", 301], ["the", 305], ["first", 309], ["time", 315], ["that", 320], ["extensive", 325], ["and", 335], ["thin", 339], ["alpha", 344], ["-", 349], ["synuclein", 350], ["-", 359], ["immunoreactive", 360], ["inclusions", 375], ["are", 386], ["present", 390], ["in", 398], ["the", 401], ["axonal", 405], ["processes", 412], ["of", 422], ["neurons", 425], [".", 432]]}
{"context": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion. The physiologic response to pharmacologically induced acute or chronic glycosuria has not been investigated in human diabetes. We evaluated 66 patients with type 2 diabetes (62 \u00b1 7 years, BMI = 31.6 \u00b1 4.6 kg/m(2), HbA1c = 55 \u00b1 8 mmol/mol, mean \u00b1 SD) at baseline, after a single dose, and following 4-week treatment with empagliflozin (25 mg). At each time point, patients received a mixed meal coupled with dual-tracer glucose administration and indirect calorimetry. Both single-dose and chronic empagliflozin treatment caused glycosuria during fasting (median, 7.8 [interquartile range {IQR}, 4.4] g/3 hours and 9.2 [IQR, 5.2] g/3 hours) and after meal ingestion (median, 29.0 [IQR, 12.5] g/5 hours and 28.2 [IQR, 15.4] g/5 hours). After 3 hours of fasting, endogenous glucose production (EGP) was increased 25%, while glycemia was 0.9 \u00b1 0.7 mmol/l lower (P < 0.0001 vs. baseline). After meal ingestion, glucose and insulin AUC decreased, whereas the glucagon response increased (all P < 0.001). While oral glucose appearance was unchanged, EGP was increased (median, 40 [IQR, 14] g and 37 [IQR, 11] g vs. 34 [IQR, 11] g, both P < 0.01). Tissue glucose disposal was reduced (median, 75 [IQR, 16] g and 70 [IQR, 21] g vs. 93 [IQR, 18] g, P < 0.0001), due to a decrease in both glucose oxidation and nonoxidative glucose disposal, with a concomitant rise in lipid oxidation after chronic administration (all P < 0.01). \u03b2 Cell glucose sensitivity increased (median, 55 [IQR, 35] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1) and 55 [IQR, 39] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1) vs. 44 [IQR, 32] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1), P < 0.0001), and insulin sensitivity was improved. Resting energy expenditure rates and those after meal ingestion were unchanged. In patients with type 2 diabetes, empagliflozin-induced glycosuria improved \u03b2 cell function and insulin sensitivity, despite the fall in insulin secretion and tissue glucose disposal and the rise in EGP after one dose, thereby lowering fasting and postprandial glycemia. Chronic dosing shifted substrate utilization from carbohydrate to lipid. Trial registration. ClinicalTrials.Gov NCT01248364 (EudraCT no. 2010-018708-99). Funding. This study was funded by Boehringer Ingelheim.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "b5538b30d15c497e8eafc6e1d38b50cf", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[6, 6]], "char_spans": [[32, 36]]}]}], "context_tokens": [["Sodium", 0], ["-", 6], ["glucose", 7], ["cotransporter", 15], ["2", 29], ["(", 31], ["SGLT2", 32], [")", 37], ["inhibitors", 39], ["lower", 50], ["glycemia", 56], ["by", 65], ["enhancing", 68], ["urinary", 78], ["glucose", 86], ["excretion", 94], [".", 103], ["The", 105], ["physiologic", 109], ["response", 121], ["to", 130], ["pharmacologically", 133], ["induced", 151], ["acute", 159], ["or", 165], ["chronic", 168], ["glycosuria", 176], ["has", 187], ["not", 191], ["been", 195], ["investigated", 200], ["in", 213], ["human", 216], ["diabetes", 222], [".", 230], ["We", 232], ["evaluated", 235], ["66", 245], ["patients", 248], ["with", 257], ["type", 262], ["2", 267], ["diabetes", 269], ["(", 278], ["62", 279], ["\u00b1", 282], ["7", 284], ["years", 286], [",", 291], ["BMI", 293], ["=", 297], ["31.6", 299], ["\u00b1", 304], ["4.6", 306], ["kg", 310], ["/", 312], ["m(2", 313], [")", 316], [",", 317], ["HbA1c", 319], ["=", 325], ["55", 327], ["\u00b1", 330], ["8", 332], ["mmol", 334], ["/", 338], ["mol", 339], [",", 342], ["mean", 344], ["\u00b1", 349], ["SD", 351], [")", 353], ["at", 355], ["baseline", 358], [",", 366], ["after", 368], ["a", 374], ["single", 376], ["dose", 383], [",", 387], ["and", 389], ["following", 393], ["4-week", 403], ["treatment", 410], ["with", 420], ["empagliflozin", 425], ["(", 439], ["25", 440], ["mg", 443], [")", 445], [".", 446], ["At", 448], ["each", 451], ["time", 456], ["point", 461], [",", 466], ["patients", 468], ["received", 477], ["a", 486], ["mixed", 488], ["meal", 494], ["coupled", 499], ["with", 507], ["dual", 512], ["-", 516], ["tracer", 517], ["glucose", 524], ["administration", 532], ["and", 547], ["indirect", 551], ["calorimetry", 560], [".", 571], ["Both", 573], ["single", 578], ["-", 584], ["dose", 585], ["and", 590], ["chronic", 594], ["empagliflozin", 602], ["treatment", 616], ["caused", 626], ["glycosuria", 633], ["during", 644], ["fasting", 651], ["(", 659], ["median", 660], [",", 666], ["7.8", 668], ["[", 672], ["interquartile", 673], ["range", 687], ["{", 693], ["IQR", 694], ["}", 697], [",", 698], ["4.4", 700], ["]", 703], ["g/3", 705], ["hours", 709], ["and", 715], ["9.2", 719], ["[", 723], ["IQR", 724], [",", 727], ["5.2", 729], ["]", 732], ["g/3", 734], ["hours", 738], [")", 743], ["and", 745], ["after", 749], ["meal", 755], ["ingestion", 760], ["(", 770], ["median", 771], [",", 777], ["29.0", 779], ["[", 784], ["IQR", 785], [",", 788], ["12.5", 790], ["]", 794], ["g/5", 796], ["hours", 800], ["and", 806], ["28.2", 810], ["[", 815], ["IQR", 816], [",", 819], ["15.4", 821], ["]", 825], ["g/5", 827], ["hours", 831], [")", 836], [".", 837], ["After", 839], ["3", 845], ["hours", 847], ["of", 853], ["fasting", 856], [",", 863], ["endogenous", 865], ["glucose", 876], ["production", 884], ["(", 895], ["EGP", 896], [")", 899], ["was", 901], ["increased", 905], ["25", 915], ["%", 917], [",", 918], ["while", 920], ["glycemia", 926], ["was", 935], ["0.9", 939], ["\u00b1", 943], ["0.7", 945], ["mmol", 949], ["/", 953], ["l", 954], ["lower", 956], ["(", 962], ["P", 963], ["<", 965], ["0.0001", 967], ["vs.", 974], ["baseline", 978], [")", 986], [".", 987], ["After", 989], ["meal", 995], ["ingestion", 1000], [",", 1009], ["glucose", 1011], ["and", 1019], ["insulin", 1023], ["AUC", 1031], ["decreased", 1035], [",", 1044], ["whereas", 1046], ["the", 1054], ["glucagon", 1058], ["response", 1067], ["increased", 1076], ["(", 1086], ["all", 1087], ["P", 1091], ["<", 1093], ["0.001", 1095], [")", 1100], [".", 1101], ["While", 1103], ["oral", 1109], ["glucose", 1114], ["appearance", 1122], ["was", 1133], ["unchanged", 1137], [",", 1146], ["EGP", 1148], ["was", 1152], ["increased", 1156], ["(", 1166], ["median", 1167], [",", 1173], ["40", 1175], ["[", 1178], ["IQR", 1179], [",", 1182], ["14", 1184], ["]", 1186], ["g", 1188], ["and", 1190], ["37", 1194], ["[", 1197], ["IQR", 1198], [",", 1201], ["11", 1203], ["]", 1205], ["g", 1207], ["vs.", 1209], ["34", 1213], ["[", 1216], ["IQR", 1217], [",", 1220], ["11", 1222], ["]", 1224], ["g", 1226], [",", 1227], ["both", 1229], ["P", 1234], ["<", 1236], ["0.01", 1238], [")", 1242], [".", 1243], ["Tissue", 1245], ["glucose", 1252], ["disposal", 1260], ["was", 1269], ["reduced", 1273], ["(", 1281], ["median", 1282], [",", 1288], ["75", 1290], ["[", 1293], ["IQR", 1294], [",", 1297], ["16", 1299], ["]", 1301], ["g", 1303], ["and", 1305], ["70", 1309], ["[", 1312], ["IQR", 1313], [",", 1316], ["21", 1318], ["]", 1320], ["g", 1322], ["vs.", 1324], ["93", 1328], ["[", 1331], ["IQR", 1332], [",", 1335], ["18", 1337], ["]", 1339], ["g", 1341], [",", 1342], ["P", 1344], ["<", 1346], ["0.0001", 1348], [")", 1354], [",", 1355], ["due", 1357], ["to", 1361], ["a", 1364], ["decrease", 1366], ["in", 1375], ["both", 1378], ["glucose", 1383], ["oxidation", 1391], ["and", 1401], ["nonoxidative", 1405], ["glucose", 1418], ["disposal", 1426], [",", 1434], ["with", 1436], ["a", 1441], ["concomitant", 1443], ["rise", 1455], ["in", 1460], ["lipid", 1463], ["oxidation", 1469], ["after", 1479], ["chronic", 1485], ["administration", 1493], ["(", 1508], ["all", 1509], ["P", 1513], ["<", 1515], ["0.01", 1517], [")", 1521], [".", 1522], ["\u03b2", 1524], ["Cell", 1526], ["glucose", 1531], ["sensitivity", 1539], ["increased", 1551], ["(", 1561], ["median", 1562], [",", 1568], ["55", 1570], ["[", 1573], ["IQR", 1574], [",", 1577], ["35", 1579], ["]", 1581], ["pmol", 1583], ["\u2022", 1588], ["min(-1", 1590], [")", 1596], ["\u2022", 1598], ["m(-2", 1600], [")", 1604], ["\u2022", 1606], ["mM(-1", 1608], [")", 1613], ["and", 1615], ["55", 1619], ["[", 1622], ["IQR", 1623], [",", 1626], ["39", 1628], ["]", 1630], ["pmol", 1632], ["\u2022", 1637], ["min(-1", 1639], [")", 1645], ["\u2022", 1647], ["m(-2", 1649], [")", 1653], ["\u2022", 1655], ["mM(-1", 1657], [")", 1662], ["vs.", 1664], ["44", 1668], ["[", 1671], ["IQR", 1672], [",", 1675], ["32", 1677], ["]", 1679], ["pmol", 1681], ["\u2022", 1686], ["min(-1", 1688], [")", 1694], ["\u2022", 1696], ["m(-2", 1698], [")", 1702], ["\u2022", 1704], ["mM(-1", 1706], [")", 1711], [",", 1712], ["P", 1714], ["<", 1716], ["0.0001", 1718], [")", 1724], [",", 1725], ["and", 1727], ["insulin", 1731], ["sensitivity", 1739], ["was", 1751], ["improved", 1755], [".", 1763], ["Resting", 1765], ["energy", 1773], ["expenditure", 1780], ["rates", 1792], ["and", 1798], ["those", 1802], ["after", 1808], ["meal", 1814], ["ingestion", 1819], ["were", 1829], ["unchanged", 1834], [".", 1843], ["In", 1845], ["patients", 1848], ["with", 1857], ["type", 1862], ["2", 1867], ["diabetes", 1869], [",", 1877], ["empagliflozin", 1879], ["-", 1892], ["induced", 1893], ["glycosuria", 1901], ["improved", 1912], ["\u03b2", 1921], ["cell", 1923], ["function", 1928], ["and", 1937], ["insulin", 1941], ["sensitivity", 1949], [",", 1960], ["despite", 1962], ["the", 1970], ["fall", 1974], ["in", 1979], ["insulin", 1982], ["secretion", 1990], ["and", 2000], ["tissue", 2004], ["glucose", 2011], ["disposal", 2019], ["and", 2028], ["the", 2032], ["rise", 2036], ["in", 2041], ["EGP", 2044], ["after", 2048], ["one", 2054], ["dose", 2058], [",", 2062], ["thereby", 2064], ["lowering", 2072], ["fasting", 2081], ["and", 2089], ["postprandial", 2093], ["glycemia", 2106], [".", 2114], ["Chronic", 2116], ["dosing", 2124], ["shifted", 2131], ["substrate", 2139], ["utilization", 2149], ["from", 2161], ["carbohydrate", 2166], ["to", 2179], ["lipid", 2182], [".", 2187], ["Trial", 2189], ["registration", 2195], [".", 2207], ["ClinicalTrials", 2209], [".", 2223], ["Gov", 2224], ["NCT01248364", 2228], ["(", 2240], ["EudraCT", 2241], ["no", 2249], [".", 2251], ["2010", 2253], ["-", 2257], ["018708", 2258], ["-", 2264], ["99", 2265], [")", 2267], [".", 2268], ["Funding", 2270], [".", 2277], ["This", 2279], ["study", 2284], ["was", 2290], ["funded", 2294], ["by", 2301], ["Boehringer", 2304], ["Ingelheim", 2315], [".", 2324]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Chronic myeloid leukemia cells contain a BCR-ABL oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal 'cause' of the leukemia. Though the precise mechanisms underlying the leukemogenesis remains enigmatic, the use of imatinib to inhibit the dysregulated kinase activity has proved remarkably successful in clinical practice. Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase activity and its success introduced the current era of molecularly targeted therapies for a number of other malignancies. In patients with chronic myeloid leukaemia who develop resistance to imatinib, the Bcr-Abl signaling pathway is often re-established. This has led to the emergence of a number of alternative treatment strategies designed to target the leukemic cell which are resistant to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "34f1609a5e28421ea7ca56e3a8591062", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[104, 106], [6, 8], [67, 69]], "char_spans": [[655, 661], [41, 47], [426, 432]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["cells", 25], ["contain", 31], ["a", 39], ["BCR", 41], ["-", 44], ["ABL", 45], ["oncoprotein", 49], ["with", 61], ["an", 66], ["enhanced", 69], ["tyrosine", 78], ["kinase", 87], ["activity", 94], [",", 102], ["which", 104], ["is", 110], ["considered", 113], ["to", 124], ["be", 127], ["the", 130], ["principal", 134], ["'cause", 144], ["'", 150], ["of", 152], ["the", 155], ["leukemia", 159], [".", 167], ["Though", 169], ["the", 176], ["precise", 180], ["mechanisms", 188], ["underlying", 199], ["the", 210], ["leukemogenesis", 214], ["remains", 229], ["enigmatic", 237], [",", 246], ["the", 248], ["use", 252], ["of", 256], ["imatinib", 259], ["to", 268], ["inhibit", 271], ["the", 279], ["dysregulated", 283], ["kinase", 296], ["activity", 303], ["has", 312], ["proved", 316], ["remarkably", 323], ["successful", 334], ["in", 345], ["clinical", 348], ["practice", 357], [".", 365], ["Imatinib", 367], ["was", 376], ["the", 380], ["first", 384], ["small", 390], ["molecule", 396], ["developed", 405], ["to", 415], ["inhibit", 418], ["BCR", 426], ["-", 429], ["ABL", 430], ["tyrosine", 434], ["kinase", 443], ["activity", 450], ["and", 459], ["its", 463], ["success", 467], ["introduced", 475], ["the", 486], ["current", 490], ["era", 498], ["of", 502], ["molecularly", 505], ["targeted", 517], ["therapies", 526], ["for", 536], ["a", 540], ["number", 542], ["of", 549], ["other", 552], ["malignancies", 558], [".", 570], ["In", 572], ["patients", 575], ["with", 584], ["chronic", 589], ["myeloid", 597], ["leukaemia", 605], ["who", 615], ["develop", 619], ["resistance", 627], ["to", 638], ["imatinib", 641], [",", 649], ["the", 651], ["Bcr", 655], ["-", 658], ["Abl", 659], ["signaling", 663], ["pathway", 673], ["is", 681], ["often", 684], ["re", 690], ["-", 692], ["established", 693], [".", 704], ["This", 706], ["has", 711], ["led", 715], ["to", 719], ["the", 722], ["emergence", 726], ["of", 736], ["a", 739], ["number", 741], ["of", 748], ["alternative", 751], ["treatment", 763], ["strategies", 773], ["designed", 784], ["to", 793], ["target", 796], ["the", 803], ["leukemic", 807], ["cell", 816], ["which", 821], ["are", 827], ["resistant", 831], ["to", 841], ["imatinib", 844], [".", 852]]}
{"context": "Restless legs syndrome (RLS) is a clinically important, common disease and should be diagnosed and treated early and adequately. At present, there have been no clinical biomarkers or methodologies that can contribute to the correct diagnosis of RLS, RLS should be diagnosed on the basis of 4 essential criteria: urge to move the legs, improvement after movement, and worsening or occurrence of symptoms in the evening and at rest. When applying the criteria, RLS mimics should be ruled out and comorbid diseases should be taken into account. The origin and pathogenesis of RLS are still under investigation; however, iron deficiency in the brain has been observed on imaging and cerebrospinal fluid analyses of patients with RLS. In contrast, the results of neuroimaging studies evaluating brain dopaminergic functions in patients with RLS have yielded inconclusive results, although involvement of the hypothalamus (A11) is thought to cause impaired dopaminergic modulation in the dorsal horn and intermediolateral nucleus, resulting in the restlessness of legs.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f86ef5e1ac664cb0a799f69a2e54f94d", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[112, 112]], "char_spans": [[617, 620]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["is", 29], ["a", 32], ["clinically", 34], ["important", 45], [",", 54], ["common", 56], ["disease", 63], ["and", 71], ["should", 75], ["be", 82], ["diagnosed", 85], ["and", 95], ["treated", 99], ["early", 107], ["and", 113], ["adequately", 117], [".", 127], ["At", 129], ["present", 132], [",", 139], ["there", 141], ["have", 147], ["been", 152], ["no", 157], ["clinical", 160], ["biomarkers", 169], ["or", 180], ["methodologies", 183], ["that", 197], ["can", 202], ["contribute", 206], ["to", 217], ["the", 220], ["correct", 224], ["diagnosis", 232], ["of", 242], ["RLS", 245], [",", 248], ["RLS", 250], ["should", 254], ["be", 261], ["diagnosed", 264], ["on", 274], ["the", 277], ["basis", 281], ["of", 287], ["4", 290], ["essential", 292], ["criteria", 302], [":", 310], ["urge", 312], ["to", 317], ["move", 320], ["the", 325], ["legs", 329], [",", 333], ["improvement", 335], ["after", 347], ["movement", 353], [",", 361], ["and", 363], ["worsening", 367], ["or", 377], ["occurrence", 380], ["of", 391], ["symptoms", 394], ["in", 403], ["the", 406], ["evening", 410], ["and", 418], ["at", 422], ["rest", 425], [".", 429], ["When", 431], ["applying", 436], ["the", 445], ["criteria", 449], [",", 457], ["RLS", 459], ["mimics", 463], ["should", 470], ["be", 477], ["ruled", 480], ["out", 486], ["and", 490], ["comorbid", 494], ["diseases", 503], ["should", 512], ["be", 519], ["taken", 522], ["into", 528], ["account", 533], [".", 540], ["The", 542], ["origin", 546], ["and", 553], ["pathogenesis", 557], ["of", 570], ["RLS", 573], ["are", 577], ["still", 581], ["under", 587], ["investigation", 593], [";", 606], ["however", 608], [",", 615], ["iron", 617], ["deficiency", 622], ["in", 633], ["the", 636], ["brain", 640], ["has", 646], ["been", 650], ["observed", 655], ["on", 664], ["imaging", 667], ["and", 675], ["cerebrospinal", 679], ["fluid", 693], ["analyses", 699], ["of", 708], ["patients", 711], ["with", 720], ["RLS", 725], [".", 728], ["In", 730], ["contrast", 733], [",", 741], ["the", 743], ["results", 747], ["of", 755], ["neuroimaging", 758], ["studies", 771], ["evaluating", 779], ["brain", 790], ["dopaminergic", 796], ["functions", 809], ["in", 819], ["patients", 822], ["with", 831], ["RLS", 836], ["have", 840], ["yielded", 845], ["inconclusive", 853], ["results", 866], [",", 873], ["although", 875], ["involvement", 884], ["of", 896], ["the", 899], ["hypothalamus", 903], ["(", 916], ["A11", 917], [")", 920], ["is", 922], ["thought", 925], ["to", 933], ["cause", 936], ["impaired", 942], ["dopaminergic", 951], ["modulation", 964], ["in", 975], ["the", 978], ["dorsal", 982], ["horn", 989], ["and", 994], ["intermediolateral", 998], ["nucleus", 1016], [",", 1023], ["resulting", 1025], ["in", 1035], ["the", 1038], ["restlessness", 1042], ["of", 1055], ["legs", 1058], [".", 1062]]}
{"context": "MicroRNAs (miRNAs) constitute a large family of noncoding RNAs that function as guide molecules in diverse gene silencing pathways. Current efforts are focused on the regulatory function of miRNAs, while little is known about how these unusual genes themselves are regulated. Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II). The primary miRNA transcripts (pri-miRNAs) contain cap structures as well as poly(A) tails, which are the unique properties of class II gene transcripts. The treatment of human cells with alpha-amanitin decreased the level of pri-miRNAs at a concentration that selectively inhibits pol II activity. Furthermore, chromatin immunoprecipitation analyses show that pol II is physically associated with a miRNA promoter. We also describe, for the first time, the detailed structure of a miRNA gene by determining the promoter and the terminator of mir-23a approximately 27a approximately 24-2. These data indicate that pol II is the main, if not the only, RNA polymerase for miRNA gene transcription. Our study offers a basis for understanding the structure and regulation of miRNA genes.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "bfbcb1b432584aff8df5bc3c70e56f62", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[59, 61]], "char_spans": [[354, 370]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["constitute", 19], ["a", 30], ["large", 32], ["family", 38], ["of", 45], ["noncoding", 48], ["RNAs", 58], ["that", 63], ["function", 68], ["as", 77], ["guide", 80], ["molecules", 86], ["in", 96], ["diverse", 99], ["gene", 107], ["silencing", 112], ["pathways", 122], [".", 130], ["Current", 132], ["efforts", 140], ["are", 148], ["focused", 152], ["on", 160], ["the", 163], ["regulatory", 167], ["function", 178], ["of", 187], ["miRNAs", 190], [",", 196], ["while", 198], ["little", 204], ["is", 211], ["known", 214], ["about", 220], ["how", 226], ["these", 230], ["unusual", 236], ["genes", 244], ["themselves", 250], ["are", 261], ["regulated", 265], [".", 274], ["Here", 276], ["we", 281], ["present", 284], ["the", 292], ["first", 296], ["direct", 302], ["evidence", 309], ["that", 318], ["miRNA", 323], ["genes", 329], ["are", 335], ["transcribed", 339], ["by", 351], ["RNA", 354], ["polymerase", 358], ["II", 369], ["(", 372], ["pol", 373], ["II", 377], [")", 379], [".", 380], ["The", 382], ["primary", 386], ["miRNA", 394], ["transcripts", 400], ["(", 412], ["pri", 413], ["-", 416], ["miRNAs", 417], [")", 423], ["contain", 425], ["cap", 433], ["structures", 437], ["as", 448], ["well", 451], ["as", 456], ["poly(A", 459], [")", 465], ["tails", 467], [",", 472], ["which", 474], ["are", 480], ["the", 484], ["unique", 488], ["properties", 495], ["of", 506], ["class", 509], ["II", 515], ["gene", 518], ["transcripts", 523], [".", 534], ["The", 536], ["treatment", 540], ["of", 550], ["human", 553], ["cells", 559], ["with", 565], ["alpha", 570], ["-", 575], ["amanitin", 576], ["decreased", 585], ["the", 595], ["level", 599], ["of", 605], ["pri", 608], ["-", 611], ["miRNAs", 612], ["at", 619], ["a", 622], ["concentration", 624], ["that", 638], ["selectively", 643], ["inhibits", 655], ["pol", 664], ["II", 668], ["activity", 671], [".", 679], ["Furthermore", 681], [",", 692], ["chromatin", 694], ["immunoprecipitation", 704], ["analyses", 724], ["show", 733], ["that", 738], ["pol", 743], ["II", 747], ["is", 750], ["physically", 753], ["associated", 764], ["with", 775], ["a", 780], ["miRNA", 782], ["promoter", 788], [".", 796], ["We", 798], ["also", 801], ["describe", 806], [",", 814], ["for", 816], ["the", 820], ["first", 824], ["time", 830], [",", 834], ["the", 836], ["detailed", 840], ["structure", 849], ["of", 859], ["a", 862], ["miRNA", 864], ["gene", 870], ["by", 875], ["determining", 878], ["the", 890], ["promoter", 894], ["and", 903], ["the", 907], ["terminator", 911], ["of", 922], ["mir-23a", 925], ["approximately", 933], ["27a", 947], ["approximately", 951], ["24", 965], ["-", 967], ["2", 968], [".", 969], ["These", 971], ["data", 977], ["indicate", 982], ["that", 991], ["pol", 996], ["II", 1000], ["is", 1003], ["the", 1006], ["main", 1010], [",", 1014], ["if", 1016], ["not", 1019], ["the", 1023], ["only", 1027], [",", 1031], ["RNA", 1033], ["polymerase", 1037], ["for", 1048], ["miRNA", 1052], ["gene", 1058], ["transcription", 1063], [".", 1076], ["Our", 1078], ["study", 1082], ["offers", 1088], ["a", 1095], ["basis", 1097], ["for", 1103], ["understanding", 1107], ["the", 1121], ["structure", 1125], ["and", 1135], ["regulation", 1139], ["of", 1150], ["miRNA", 1153], ["genes", 1159], [".", 1164]]}
{"context": "Trimethylation of histone H3 Lys4 (H3K4) is associated with transcriptional activation. One of the chief effectors of H3K4 methylation is mixed-lineage leukemia 1 (MLL1), a gene that is disrupted by chromosomal translocation in acute leukemia and a master regulator of Hox and other genes. In a recent paper, core components of the human MLL histone methyltransferase (MT) complex were found to form a structural platform, with one component (WDR5) mediating association between the specific histone H3K4 substrate and the MT. This novel regulatory mechanism, which is conserved from yeast to human, is required for both methylation and downstream target gene transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "f5a528ae5c1742e2a05b03ecd56fb554", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[20, 20], [90, 90], [6, 6]], "char_spans": [[118, 121], [500, 503], [35, 38]]}]}], "context_tokens": [["Trimethylation", 0], ["of", 15], ["histone", 18], ["H3", 26], ["Lys4", 29], ["(", 34], ["H3K4", 35], [")", 39], ["is", 41], ["associated", 44], ["with", 55], ["transcriptional", 60], ["activation", 76], [".", 86], ["One", 88], ["of", 92], ["the", 95], ["chief", 99], ["effectors", 105], ["of", 115], ["H3K4", 118], ["methylation", 123], ["is", 135], ["mixed", 138], ["-", 143], ["lineage", 144], ["leukemia", 152], ["1", 161], ["(", 163], ["MLL1", 164], [")", 168], [",", 169], ["a", 171], ["gene", 173], ["that", 178], ["is", 183], ["disrupted", 186], ["by", 196], ["chromosomal", 199], ["translocation", 211], ["in", 225], ["acute", 228], ["leukemia", 234], ["and", 243], ["a", 247], ["master", 249], ["regulator", 256], ["of", 266], ["Hox", 269], ["and", 273], ["other", 277], ["genes", 283], [".", 288], ["In", 290], ["a", 293], ["recent", 295], ["paper", 302], [",", 307], ["core", 309], ["components", 314], ["of", 325], ["the", 328], ["human", 332], ["MLL", 338], ["histone", 342], ["methyltransferase", 350], ["(", 368], ["MT", 369], [")", 371], ["complex", 373], ["were", 381], ["found", 386], ["to", 392], ["form", 395], ["a", 400], ["structural", 402], ["platform", 413], [",", 421], ["with", 423], ["one", 428], ["component", 432], ["(", 442], ["WDR5", 443], [")", 447], ["mediating", 449], ["association", 459], ["between", 471], ["the", 479], ["specific", 483], ["histone", 492], ["H3K4", 500], ["substrate", 505], ["and", 515], ["the", 519], ["MT", 523], [".", 525], ["This", 527], ["novel", 532], ["regulatory", 538], ["mechanism", 549], [",", 558], ["which", 560], ["is", 566], ["conserved", 569], ["from", 579], ["yeast", 584], ["to", 590], ["human", 593], [",", 598], ["is", 600], ["required", 603], ["for", 612], ["both", 616], ["methylation", 621], ["and", 633], ["downstream", 637], ["target", 648], ["gene", 655], ["transcription", 660], [".", 673]]}
{"context": "The actin-cross-linking protein spectrin is a prominent component of the membrane cytoskeleton. Spectrin is a tetramer of two antiparallel alphabeta-dimers which share a unique and ancient gene structure. The alpha-spectrin and beta-spectrin genes are composed primarily of tandemly repeated 106-amino-acid segments, each of which forms a triple alpha-helical coiled coil. Both the genes and the repeats themselves are homologous. The two genes are thought to be the result of a gene duplication event, and each gene is the product of duplications of the 106-amino-acid repeats. In this work we compare the process of molecular evolution across the repeated segments of the alpha- and beta-spectrin genes. We find that the alpha-spectrin segments have, for the most part, evolved in a homogeneous fashion, while considerable heterogeneity is found among beta-spectrin segments. Several segments with unique known functions are found to have evolved differently than the others. On the basis of heterogeneity of the evolutionary process, we suggest that at least one repeat has a unique function that has yet to be documented. We also present new statistical methods for comparing the evolutionary process between different regions of DNA sequences.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "b37db289ef2948e9b5e75fbc0cbd66bf", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[23, 23]], "char_spans": [[126, 137]]}]}], "context_tokens": [["The", 0], ["actin", 4], ["-", 9], ["cross", 10], ["-", 15], ["linking", 16], ["protein", 24], ["spectrin", 32], ["is", 41], ["a", 44], ["prominent", 46], ["component", 56], ["of", 66], ["the", 69], ["membrane", 73], ["cytoskeleton", 82], [".", 94], ["Spectrin", 96], ["is", 105], ["a", 108], ["tetramer", 110], ["of", 119], ["two", 122], ["antiparallel", 126], ["alphabeta", 139], ["-", 148], ["dimers", 149], ["which", 156], ["share", 162], ["a", 168], ["unique", 170], ["and", 177], ["ancient", 181], ["gene", 189], ["structure", 194], [".", 203], ["The", 205], ["alpha", 209], ["-", 214], ["spectrin", 215], ["and", 224], ["beta", 228], ["-", 232], ["spectrin", 233], ["genes", 242], ["are", 248], ["composed", 252], ["primarily", 261], ["of", 271], ["tandemly", 274], ["repeated", 283], ["106-amino", 292], ["-", 301], ["acid", 302], ["segments", 307], [",", 315], ["each", 317], ["of", 322], ["which", 325], ["forms", 331], ["a", 337], ["triple", 339], ["alpha", 346], ["-", 351], ["helical", 352], ["coiled", 360], ["coil", 367], [".", 371], ["Both", 373], ["the", 378], ["genes", 382], ["and", 388], ["the", 392], ["repeats", 396], ["themselves", 404], ["are", 415], ["homologous", 419], [".", 429], ["The", 431], ["two", 435], ["genes", 439], ["are", 445], ["thought", 449], ["to", 457], ["be", 460], ["the", 463], ["result", 467], ["of", 474], ["a", 477], ["gene", 479], ["duplication", 484], ["event", 496], [",", 501], ["and", 503], ["each", 507], ["gene", 512], ["is", 517], ["the", 520], ["product", 524], ["of", 532], ["duplications", 535], ["of", 548], ["the", 551], ["106-amino", 555], ["-", 564], ["acid", 565], ["repeats", 570], [".", 577], ["In", 579], ["this", 582], ["work", 587], ["we", 592], ["compare", 595], ["the", 603], ["process", 607], ["of", 615], ["molecular", 618], ["evolution", 628], ["across", 638], ["the", 645], ["repeated", 649], ["segments", 658], ["of", 667], ["the", 670], ["alpha-", 674], ["and", 681], ["beta", 685], ["-", 689], ["spectrin", 690], ["genes", 699], [".", 704], ["We", 706], ["find", 709], ["that", 714], ["the", 719], ["alpha", 723], ["-", 728], ["spectrin", 729], ["segments", 738], ["have", 747], [",", 751], ["for", 753], ["the", 757], ["most", 761], ["part", 766], [",", 770], ["evolved", 772], ["in", 780], ["a", 783], ["homogeneous", 785], ["fashion", 797], [",", 804], ["while", 806], ["considerable", 812], ["heterogeneity", 825], ["is", 839], ["found", 842], ["among", 848], ["beta", 854], ["-", 858], ["spectrin", 859], ["segments", 868], [".", 876], ["Several", 878], ["segments", 886], ["with", 895], ["unique", 900], ["known", 907], ["functions", 913], ["are", 923], ["found", 927], ["to", 933], ["have", 936], ["evolved", 941], ["differently", 949], ["than", 961], ["the", 966], ["others", 970], [".", 976], ["On", 978], ["the", 981], ["basis", 985], ["of", 991], ["heterogeneity", 994], ["of", 1008], ["the", 1011], ["evolutionary", 1015], ["process", 1028], [",", 1035], ["we", 1037], ["suggest", 1040], ["that", 1048], ["at", 1053], ["least", 1056], ["one", 1062], ["repeat", 1066], ["has", 1073], ["a", 1077], ["unique", 1079], ["function", 1086], ["that", 1095], ["has", 1100], ["yet", 1104], ["to", 1108], ["be", 1111], ["documented", 1114], [".", 1124], ["We", 1126], ["also", 1129], ["present", 1134], ["new", 1142], ["statistical", 1146], ["methods", 1158], ["for", 1166], ["comparing", 1170], ["the", 1180], ["evolutionary", 1184], ["process", 1197], ["between", 1205], ["different", 1213], ["regions", 1223], ["of", 1231], ["DNA", 1234], ["sequences", 1238], [".", 1247]]}
{"context": "Mutations in NOTCH3 are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary angiopathy causing stroke and vascular dementia. All CADASIL mutations identified so far result in the loss or gain of one cysteine residue within epidermal growth factor (EGF)-like repeat domains. Here an in-frame deletion causing a loss of three cysteine residues within EGF repeat 6 is reported. These data are consistent with the hypothesis that the change toward an odd number of cysteine residues within a given EGF repeat and therefore an unpaired, reactive cysteine residue is the common and critical molecular event in CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "04da2c70e07e4c2581afe158af0e1759", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [89, 89], [43, 43], [102, 102]], "char_spans": [[400, 407], [537, 544], [275, 282], [617, 624]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["NOTCH3", 13], ["are", 20], ["the", 24], ["cause", 28], ["of", 34], ["cerebral", 37], ["autosomal", 46], ["dominant", 56], ["arteriopathy", 65], ["with", 78], ["subcortical", 83], ["infarcts", 95], ["and", 104], ["leukoencephalopathy", 108], ["(", 128], ["CADASIL", 129], [")", 136], [",", 137], ["a", 139], ["hereditary", 141], ["angiopathy", 152], ["causing", 163], ["stroke", 171], ["and", 178], ["vascular", 182], ["dementia", 191], [".", 199], ["All", 201], ["CADASIL", 205], ["mutations", 213], ["identified", 223], ["so", 234], ["far", 237], ["result", 241], ["in", 248], ["the", 251], ["loss", 255], ["or", 260], ["gain", 263], ["of", 268], ["one", 271], ["cysteine", 275], ["residue", 284], ["within", 292], ["epidermal", 299], ["growth", 309], ["factor", 316], ["(", 323], ["EGF)-like", 324], ["repeat", 334], ["domains", 341], [".", 348], ["Here", 350], ["an", 355], ["in", 358], ["-", 360], ["frame", 361], ["deletion", 367], ["causing", 376], ["a", 384], ["loss", 386], ["of", 391], ["three", 394], ["cysteine", 400], ["residues", 409], ["within", 418], ["EGF", 425], ["repeat", 429], ["6", 436], ["is", 438], ["reported", 441], [".", 449], ["These", 451], ["data", 457], ["are", 462], ["consistent", 466], ["with", 477], ["the", 482], ["hypothesis", 486], ["that", 497], ["the", 502], ["change", 506], ["toward", 513], ["an", 520], ["odd", 523], ["number", 527], ["of", 534], ["cysteine", 537], ["residues", 546], ["within", 555], ["a", 562], ["given", 564], ["EGF", 570], ["repeat", 574], ["and", 581], ["therefore", 585], ["an", 595], ["unpaired", 598], [",", 606], ["reactive", 608], ["cysteine", 617], ["residue", 626], ["is", 634], ["the", 637], ["common", 641], ["and", 648], ["critical", 652], ["molecular", 661], ["event", 671], ["in", 677], ["CADASIL", 680], [".", 687]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Epigenomic mapping of enhancer-associated chromatin modifications facilitates the genome-wide discovery of tissue-specific enhancers in vivo. However, reliance on single chromatin marks leads to high rates of false-positive predictions. More sophisticated, integrative methods have been described, but commonly suffer from limited accessibility to the resulting predictions and reduced biological interpretability. Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface. We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements. By combining different statistical models, our approach outperforms current state-of-the-art methods and provides interpretable measures of feature importance. Our results indicate that including a previously unappreciated score that quantifies tissue-specific nuclease accessibility significantly improves prediction performance. We demonstrate the utility of our approach through in vivo validation of newly predicted elements. Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.", "qas": [{"question": "Which resource contains accurate enhancer predictions in the developing limb?", "answers": ["Limb-Enhancer Genie (LEG)"], "qid": "a1f4e0c1a4c84385836fb9879b463d73", "question_tokens": [["Which", 0], ["resource", 6], ["contains", 15], ["accurate", 24], ["enhancer", 33], ["predictions", 42], ["in", 54], ["the", 57], ["developing", 61], ["limb", 72], ["?", 76]], "detected_answers": [{"text": "Limb-Enhancer Genie (LEG)", "token_spans": [[67, 72]], "char_spans": [[435, 458]]}]}], "context_tokens": [["Epigenomic", 0], ["mapping", 11], ["of", 19], ["enhancer", 22], ["-", 30], ["associated", 31], ["chromatin", 42], ["modifications", 52], ["facilitates", 66], ["the", 78], ["genome", 82], ["-", 88], ["wide", 89], ["discovery", 94], ["of", 104], ["tissue", 107], ["-", 113], ["specific", 114], ["enhancers", 123], ["in", 133], ["vivo", 136], [".", 140], ["However", 142], [",", 149], ["reliance", 151], ["on", 160], ["single", 163], ["chromatin", 170], ["marks", 180], ["leads", 186], ["to", 192], ["high", 195], ["rates", 200], ["of", 206], ["false", 209], ["-", 214], ["positive", 215], ["predictions", 224], [".", 235], ["More", 237], ["sophisticated", 242], [",", 255], ["integrative", 257], ["methods", 269], ["have", 277], ["been", 282], ["described", 287], [",", 296], ["but", 298], ["commonly", 302], ["suffer", 311], ["from", 318], ["limited", 323], ["accessibility", 331], ["to", 345], ["the", 348], ["resulting", 352], ["predictions", 362], ["and", 374], ["reduced", 378], ["biological", 386], ["interpretability", 397], [".", 413], ["Here", 415], ["we", 420], ["present", 423], ["the", 431], ["Limb", 435], ["-", 439], ["Enhancer", 440], ["Genie", 449], ["(", 455], ["LEG", 456], [")", 459], [",", 460], ["a", 462], ["collection", 464], ["of", 475], ["highly", 478], ["accurate", 485], [",", 493], ["genome", 495], ["-", 501], ["wide", 502], ["predictions", 507], ["of", 519], ["enhancers", 522], ["in", 532], ["the", 535], ["developing", 539], ["limb", 550], [",", 554], ["available", 556], ["through", 566], ["a", 574], ["user", 576], ["-", 580], ["friendly", 581], ["online", 590], ["interface", 597], [".", 606], ["We", 608], ["predict", 611], ["limb", 619], ["enhancers", 624], ["using", 634], ["a", 640], ["combination", 642], ["of", 654], [">", 657], ["50", 658], ["published", 661], ["limb", 671], ["-", 675], ["specific", 676], ["datasets", 685], ["and", 694], ["clusters", 698], ["of", 707], ["evolutionarily", 710], ["conserved", 725], ["transcription", 735], ["factor", 749], ["binding", 756], ["sites", 764], [",", 769], ["taking", 771], ["advantage", 778], ["of", 788], ["the", 791], ["patterns", 795], ["observed", 804], ["at", 813], ["previously", 816], ["in", 827], ["vivo", 830], ["validated", 835], ["elements", 845], [".", 853], ["By", 855], ["combining", 858], ["different", 868], ["statistical", 878], ["models", 890], [",", 896], ["our", 898], ["approach", 902], ["outperforms", 911], ["current", 923], ["state", 931], ["-", 936], ["of", 937], ["-", 939], ["the", 940], ["-", 943], ["art", 944], ["methods", 948], ["and", 956], ["provides", 960], ["interpretable", 969], ["measures", 983], ["of", 992], ["feature", 995], ["importance", 1003], [".", 1013], ["Our", 1015], ["results", 1019], ["indicate", 1027], ["that", 1036], ["including", 1041], ["a", 1051], ["previously", 1053], ["unappreciated", 1064], ["score", 1078], ["that", 1084], ["quantifies", 1089], ["tissue", 1100], ["-", 1106], ["specific", 1107], ["nuclease", 1116], ["accessibility", 1125], ["significantly", 1139], ["improves", 1153], ["prediction", 1162], ["performance", 1173], [".", 1184], ["We", 1186], ["demonstrate", 1189], ["the", 1201], ["utility", 1205], ["of", 1213], ["our", 1216], ["approach", 1220], ["through", 1229], ["in", 1237], ["vivo", 1240], ["validation", 1245], ["of", 1256], ["newly", 1259], ["predicted", 1265], ["elements", 1275], [".", 1283], ["Moreover", 1285], [",", 1293], ["we", 1295], ["describe", 1298], ["general", 1307], ["features", 1315], ["that", 1324], ["can", 1329], ["guide", 1333], ["the", 1339], ["type", 1343], ["of", 1348], ["datasets", 1351], ["to", 1360], ["include", 1363], ["when", 1371], ["predicting", 1376], ["tissue", 1387], ["-", 1393], ["specific", 1394], ["enhancers", 1403], ["genome", 1413], ["-", 1419], ["wide", 1420], [",", 1424], ["while", 1426], ["providing", 1432], ["an", 1442], ["accessible", 1445], ["resource", 1456], ["to", 1465], ["the", 1468], ["general", 1472], ["biological", 1480], ["community", 1491], ["and", 1501], ["facilitating", 1505], ["the", 1518], ["functional", 1522], ["interpretation", 1533], ["of", 1548], ["genetic", 1551], ["studies", 1559], ["of", 1567], ["limb", 1570], ["malformations", 1575], [".", 1588]]}
{"context": "To assess the efficacy, usefulness, safety, and dosages of flumazenil required when flumazenil is used in the diagnosis of benzodiazepine-induced coma (vs. other drug-induced coma), and to reverse or prevent the recurrence of unconsciousness. A two-phase study: a controlled, randomized, double-blind study followed by a prospective, open study. An 800-bed, teaching, university-affiliated hospital. Unconscious patients (n = 110) suspected of benzodiazepine overdose, graded 2 to 4 on the Matthew and Lawson coma scale, were treated with flumazenil, the specific benzodiazepine receptor antagonist. The first 31 patients were studied in a double-blind fashion, while the rest of the patients were given flumazenil according to an open protocol. INTERVENTIONS; All patients received supplemental oxygen; endotracheal intubation was performed, and synchronized intermittent mandatory ventilation was initiated whenever it was deemed necessary. A peripheral intravenous cannula was inserted, as were indwelling arterial and urinary bladder catheters. Blood pressure, electrocardiogram, respiratory rate, end-tidal CO2, and core temperature were continuously monitored. The first 31 double-blind patients received either intravenous flumazenil (to a maximum of 1 mg) or saline, while the rest of the patients were given flumazenil until either regaining consciousness or a maximum of 2.5 mg was injected. Patients remaining unconscious among double-blind patients or those patients relapsing into coma after the first dose were later treated in the open phase of the study. Treatment continued by boluses or infusion as long as efficacious. Fourteen of 17 double-blind, flumazenil-treated patients woke after a mean of 0.8 +/- 0.3 (SD) mg vs. one of 14 placebo patients (p < .001). Seventy-five percent of the aggregated controlled and uncontrolled patients awoke from coma scores of 3.1 +/- 0.6 to 0.4 +/- 0.5 (p < .01) after the injection of 0.7 +/- 0.3 mg of flumazenil. These patients had high benzodiazepine serum blood concentrations. Twenty-five percent of the patients did not regain consciousness. These patients had very high serum concentrations of nonbenzodiazepine drugs. Sixty percent of the responders who had primarily ingested benzodiazepines remained awake for 72 +/- 37 mins after flumazenil administration; 40% relapsed into coma after 18 +/- 7 mins and various central nervous system depressant drugs were detected in their blood in addition to benzodiazepines. Seventy-one percent of the patients had ingested tricyclic antidepressants. Seventy-eight percent of the responders were continually and efficaciously treated for < or = 8 days. Fourteen (25%) of the intubated patients were extubated safely while 12 patients, who had shown increased respiratory insufficiency, resumed satisfactory respiration after flumazenil injection. Five cases of transient increase in blood pressure and heart rate were encountered. There were 27 mildly unpleasant \"waking\" episodes, such as anxiety, restlessness, and aggression, but no patient had benzodiazepine withdrawal signs, convulsions, or dysrhythmia, most noticeably absent in tricyclic antidepressant-intoxicated patients. Flumazenil is a valid diagnostic tool for distinguishing pure benzodiazepine from mixed-drug intoxication or nondrug-induced coma. Flumazenil is effective in preventing recurrence of benzodiazepine-induced coma. Respiratory insufficiency is reversed after its administration. Flumazenil is safe when administered cautiously, even in patients with coma caused by a mixed overdose of benzodiazepine plus tricyclic antidepressants.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "703c26f6e3614fc3ad84fedea34fc7ed", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[416, 416], [213, 213], [363, 363], [134, 134], [294, 294], [605, 605], [12, 12], [564, 564], [105, 105], [233, 233], [505, 505], [585, 585], [15, 15]], "char_spans": [[2297, 2306], [1230, 1239], [1959, 1968], [704, 713], [1667, 1676], [3464, 3473], [59, 68], [3188, 3197], [539, 548], [1317, 1326], [2830, 2839], [3319, 3328], [84, 93]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], [",", 22], ["usefulness", 24], [",", 34], ["safety", 36], [",", 42], ["and", 44], ["dosages", 48], ["of", 56], ["flumazenil", 59], ["required", 70], ["when", 79], ["flumazenil", 84], ["is", 95], ["used", 98], ["in", 103], ["the", 106], ["diagnosis", 110], ["of", 120], ["benzodiazepine", 123], ["-", 137], ["induced", 138], ["coma", 146], ["(", 151], ["vs.", 152], ["other", 156], ["drug", 162], ["-", 166], ["induced", 167], ["coma", 175], [")", 179], [",", 180], ["and", 182], ["to", 186], ["reverse", 189], ["or", 197], ["prevent", 200], ["the", 208], ["recurrence", 212], ["of", 223], ["unconsciousness", 226], [".", 241], ["A", 243], ["two", 245], ["-", 248], ["phase", 249], ["study", 255], [":", 260], ["a", 262], ["controlled", 264], [",", 274], ["randomized", 276], [",", 286], ["double", 288], ["-", 294], ["blind", 295], ["study", 301], ["followed", 307], ["by", 316], ["a", 319], ["prospective", 321], [",", 332], ["open", 334], ["study", 339], [".", 344], ["An", 346], ["800-bed", 349], [",", 356], ["teaching", 358], [",", 366], ["university", 368], ["-", 378], ["affiliated", 379], ["hospital", 390], [".", 398], ["Unconscious", 400], ["patients", 412], ["(", 421], ["n", 422], ["=", 424], ["110", 426], [")", 429], ["suspected", 431], ["of", 441], ["benzodiazepine", 444], ["overdose", 459], [",", 467], ["graded", 469], ["2", 476], ["to", 478], ["4", 481], ["on", 483], ["the", 486], ["Matthew", 490], ["and", 498], ["Lawson", 502], ["coma", 509], ["scale", 514], [",", 519], ["were", 521], ["treated", 526], ["with", 534], ["flumazenil", 539], [",", 549], ["the", 551], ["specific", 555], ["benzodiazepine", 564], ["receptor", 579], ["antagonist", 588], [".", 598], ["The", 600], ["first", 604], ["31", 610], ["patients", 613], ["were", 622], ["studied", 627], ["in", 635], ["a", 638], ["double", 640], ["-", 646], ["blind", 647], ["fashion", 653], [",", 660], ["while", 662], ["the", 668], ["rest", 672], ["of", 677], ["the", 680], ["patients", 684], ["were", 693], ["given", 698], ["flumazenil", 704], ["according", 715], ["to", 725], ["an", 728], ["open", 731], ["protocol", 736], [".", 744], ["INTERVENTIONS", 746], [";", 759], ["All", 761], ["patients", 765], ["received", 774], ["supplemental", 783], ["oxygen", 796], [";", 802], ["endotracheal", 804], ["intubation", 817], ["was", 828], ["performed", 832], [",", 841], ["and", 843], ["synchronized", 847], ["intermittent", 860], ["mandatory", 873], ["ventilation", 883], ["was", 895], ["initiated", 899], ["whenever", 909], ["it", 918], ["was", 921], ["deemed", 925], ["necessary", 932], [".", 941], ["A", 943], ["peripheral", 945], ["intravenous", 956], ["cannula", 968], ["was", 976], ["inserted", 980], [",", 988], ["as", 990], ["were", 993], ["indwelling", 998], ["arterial", 1009], ["and", 1018], ["urinary", 1022], ["bladder", 1030], ["catheters", 1038], [".", 1047], ["Blood", 1049], ["pressure", 1055], [",", 1063], ["electrocardiogram", 1065], [",", 1082], ["respiratory", 1084], ["rate", 1096], [",", 1100], ["end", 1102], ["-", 1105], ["tidal", 1106], ["CO2", 1112], [",", 1115], ["and", 1117], ["core", 1121], ["temperature", 1126], ["were", 1138], ["continuously", 1143], ["monitored", 1156], [".", 1165], ["The", 1167], ["first", 1171], ["31", 1177], ["double", 1180], ["-", 1186], ["blind", 1187], ["patients", 1193], ["received", 1202], ["either", 1211], ["intravenous", 1218], ["flumazenil", 1230], ["(", 1241], ["to", 1242], ["a", 1245], ["maximum", 1247], ["of", 1255], ["1", 1258], ["mg", 1260], [")", 1262], ["or", 1264], ["saline", 1267], [",", 1273], ["while", 1275], ["the", 1281], ["rest", 1285], ["of", 1290], ["the", 1293], ["patients", 1297], ["were", 1306], ["given", 1311], ["flumazenil", 1317], ["until", 1328], ["either", 1334], ["regaining", 1341], ["consciousness", 1351], ["or", 1365], ["a", 1368], ["maximum", 1370], ["of", 1378], ["2.5", 1381], ["mg", 1385], ["was", 1388], ["injected", 1392], [".", 1400], ["Patients", 1402], ["remaining", 1411], ["unconscious", 1421], ["among", 1433], ["double", 1439], ["-", 1445], ["blind", 1446], ["patients", 1452], ["or", 1461], ["those", 1464], ["patients", 1470], ["relapsing", 1479], ["into", 1489], ["coma", 1494], ["after", 1499], ["the", 1505], ["first", 1509], ["dose", 1515], ["were", 1520], ["later", 1525], ["treated", 1531], ["in", 1539], ["the", 1542], ["open", 1546], ["phase", 1551], ["of", 1557], ["the", 1560], ["study", 1564], [".", 1569], ["Treatment", 1571], ["continued", 1581], ["by", 1591], ["boluses", 1594], ["or", 1602], ["infusion", 1605], ["as", 1614], ["long", 1617], ["as", 1622], ["efficacious", 1625], [".", 1636], ["Fourteen", 1638], ["of", 1647], ["17", 1650], ["double", 1653], ["-", 1659], ["blind", 1660], [",", 1665], ["flumazenil", 1667], ["-", 1677], ["treated", 1678], ["patients", 1686], ["woke", 1695], ["after", 1700], ["a", 1706], ["mean", 1708], ["of", 1713], ["0.8", 1716], ["+", 1720], ["/-", 1721], ["0.3", 1724], ["(", 1728], ["SD", 1729], [")", 1731], ["mg", 1733], ["vs.", 1736], ["one", 1740], ["of", 1744], ["14", 1747], ["placebo", 1750], ["patients", 1758], ["(", 1767], ["p", 1768], ["<", 1770], [".001", 1772], [")", 1776], [".", 1777], ["Seventy", 1779], ["-", 1786], ["five", 1787], ["percent", 1792], ["of", 1800], ["the", 1803], ["aggregated", 1807], ["controlled", 1818], ["and", 1829], ["uncontrolled", 1833], ["patients", 1846], ["awoke", 1855], ["from", 1861], ["coma", 1866], ["scores", 1871], ["of", 1878], ["3.1", 1881], ["+", 1885], ["/-", 1886], ["0.6", 1889], ["to", 1893], ["0.4", 1896], ["+", 1900], ["/-", 1901], ["0.5", 1904], ["(", 1908], ["p", 1909], ["<", 1911], [".01", 1913], [")", 1916], ["after", 1918], ["the", 1924], ["injection", 1928], ["of", 1938], ["0.7", 1941], ["+", 1945], ["/-", 1946], ["0.3", 1949], ["mg", 1953], ["of", 1956], ["flumazenil", 1959], [".", 1969], ["These", 1971], ["patients", 1977], ["had", 1986], ["high", 1990], ["benzodiazepine", 1995], ["serum", 2010], ["blood", 2016], ["concentrations", 2022], [".", 2036], ["Twenty", 2038], ["-", 2044], ["five", 2045], ["percent", 2050], ["of", 2058], ["the", 2061], ["patients", 2065], ["did", 2074], ["not", 2078], ["regain", 2082], ["consciousness", 2089], [".", 2102], ["These", 2104], ["patients", 2110], ["had", 2119], ["very", 2123], ["high", 2128], ["serum", 2133], ["concentrations", 2139], ["of", 2154], ["nonbenzodiazepine", 2157], ["drugs", 2175], [".", 2180], ["Sixty", 2182], ["percent", 2188], ["of", 2196], ["the", 2199], ["responders", 2203], ["who", 2214], ["had", 2218], ["primarily", 2222], ["ingested", 2232], ["benzodiazepines", 2241], ["remained", 2257], ["awake", 2266], ["for", 2272], ["72", 2276], ["+", 2279], ["/-", 2280], ["37", 2283], ["mins", 2286], ["after", 2291], ["flumazenil", 2297], ["administration", 2308], [";", 2322], ["40", 2324], ["%", 2326], ["relapsed", 2328], ["into", 2337], ["coma", 2342], ["after", 2347], ["18", 2353], ["+", 2356], ["/-", 2357], ["7", 2360], ["mins", 2362], ["and", 2367], ["various", 2371], ["central", 2379], ["nervous", 2387], ["system", 2395], ["depressant", 2402], ["drugs", 2413], ["were", 2419], ["detected", 2424], ["in", 2433], ["their", 2436], ["blood", 2442], ["in", 2448], ["addition", 2451], ["to", 2460], ["benzodiazepines", 2463], [".", 2478], ["Seventy", 2480], ["-", 2487], ["one", 2488], ["percent", 2492], ["of", 2500], ["the", 2503], ["patients", 2507], ["had", 2516], ["ingested", 2520], ["tricyclic", 2529], ["antidepressants", 2539], [".", 2554], ["Seventy", 2556], ["-", 2563], ["eight", 2564], ["percent", 2570], ["of", 2578], ["the", 2581], ["responders", 2585], ["were", 2596], ["continually", 2601], ["and", 2613], ["efficaciously", 2617], ["treated", 2631], ["for", 2639], ["<", 2643], ["or", 2645], ["=", 2648], ["8", 2650], ["days", 2652], [".", 2656], ["Fourteen", 2658], ["(", 2667], ["25", 2668], ["%", 2670], [")", 2671], ["of", 2673], ["the", 2676], ["intubated", 2680], ["patients", 2690], ["were", 2699], ["extubated", 2704], ["safely", 2714], ["while", 2721], ["12", 2727], ["patients", 2730], [",", 2738], ["who", 2740], ["had", 2744], ["shown", 2748], ["increased", 2754], ["respiratory", 2764], ["insufficiency", 2776], [",", 2789], ["resumed", 2791], ["satisfactory", 2799], ["respiration", 2812], ["after", 2824], ["flumazenil", 2830], ["injection", 2841], [".", 2850], ["Five", 2852], ["cases", 2857], ["of", 2863], ["transient", 2866], ["increase", 2876], ["in", 2885], ["blood", 2888], ["pressure", 2894], ["and", 2903], ["heart", 2907], ["rate", 2913], ["were", 2918], ["encountered", 2923], [".", 2934], ["There", 2936], ["were", 2942], ["27", 2947], ["mildly", 2950], ["unpleasant", 2957], ["\"", 2968], ["waking", 2969], ["\"", 2975], ["episodes", 2977], [",", 2985], ["such", 2987], ["as", 2992], ["anxiety", 2995], [",", 3002], ["restlessness", 3004], [",", 3016], ["and", 3018], ["aggression", 3022], [",", 3032], ["but", 3034], ["no", 3038], ["patient", 3041], ["had", 3049], ["benzodiazepine", 3053], ["withdrawal", 3068], ["signs", 3079], [",", 3084], ["convulsions", 3086], [",", 3097], ["or", 3099], ["dysrhythmia", 3102], [",", 3113], ["most", 3115], ["noticeably", 3120], ["absent", 3131], ["in", 3138], ["tricyclic", 3141], ["antidepressant", 3151], ["-", 3165], ["intoxicated", 3166], ["patients", 3178], [".", 3186], ["Flumazenil", 3188], ["is", 3199], ["a", 3202], ["valid", 3204], ["diagnostic", 3210], ["tool", 3221], ["for", 3226], ["distinguishing", 3230], ["pure", 3245], ["benzodiazepine", 3250], ["from", 3265], ["mixed", 3270], ["-", 3275], ["drug", 3276], ["intoxication", 3281], ["or", 3294], ["nondrug", 3297], ["-", 3304], ["induced", 3305], ["coma", 3313], [".", 3317], ["Flumazenil", 3319], ["is", 3330], ["effective", 3333], ["in", 3343], ["preventing", 3346], ["recurrence", 3357], ["of", 3368], ["benzodiazepine", 3371], ["-", 3385], ["induced", 3386], ["coma", 3394], [".", 3398], ["Respiratory", 3400], ["insufficiency", 3412], ["is", 3426], ["reversed", 3429], ["after", 3438], ["its", 3444], ["administration", 3448], [".", 3462], ["Flumazenil", 3464], ["is", 3475], ["safe", 3478], ["when", 3483], ["administered", 3488], ["cautiously", 3501], [",", 3511], ["even", 3513], ["in", 3518], ["patients", 3521], ["with", 3530], ["coma", 3535], ["caused", 3540], ["by", 3547], ["a", 3550], ["mixed", 3552], ["overdose", 3558], ["of", 3567], ["benzodiazepine", 3570], ["plus", 3585], ["tricyclic", 3590], ["antidepressants", 3600], [".", 3615]]}
{"context": "1. In order to investigate the biological function of the human CLN3 gene that is defective in Batten disease, we created a yeast strain by PCR-targeted disruption of the yeast gene (YHC3), which is a homologue of the human CLN3 gene. 2. The phenotypic characterization revealed that the yhc3 delta mutants are more sensitive to combined heat and alkaline stress than the wild-type strains as determined by inhibition of cell proliferation. 3. This suggests that the yhc3 delta mutant is a good model to investigate the biological function of human CLN3 gene in mammalian cells and to understand the pathophysiology of juvenile Batten disease.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "9bb5d9f90f804b34971f0a239f63343b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[18, 19], [115, 116]], "char_spans": [[95, 108], [628, 641]]}]}], "context_tokens": [["1", 0], [".", 1], ["In", 3], ["order", 6], ["to", 12], ["investigate", 15], ["the", 27], ["biological", 31], ["function", 42], ["of", 51], ["the", 54], ["human", 58], ["CLN3", 64], ["gene", 69], ["that", 74], ["is", 79], ["defective", 82], ["in", 92], ["Batten", 95], ["disease", 102], [",", 109], ["we", 111], ["created", 114], ["a", 122], ["yeast", 124], ["strain", 130], ["by", 137], ["PCR", 140], ["-", 143], ["targeted", 144], ["disruption", 153], ["of", 164], ["the", 167], ["yeast", 171], ["gene", 177], ["(", 182], ["YHC3", 183], [")", 187], [",", 188], ["which", 190], ["is", 196], ["a", 199], ["homologue", 201], ["of", 211], ["the", 214], ["human", 218], ["CLN3", 224], ["gene", 229], [".", 233], ["2", 235], [".", 236], ["The", 238], ["phenotypic", 242], ["characterization", 253], ["revealed", 270], ["that", 279], ["the", 284], ["yhc3", 288], ["delta", 293], ["mutants", 299], ["are", 307], ["more", 311], ["sensitive", 316], ["to", 326], ["combined", 329], ["heat", 338], ["and", 343], ["alkaline", 347], ["stress", 356], ["than", 363], ["the", 368], ["wild", 372], ["-", 376], ["type", 377], ["strains", 382], ["as", 390], ["determined", 393], ["by", 404], ["inhibition", 407], ["of", 418], ["cell", 421], ["proliferation", 426], [".", 439], ["3", 441], [".", 442], ["This", 444], ["suggests", 449], ["that", 458], ["the", 463], ["yhc3", 467], ["delta", 472], ["mutant", 478], ["is", 485], ["a", 488], ["good", 490], ["model", 495], ["to", 501], ["investigate", 504], ["the", 516], ["biological", 520], ["function", 531], ["of", 540], ["human", 543], ["CLN3", 549], ["gene", 554], ["in", 559], ["mammalian", 562], ["cells", 572], ["and", 578], ["to", 582], ["understand", 585], ["the", 596], ["pathophysiology", 600], ["of", 616], ["juvenile", 619], ["Batten", 628], ["disease", 635], [".", 642]]}
{"context": "With an ageing population and improving cancer therapies, the two most common benign and malignant bone diseases, osteoporosis and bone metastases, will continue to affect an increasing number of patients. Our expanding knowledge of the molecular processes underlying these conditions has resulted in novel bone targets that are currently being explored in clinical trials. Clearly, the approval of denosumab, a monoclonal antibody directed against RANKL, has just marked the beginning of a new era for bone therapy with several additional new therapies lining up for clinical approval in the coming years. Potential agents targeting the osteoclast include cathepsin K, currently in phase 3 trials, and src inhibitors. Amongst anabolic agents, inhibitors of the Wnt-inhibitor sclerostin and dickkopf-1 are promising in clinical trials. Here, we will provide a comprehensive overview of the most promising agents currently explored for the treatment of bone diseases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "ba391f992ee74328aaba8df43265479c", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[71, 71]], "char_spans": [[449, 453]]}]}], "context_tokens": [["With", 0], ["an", 5], ["ageing", 8], ["population", 15], ["and", 26], ["improving", 30], ["cancer", 40], ["therapies", 47], [",", 56], ["the", 58], ["two", 62], ["most", 66], ["common", 71], ["benign", 78], ["and", 85], ["malignant", 89], ["bone", 99], ["diseases", 104], [",", 112], ["osteoporosis", 114], ["and", 127], ["bone", 131], ["metastases", 136], [",", 146], ["will", 148], ["continue", 153], ["to", 162], ["affect", 165], ["an", 172], ["increasing", 175], ["number", 186], ["of", 193], ["patients", 196], [".", 204], ["Our", 206], ["expanding", 210], ["knowledge", 220], ["of", 230], ["the", 233], ["molecular", 237], ["processes", 247], ["underlying", 257], ["these", 268], ["conditions", 274], ["has", 285], ["resulted", 289], ["in", 298], ["novel", 301], ["bone", 307], ["targets", 312], ["that", 320], ["are", 325], ["currently", 329], ["being", 339], ["explored", 345], ["in", 354], ["clinical", 357], ["trials", 366], [".", 372], ["Clearly", 374], [",", 381], ["the", 383], ["approval", 387], ["of", 396], ["denosumab", 399], [",", 408], ["a", 410], ["monoclonal", 412], ["antibody", 423], ["directed", 432], ["against", 441], ["RANKL", 449], [",", 454], ["has", 456], ["just", 460], ["marked", 465], ["the", 472], ["beginning", 476], ["of", 486], ["a", 489], ["new", 491], ["era", 495], ["for", 499], ["bone", 503], ["therapy", 508], ["with", 516], ["several", 521], ["additional", 529], ["new", 540], ["therapies", 544], ["lining", 554], ["up", 561], ["for", 564], ["clinical", 568], ["approval", 577], ["in", 586], ["the", 589], ["coming", 593], ["years", 600], [".", 605], ["Potential", 607], ["agents", 617], ["targeting", 624], ["the", 634], ["osteoclast", 638], ["include", 649], ["cathepsin", 657], ["K", 667], [",", 668], ["currently", 670], ["in", 680], ["phase", 683], ["3", 689], ["trials", 691], [",", 697], ["and", 699], ["src", 703], ["inhibitors", 707], [".", 717], ["Amongst", 719], ["anabolic", 727], ["agents", 736], [",", 742], ["inhibitors", 744], ["of", 755], ["the", 758], ["Wnt", 762], ["-", 765], ["inhibitor", 766], ["sclerostin", 776], ["and", 787], ["dickkopf-1", 791], ["are", 802], ["promising", 806], ["in", 816], ["clinical", 819], ["trials", 828], [".", 834], ["Here", 836], [",", 840], ["we", 842], ["will", 845], ["provide", 850], ["a", 858], ["comprehensive", 860], ["overview", 874], ["of", 883], ["the", 886], ["most", 890], ["promising", 895], ["agents", 905], ["currently", 912], ["explored", 922], ["for", 931], ["the", 935], ["treatment", 939], ["of", 949], ["bone", 952], ["diseases", 957], [".", 965]]}
{"context": "Nestin is a unique intermediate filament protein. While it is robustly expressed in developing brain, postnatal expression is limited to the brain's subventricular zone (SVZ) and endothelial cells. Reexpression occurs, however, under several pathological conditions, including injury and neoplasia. We hypothesized that nestin would be a sensitive marker of early neoplasia after transplacental exposure of rats to ethylnitrosourea (ENU). Rats of various ages were administered bromodeoxyuridine (BudR) before sacrifice, and brain sections were examined for proliferative cells and several immunohistochemical markers, including nestin. Additional rats were examined after a stab wound injury to assess the expression of two of these markers, GFAP and nestin, in reactive astrocytes. All ENU-induced brain tumors (n = 9) were classified as gliomas (astrocytomas or oligoastrocytomas) based on their histology and immunophenotype. Nestin expression was noted in all tumors examined and was present in tumor cells as well as endothelial cells. During tumor development, we consistently noted nestin-expressing cells bearing multiple processes distributed throughout brain parenchyma. Both single cells and multiple cell clusters were observed as early as postnatal day 30 in all ENU-exposed brains examined (n = 11). Such distinctive nestin-expressing cells were not seen in nestin-stained control brains or ENU-exposed brains stained for GFAP or vimentin, nor was such a cell seen in a stab wound model used to assess reactive astrocytosis. While the number of these clusters was highly variable among rats, their size increased between 30 and 90 days. The data suggest that these nestin-expressing cells represent an early stage of the neoplastic process. It remains to be determined whether these cells become apparent at 30 days of age due to \"dedifferentiation\" of a local resident astrocyte or astrocyte precursor cell or migration of a relatively undifferentiated precursor/stem cell from the SVZ.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "36dc5cbeedc44c65ab77495e3f481e0d", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[0, 0], [224, 224], [99, 99], [155, 155], [122, 122], [182, 182], [291, 291], [52, 52], [232, 232]], "char_spans": [[0, 5], [1332, 1337], [629, 634], [930, 935], [752, 757], [1090, 1095], [1680, 1685], [320, 325], [1373, 1378]]}]}], "context_tokens": [["Nestin", 0], ["is", 7], ["a", 10], ["unique", 12], ["intermediate", 19], ["filament", 32], ["protein", 41], [".", 48], ["While", 50], ["it", 56], ["is", 59], ["robustly", 62], ["expressed", 71], ["in", 81], ["developing", 84], ["brain", 95], [",", 100], ["postnatal", 102], ["expression", 112], ["is", 123], ["limited", 126], ["to", 134], ["the", 137], ["brain", 141], ["'s", 146], ["subventricular", 149], ["zone", 164], ["(", 169], ["SVZ", 170], [")", 173], ["and", 175], ["endothelial", 179], ["cells", 191], [".", 196], ["Reexpression", 198], ["occurs", 211], [",", 217], ["however", 219], [",", 226], ["under", 228], ["several", 234], ["pathological", 242], ["conditions", 255], [",", 265], ["including", 267], ["injury", 277], ["and", 284], ["neoplasia", 288], [".", 297], ["We", 299], ["hypothesized", 302], ["that", 315], ["nestin", 320], ["would", 327], ["be", 333], ["a", 336], ["sensitive", 338], ["marker", 348], ["of", 355], ["early", 358], ["neoplasia", 364], ["after", 374], ["transplacental", 380], ["exposure", 395], ["of", 404], ["rats", 407], ["to", 412], ["ethylnitrosourea", 415], ["(", 432], ["ENU", 433], [")", 436], [".", 437], ["Rats", 439], ["of", 444], ["various", 447], ["ages", 455], ["were", 460], ["administered", 465], ["bromodeoxyuridine", 478], ["(", 496], ["BudR", 497], [")", 501], ["before", 503], ["sacrifice", 510], [",", 519], ["and", 521], ["brain", 525], ["sections", 531], ["were", 540], ["examined", 545], ["for", 554], ["proliferative", 558], ["cells", 572], ["and", 578], ["several", 582], ["immunohistochemical", 590], ["markers", 610], [",", 617], ["including", 619], ["nestin", 629], [".", 635], ["Additional", 637], ["rats", 648], ["were", 653], ["examined", 658], ["after", 667], ["a", 673], ["stab", 675], ["wound", 680], ["injury", 686], ["to", 693], ["assess", 696], ["the", 703], ["expression", 707], ["of", 718], ["two", 721], ["of", 725], ["these", 728], ["markers", 734], [",", 741], ["GFAP", 743], ["and", 748], ["nestin", 752], [",", 758], ["in", 760], ["reactive", 763], ["astrocytes", 772], [".", 782], ["All", 784], ["ENU", 788], ["-", 791], ["induced", 792], ["brain", 800], ["tumors", 806], ["(", 813], ["n", 814], ["=", 816], ["9", 818], [")", 819], ["were", 821], ["classified", 826], ["as", 837], ["gliomas", 840], ["(", 848], ["astrocytomas", 849], ["or", 862], ["oligoastrocytomas", 865], [")", 882], ["based", 884], ["on", 890], ["their", 893], ["histology", 899], ["and", 909], ["immunophenotype", 913], [".", 928], ["Nestin", 930], ["expression", 937], ["was", 948], ["noted", 952], ["in", 958], ["all", 961], ["tumors", 965], ["examined", 972], ["and", 981], ["was", 985], ["present", 989], ["in", 997], ["tumor", 1000], ["cells", 1006], ["as", 1012], ["well", 1015], ["as", 1020], ["endothelial", 1023], ["cells", 1035], [".", 1040], ["During", 1042], ["tumor", 1049], ["development", 1055], [",", 1066], ["we", 1068], ["consistently", 1071], ["noted", 1084], ["nestin", 1090], ["-", 1096], ["expressing", 1097], ["cells", 1108], ["bearing", 1114], ["multiple", 1122], ["processes", 1131], ["distributed", 1141], ["throughout", 1153], ["brain", 1164], ["parenchyma", 1170], [".", 1180], ["Both", 1182], ["single", 1187], ["cells", 1194], ["and", 1200], ["multiple", 1204], ["cell", 1213], ["clusters", 1218], ["were", 1227], ["observed", 1232], ["as", 1241], ["early", 1244], ["as", 1250], ["postnatal", 1253], ["day", 1263], ["30", 1267], ["in", 1270], ["all", 1273], ["ENU", 1277], ["-", 1280], ["exposed", 1281], ["brains", 1289], ["examined", 1296], ["(", 1305], ["n", 1306], ["=", 1308], ["11", 1310], [")", 1312], [".", 1313], ["Such", 1315], ["distinctive", 1320], ["nestin", 1332], ["-", 1338], ["expressing", 1339], ["cells", 1350], ["were", 1356], ["not", 1361], ["seen", 1365], ["in", 1370], ["nestin", 1373], ["-", 1379], ["stained", 1380], ["control", 1388], ["brains", 1396], ["or", 1403], ["ENU", 1406], ["-", 1409], ["exposed", 1410], ["brains", 1418], ["stained", 1425], ["for", 1433], ["GFAP", 1437], ["or", 1442], ["vimentin", 1445], [",", 1453], ["nor", 1455], ["was", 1459], ["such", 1463], ["a", 1468], ["cell", 1470], ["seen", 1475], ["in", 1480], ["a", 1483], ["stab", 1485], ["wound", 1490], ["model", 1496], ["used", 1502], ["to", 1507], ["assess", 1510], ["reactive", 1517], ["astrocytosis", 1526], [".", 1538], ["While", 1540], ["the", 1546], ["number", 1550], ["of", 1557], ["these", 1560], ["clusters", 1566], ["was", 1575], ["highly", 1579], ["variable", 1586], ["among", 1595], ["rats", 1601], [",", 1605], ["their", 1607], ["size", 1613], ["increased", 1618], ["between", 1628], ["30", 1636], ["and", 1639], ["90", 1643], ["days", 1646], [".", 1650], ["The", 1652], ["data", 1656], ["suggest", 1661], ["that", 1669], ["these", 1674], ["nestin", 1680], ["-", 1686], ["expressing", 1687], ["cells", 1698], ["represent", 1704], ["an", 1714], ["early", 1717], ["stage", 1723], ["of", 1729], ["the", 1732], ["neoplastic", 1736], ["process", 1747], [".", 1754], ["It", 1756], ["remains", 1759], ["to", 1767], ["be", 1770], ["determined", 1773], ["whether", 1784], ["these", 1792], ["cells", 1798], ["become", 1804], ["apparent", 1811], ["at", 1820], ["30", 1823], ["days", 1826], ["of", 1831], ["age", 1834], ["due", 1838], ["to", 1842], ["\"", 1845], ["dedifferentiation", 1846], ["\"", 1863], ["of", 1865], ["a", 1868], ["local", 1870], ["resident", 1876], ["astrocyte", 1885], ["or", 1895], ["astrocyte", 1898], ["precursor", 1908], ["cell", 1918], ["or", 1923], ["migration", 1926], ["of", 1936], ["a", 1939], ["relatively", 1941], ["undifferentiated", 1952], ["precursor", 1969], ["/", 1978], ["stem", 1979], ["cell", 1984], ["from", 1989], ["the", 1994], ["SVZ", 1998], [".", 2001]]}
{"context": "Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "630e6932bb704bc7a85107087e4dd2ea", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegnerative", 30], ["disorder", 47], ["that", 56], ["is", 61], ["pathologically", 64], ["characterized", 79], ["by", 93], ["the", 96], ["presence", 100], ["of", 109], ["Lewy", 112], ["bodies", 117], ["in", 124], ["the", 127], ["brain", 131], [".", 136], ["We", 138], ["show", 141], ["that", 146], ["Lewy", 151], ["bodies", 156], ["in", 163], ["PD", 166], ["are", 169], ["strongly", 173], ["immunoreactive", 182], ["for", 197], ["torsinA", 201], [",", 208], ["the", 210], ["protein", 214], ["product", 222], ["of", 230], ["the", 233], ["DYT1", 237], ["gene", 242], [",", 246], ["which", 248], ["is", 254], ["associated", 257], ["with", 268], ["primary", 273], ["generalized", 281], ["dystonia", 293], [".", 301], ["In", 303], ["the", 306], ["substantia", 310], ["nigra", 321], [",", 326], ["torsinA", 328], ["immunoreactivity", 336], ["is", 353], ["localized", 356], ["to", 366], ["the", 369], ["periphery", 373], ["of", 383], ["Lewy", 386], ["bodies", 391], [",", 397], ["whereas", 399], [",", 406], ["in", 408], ["cortical", 411], ["Lewy", 420], ["bodies", 425], ["it", 432], ["is", 435], ["uniformly", 438], ["distributed", 448], [".", 459], ["The", 461], ["significance", 465], ["of", 478], ["this", 481], ["finding", 486], ["is", 494], ["unknown", 497], [",", 504], ["but", 506], ["may", 510], ["implicate", 514], ["torsinA", 524], ["in", 532], ["neuronal", 535], ["dysfunction", 544], ["that", 556], ["occurs", 561], ["in", 568], ["PD", 571], ["as", 574], ["well", 577], ["as", 582], ["in", 585], ["primary", 588], ["dystonia", 596], [".", 604]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate (STI571; formerly CGP57148B), successfully suppressed proliferation/survival of the BCR-ABL positive clones. In clinical studies, hematologic and cytogenetic remissions have been achieved in most patients with chronic phase CML; in accelerated and blastic phases of CML, STI571 appeared less effective. In the current study, the authors tested combinations of STI571 and cytarabine and homoharringtonine (HHT), drugs with documented activity in CML. The single agents and their combinations were studied for in vitro effect on proliferation of BCR-ABL positive cell lines KBM5 and KBM7 by 3(4,5-dimethylthiazol-2yl)-2,5 diphenyl-tetrazolium bromide assay and on primary patient-derived BCR-ABL cells by clonogenic assays. The in vitro additive, synergistic, or antagonistic effects of cytarabine and HHT with STI571 were then investigated by computer-assisted analysis using the CalcuSyn software. STI571 consistently suppressed BCR-ABL positive cell proliferation with a dose-effect correlation. In the model system used, STI571/cytarabine and STI571/HHT combinations were more effective in inhibiting KBM5 and KBM7 cell growth than each drug as single agent. These results were also verified in primary CML-derived clonogenic cells in semisolid cultures. In this experimental system, our studies documented additive or synergistic effects with STI571 plus cytarabine or HHT, supporting the future use of STI571 combinations in clinical trials in patients with Philadelphia chromosome-positive leukemias.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee0fc9bc759e4496ab701a203ebb0a81", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[148, 150], [69, 71], [170, 172], [40, 42], [210, 212], [15, 17]], "char_spans": [[853, 859], [393, 399], [995, 1001], [218, 224], [1238, 1244], [88, 94]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["a", 55], ["molecular", 57], ["aberration", 67], [",", 77], ["a", 79], ["fusion", 81], ["BCR", 88], ["-", 91], ["ABL", 92], ["gene", 96], ["encoding", 101], ["for", 110], ["aberrant", 114], ["tyrosine", 123], ["kinase", 132], ["activity", 139], [",", 147], ["which", 149], ["is", 155], ["crucial", 158], ["in", 166], ["the", 169], ["pathogenesis", 173], ["of", 186], ["CML", 189], [".", 192], ["In", 194], ["vitro", 197], [",", 202], ["inhibition", 204], ["of", 215], ["BCR", 218], ["-", 221], ["ABL", 222], ["protein", 226], ["tyrosine", 234], ["kinase", 243], ["activity", 250], ["by", 259], ["a", 262], ["tyrosine", 264], ["kinase", 273], ["inhibitor", 280], [",", 289], ["Imatinib", 291], ["mesylate", 300], ["(", 309], ["STI571", 310], [";", 316], ["formerly", 318], ["CGP57148B", 327], [")", 336], [",", 337], ["successfully", 339], ["suppressed", 352], ["proliferation", 363], ["/", 376], ["survival", 377], ["of", 386], ["the", 389], ["BCR", 393], ["-", 396], ["ABL", 397], ["positive", 401], ["clones", 410], [".", 416], ["In", 418], ["clinical", 421], ["studies", 430], [",", 437], ["hematologic", 439], ["and", 451], ["cytogenetic", 455], ["remissions", 467], ["have", 478], ["been", 483], ["achieved", 488], ["in", 497], ["most", 500], ["patients", 505], ["with", 514], ["chronic", 519], ["phase", 527], ["CML", 533], [";", 536], ["in", 538], ["accelerated", 541], ["and", 553], ["blastic", 557], ["phases", 565], ["of", 572], ["CML", 575], [",", 578], ["STI571", 580], ["appeared", 587], ["less", 596], ["effective", 601], [".", 610], ["In", 612], ["the", 615], ["current", 619], ["study", 627], [",", 632], ["the", 634], ["authors", 638], ["tested", 646], ["combinations", 653], ["of", 666], ["STI571", 669], ["and", 676], ["cytarabine", 680], ["and", 691], ["homoharringtonine", 695], ["(", 713], ["HHT", 714], [")", 717], [",", 718], ["drugs", 720], ["with", 726], ["documented", 731], ["activity", 742], ["in", 751], ["CML", 754], [".", 757], ["The", 759], ["single", 763], ["agents", 770], ["and", 777], ["their", 781], ["combinations", 787], ["were", 800], ["studied", 805], ["for", 813], ["in", 817], ["vitro", 820], ["effect", 826], ["on", 833], ["proliferation", 836], ["of", 850], ["BCR", 853], ["-", 856], ["ABL", 857], ["positive", 861], ["cell", 870], ["lines", 875], ["KBM5", 881], ["and", 886], ["KBM7", 890], ["by", 895], ["3(4,5-dimethylthiazol-2yl)-2,5", 898], ["diphenyl", 929], ["-", 937], ["tetrazolium", 938], ["bromide", 950], ["assay", 958], ["and", 964], ["on", 968], ["primary", 971], ["patient", 979], ["-", 986], ["derived", 987], ["BCR", 995], ["-", 998], ["ABL", 999], ["cells", 1003], ["by", 1009], ["clonogenic", 1012], ["assays", 1023], [".", 1029], ["The", 1031], ["in", 1035], ["vitro", 1038], ["additive", 1044], [",", 1052], ["synergistic", 1054], [",", 1065], ["or", 1067], ["antagonistic", 1070], ["effects", 1083], ["of", 1091], ["cytarabine", 1094], ["and", 1105], ["HHT", 1109], ["with", 1113], ["STI571", 1118], ["were", 1125], ["then", 1130], ["investigated", 1135], ["by", 1148], ["computer", 1151], ["-", 1159], ["assisted", 1160], ["analysis", 1169], ["using", 1178], ["the", 1184], ["CalcuSyn", 1188], ["software", 1197], [".", 1205], ["STI571", 1207], ["consistently", 1214], ["suppressed", 1227], ["BCR", 1238], ["-", 1241], ["ABL", 1242], ["positive", 1246], ["cell", 1255], ["proliferation", 1260], ["with", 1274], ["a", 1279], ["dose", 1281], ["-", 1285], ["effect", 1286], ["correlation", 1293], [".", 1304], ["In", 1306], ["the", 1309], ["model", 1313], ["system", 1319], ["used", 1326], [",", 1330], ["STI571/cytarabine", 1332], ["and", 1350], ["STI571/HHT", 1354], ["combinations", 1365], ["were", 1378], ["more", 1383], ["effective", 1388], ["in", 1398], ["inhibiting", 1401], ["KBM5", 1412], ["and", 1417], ["KBM7", 1421], ["cell", 1426], ["growth", 1431], ["than", 1438], ["each", 1443], ["drug", 1448], ["as", 1453], ["single", 1456], ["agent", 1463], [".", 1468], ["These", 1470], ["results", 1476], ["were", 1484], ["also", 1489], ["verified", 1494], ["in", 1503], ["primary", 1506], ["CML", 1514], ["-", 1517], ["derived", 1518], ["clonogenic", 1526], ["cells", 1537], ["in", 1543], ["semisolid", 1546], ["cultures", 1556], [".", 1564], ["In", 1566], ["this", 1569], ["experimental", 1574], ["system", 1587], [",", 1593], ["our", 1595], ["studies", 1599], ["documented", 1607], ["additive", 1618], ["or", 1627], ["synergistic", 1630], ["effects", 1642], ["with", 1650], ["STI571", 1655], ["plus", 1662], ["cytarabine", 1667], ["or", 1678], ["HHT", 1681], [",", 1684], ["supporting", 1686], ["the", 1697], ["future", 1701], ["use", 1708], ["of", 1712], ["STI571", 1715], ["combinations", 1722], ["in", 1735], ["clinical", 1738], ["trials", 1747], ["in", 1754], ["patients", 1757], ["with", 1766], ["Philadelphia", 1771], ["chromosome", 1784], ["-", 1794], ["positive", 1795], ["leukemias", 1804], [".", 1813]]}
{"context": "Linkage analysis and DNA sequencing in a family exhibiting an X-linked mental retardation (XLMR) syndrome, characterized by microcephaly, epilepsy, ataxia, and absent speech and resembling Angelman syndrome, identified a deletion in the SLC9A6 gene encoding the Na(+)/H(+) exchanger NHE6. Subsequently, other mutations were found in a male with mental retardation (MR) who had been investigated for Angelman syndrome and in two XLMR families with epilepsy and ataxia, including the family designated as having Christianson syndrome. Therefore, mutations in SLC9A6 cause X-linked mental retardation. Additionally, males with findings suggestive of unexplained Angelman syndrome should be considered as potential candidates for SLC9A6 mutations.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "b926d6e0091141cb9a74f555ced0e3ae", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[95, 95], [120, 120], [41, 41]], "char_spans": [[557, 562], [726, 731], [237, 242]]}]}], "context_tokens": [["Linkage", 0], ["analysis", 8], ["and", 17], ["DNA", 21], ["sequencing", 25], ["in", 36], ["a", 39], ["family", 41], ["exhibiting", 48], ["an", 59], ["X", 62], ["-", 63], ["linked", 64], ["mental", 71], ["retardation", 78], ["(", 90], ["XLMR", 91], [")", 95], ["syndrome", 97], [",", 105], ["characterized", 107], ["by", 121], ["microcephaly", 124], [",", 136], ["epilepsy", 138], [",", 146], ["ataxia", 148], [",", 154], ["and", 156], ["absent", 160], ["speech", 167], ["and", 174], ["resembling", 178], ["Angelman", 189], ["syndrome", 198], [",", 206], ["identified", 208], ["a", 219], ["deletion", 221], ["in", 230], ["the", 233], ["SLC9A6", 237], ["gene", 244], ["encoding", 249], ["the", 258], ["Na(+)/H(+", 262], [")", 271], ["exchanger", 273], ["NHE6", 283], [".", 287], ["Subsequently", 289], [",", 301], ["other", 303], ["mutations", 309], ["were", 319], ["found", 324], ["in", 330], ["a", 333], ["male", 335], ["with", 340], ["mental", 345], ["retardation", 352], ["(", 364], ["MR", 365], [")", 367], ["who", 369], ["had", 373], ["been", 377], ["investigated", 382], ["for", 395], ["Angelman", 399], ["syndrome", 408], ["and", 417], ["in", 421], ["two", 424], ["XLMR", 428], ["families", 433], ["with", 442], ["epilepsy", 447], ["and", 456], ["ataxia", 460], [",", 466], ["including", 468], ["the", 478], ["family", 482], ["designated", 489], ["as", 500], ["having", 503], ["Christianson", 510], ["syndrome", 523], [".", 531], ["Therefore", 533], [",", 542], ["mutations", 544], ["in", 554], ["SLC9A6", 557], ["cause", 564], ["X", 570], ["-", 571], ["linked", 572], ["mental", 579], ["retardation", 586], [".", 597], ["Additionally", 599], [",", 611], ["males", 613], ["with", 619], ["findings", 624], ["suggestive", 633], ["of", 644], ["unexplained", 647], ["Angelman", 659], ["syndrome", 668], ["should", 677], ["be", 684], ["considered", 687], ["as", 698], ["potential", 701], ["candidates", 711], ["for", 722], ["SLC9A6", 726], ["mutations", 733], [".", 742]]}
{"context": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph). We applied FISH to study three CML patients showing variant Ph chromosome (either complex or simple type). The results demonstrate that the use of a yeast artificial chromosome (YAC)-derived probe (D107F9) and a cosmid probe (cos-abl 8), specific for BCR and ABL genes respectively, allows also the detection of the BCR-ABL fusion in CML patients with variant Ph.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "97cb4d97afcb4eb2952fd63b3de90dbf", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[15, 19]], "char_spans": [[93, 111]]}]}], "context_tokens": [["Fluorescence", 0], ["in", 13], ["situ", 16], ["hybridization", 21], ["(", 35], ["FISH", 36], [")", 40], ["technique", 42], ["has", 52], ["been", 56], ["successfully", 61], ["used", 74], ["to", 79], ["detect", 82], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["gene", 101], ["fusion", 106], ["in", 113], ["chronic", 116], ["myeloid", 124], ["leukemia", 132], ["(", 141], ["CML", 142], [")", 145], ["with", 147], ["the", 152], ["classic", 156], ["form", 164], ["of", 169], ["the", 172], ["Philadelphia", 176], ["chromosome", 189], ["(", 200], ["Ph", 201], [")", 203], [".", 204], ["We", 206], ["applied", 209], ["FISH", 217], ["to", 222], ["study", 225], ["three", 231], ["CML", 237], ["patients", 241], ["showing", 250], ["variant", 258], ["Ph", 266], ["chromosome", 269], ["(", 280], ["either", 281], ["complex", 288], ["or", 296], ["simple", 299], ["type", 306], [")", 310], [".", 311], ["The", 313], ["results", 317], ["demonstrate", 325], ["that", 337], ["the", 342], ["use", 346], ["of", 350], ["a", 353], ["yeast", 355], ["artificial", 361], ["chromosome", 372], ["(", 383], ["YAC)-derived", 384], ["probe", 397], ["(", 403], ["D107F9", 404], [")", 410], ["and", 412], ["a", 416], ["cosmid", 418], ["probe", 425], ["(", 431], ["cos", 432], ["-", 435], ["abl", 436], ["8)", 440], [",", 442], ["specific", 444], ["for", 453], ["BCR", 457], ["and", 461], ["ABL", 465], ["genes", 469], ["respectively", 475], [",", 487], ["allows", 489], ["also", 496], ["the", 501], ["detection", 505], ["of", 515], ["the", 518], ["BCR", 522], ["-", 525], ["ABL", 526], ["fusion", 530], ["in", 537], ["CML", 540], ["patients", 544], ["with", 553], ["variant", 558], ["Ph", 566], [".", 568]]}
{"context": "The Ehlers-Danlos Syndrome (EDS) is a rare connective tissue disorder characterised by fragility of the soft connective tissues and widespread manifestations in skin, ligaments, joints, blood vessels and internal organs. We report a case of a 12-year-old boy, previously diagnosed with kyphoscoliosis-type EDS (type VI), presenting with a left brachial artery pseudo-aneursym with history of multiple spontaneous and post-traumatic arterial ruptures. Surgical management of this patient was performed successfully by primary repair of brachial artery lesion.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "151aa629d0054dd180576c092fb49055", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[11, 12]], "char_spans": [[43, 59]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["Syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["is", 33], ["a", 36], ["rare", 38], ["connective", 43], ["tissue", 54], ["disorder", 61], ["characterised", 70], ["by", 84], ["fragility", 87], ["of", 97], ["the", 100], ["soft", 104], ["connective", 109], ["tissues", 120], ["and", 128], ["widespread", 132], ["manifestations", 143], ["in", 158], ["skin", 161], [",", 165], ["ligaments", 167], [",", 176], ["joints", 178], [",", 184], ["blood", 186], ["vessels", 192], ["and", 200], ["internal", 204], ["organs", 213], [".", 219], ["We", 221], ["report", 224], ["a", 231], ["case", 233], ["of", 238], ["a", 241], ["12-year", 243], ["-", 250], ["old", 251], ["boy", 255], [",", 258], ["previously", 260], ["diagnosed", 271], ["with", 281], ["kyphoscoliosis", 286], ["-", 300], ["type", 301], ["EDS", 306], ["(", 310], ["type", 311], ["VI", 316], [")", 318], [",", 319], ["presenting", 321], ["with", 332], ["a", 337], ["left", 339], ["brachial", 344], ["artery", 353], ["pseudo", 360], ["-", 366], ["aneursym", 367], ["with", 376], ["history", 381], ["of", 389], ["multiple", 392], ["spontaneous", 401], ["and", 413], ["post", 417], ["-", 421], ["traumatic", 422], ["arterial", 432], ["ruptures", 441], [".", 449], ["Surgical", 451], ["management", 460], ["of", 471], ["this", 474], ["patient", 479], ["was", 487], ["performed", 491], ["successfully", 501], ["by", 514], ["primary", 517], ["repair", 525], ["of", 532], ["brachial", 535], ["artery", 544], ["lesion", 551], [".", 557]]}
{"context": "Mutations in rfx6 were recently associated with Mitchell-Riley syndrome, which involves neonatal diabetes, and other digestive system defects. To better define the function of Rfx6 in early endoderm development we cloned the Xenopus homologue. Expression of rfx6 begins early, showing broad expression throughout the anterior endoderm; at later stages rfx6 expression becomes restricted to the endocrine cells of the gut and pancreas. Morpholino knockdown of rfx6 caused a loss of pancreas marker expression, as well as other abnormalities. Co-injection of exogenous wild-type rfx6 rescued the morpholino phenotype in Xenopus tadpoles, whereas attempts to rescue the loss-of-function phenotype using mutant rfx6 based on Mitchell-Riley patients were unsuccessful. To better define the pleiotropic effects, we performed microarray analyses of gene expression in knockdown foregut tissue. In addition to pancreatic defects, the microarray analyses revealed downregulation of lung, stomach and heart markers and an upregulation of kidney markers. We verified these results using RT-PCR and in situ hybridization. Based on the different rfx6 expression patterns and our functional analyses, we propose that rfx6 has both early and late functions. In early development Rfx6 plays a broad role, being essential for development of most anterior endodermal organs. At later stages however, Rfx6 function is restricted to endocrine cells.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "23231ba1735c46b7b4dbacd35b95a111", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[29, 29], [42, 42], [74, 74], [212, 212], [57, 57], [119, 119], [201, 201], [233, 233], [190, 190], [2, 2], [97, 97]], "char_spans": [[176, 179], [258, 261], [459, 462], [1264, 1267], [352, 355], [707, 710], [1203, 1206], [1382, 1385], [1133, 1136], [13, 16], [577, 580]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["rfx6", 13], ["were", 18], ["recently", 23], ["associated", 32], ["with", 43], ["Mitchell", 48], ["-", 56], ["Riley", 57], ["syndrome", 63], [",", 71], ["which", 73], ["involves", 79], ["neonatal", 88], ["diabetes", 97], [",", 105], ["and", 107], ["other", 111], ["digestive", 117], ["system", 127], ["defects", 134], [".", 141], ["To", 143], ["better", 146], ["define", 153], ["the", 160], ["function", 164], ["of", 173], ["Rfx6", 176], ["in", 181], ["early", 184], ["endoderm", 190], ["development", 199], ["we", 211], ["cloned", 214], ["the", 221], ["Xenopus", 225], ["homologue", 233], [".", 242], ["Expression", 244], ["of", 255], ["rfx6", 258], ["begins", 263], ["early", 270], [",", 275], ["showing", 277], ["broad", 285], ["expression", 291], ["throughout", 302], ["the", 313], ["anterior", 317], ["endoderm", 326], [";", 334], ["at", 336], ["later", 339], ["stages", 345], ["rfx6", 352], ["expression", 357], ["becomes", 368], ["restricted", 376], ["to", 387], ["the", 390], ["endocrine", 394], ["cells", 404], ["of", 410], ["the", 413], ["gut", 417], ["and", 421], ["pancreas", 425], [".", 433], ["Morpholino", 435], ["knockdown", 446], ["of", 456], ["rfx6", 459], ["caused", 464], ["a", 471], ["loss", 473], ["of", 478], ["pancreas", 481], ["marker", 490], ["expression", 497], [",", 507], ["as", 509], ["well", 512], ["as", 517], ["other", 520], ["abnormalities", 526], [".", 539], ["Co", 541], ["-", 543], ["injection", 544], ["of", 554], ["exogenous", 557], ["wild", 567], ["-", 571], ["type", 572], ["rfx6", 577], ["rescued", 582], ["the", 590], ["morpholino", 594], ["phenotype", 605], ["in", 615], ["Xenopus", 618], ["tadpoles", 626], [",", 634], ["whereas", 636], ["attempts", 644], ["to", 653], ["rescue", 656], ["the", 663], ["loss", 667], ["-", 671], ["of", 672], ["-", 674], ["function", 675], ["phenotype", 684], ["using", 694], ["mutant", 700], ["rfx6", 707], ["based", 712], ["on", 718], ["Mitchell", 721], ["-", 729], ["Riley", 730], ["patients", 736], ["were", 745], ["unsuccessful", 750], [".", 762], ["To", 764], ["better", 767], ["define", 774], ["the", 781], ["pleiotropic", 785], ["effects", 797], [",", 804], ["we", 806], ["performed", 809], ["microarray", 819], ["analyses", 830], ["of", 839], ["gene", 842], ["expression", 847], ["in", 858], ["knockdown", 861], ["foregut", 871], ["tissue", 879], [".", 885], ["In", 887], ["addition", 890], ["to", 899], ["pancreatic", 902], ["defects", 913], [",", 920], ["the", 922], ["microarray", 926], ["analyses", 937], ["revealed", 946], ["downregulation", 955], ["of", 970], ["lung", 973], [",", 977], ["stomach", 979], ["and", 987], ["heart", 991], ["markers", 997], ["and", 1005], ["an", 1009], ["upregulation", 1012], ["of", 1025], ["kidney", 1028], ["markers", 1035], [".", 1042], ["We", 1044], ["verified", 1047], ["these", 1056], ["results", 1062], ["using", 1070], ["RT", 1076], ["-", 1078], ["PCR", 1079], ["and", 1083], ["in", 1087], ["situ", 1090], ["hybridization", 1095], [".", 1108], ["Based", 1110], ["on", 1116], ["the", 1119], ["different", 1123], ["rfx6", 1133], ["expression", 1138], ["patterns", 1149], ["and", 1158], ["our", 1162], ["functional", 1166], ["analyses", 1177], [",", 1185], ["we", 1187], ["propose", 1190], ["that", 1198], ["rfx6", 1203], ["has", 1208], ["both", 1212], ["early", 1217], ["and", 1223], ["late", 1227], ["functions", 1232], [".", 1241], ["In", 1243], ["early", 1246], ["development", 1252], ["Rfx6", 1264], ["plays", 1269], ["a", 1275], ["broad", 1277], ["role", 1283], [",", 1287], ["being", 1289], ["essential", 1295], ["for", 1305], ["development", 1309], ["of", 1321], ["most", 1324], ["anterior", 1329], ["endodermal", 1338], ["organs", 1349], [".", 1355], ["At", 1357], ["later", 1360], ["stages", 1366], ["however", 1373], [",", 1380], ["Rfx6", 1382], ["function", 1387], ["is", 1396], ["restricted", 1399], ["to", 1410], ["endocrine", 1413], ["cells", 1423], [".", 1428]]}
{"context": "RNA editing by deamination of specific adenosine bases to inosines during pre-mRNA processing generates edited isoforms of proteins. Recoding RNA editing is more widespread in Drosophila than in vertebrates. Editing levels rise strongly at metamorphosis, and Adar(5G1) null mutant flies lack editing events in hundreds of CNS transcripts; mutant flies have reduced viability, severely defective locomotion and age-dependent neurodegeneration. On the other hand, overexpressing an adult dADAR isoform with high enzymatic activity ubiquitously during larval and pupal stages is lethal. Advantage was taken of this to screen for genetic modifiers; Adar overexpression lethality is rescued by reduced dosage of the Rdl (Resistant to dieldrin), gene encoding a subunit of inhibitory GABA receptors. Reduced dosage of the Gad1 gene encoding the GABA synthetase also rescues Adar overexpression lethality. Drosophila Adar(5G1) mutant phenotypes are ameliorated by feeding GABA modulators. We demonstrate that neuronal excitability is linked to dADAR expression levels in individual neurons; Adar-overexpressing larval motor neurons show reduced excitability whereas Adar(5G1) null mutant or targeted Adar knockdown motor neurons exhibit increased excitability. GABA inhibitory signalling is impaired in human epileptic and autistic conditions, and vertebrate ADARs may have a relevant evolutionarily conserved control over neuronal excitability.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "8c9513c5db4344709452efcb0a8fca01", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[104, 104], [189, 189], [173, 173], [142, 142]], "char_spans": [[645, 648], [1193, 1196], [1084, 1087], [868, 871]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["by", 12], ["deamination", 15], ["of", 27], ["specific", 30], ["adenosine", 39], ["bases", 49], ["to", 55], ["inosines", 58], ["during", 67], ["pre", 74], ["-", 77], ["mRNA", 78], ["processing", 83], ["generates", 94], ["edited", 104], ["isoforms", 111], ["of", 120], ["proteins", 123], [".", 131], ["Recoding", 133], ["RNA", 142], ["editing", 146], ["is", 154], ["more", 157], ["widespread", 162], ["in", 173], ["Drosophila", 176], ["than", 187], ["in", 192], ["vertebrates", 195], [".", 206], ["Editing", 208], ["levels", 216], ["rise", 223], ["strongly", 228], ["at", 237], ["metamorphosis", 240], [",", 253], ["and", 255], ["Adar(5G1", 259], [")", 267], ["null", 269], ["mutant", 274], ["flies", 281], ["lack", 287], ["editing", 292], ["events", 300], ["in", 307], ["hundreds", 310], ["of", 319], ["CNS", 322], ["transcripts", 326], [";", 337], ["mutant", 339], ["flies", 346], ["have", 352], ["reduced", 357], ["viability", 365], [",", 374], ["severely", 376], ["defective", 385], ["locomotion", 395], ["and", 406], ["age", 410], ["-", 413], ["dependent", 414], ["neurodegeneration", 424], [".", 441], ["On", 443], ["the", 446], ["other", 450], ["hand", 456], [",", 460], ["overexpressing", 462], ["an", 477], ["adult", 480], ["dADAR", 486], ["isoform", 492], ["with", 500], ["high", 505], ["enzymatic", 510], ["activity", 520], ["ubiquitously", 529], ["during", 542], ["larval", 549], ["and", 556], ["pupal", 560], ["stages", 566], ["is", 573], ["lethal", 576], [".", 582], ["Advantage", 584], ["was", 594], ["taken", 598], ["of", 604], ["this", 607], ["to", 612], ["screen", 615], ["for", 622], ["genetic", 626], ["modifiers", 634], [";", 643], ["Adar", 645], ["overexpression", 650], ["lethality", 665], ["is", 675], ["rescued", 678], ["by", 686], ["reduced", 689], ["dosage", 697], ["of", 704], ["the", 707], ["Rdl", 711], ["(", 715], ["Resistant", 716], ["to", 726], ["dieldrin", 729], [")", 737], [",", 738], ["gene", 740], ["encoding", 745], ["a", 754], ["subunit", 756], ["of", 764], ["inhibitory", 767], ["GABA", 778], ["receptors", 783], [".", 792], ["Reduced", 794], ["dosage", 802], ["of", 809], ["the", 812], ["Gad1", 816], ["gene", 821], ["encoding", 826], ["the", 835], ["GABA", 839], ["synthetase", 844], ["also", 855], ["rescues", 860], ["Adar", 868], ["overexpression", 873], ["lethality", 888], [".", 897], ["Drosophila", 899], ["Adar(5G1", 910], [")", 918], ["mutant", 920], ["phenotypes", 927], ["are", 938], ["ameliorated", 942], ["by", 954], ["feeding", 957], ["GABA", 965], ["modulators", 970], [".", 980], ["We", 982], ["demonstrate", 985], ["that", 997], ["neuronal", 1002], ["excitability", 1011], ["is", 1024], ["linked", 1027], ["to", 1034], ["dADAR", 1037], ["expression", 1043], ["levels", 1054], ["in", 1061], ["individual", 1064], ["neurons", 1075], [";", 1082], ["Adar", 1084], ["-", 1088], ["overexpressing", 1089], ["larval", 1104], ["motor", 1111], ["neurons", 1117], ["show", 1125], ["reduced", 1130], ["excitability", 1138], ["whereas", 1151], ["Adar(5G1", 1159], [")", 1167], ["null", 1169], ["mutant", 1174], ["or", 1181], ["targeted", 1184], ["Adar", 1193], ["knockdown", 1198], ["motor", 1208], ["neurons", 1214], ["exhibit", 1222], ["increased", 1230], ["excitability", 1240], [".", 1252], ["GABA", 1254], ["inhibitory", 1259], ["signalling", 1270], ["is", 1281], ["impaired", 1284], ["in", 1293], ["human", 1296], ["epileptic", 1302], ["and", 1312], ["autistic", 1316], ["conditions", 1325], [",", 1335], ["and", 1337], ["vertebrate", 1341], ["ADARs", 1352], ["may", 1358], ["have", 1362], ["a", 1367], ["relevant", 1369], ["evolutionarily", 1378], ["conserved", 1393], ["control", 1403], ["over", 1411], ["neuronal", 1416], ["excitability", 1425], [".", 1437]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by abnormal deposition of \u03b1-synuclein aggregates in many regions of the central and peripheral nervous systems. Accumulating evidence suggests that the \u03b1-synuclein pathology initiates in a few discrete regions and spreads to larger areas in the nervous system. Recent pathological studies of PD patients have raised the possibility that the enteric nervous system is one of the initial sites of \u03b1-synuclein aggregation and propagation. Here, we evaluated the induction and propagation of \u03b1-synuclein aggregates in the enteric nervous system of the A53T \u03b1-synuclein transgenic mice after injection of human brain tissue extracts into the gastric walls of the mice. Western analysis of the brain extracts showed that the DLB extract contained detergent-stable \u03b1-synuclein aggregates, but the normal brain extract did not. Injection of the DLB extract resulted in an increased deposition of \u03b1-synuclein in the myenteric neurons, in which \u03b1-synuclein formed punctate aggregates over time up to 4 months. In these mice, inflammatory responses were increased transiently at early time points. None of these changes were observed in the A53T mice injected with saline or the normal brain extract, nor were these found in the wild type mice injected with the DLB extract. These results demonstrate that pathological \u03b1-synuclein aggregates present in the brain of DLB patient can induce the aggregation of endogenous \u03b1-synuclein in the myenteric neurons in A53T mice, suggesting the transmission of synucleinopathy lesions in the enteric nervous system.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "9a225d6aa2034d27a58fc2dea42dbe40", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["(", 55], ["DLB", 56], [")", 59], ["are", 61], ["characterized", 65], ["by", 79], ["abnormal", 82], ["deposition", 91], ["of", 102], ["\u03b1", 105], ["-", 106], ["synuclein", 107], ["aggregates", 117], ["in", 128], ["many", 131], ["regions", 136], ["of", 144], ["the", 147], ["central", 151], ["and", 159], ["peripheral", 163], ["nervous", 174], ["systems", 182], [".", 189], ["Accumulating", 191], ["evidence", 204], ["suggests", 213], ["that", 222], ["the", 227], ["\u03b1", 231], ["-", 232], ["synuclein", 233], ["pathology", 243], ["initiates", 253], ["in", 263], ["a", 266], ["few", 268], ["discrete", 272], ["regions", 281], ["and", 289], ["spreads", 293], ["to", 301], ["larger", 304], ["areas", 311], ["in", 317], ["the", 320], ["nervous", 324], ["system", 332], [".", 338], ["Recent", 340], ["pathological", 347], ["studies", 360], ["of", 368], ["PD", 371], ["patients", 374], ["have", 383], ["raised", 388], ["the", 395], ["possibility", 399], ["that", 411], ["the", 416], ["enteric", 420], ["nervous", 428], ["system", 436], ["is", 443], ["one", 446], ["of", 450], ["the", 453], ["initial", 457], ["sites", 465], ["of", 471], ["\u03b1", 474], ["-", 475], ["synuclein", 476], ["aggregation", 486], ["and", 498], ["propagation", 502], [".", 513], ["Here", 515], [",", 519], ["we", 521], ["evaluated", 524], ["the", 534], ["induction", 538], ["and", 548], ["propagation", 552], ["of", 564], ["\u03b1", 567], ["-", 568], ["synuclein", 569], ["aggregates", 579], ["in", 590], ["the", 593], ["enteric", 597], ["nervous", 605], ["system", 613], ["of", 620], ["the", 623], ["A53", 627], ["T", 630], ["\u03b1", 632], ["-", 633], ["synuclein", 634], ["transgenic", 644], ["mice", 655], ["after", 660], ["injection", 666], ["of", 676], ["human", 679], ["brain", 685], ["tissue", 691], ["extracts", 698], ["into", 707], ["the", 712], ["gastric", 716], ["walls", 724], ["of", 730], ["the", 733], ["mice", 737], [".", 741], ["Western", 743], ["analysis", 751], ["of", 760], ["the", 763], ["brain", 767], ["extracts", 773], ["showed", 782], ["that", 789], ["the", 794], ["DLB", 798], ["extract", 802], ["contained", 810], ["detergent", 820], ["-", 829], ["stable", 830], ["\u03b1", 837], ["-", 838], ["synuclein", 839], ["aggregates", 849], [",", 859], ["but", 861], ["the", 865], ["normal", 869], ["brain", 876], ["extract", 882], ["did", 890], ["not", 894], [".", 897], ["Injection", 899], ["of", 909], ["the", 912], ["DLB", 916], ["extract", 920], ["resulted", 928], ["in", 937], ["an", 940], ["increased", 943], ["deposition", 953], ["of", 964], ["\u03b1", 967], ["-", 968], ["synuclein", 969], ["in", 979], ["the", 982], ["myenteric", 986], ["neurons", 996], [",", 1003], ["in", 1005], ["which", 1008], ["\u03b1", 1014], ["-", 1015], ["synuclein", 1016], ["formed", 1026], ["punctate", 1033], ["aggregates", 1042], ["over", 1053], ["time", 1058], ["up", 1063], ["to", 1066], ["4", 1069], ["months", 1071], [".", 1077], ["In", 1079], ["these", 1082], ["mice", 1088], [",", 1092], ["inflammatory", 1094], ["responses", 1107], ["were", 1117], ["increased", 1122], ["transiently", 1132], ["at", 1144], ["early", 1147], ["time", 1153], ["points", 1158], [".", 1164], ["None", 1166], ["of", 1171], ["these", 1174], ["changes", 1180], ["were", 1188], ["observed", 1193], ["in", 1202], ["the", 1205], ["A53", 1209], ["T", 1212], ["mice", 1214], ["injected", 1219], ["with", 1228], ["saline", 1233], ["or", 1240], ["the", 1243], ["normal", 1247], ["brain", 1254], ["extract", 1260], [",", 1267], ["nor", 1269], ["were", 1273], ["these", 1278], ["found", 1284], ["in", 1290], ["the", 1293], ["wild", 1297], ["type", 1302], ["mice", 1307], ["injected", 1312], ["with", 1321], ["the", 1326], ["DLB", 1330], ["extract", 1334], [".", 1341], ["These", 1343], ["results", 1349], ["demonstrate", 1357], ["that", 1369], ["pathological", 1374], ["\u03b1", 1387], ["-", 1388], ["synuclein", 1389], ["aggregates", 1399], ["present", 1410], ["in", 1418], ["the", 1421], ["brain", 1425], ["of", 1431], ["DLB", 1434], ["patient", 1438], ["can", 1446], ["induce", 1450], ["the", 1457], ["aggregation", 1461], ["of", 1473], ["endogenous", 1476], ["\u03b1", 1487], ["-", 1488], ["synuclein", 1489], ["in", 1499], ["the", 1502], ["myenteric", 1506], ["neurons", 1516], ["in", 1524], ["A53", 1527], ["T", 1530], ["mice", 1532], [",", 1536], ["suggesting", 1538], ["the", 1549], ["transmission", 1553], ["of", 1566], ["synucleinopathy", 1569], ["lesions", 1585], ["in", 1593], ["the", 1596], ["enteric", 1600], ["nervous", 1608], ["system", 1616], [".", 1622]]}
{"context": "A monoclonal antibody (mAb) has been produced which reacts with human mitofilin, a mitochondrial inner membrane protein. This mAb immunocaptures its target protein in association with six other proteins, metaxins 1 and 2, SAM50, CHCHD3, CHCHD6 and DnaJC11, respectively. The first three are outer membrane proteins, CHCHD3 has been assigned to the matrix space, and the other two proteins have not been described in mitochondria previously. The functional role of this new complex is uncertain. However, a role in protein import related to maintenance of mitochondrial structure is suggested as mitofilin helps regulate mitochondrial morphology and at least four of the associated proteins (metaxins 1 and 2, SAM50 and CHCHD3) have been implicated in protein import, while DnaJC11 is a chaperone-like protein that may have a similar role.", "qas": [{"question": "What is the localization of the protein encoded by the gene DNAJC11?", "answers": ["mitochondrial inner membrane"], "qid": "8c2a0605602f461d93cb146b331734aa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["localization", 12], ["of", 25], ["the", 28], ["protein", 32], ["encoded", 40], ["by", 48], ["the", 51], ["gene", 55], ["DNAJC11", 60], ["?", 67]], "detected_answers": [{"text": "mitochondrial inner membrane", "token_spans": [[16, 18]], "char_spans": [[83, 110]]}]}], "context_tokens": [["A", 0], ["monoclonal", 2], ["antibody", 13], ["(", 22], ["mAb", 23], [")", 26], ["has", 28], ["been", 32], ["produced", 37], ["which", 46], ["reacts", 52], ["with", 59], ["human", 64], ["mitofilin", 70], [",", 79], ["a", 81], ["mitochondrial", 83], ["inner", 97], ["membrane", 103], ["protein", 112], [".", 119], ["This", 121], ["mAb", 126], ["immunocaptures", 130], ["its", 145], ["target", 149], ["protein", 156], ["in", 164], ["association", 167], ["with", 179], ["six", 184], ["other", 188], ["proteins", 194], [",", 202], ["metaxins", 204], ["1", 213], ["and", 215], ["2", 219], [",", 220], ["SAM50", 222], [",", 227], ["CHCHD3", 229], [",", 235], ["CHCHD6", 237], ["and", 244], ["DnaJC11", 248], [",", 255], ["respectively", 257], [".", 269], ["The", 271], ["first", 275], ["three", 281], ["are", 287], ["outer", 291], ["membrane", 297], ["proteins", 306], [",", 314], ["CHCHD3", 316], ["has", 323], ["been", 327], ["assigned", 332], ["to", 341], ["the", 344], ["matrix", 348], ["space", 355], [",", 360], ["and", 362], ["the", 366], ["other", 370], ["two", 376], ["proteins", 380], ["have", 389], ["not", 394], ["been", 398], ["described", 403], ["in", 413], ["mitochondria", 416], ["previously", 429], [".", 439], ["The", 441], ["functional", 445], ["role", 456], ["of", 461], ["this", 464], ["new", 469], ["complex", 473], ["is", 481], ["uncertain", 484], [".", 493], ["However", 495], [",", 502], ["a", 504], ["role", 506], ["in", 511], ["protein", 514], ["import", 522], ["related", 529], ["to", 537], ["maintenance", 540], ["of", 552], ["mitochondrial", 555], ["structure", 569], ["is", 579], ["suggested", 582], ["as", 592], ["mitofilin", 595], ["helps", 605], ["regulate", 611], ["mitochondrial", 620], ["morphology", 634], ["and", 645], ["at", 649], ["least", 652], ["four", 658], ["of", 663], ["the", 666], ["associated", 670], ["proteins", 681], ["(", 690], ["metaxins", 691], ["1", 700], ["and", 702], ["2", 706], [",", 707], ["SAM50", 709], ["and", 715], ["CHCHD3", 719], [")", 725], ["have", 727], ["been", 732], ["implicated", 737], ["in", 748], ["protein", 751], ["import", 759], [",", 765], ["while", 767], ["DnaJC11", 773], ["is", 781], ["a", 784], ["chaperone", 786], ["-", 795], ["like", 796], ["protein", 801], ["that", 809], ["may", 814], ["have", 818], ["a", 823], ["similar", 825], ["role", 833], [".", 837]]}
{"context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are dominant regulators of bone resorption. Many hormones, cytokines and growth factors mediate bone resorption by altering the ratio of RANKL to OPG. RANKL and OPG expression is also altered in numerous bone diseases, and these changes can reflect disease etiology or compensatory responses to disease. RANKL stimulates osteoclast formation, function and survival, and each of these effects is inhibited by OPG. OPG suppresses bone resorption and increases the density, area and strength of both cancellous and cortical bone. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "bd9c8ec49b8446ba9d107c61a8280a06", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[117, 117], [67, 67], [42, 42], [38, 38], [14, 14]], "char_spans": [[670, 674], [389, 393], [236, 240], [222, 226], [78, 82]]}]}], "context_tokens": [["Osteoprotegerin", 0], ["(", 16], ["OPG", 17], [")", 20], ["and", 22], ["receptor", 26], ["activator", 35], ["of", 45], ["nuclear", 48], ["factor", 56], ["-", 62], ["kappaB", 63], ["ligand", 70], ["(", 77], ["RANKL", 78], [")", 83], ["are", 85], ["dominant", 89], ["regulators", 98], ["of", 109], ["bone", 112], ["resorption", 117], [".", 127], ["Many", 129], ["hormones", 134], [",", 142], ["cytokines", 144], ["and", 154], ["growth", 158], ["factors", 165], ["mediate", 173], ["bone", 181], ["resorption", 186], ["by", 197], ["altering", 200], ["the", 209], ["ratio", 213], ["of", 219], ["RANKL", 222], ["to", 228], ["OPG", 231], [".", 234], ["RANKL", 236], ["and", 242], ["OPG", 246], ["expression", 250], ["is", 261], ["also", 264], ["altered", 269], ["in", 277], ["numerous", 280], ["bone", 289], ["diseases", 294], [",", 302], ["and", 304], ["these", 308], ["changes", 314], ["can", 322], ["reflect", 326], ["disease", 334], ["etiology", 342], ["or", 351], ["compensatory", 354], ["responses", 367], ["to", 377], ["disease", 380], [".", 387], ["RANKL", 389], ["stimulates", 395], ["osteoclast", 406], ["formation", 417], [",", 426], ["function", 428], ["and", 437], ["survival", 441], [",", 449], ["and", 451], ["each", 455], ["of", 460], ["these", 463], ["effects", 469], ["is", 477], ["inhibited", 480], ["by", 490], ["OPG", 493], [".", 496], ["OPG", 498], ["suppresses", 502], ["bone", 513], ["resorption", 518], ["and", 529], ["increases", 533], ["the", 543], ["density", 547], [",", 554], ["area", 556], ["and", 561], ["strength", 565], ["of", 574], ["both", 577], ["cancellous", 582], ["and", 593], ["cortical", 597], ["bone", 606], [".", 610], ["Denosumab", 612], ["(", 622], ["AMG", 623], ["162", 627], [")", 630], [",", 631], ["a", 633], ["fully", 635], ["human", 641], ["monoclonal", 647], ["antibody", 658], ["to", 667], ["RANKL", 670], [",", 675], ["shares", 677], ["the", 684], ["pharmacologic", 688], ["attributes", 702], ["of", 713], ["OPG", 716], ["but", 720], ["has", 724], ["a", 728], ["significantly", 730], ["longer", 744], ["half", 751], ["-", 755], ["life", 756], ["that", 761], ["allows", 766], ["less", 773], ["frequent", 778], ["administration", 787], [".", 801]]}
{"context": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Imatinib induces complete haematological and cytogenetic response in high percentage of patients. The aim of this study was to identify potential prognostic factors before beginning treatment with imatinib associated with complete cytogenetic response. We analyzed 20 patients with newly diagnosed Philadelphia positive chronic myelogenous leukemia treated at our institution from June 2006 until May 2009. These patients were treated with imatinib mesylate in oral dose of 400 to 800 mg daily. Complete blood counts were performed every month, while serum chemistry evaluations and bone marrow evaluations including morphology and cytogenetics were performed every 6 months. Of the 20 patients analyzed in this study, 19 (95%) achieved complete haematologic response within three months. In all patients cytogenetic analyses were done and all have achieved absolute cytogenetic response. The best cytogenetic response rate at any time during study treatment among 20 patients was: complete cytogenetic response in 15, partial cytogenetic response in three and minor cytogenetic response in two patients. Among 11 observed base-line patients' characteristics five were independent predictors of a high rate of complete cytogenetic response; the absence of blasts and basophils in peripheral blood, the presence of less than 5 percent of bone marrow blasts, white blood cell count less than 10 x 10(9)/L and the absence of splenomegaly (p < 0.01). Our results showed that some pre-treatment characteristics of patients might be the cause of differences in treatment outcome. On the basis of this analysis, we identified several pre-treatment patients' characteristics to be independent prognostic factors for achievement of complete cytogenetic response.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a2e5c9b921c417c892010de2379c6d7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7]], "char_spans": [[31, 37]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["selective", 21], ["Bcr", 31], ["-", 34], ["Abl", 35], ["tyrosine", 39], ["kinase", 48], ["inhibitor", 55], [",", 64], ["has", 66], ["proved", 70], ["to", 77], ["be", 80], ["most", 83], ["effective", 88], ["therapy", 98], ["of", 106], ["Philadelphia", 109], ["chromosome", 122], ["-", 132], ["positive", 133], ["chronic", 142], ["myelogenous", 150], ["leukemia", 162], [".", 170], ["Imatinib", 172], ["induces", 181], ["complete", 189], ["haematological", 198], ["and", 213], ["cytogenetic", 217], ["response", 229], ["in", 238], ["high", 241], ["percentage", 246], ["of", 257], ["patients", 260], [".", 268], ["The", 270], ["aim", 274], ["of", 278], ["this", 281], ["study", 286], ["was", 292], ["to", 296], ["identify", 299], ["potential", 308], ["prognostic", 318], ["factors", 329], ["before", 337], ["beginning", 344], ["treatment", 354], ["with", 364], ["imatinib", 369], ["associated", 378], ["with", 389], ["complete", 394], ["cytogenetic", 403], ["response", 415], [".", 423], ["We", 425], ["analyzed", 428], ["20", 437], ["patients", 440], ["with", 449], ["newly", 454], ["diagnosed", 460], ["Philadelphia", 470], ["positive", 483], ["chronic", 492], ["myelogenous", 500], ["leukemia", 512], ["treated", 521], ["at", 529], ["our", 532], ["institution", 536], ["from", 548], ["June", 553], ["2006", 558], ["until", 563], ["May", 569], ["2009", 573], [".", 577], ["These", 579], ["patients", 585], ["were", 594], ["treated", 599], ["with", 607], ["imatinib", 612], ["mesylate", 621], ["in", 630], ["oral", 633], ["dose", 638], ["of", 643], ["400", 646], ["to", 650], ["800", 653], ["mg", 657], ["daily", 660], [".", 665], ["Complete", 667], ["blood", 676], ["counts", 682], ["were", 689], ["performed", 694], ["every", 704], ["month", 710], [",", 715], ["while", 717], ["serum", 723], ["chemistry", 729], ["evaluations", 739], ["and", 751], ["bone", 755], ["marrow", 760], ["evaluations", 767], ["including", 779], ["morphology", 789], ["and", 800], ["cytogenetics", 804], ["were", 817], ["performed", 822], ["every", 832], ["6", 838], ["months", 840], [".", 846], ["Of", 848], ["the", 851], ["20", 855], ["patients", 858], ["analyzed", 867], ["in", 876], ["this", 879], ["study", 884], [",", 889], ["19", 891], ["(", 894], ["95", 895], ["%", 897], [")", 898], ["achieved", 900], ["complete", 909], ["haematologic", 918], ["response", 931], ["within", 940], ["three", 947], ["months", 953], [".", 959], ["In", 961], ["all", 964], ["patients", 968], ["cytogenetic", 977], ["analyses", 989], ["were", 998], ["done", 1003], ["and", 1008], ["all", 1012], ["have", 1016], ["achieved", 1021], ["absolute", 1030], ["cytogenetic", 1039], ["response", 1051], [".", 1059], ["The", 1061], ["best", 1065], ["cytogenetic", 1070], ["response", 1082], ["rate", 1091], ["at", 1096], ["any", 1099], ["time", 1103], ["during", 1108], ["study", 1115], ["treatment", 1121], ["among", 1131], ["20", 1137], ["patients", 1140], ["was", 1149], [":", 1152], ["complete", 1154], ["cytogenetic", 1163], ["response", 1175], ["in", 1184], ["15", 1187], [",", 1189], ["partial", 1191], ["cytogenetic", 1199], ["response", 1211], ["in", 1220], ["three", 1223], ["and", 1229], ["minor", 1233], ["cytogenetic", 1239], ["response", 1251], ["in", 1260], ["two", 1263], ["patients", 1267], [".", 1275], ["Among", 1277], ["11", 1283], ["observed", 1286], ["base", 1295], ["-", 1299], ["line", 1300], ["patients", 1305], ["'", 1313], ["characteristics", 1315], ["five", 1331], ["were", 1336], ["independent", 1341], ["predictors", 1353], ["of", 1364], ["a", 1367], ["high", 1369], ["rate", 1374], ["of", 1379], ["complete", 1382], ["cytogenetic", 1391], ["response", 1403], [";", 1411], ["the", 1413], ["absence", 1417], ["of", 1425], ["blasts", 1428], ["and", 1435], ["basophils", 1439], ["in", 1449], ["peripheral", 1452], ["blood", 1463], [",", 1468], ["the", 1470], ["presence", 1474], ["of", 1483], ["less", 1486], ["than", 1491], ["5", 1496], ["percent", 1498], ["of", 1506], ["bone", 1509], ["marrow", 1514], ["blasts", 1521], [",", 1527], ["white", 1529], ["blood", 1535], ["cell", 1541], ["count", 1546], ["less", 1552], ["than", 1557], ["10", 1562], ["x", 1565], ["10(9)/L", 1567], ["and", 1575], ["the", 1579], ["absence", 1583], ["of", 1591], ["splenomegaly", 1594], ["(", 1607], ["p", 1608], ["<", 1610], ["0.01", 1612], [")", 1616], [".", 1617], ["Our", 1619], ["results", 1623], ["showed", 1631], ["that", 1638], ["some", 1643], ["pre", 1648], ["-", 1651], ["treatment", 1652], ["characteristics", 1662], ["of", 1678], ["patients", 1681], ["might", 1690], ["be", 1696], ["the", 1699], ["cause", 1703], ["of", 1709], ["differences", 1712], ["in", 1724], ["treatment", 1727], ["outcome", 1737], [".", 1744], ["On", 1746], ["the", 1749], ["basis", 1753], ["of", 1759], ["this", 1762], ["analysis", 1767], [",", 1775], ["we", 1777], ["identified", 1780], ["several", 1791], ["pre", 1799], ["-", 1802], ["treatment", 1803], ["patients", 1813], ["'", 1821], ["characteristics", 1823], ["to", 1839], ["be", 1842], ["independent", 1845], ["prognostic", 1857], ["factors", 1868], ["for", 1876], ["achievement", 1880], ["of", 1892], ["complete", 1895], ["cytogenetic", 1904], ["response", 1916], [".", 1924]]}
{"context": "Epidemiology of Clostridium difficile is characterized by worldwide increase of C. difficile infections (CDI) and the emergence of new epidemic outbreak strains with the capacity for global spreading. Long-term local surveillance at the University of Saarland Medical Center between 2000 and 2013 shows that the incidence rate of laboratory-confirmed CDI was influenced by local epidemiology as well as by testing strategies. Since 2008, molecular typing of C. difficile was regularly performed for symptomatic hospitalized patients by surface-layer protein A sequence typing (slpAST), which is an established highly standardized technique for genotyping of C. difficile. The results were assigned to known ribotypes for better comparison to international data. It could be demonstrated that distribution of genotypes was different between age groups. Older patients were predominantly infected with ribotype 001 and 027, whereas ribotype 027 was not detected in the pediatric population. Molecular typing of German isolates sent to the advisory laboratory between 2011 and 2013 revealed that ribotype 027 is present with high percentages in most German regions except for the very North. In conclusion, optimized testing of all hospitalized patients with diarrhea should be generally implemented to avoid under-diagnosis of C. difficile infection. Ribotype 027 is highly prevalent in Germany, but its infections are restricted to older patients, while absent in children. Molecular typing of suspected hospital outbreaks and of patients with severe or recurrent disease may help to better understand virulence and epidemic spreading of C. difficile.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "e08396e636f94ad19455f09fad2df0c8", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[149, 150], [175, 176], [217, 218]], "char_spans": [[930, 941], [1093, 1104], [1349, 1360]]}]}], "context_tokens": [["Epidemiology", 0], ["of", 13], ["Clostridium", 16], ["difficile", 28], ["is", 38], ["characterized", 41], ["by", 55], ["worldwide", 58], ["increase", 68], ["of", 77], ["C.", 80], ["difficile", 83], ["infections", 93], ["(", 104], ["CDI", 105], [")", 108], ["and", 110], ["the", 114], ["emergence", 118], ["of", 128], ["new", 131], ["epidemic", 135], ["outbreak", 144], ["strains", 153], ["with", 161], ["the", 166], ["capacity", 170], ["for", 179], ["global", 183], ["spreading", 190], [".", 199], ["Long", 201], ["-", 205], ["term", 206], ["local", 211], ["surveillance", 217], ["at", 230], ["the", 233], ["University", 237], ["of", 248], ["Saarland", 251], ["Medical", 260], ["Center", 268], ["between", 275], ["2000", 283], ["and", 288], ["2013", 292], ["shows", 297], ["that", 303], ["the", 308], ["incidence", 312], ["rate", 322], ["of", 327], ["laboratory", 330], ["-", 340], ["confirmed", 341], ["CDI", 351], ["was", 355], ["influenced", 359], ["by", 370], ["local", 373], ["epidemiology", 379], ["as", 392], ["well", 395], ["as", 400], ["by", 403], ["testing", 406], ["strategies", 414], [".", 424], ["Since", 426], ["2008", 432], [",", 436], ["molecular", 438], ["typing", 448], ["of", 455], ["C.", 458], ["difficile", 461], ["was", 471], ["regularly", 475], ["performed", 485], ["for", 495], ["symptomatic", 499], ["hospitalized", 511], ["patients", 524], ["by", 533], ["surface", 536], ["-", 543], ["layer", 544], ["protein", 550], ["A", 558], ["sequence", 560], ["typing", 569], ["(", 576], ["slpAST", 577], [")", 583], [",", 584], ["which", 586], ["is", 592], ["an", 595], ["established", 598], ["highly", 610], ["standardized", 617], ["technique", 630], ["for", 640], ["genotyping", 644], ["of", 655], ["C.", 658], ["difficile", 661], [".", 670], ["The", 672], ["results", 676], ["were", 684], ["assigned", 689], ["to", 698], ["known", 701], ["ribotypes", 707], ["for", 717], ["better", 721], ["comparison", 728], ["to", 739], ["international", 742], ["data", 756], [".", 760], ["It", 762], ["could", 765], ["be", 771], ["demonstrated", 774], ["that", 787], ["distribution", 792], ["of", 805], ["genotypes", 808], ["was", 818], ["different", 822], ["between", 832], ["age", 840], ["groups", 844], [".", 850], ["Older", 852], ["patients", 858], ["were", 867], ["predominantly", 872], ["infected", 886], ["with", 895], ["ribotype", 900], ["001", 909], ["and", 913], ["027", 917], [",", 920], ["whereas", 922], ["ribotype", 930], ["027", 939], ["was", 943], ["not", 947], ["detected", 951], ["in", 960], ["the", 963], ["pediatric", 967], ["population", 977], [".", 987], ["Molecular", 989], ["typing", 999], ["of", 1006], ["German", 1009], ["isolates", 1016], ["sent", 1025], ["to", 1030], ["the", 1033], ["advisory", 1037], ["laboratory", 1046], ["between", 1057], ["2011", 1065], ["and", 1070], ["2013", 1074], ["revealed", 1079], ["that", 1088], ["ribotype", 1093], ["027", 1102], ["is", 1106], ["present", 1109], ["with", 1117], ["high", 1122], ["percentages", 1127], ["in", 1139], ["most", 1142], ["German", 1147], ["regions", 1154], ["except", 1162], ["for", 1169], ["the", 1173], ["very", 1177], ["North", 1182], [".", 1187], ["In", 1189], ["conclusion", 1192], [",", 1202], ["optimized", 1204], ["testing", 1214], ["of", 1222], ["all", 1225], ["hospitalized", 1229], ["patients", 1242], ["with", 1251], ["diarrhea", 1256], ["should", 1265], ["be", 1272], ["generally", 1275], ["implemented", 1285], ["to", 1297], ["avoid", 1300], ["under", 1306], ["-", 1311], ["diagnosis", 1312], ["of", 1322], ["C.", 1325], ["difficile", 1328], ["infection", 1338], [".", 1347], ["Ribotype", 1349], ["027", 1358], ["is", 1362], ["highly", 1365], ["prevalent", 1372], ["in", 1382], ["Germany", 1385], [",", 1392], ["but", 1394], ["its", 1398], ["infections", 1402], ["are", 1413], ["restricted", 1417], ["to", 1428], ["older", 1431], ["patients", 1437], [",", 1445], ["while", 1447], ["absent", 1453], ["in", 1460], ["children", 1463], [".", 1471], ["Molecular", 1473], ["typing", 1483], ["of", 1490], ["suspected", 1493], ["hospital", 1503], ["outbreaks", 1512], ["and", 1522], ["of", 1526], ["patients", 1529], ["with", 1538], ["severe", 1543], ["or", 1550], ["recurrent", 1553], ["disease", 1563], ["may", 1571], ["help", 1575], ["to", 1580], ["better", 1583], ["understand", 1590], ["virulence", 1601], ["and", 1611], ["epidemic", 1615], ["spreading", 1624], ["of", 1634], ["C.", 1637], ["difficile", 1640], [".", 1649]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial gestalt and mental retardation of variable severity. Haploinsufficiency of the NSD1 gene has been implicated as the major cause of Sotos syndrome, with a predominance of microdeletions reported in Japanese patients. This study was conducted to investigate into the spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome. Thirty-six Chinese patients with Sotos syndrome and two patients with Weaver syndrome were subject to molecular testing. NSD1 gene mutations were detected in 26 (72%) Sotos patients. Microdeletion was found in only 3 patients, while the other 23 had point mutations (6 frameshift, 8 nonsense, 2 spice site, and 7 missense). Of these, 19 mutations were never reported. NSD1 gene mutations were not found in the two patients with Weaver syndrome. Most cases of Sotos syndrome are caused by NSD1 gene defects, but the spectrum of mutations is different from that of Japanese patients. Genotype-phenotype correlation showed that patients with microdeletions might be more prone to congenital heart disease but less likely to have somatic overgrowth. The two patients with Weaver syndrome were not found to have NSD1 gene mutations, but the number was too small for any conclusion to be drawn.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "2cf9e36ee549421b84170a93d439b69d", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[160, 161], [138, 139], [20, 21], [84, 85], [53, 54], [213, 214]], "char_spans": [[903, 911], [783, 791], [147, 155], [536, 544], [345, 353], [1222, 1230]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["gestalt", 68], ["and", 76], ["mental", 80], ["retardation", 87], ["of", 99], ["variable", 102], ["severity", 111], [".", 119], ["Haploinsufficiency", 121], ["of", 140], ["the", 143], ["NSD1", 147], ["gene", 152], ["has", 157], ["been", 161], ["implicated", 166], ["as", 177], ["the", 180], ["major", 184], ["cause", 190], ["of", 196], ["Sotos", 199], ["syndrome", 205], [",", 213], ["with", 215], ["a", 220], ["predominance", 222], ["of", 235], ["microdeletions", 238], ["reported", 253], ["in", 262], ["Japanese", 265], ["patients", 274], [".", 282], ["This", 284], ["study", 289], ["was", 295], ["conducted", 299], ["to", 309], ["investigate", 312], ["into", 324], ["the", 329], ["spectrum", 333], ["of", 342], ["NSD1", 345], ["gene", 350], ["mutations", 355], ["in", 365], ["southern", 368], ["Chinese", 377], ["patients", 385], ["with", 394], ["Sotos", 399], ["syndrome", 405], [".", 413], ["Thirty", 415], ["-", 421], ["six", 422], ["Chinese", 426], ["patients", 434], ["with", 443], ["Sotos", 448], ["syndrome", 454], ["and", 463], ["two", 467], ["patients", 471], ["with", 480], ["Weaver", 485], ["syndrome", 492], ["were", 501], ["subject", 506], ["to", 514], ["molecular", 517], ["testing", 527], [".", 534], ["NSD1", 536], ["gene", 541], ["mutations", 546], ["were", 556], ["detected", 561], ["in", 570], ["26", 573], ["(", 576], ["72", 577], ["%", 579], [")", 580], ["Sotos", 582], ["patients", 588], [".", 596], ["Microdeletion", 598], ["was", 612], ["found", 616], ["in", 622], ["only", 625], ["3", 630], ["patients", 632], [",", 640], ["while", 642], ["the", 648], ["other", 652], ["23", 658], ["had", 661], ["point", 665], ["mutations", 671], ["(", 681], ["6", 682], ["frameshift", 684], [",", 694], ["8", 696], ["nonsense", 698], [",", 706], ["2", 708], ["spice", 710], ["site", 716], [",", 720], ["and", 722], ["7", 726], ["missense", 728], [")", 736], [".", 737], ["Of", 739], ["these", 742], [",", 747], ["19", 749], ["mutations", 752], ["were", 762], ["never", 767], ["reported", 773], [".", 781], ["NSD1", 783], ["gene", 788], ["mutations", 793], ["were", 803], ["not", 808], ["found", 812], ["in", 818], ["the", 821], ["two", 825], ["patients", 829], ["with", 838], ["Weaver", 843], ["syndrome", 850], [".", 858], ["Most", 860], ["cases", 865], ["of", 871], ["Sotos", 874], ["syndrome", 880], ["are", 889], ["caused", 893], ["by", 900], ["NSD1", 903], ["gene", 908], ["defects", 913], [",", 920], ["but", 922], ["the", 926], ["spectrum", 930], ["of", 939], ["mutations", 942], ["is", 952], ["different", 955], ["from", 965], ["that", 970], ["of", 975], ["Japanese", 978], ["patients", 987], [".", 995], ["Genotype", 997], ["-", 1005], ["phenotype", 1006], ["correlation", 1016], ["showed", 1028], ["that", 1035], ["patients", 1040], ["with", 1049], ["microdeletions", 1054], ["might", 1069], ["be", 1075], ["more", 1078], ["prone", 1083], ["to", 1089], ["congenital", 1092], ["heart", 1103], ["disease", 1109], ["but", 1117], ["less", 1121], ["likely", 1126], ["to", 1133], ["have", 1136], ["somatic", 1141], ["overgrowth", 1149], [".", 1159], ["The", 1161], ["two", 1165], ["patients", 1169], ["with", 1178], ["Weaver", 1183], ["syndrome", 1190], ["were", 1199], ["not", 1204], ["found", 1208], ["to", 1214], ["have", 1217], ["NSD1", 1222], ["gene", 1227], ["mutations", 1232], [",", 1241], ["but", 1243], ["the", 1247], ["number", 1251], ["was", 1258], ["too", 1262], ["small", 1266], ["for", 1272], ["any", 1276], ["conclusion", 1280], ["to", 1291], ["be", 1294], ["drawn", 1297], [".", 1302]]}
{"context": "The RTS,S/AS01(E) candidate malaria vaccine is being developed for immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 month follow-up data have been reported for safety and immunogenicity of RTS,S/AS01(E) when integrated into the EPI. We report extended follow-up to 19 months, including efficacy results. We did a randomised, open-label, phase 2 trial of safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with EPI vaccines between April 30, 2007, and Oct 7, 2009, in Ghana, Tanzania, and Gabon. Eligible children were 6-10 weeks of age at first vaccination, without serious acute or chronic illness. All children received the EPI diphtheria, tetanus, pertussis (inactivated whole-cell), and hepatitis-B vaccines, Haemophilus influenzae type b vaccine, and oral polio vaccine at study months 0, 1, and 2, and measles vaccine and yellow fever vaccines at study month 7. Participants were randomly assigned (1:1:1) to receive three doses of RTS,S/AS01(E) at 6, 10, and 14 weeks (0, 1, 2 month schedule) or at 6 weeks, 10 weeks, and 9 months (0, 2, 7 month schedule) or placebo. Randomisation was according to a predefined block list with a computer-generated randomisation code. Detection of serious adverse events and malaria was by passive case detection. Antibodies against Plasmodium falciparum circumsporozoite protein and HBsAg were monitored for 19 months. This study is registered with ClinicalTrials.gov, number NCT00436007. 511 children were enrolled. Serious adverse events occurred in 57 participants in the RTS,S/AS01(E) 0, 1, 2 month group (34%, 95% CI 27-41), 47 in the 0, 1, 7 month group (28%, 21-35), and 49 (29%, 22-36) in the control group; none were judged to be related to study vaccination. At month 19, anticircumsporozoite immune responses were significantly higher in the RTS,S/AS01(E) groups than in the control group. Vaccine efficacy for the 0, 1, 2 month schedule (2 weeks after dose three to month 19, site-adjusted according-to-protocol analysis) was 53% (95% CI 26-70; p=0\u00b70012) against first malaria episodes and 59% (36-74; p=0\u00b70001) against all malaria episodes. For the entire study period, (total vaccinated cohort) vaccine efficacy against all malaria episodes was higher with the 0, 1, 2 month schedule (57%, 95% CI 33-73; p=0\u00b70002) than with the 0, 1, 7 month schedule (32% CI 16-45; p=0\u00b70003). 1 year after dose three, vaccine efficacy against first malaria episodes was similar for both schedules (0, 1, 2 month group, 61\u00b76% [95% CI 35\u00b76-77\u00b71], p<0\u00b7001; 0, 1, 7 month group, 63\u00b78% [40\u00b74-78\u00b70], p<0\u00b7001, according-to-protocol cohort). Vaccine efficacy was consistent with the target put forward by the WHO-sponsored malaria vaccine technology roadmap for a first-generation malaria vaccine. The 0, 1, 2 month vaccine schedule has been selected for phase 3 candidate vaccine assessment. Program for Appropriate Technology in Health Malaria Vaccine Initiative; GlaxoSmithKline Biologicals.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e902e6f0d961453ba6bc3e8ea9ab9588", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[275, 275], [549, 549], [474, 474], [618, 618], [627, 627], [460, 460], [492, 492], [8, 8], [94, 94], [655, 655]], "char_spans": [[1279, 1285], [2452, 2458], [2141, 2147], [2718, 2724], [2776, 2782], [2086, 2092], [2243, 2249], [28, 34], [446, 452], [2933, 2939]]}]}], "context_tokens": [["The", 0], ["RTS", 4], [",", 7], ["S", 8], ["/", 9], ["AS01(E", 10], [")", 16], ["candidate", 18], ["malaria", 28], ["vaccine", 36], ["is", 44], ["being", 47], ["developed", 53], ["for", 63], ["immunisation", 67], ["of", 80], ["infants", 83], ["in", 91], ["Africa", 94], ["through", 101], ["the", 109], ["expanded", 113], ["programme", 122], ["on", 132], ["immunisation", 135], ["(", 148], ["EPI", 149], [")", 152], [".", 153], ["8", 155], ["month", 157], ["follow", 163], ["-", 169], ["up", 170], ["data", 173], ["have", 178], ["been", 183], ["reported", 188], ["for", 197], ["safety", 201], ["and", 208], ["immunogenicity", 212], ["of", 227], ["RTS", 230], [",", 233], ["S", 234], ["/", 235], ["AS01(E", 236], [")", 242], ["when", 244], ["integrated", 249], ["into", 260], ["the", 265], ["EPI", 269], [".", 272], ["We", 274], ["report", 277], ["extended", 284], ["follow", 293], ["-", 299], ["up", 300], ["to", 303], ["19", 306], ["months", 309], [",", 315], ["including", 317], ["efficacy", 327], ["results", 336], [".", 343], ["We", 345], ["did", 348], ["a", 352], ["randomised", 354], [",", 364], ["open", 366], ["-", 370], ["label", 371], [",", 376], ["phase", 378], ["2", 384], ["trial", 386], ["of", 392], ["safety", 395], ["and", 402], ["efficacy", 406], ["of", 415], ["the", 418], ["RTS", 422], [",", 425], ["S", 426], ["/", 427], ["AS01(E", 428], [")", 434], ["candidate", 436], ["malaria", 446], ["vaccine", 454], ["given", 462], ["with", 468], ["EPI", 473], ["vaccines", 477], ["between", 486], ["April", 494], ["30", 500], [",", 502], ["2007", 504], [",", 508], ["and", 510], ["Oct", 514], ["7", 518], [",", 519], ["2009", 521], [",", 525], ["in", 527], ["Ghana", 530], [",", 535], ["Tanzania", 537], [",", 545], ["and", 547], ["Gabon", 551], [".", 556], ["Eligible", 558], ["children", 567], ["were", 576], ["6", 581], ["-", 582], ["10", 583], ["weeks", 586], ["of", 592], ["age", 595], ["at", 599], ["first", 602], ["vaccination", 608], [",", 619], ["without", 621], ["serious", 629], ["acute", 637], ["or", 643], ["chronic", 646], ["illness", 654], [".", 661], ["All", 663], ["children", 667], ["received", 676], ["the", 685], ["EPI", 689], ["diphtheria", 693], [",", 703], ["tetanus", 705], [",", 712], ["pertussis", 714], ["(", 724], ["inactivated", 725], ["whole", 737], ["-", 742], ["cell", 743], [")", 747], [",", 748], ["and", 750], ["hepatitis", 754], ["-", 763], ["B", 764], ["vaccines", 766], [",", 774], ["Haemophilus", 776], ["influenzae", 788], ["type", 799], ["b", 804], ["vaccine", 806], [",", 813], ["and", 815], ["oral", 819], ["polio", 824], ["vaccine", 830], ["at", 838], ["study", 841], ["months", 847], ["0", 854], [",", 855], ["1", 857], [",", 858], ["and", 860], ["2", 864], [",", 865], ["and", 867], ["measles", 871], ["vaccine", 879], ["and", 887], ["yellow", 891], ["fever", 898], ["vaccines", 904], ["at", 913], ["study", 916], ["month", 922], ["7", 928], [".", 929], ["Participants", 931], ["were", 944], ["randomly", 949], ["assigned", 958], ["(", 967], ["1:1:1", 968], [")", 973], ["to", 975], ["receive", 978], ["three", 986], ["doses", 992], ["of", 998], ["RTS", 1001], [",", 1004], ["S", 1005], ["/", 1006], ["AS01(E", 1007], [")", 1013], ["at", 1015], ["6", 1018], [",", 1019], ["10", 1021], [",", 1023], ["and", 1025], ["14", 1029], ["weeks", 1032], ["(", 1038], ["0", 1039], [",", 1040], ["1", 1042], [",", 1043], ["2", 1045], ["month", 1047], ["schedule", 1053], [")", 1061], ["or", 1063], ["at", 1066], ["6", 1069], ["weeks", 1071], [",", 1076], ["10", 1078], ["weeks", 1081], [",", 1086], ["and", 1088], ["9", 1092], ["months", 1094], ["(", 1101], ["0", 1102], [",", 1103], ["2", 1105], [",", 1106], ["7", 1108], ["month", 1110], ["schedule", 1116], [")", 1124], ["or", 1126], ["placebo", 1129], [".", 1136], ["Randomisation", 1138], ["was", 1152], ["according", 1156], ["to", 1166], ["a", 1169], ["predefined", 1171], ["block", 1182], ["list", 1188], ["with", 1193], ["a", 1198], ["computer", 1200], ["-", 1208], ["generated", 1209], ["randomisation", 1219], ["code", 1233], [".", 1237], ["Detection", 1239], ["of", 1249], ["serious", 1252], ["adverse", 1260], ["events", 1268], ["and", 1275], ["malaria", 1279], ["was", 1287], ["by", 1291], ["passive", 1294], ["case", 1302], ["detection", 1307], [".", 1316], ["Antibodies", 1318], ["against", 1329], ["Plasmodium", 1337], ["falciparum", 1348], ["circumsporozoite", 1359], ["protein", 1376], ["and", 1384], ["HBsAg", 1388], ["were", 1394], ["monitored", 1399], ["for", 1409], ["19", 1413], ["months", 1416], [".", 1422], ["This", 1424], ["study", 1429], ["is", 1435], ["registered", 1438], ["with", 1449], ["ClinicalTrials.gov", 1454], [",", 1472], ["number", 1474], ["NCT00436007", 1481], [".", 1492], ["511", 1494], ["children", 1498], ["were", 1507], ["enrolled", 1512], [".", 1520], ["Serious", 1522], ["adverse", 1530], ["events", 1538], ["occurred", 1545], ["in", 1554], ["57", 1557], ["participants", 1560], ["in", 1573], ["the", 1576], ["RTS", 1580], [",", 1583], ["S", 1584], ["/", 1585], ["AS01(E", 1586], [")", 1592], ["0", 1594], [",", 1595], ["1", 1597], [",", 1598], ["2", 1600], ["month", 1602], ["group", 1608], ["(", 1614], ["34", 1615], ["%", 1617], [",", 1618], ["95", 1620], ["%", 1622], ["CI", 1624], ["27", 1627], ["-", 1629], ["41", 1630], [")", 1632], [",", 1633], ["47", 1635], ["in", 1638], ["the", 1641], ["0", 1645], [",", 1646], ["1", 1648], [",", 1649], ["7", 1651], ["month", 1653], ["group", 1659], ["(", 1665], ["28", 1666], ["%", 1668], [",", 1669], ["21", 1671], ["-", 1673], ["35", 1674], [")", 1676], [",", 1677], ["and", 1679], ["49", 1683], ["(", 1686], ["29", 1687], ["%", 1689], [",", 1690], ["22", 1692], ["-", 1694], ["36", 1695], [")", 1697], ["in", 1699], ["the", 1702], ["control", 1706], ["group", 1714], [";", 1719], ["none", 1721], ["were", 1726], ["judged", 1731], ["to", 1738], ["be", 1741], ["related", 1744], ["to", 1752], ["study", 1755], ["vaccination", 1761], [".", 1772], ["At", 1774], ["month", 1777], ["19", 1783], [",", 1785], ["anticircumsporozoite", 1787], ["immune", 1808], ["responses", 1815], ["were", 1825], ["significantly", 1830], ["higher", 1844], ["in", 1851], ["the", 1854], ["RTS", 1858], [",", 1861], ["S", 1862], ["/", 1863], ["AS01(E", 1864], [")", 1870], ["groups", 1872], ["than", 1879], ["in", 1884], ["the", 1887], ["control", 1891], ["group", 1899], [".", 1904], ["Vaccine", 1906], ["efficacy", 1914], ["for", 1923], ["the", 1927], ["0", 1931], [",", 1932], ["1", 1934], [",", 1935], ["2", 1937], ["month", 1939], ["schedule", 1945], ["(", 1954], ["2", 1955], ["weeks", 1957], ["after", 1963], ["dose", 1969], ["three", 1974], ["to", 1980], ["month", 1983], ["19", 1989], [",", 1991], ["site", 1993], ["-", 1997], ["adjusted", 1998], ["according", 2007], ["-", 2016], ["to", 2017], ["-", 2019], ["protocol", 2020], ["analysis", 2029], [")", 2037], ["was", 2039], ["53", 2043], ["%", 2045], ["(", 2047], ["95", 2048], ["%", 2050], ["CI", 2052], ["26", 2055], ["-", 2057], ["70", 2058], [";", 2060], ["p=0\u00b70012", 2062], [")", 2070], ["against", 2072], ["first", 2080], ["malaria", 2086], ["episodes", 2094], ["and", 2103], ["59", 2107], ["%", 2109], ["(", 2111], ["36", 2112], ["-", 2114], ["74", 2115], [";", 2117], ["p=0\u00b70001", 2119], [")", 2127], ["against", 2129], ["all", 2137], ["malaria", 2141], ["episodes", 2149], [".", 2157], ["For", 2159], ["the", 2163], ["entire", 2167], ["study", 2174], ["period", 2180], [",", 2186], ["(", 2188], ["total", 2189], ["vaccinated", 2195], ["cohort", 2206], [")", 2212], ["vaccine", 2214], ["efficacy", 2222], ["against", 2231], ["all", 2239], ["malaria", 2243], ["episodes", 2251], ["was", 2260], ["higher", 2264], ["with", 2271], ["the", 2276], ["0", 2280], [",", 2281], ["1", 2283], [",", 2284], ["2", 2286], ["month", 2288], ["schedule", 2294], ["(", 2303], ["57", 2304], ["%", 2306], [",", 2307], ["95", 2309], ["%", 2311], ["CI", 2313], ["33", 2316], ["-", 2318], ["73", 2319], [";", 2321], ["p=0\u00b70002", 2323], [")", 2331], ["than", 2333], ["with", 2338], ["the", 2343], ["0", 2347], [",", 2348], ["1", 2350], [",", 2351], ["7", 2353], ["month", 2355], ["schedule", 2361], ["(", 2370], ["32", 2371], ["%", 2373], ["CI", 2375], ["16", 2378], ["-", 2380], ["45", 2381], [";", 2383], ["p=0\u00b70003", 2385], [")", 2393], [".", 2394], ["1", 2396], ["year", 2398], ["after", 2403], ["dose", 2409], ["three", 2414], [",", 2419], ["vaccine", 2421], ["efficacy", 2429], ["against", 2438], ["first", 2446], ["malaria", 2452], ["episodes", 2460], ["was", 2469], ["similar", 2473], ["for", 2481], ["both", 2485], ["schedules", 2490], ["(", 2500], ["0", 2501], [",", 2502], ["1", 2504], [",", 2505], ["2", 2507], ["month", 2509], ["group", 2515], [",", 2520], ["61\u00b76", 2522], ["%", 2526], ["[", 2528], ["95", 2529], ["%", 2531], ["CI", 2533], ["35\u00b76", 2536], ["-", 2540], ["77\u00b71", 2541], ["]", 2545], [",", 2546], ["p<0\u00b7001", 2548], [";", 2555], ["0", 2557], [",", 2558], ["1", 2560], [",", 2561], ["7", 2563], ["month", 2565], ["group", 2571], [",", 2576], ["63\u00b78", 2578], ["%", 2582], ["[", 2584], ["40\u00b74", 2585], ["-", 2589], ["78\u00b70", 2590], ["]", 2594], [",", 2595], ["p<0\u00b7001", 2597], [",", 2604], ["according", 2606], ["-", 2615], ["to", 2616], ["-", 2618], ["protocol", 2619], ["cohort", 2628], [")", 2634], [".", 2635], ["Vaccine", 2637], ["efficacy", 2645], ["was", 2654], ["consistent", 2658], ["with", 2669], ["the", 2674], ["target", 2678], ["put", 2685], ["forward", 2689], ["by", 2697], ["the", 2700], ["WHO", 2704], ["-", 2707], ["sponsored", 2708], ["malaria", 2718], ["vaccine", 2726], ["technology", 2734], ["roadmap", 2745], ["for", 2753], ["a", 2757], ["first", 2759], ["-", 2764], ["generation", 2765], ["malaria", 2776], ["vaccine", 2784], [".", 2791], ["The", 2793], ["0", 2797], [",", 2798], ["1", 2800], [",", 2801], ["2", 2803], ["month", 2805], ["vaccine", 2811], ["schedule", 2819], ["has", 2828], ["been", 2832], ["selected", 2837], ["for", 2846], ["phase", 2850], ["3", 2856], ["candidate", 2858], ["vaccine", 2868], ["assessment", 2876], [".", 2886], ["Program", 2888], ["for", 2896], ["Appropriate", 2900], ["Technology", 2912], ["in", 2923], ["Health", 2926], ["Malaria", 2933], ["Vaccine", 2941], ["Initiative", 2949], [";", 2959], ["GlaxoSmithKline", 2961], ["Biologicals", 2977], [".", 2988]]}
{"context": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). Its hematologic and cytogenetic effects have been evaluated in a series of clinical trials. The aim of this study was to report hematologic and cytogenetic response in CML patients during the treatment with imatinib mesylate. A total of 21 patients were treated and observed from July 2006 to December 2008. The median time from CML diagnosis was no more than 12 months, so all the patients received previous treatment with hydroxyurea for which the median time was 3 months. The patients received imatinib mesylate in an effective oral dose of 400 to 800 mg daily, which was followed with peripheral blood counts, bone marrow examination, and cytogenetic studies at 6, 12, 18 and 24 months. Complete hematologic responses were reported for 19 (90.48%) of 21 patients studied. Among 19 patients who had a response, 16 (86%) did so within 3 months. The best cytogenetic response rate at any time during the study treatment with imatinib mesylate, among 14 patients in which cytogenetic response evaluated was: complete cytogenetic response in 7 (50%) patients, partial cytogenetic response in 6 (42.9%) patients and minor cytogenetic response in 1 (7.1%) patient. No patients had progressed to accelerated or blastic phase. The most frequent adverse effects that seemed to be related to treatment with imatinib mesylate were edema and musculoskeletal pain; overall, most were mild. Only one patient discontinued treatment because of hematologic toxic effects. The results obtained in this study confirm that imatinib mesylate induces a complete hematological and cytogenetic response in a high percentage of patients with chronic-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a1078ce36c74d609a098b1b566be822", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[20, 22]], "char_spans": [[134, 140]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["tyrosine", 21], ["kinase", 30], ["inhibitor", 37], ["with", 47], ["specific", 52], ["activity", 61], ["against", 70], ["the", 78], ["breakpoint", 82], ["cluster", 93], ["region", 101], ["--", 107], ["Abelson", 109], ["murine", 117], ["leukemia", 124], ["(", 133], ["BCR", 134], ["-", 137], ["ABL", 138], [")", 141], ["tyrosine", 143], ["kinase", 152], ["has", 159], ["been", 163], ["developed", 168], ["for", 178], ["treatment", 182], ["of", 192], ["chronic", 195], ["myelogenous", 203], ["leukemia", 215], ["(", 224], ["CML", 225], [")", 228], [".", 229], ["Its", 231], ["hematologic", 235], ["and", 247], ["cytogenetic", 251], ["effects", 263], ["have", 271], ["been", 276], ["evaluated", 281], ["in", 291], ["a", 294], ["series", 296], ["of", 303], ["clinical", 306], ["trials", 315], [".", 321], ["The", 323], ["aim", 327], ["of", 331], ["this", 334], ["study", 339], ["was", 345], ["to", 349], ["report", 352], ["hematologic", 359], ["and", 371], ["cytogenetic", 375], ["response", 387], ["in", 396], ["CML", 399], ["patients", 403], ["during", 412], ["the", 419], ["treatment", 423], ["with", 433], ["imatinib", 438], ["mesylate", 447], [".", 455], ["A", 457], ["total", 459], ["of", 465], ["21", 468], ["patients", 471], ["were", 480], ["treated", 485], ["and", 493], ["observed", 497], ["from", 506], ["July", 511], ["2006", 516], ["to", 521], ["December", 524], ["2008", 533], [".", 537], ["The", 539], ["median", 543], ["time", 550], ["from", 555], ["CML", 560], ["diagnosis", 564], ["was", 574], ["no", 578], ["more", 581], ["than", 586], ["12", 591], ["months", 594], [",", 600], ["so", 602], ["all", 605], ["the", 609], ["patients", 613], ["received", 622], ["previous", 631], ["treatment", 640], ["with", 650], ["hydroxyurea", 655], ["for", 667], ["which", 671], ["the", 677], ["median", 681], ["time", 688], ["was", 693], ["3", 697], ["months", 699], [".", 705], ["The", 707], ["patients", 711], ["received", 720], ["imatinib", 729], ["mesylate", 738], ["in", 747], ["an", 750], ["effective", 753], ["oral", 763], ["dose", 768], ["of", 773], ["400", 776], ["to", 780], ["800", 783], ["mg", 787], ["daily", 790], [",", 795], ["which", 797], ["was", 803], ["followed", 807], ["with", 816], ["peripheral", 821], ["blood", 832], ["counts", 838], [",", 844], ["bone", 846], ["marrow", 851], ["examination", 858], [",", 869], ["and", 871], ["cytogenetic", 875], ["studies", 887], ["at", 895], ["6", 898], [",", 899], ["12", 901], [",", 903], ["18", 905], ["and", 908], ["24", 912], ["months", 915], [".", 921], ["Complete", 923], ["hematologic", 932], ["responses", 944], ["were", 954], ["reported", 959], ["for", 968], ["19", 972], ["(", 975], ["90.48", 976], ["%", 981], [")", 982], ["of", 984], ["21", 987], ["patients", 990], ["studied", 999], [".", 1006], ["Among", 1008], ["19", 1014], ["patients", 1017], ["who", 1026], ["had", 1030], ["a", 1034], ["response", 1036], [",", 1044], ["16", 1046], ["(", 1049], ["86", 1050], ["%", 1052], [")", 1053], ["did", 1055], ["so", 1059], ["within", 1062], ["3", 1069], ["months", 1071], [".", 1077], ["The", 1079], ["best", 1083], ["cytogenetic", 1088], ["response", 1100], ["rate", 1109], ["at", 1114], ["any", 1117], ["time", 1121], ["during", 1126], ["the", 1133], ["study", 1137], ["treatment", 1143], ["with", 1153], ["imatinib", 1158], ["mesylate", 1167], [",", 1175], ["among", 1177], ["14", 1183], ["patients", 1186], ["in", 1195], ["which", 1198], ["cytogenetic", 1204], ["response", 1216], ["evaluated", 1225], ["was", 1235], [":", 1238], ["complete", 1240], ["cytogenetic", 1249], ["response", 1261], ["in", 1270], ["7", 1273], ["(", 1275], ["50", 1276], ["%", 1278], [")", 1279], ["patients", 1281], [",", 1289], ["partial", 1291], ["cytogenetic", 1299], ["response", 1311], ["in", 1320], ["6", 1323], ["(", 1325], ["42.9", 1326], ["%", 1330], [")", 1331], ["patients", 1333], ["and", 1342], ["minor", 1346], ["cytogenetic", 1352], ["response", 1364], ["in", 1373], ["1", 1376], ["(", 1378], ["7.1", 1379], ["%", 1382], [")", 1383], ["patient", 1385], [".", 1392], ["No", 1394], ["patients", 1397], ["had", 1406], ["progressed", 1410], ["to", 1421], ["accelerated", 1424], ["or", 1436], ["blastic", 1439], ["phase", 1447], [".", 1452], ["The", 1454], ["most", 1458], ["frequent", 1463], ["adverse", 1472], ["effects", 1480], ["that", 1488], ["seemed", 1493], ["to", 1500], ["be", 1503], ["related", 1506], ["to", 1514], ["treatment", 1517], ["with", 1527], ["imatinib", 1532], ["mesylate", 1541], ["were", 1550], ["edema", 1555], ["and", 1561], ["musculoskeletal", 1565], ["pain", 1581], [";", 1585], ["overall", 1587], [",", 1594], ["most", 1596], ["were", 1601], ["mild", 1606], [".", 1610], ["Only", 1612], ["one", 1617], ["patient", 1621], ["discontinued", 1629], ["treatment", 1642], ["because", 1652], ["of", 1660], ["hematologic", 1663], ["toxic", 1675], ["effects", 1681], [".", 1688], ["The", 1690], ["results", 1694], ["obtained", 1702], ["in", 1711], ["this", 1714], ["study", 1719], ["confirm", 1725], ["that", 1733], ["imatinib", 1738], ["mesylate", 1747], ["induces", 1756], ["a", 1764], ["complete", 1766], ["hematological", 1775], ["and", 1789], ["cytogenetic", 1793], ["response", 1805], ["in", 1814], ["a", 1817], ["high", 1819], ["percentage", 1824], ["of", 1835], ["patients", 1838], ["with", 1847], ["chronic", 1852], ["-", 1859], ["phase", 1860], ["CML", 1866], [".", 1869]]}
{"context": "Coexpression of PU.1 and GATA-1 is required for proper specification of the mast cell lineage; however, in the myeloid and erythroid lineages, PU.1 and GATA-1 are functionally antagonistic. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. We isolated a variant mRNA isoform of GATA-1 in murine mast cells that is significantly upregulated during mast cell differentiation. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. In contrast to erythroid and megakaryocyte cells, in mast cells we show that PU.1 and GATA-2 predominantly occupy potential cis-regulatory elements in the IB exon region in vivo. Using reporter assays, we identify an enhancer flanking the IB exon that is activated by PU.1. Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Our results are consistent with a transcriptional hierarchy in which PU.1, possibly in concert with GATA-2, activates GATA-1 expression in mast cells in a pathway distinct from that seen in the erythroid and megakaryocytic lineages.", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "f6516640f1d44d11963b1679aae29f07", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[117, 117], [43, 43], [151, 151], [25, 25], [185, 185], [215, 215], [2, 2], [159, 159]], "char_spans": [[689, 692], [250, 253], [880, 883], [143, 146], [1053, 1056], [1256, 1259], [16, 19], [918, 925]]}]}], "context_tokens": [["Coexpression", 0], ["of", 13], ["PU.1", 16], ["and", 21], ["GATA-1", 25], ["is", 32], ["required", 35], ["for", 44], ["proper", 48], ["specification", 55], ["of", 69], ["the", 72], ["mast", 76], ["cell", 81], ["lineage", 86], [";", 93], ["however", 95], [",", 102], ["in", 104], ["the", 107], ["myeloid", 111], ["and", 119], ["erythroid", 123], ["lineages", 133], [",", 141], ["PU.1", 143], ["and", 148], ["GATA-1", 152], ["are", 159], ["functionally", 163], ["antagonistic", 176], [".", 188], ["In", 190], ["this", 193], ["study", 198], [",", 203], ["we", 205], ["report", 208], ["a", 215], ["transcriptional", 217], ["network", 233], ["in", 241], ["which", 244], ["PU.1", 250], ["positively", 255], ["regulates", 266], ["GATA-1", 276], ["expression", 283], ["in", 294], ["mast", 297], ["cell", 302], ["development", 307], [".", 318], ["We", 320], ["isolated", 323], ["a", 332], ["variant", 334], ["mRNA", 342], ["isoform", 347], ["of", 355], ["GATA-1", 358], ["in", 365], ["murine", 368], ["mast", 375], ["cells", 380], ["that", 386], ["is", 391], ["significantly", 394], ["upregulated", 408], ["during", 420], ["mast", 427], ["cell", 432], ["differentiation", 437], [".", 452], ["This", 454], ["isoform", 459], ["contains", 467], ["an", 476], ["alternatively", 479], ["spliced", 493], ["first", 501], ["exon", 507], ["(", 512], ["IB", 513], [")", 515], ["that", 517], ["is", 522], ["distinct", 525], ["from", 534], ["the", 539], ["first", 543], ["exon", 549], ["(", 554], ["IE", 555], [")", 557], ["incorporated", 559], ["in", 572], ["the", 575], ["major", 579], ["erythroid", 585], ["mRNA", 595], ["transcript", 600], [".", 610], ["In", 612], ["contrast", 615], ["to", 624], ["erythroid", 627], ["and", 637], ["megakaryocyte", 641], ["cells", 655], [",", 660], ["in", 662], ["mast", 665], ["cells", 670], ["we", 676], ["show", 679], ["that", 684], ["PU.1", 689], ["and", 694], ["GATA-2", 698], ["predominantly", 705], ["occupy", 719], ["potential", 726], ["cis", 736], ["-", 739], ["regulatory", 740], ["elements", 751], ["in", 760], ["the", 763], ["IB", 767], ["exon", 770], ["region", 775], ["in", 782], ["vivo", 785], [".", 789], ["Using", 791], ["reporter", 797], ["assays", 806], [",", 812], ["we", 814], ["identify", 817], ["an", 826], ["enhancer", 829], ["flanking", 838], ["the", 847], ["IB", 851], ["exon", 854], ["that", 859], ["is", 864], ["activated", 867], ["by", 877], ["PU.1", 880], [".", 884], ["Furthermore", 886], [",", 897], ["we", 899], ["observe", 902], ["that", 910], ["in", 915], ["PU.1(-/-", 918], [")", 926], ["fetal", 928], ["liver", 934], ["cells", 940], [",", 945], ["low", 947], ["levels", 951], ["of", 958], ["the", 961], ["IE", 965], ["GATA-1", 968], ["isoform", 975], ["is", 983], ["expressed", 986], [",", 995], ["but", 997], ["the", 1001], ["variant", 1005], ["IB", 1013], ["isoform", 1016], ["is", 1024], ["absent", 1027], [".", 1033], ["Reintroduction", 1035], ["of", 1050], ["PU.1", 1053], ["restores", 1058], ["variant", 1067], ["IB", 1075], ["isoform", 1078], ["and", 1086], ["upregulates", 1090], ["total", 1102], ["GATA-1", 1108], ["protein", 1115], ["expression", 1123], [",", 1133], ["which", 1135], ["is", 1141], ["concurrent", 1144], ["with", 1155], ["mast", 1160], ["cell", 1165], ["differentiation", 1170], [".", 1185], ["Our", 1187], ["results", 1191], ["are", 1199], ["consistent", 1203], ["with", 1214], ["a", 1219], ["transcriptional", 1221], ["hierarchy", 1237], ["in", 1247], ["which", 1250], ["PU.1", 1256], [",", 1260], ["possibly", 1262], ["in", 1271], ["concert", 1274], ["with", 1282], ["GATA-2", 1287], [",", 1293], ["activates", 1295], ["GATA-1", 1305], ["expression", 1312], ["in", 1323], ["mast", 1326], ["cells", 1331], ["in", 1337], ["a", 1340], ["pathway", 1342], ["distinct", 1350], ["from", 1359], ["that", 1364], ["seen", 1369], ["in", 1374], ["the", 1377], ["erythroid", 1381], ["and", 1391], ["megakaryocytic", 1395], ["lineages", 1410], [".", 1418]]}
{"context": "Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs. Girls with TS may also have occult Y chromosome sequences. Whereas some girls with TS are identified in infancy or early childhood, many girls with TS are not detected until after 10 yr of age, resulting in delayed evaluation and treatment. To prevent the delayed recognition and treatment of TS, a quantitative method of genotyping that can be performed as part of newborn screening is needed. To screen for sex chromosome abnormalities, we assembled a panel of informative single nucleotide polymorphism (SNP) markers that span the X chromosome from the dbSNP database. Pyrosequencing assays suitable for quantitative assessment of signal strength from single nucleotides were designed and used to genotype 46,XX; 46,XY; 45,X; and TS mosaics, examining zygosity and signal strength for individual alleles. Pyrosequencing assays were also designed for the detection of Y chromosome material. With just four informative SNP markers for the X chromosome, all TS girls with 45,X, partial X chromosome deletions, or mosaicism were identified with 100% sensitivity. In mosaic individuals, Y chromosomal material was detected with 100% sensitivity. These results suggest that inexpensive high-throughput screening is possible for TS and other sex chromosome disorders using quantitative genotyping approaches.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "4d9adbc83c164890a231325d350c9a93", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[131, 131], [26, 26], [196, 196], [206, 206], [17, 17]], "char_spans": [[735, 735], [142, 142], [1141, 1141], [1187, 1187], [91, 91]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["(", 16], ["TS", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["genetic", 40], ["problem", 48], ["affecting", 56], ["women", 66], ["and", 72], ["occurs", 76], ["when", 83], ["an", 88], ["X", 91], ["chromosome", 93], ["is", 104], ["completely", 107], ["deleted", 118], [",", 125], ["portions", 127], ["of", 136], ["an", 139], ["X", 142], ["chromosome", 144], ["are", 155], ["deleted", 159], [",", 166], ["or", 168], ["chromosomal", 171], ["mosaicism", 183], ["occurs", 193], [".", 199], ["Girls", 201], ["with", 207], ["TS", 212], ["may", 215], ["also", 219], ["have", 224], ["occult", 229], ["Y", 236], ["chromosome", 238], ["sequences", 249], [".", 258], ["Whereas", 260], ["some", 268], ["girls", 273], ["with", 279], ["TS", 284], ["are", 287], ["identified", 291], ["in", 302], ["infancy", 305], ["or", 313], ["early", 316], ["childhood", 322], [",", 331], ["many", 333], ["girls", 338], ["with", 344], ["TS", 349], ["are", 352], ["not", 356], ["detected", 360], ["until", 369], ["after", 375], ["10", 381], ["yr", 384], ["of", 387], ["age", 390], [",", 393], ["resulting", 395], ["in", 405], ["delayed", 408], ["evaluation", 416], ["and", 427], ["treatment", 431], [".", 440], ["To", 442], ["prevent", 445], ["the", 453], ["delayed", 457], ["recognition", 465], ["and", 477], ["treatment", 481], ["of", 491], ["TS", 494], [",", 496], ["a", 498], ["quantitative", 500], ["method", 513], ["of", 520], ["genotyping", 523], ["that", 534], ["can", 539], ["be", 543], ["performed", 546], ["as", 556], ["part", 559], ["of", 564], ["newborn", 567], ["screening", 575], ["is", 585], ["needed", 588], [".", 594], ["To", 596], ["screen", 599], ["for", 606], ["sex", 610], ["chromosome", 614], ["abnormalities", 625], [",", 638], ["we", 640], ["assembled", 643], ["a", 653], ["panel", 655], ["of", 661], ["informative", 664], ["single", 676], ["nucleotide", 683], ["polymorphism", 694], ["(", 707], ["SNP", 708], [")", 711], ["markers", 713], ["that", 721], ["span", 726], ["the", 731], ["X", 735], ["chromosome", 737], ["from", 748], ["the", 753], ["dbSNP", 757], ["database", 763], [".", 771], ["Pyrosequencing", 773], ["assays", 788], ["suitable", 795], ["for", 804], ["quantitative", 808], ["assessment", 821], ["of", 832], ["signal", 835], ["strength", 842], ["from", 851], ["single", 856], ["nucleotides", 863], ["were", 875], ["designed", 880], ["and", 889], ["used", 893], ["to", 898], ["genotype", 901], ["46,XX", 910], [";", 915], ["46,XY", 917], [";", 922], ["45,X", 924], [";", 928], ["and", 930], ["TS", 934], ["mosaics", 937], [",", 944], ["examining", 946], ["zygosity", 956], ["and", 965], ["signal", 969], ["strength", 976], ["for", 985], ["individual", 989], ["alleles", 1000], [".", 1007], ["Pyrosequencing", 1009], ["assays", 1024], ["were", 1031], ["also", 1036], ["designed", 1041], ["for", 1050], ["the", 1054], ["detection", 1058], ["of", 1068], ["Y", 1071], ["chromosome", 1073], ["material", 1084], [".", 1092], ["With", 1094], ["just", 1099], ["four", 1104], ["informative", 1109], ["SNP", 1121], ["markers", 1125], ["for", 1133], ["the", 1137], ["X", 1141], ["chromosome", 1143], [",", 1153], ["all", 1155], ["TS", 1159], ["girls", 1162], ["with", 1168], ["45,X", 1173], [",", 1177], ["partial", 1179], ["X", 1187], ["chromosome", 1189], ["deletions", 1200], [",", 1209], ["or", 1211], ["mosaicism", 1214], ["were", 1224], ["identified", 1229], ["with", 1240], ["100", 1245], ["%", 1248], ["sensitivity", 1250], [".", 1261], ["In", 1263], ["mosaic", 1266], ["individuals", 1273], [",", 1284], ["Y", 1286], ["chromosomal", 1288], ["material", 1300], ["was", 1309], ["detected", 1313], ["with", 1322], ["100", 1327], ["%", 1330], ["sensitivity", 1332], [".", 1343], ["These", 1345], ["results", 1351], ["suggest", 1359], ["that", 1367], ["inexpensive", 1372], ["high", 1384], ["-", 1388], ["throughput", 1389], ["screening", 1400], ["is", 1410], ["possible", 1413], ["for", 1422], ["TS", 1426], ["and", 1429], ["other", 1433], ["sex", 1439], ["chromosome", 1443], ["disorders", 1454], ["using", 1464], ["quantitative", 1470], ["genotyping", 1483], ["approaches", 1494], [".", 1504]]}
{"context": "Patients receiving tumor necrosis factor alpha inhibitors for the treatment of rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) are at high risk of developing tuberculosis during treatment. This article gives the recommendations for the prevention and management of tuberculosis in patients with rheumatic diseases before initiating therapy with tumor necrosis factor alpha inhibitors. They are adapted considering the high prevalence of tuberculosis, high drug resistance of Mycobacterium tuberculosis, and extensive bacille Calmette-Gu\u00e9rin vaccination against tuberculosis in Lithuania. In order to reduce the risk of tuberculosis, the screening should be done before starting antitumor necrosis factor alpha therapy. This includes complete medical history and posterior-anterior, lateral chest radiography. Tuberculin skin test using the Mantoux method with 5 tuberculin units and interferon-gamma release assay should be performed in patients without posttuberculous radiological lesions. If Ghon's complex or untreated posttuberculous lesions are present, or if the results the Mantoux test or interferon-gamma release assay are positive, the patient should be treated for latent tuberculosis. For the treatment of latent tuberculosis, isoniazid and rifampicin are given for 3 months, and the introduction of antitumor necrosis factor alpha therapy is delayed at least for one month. In cases of suspected active Mycobacterium tuberculosis infection, tuberculosis should be confirmed microbiologically or morphologically, and adequate antituberculosis treatment should be initiated.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "a96c132fbe5e40d5a762f6f9583a5c81", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[96, 96], [75, 75], [29, 29], [85, 85], [186, 186], [227, 227], [230, 230], [68, 68], [44, 44], [193, 193]], "char_spans": [[658, 669], [528, 539], [197, 208], [600, 611], [1223, 1234], [1470, 1481], [1494, 1505], [476, 487], [304, 315], [1265, 1276]]}]}], "context_tokens": [["Patients", 0], ["receiving", 9], ["tumor", 19], ["necrosis", 25], ["factor", 34], ["alpha", 41], ["inhibitors", 47], ["for", 58], ["the", 62], ["treatment", 66], ["of", 76], ["rheumatic", 79], ["diseases", 89], ["(", 98], ["rheumatoid", 99], ["arthritis", 110], [",", 119], ["psoriatic", 121], ["arthritis", 131], [",", 140], ["ankylosing", 142], ["spondylitis", 153], [")", 164], ["are", 166], ["at", 170], ["high", 173], ["risk", 178], ["of", 183], ["developing", 186], ["tuberculosis", 197], ["during", 210], ["treatment", 217], [".", 226], ["This", 228], ["article", 233], ["gives", 241], ["the", 247], ["recommendations", 251], ["for", 267], ["the", 271], ["prevention", 275], ["and", 286], ["management", 290], ["of", 301], ["tuberculosis", 304], ["in", 317], ["patients", 320], ["with", 329], ["rheumatic", 334], ["diseases", 344], ["before", 353], ["initiating", 360], ["therapy", 371], ["with", 379], ["tumor", 384], ["necrosis", 390], ["factor", 399], ["alpha", 406], ["inhibitors", 412], [".", 422], ["They", 424], ["are", 429], ["adapted", 433], ["considering", 441], ["the", 453], ["high", 457], ["prevalence", 462], ["of", 473], ["tuberculosis", 476], [",", 488], ["high", 490], ["drug", 495], ["resistance", 500], ["of", 511], ["Mycobacterium", 514], ["tuberculosis", 528], [",", 540], ["and", 542], ["extensive", 546], ["bacille", 556], ["Calmette", 564], ["-", 572], ["Gu\u00e9rin", 573], ["vaccination", 580], ["against", 592], ["tuberculosis", 600], ["in", 613], ["Lithuania", 616], [".", 625], ["In", 627], ["order", 630], ["to", 636], ["reduce", 639], ["the", 646], ["risk", 650], ["of", 655], ["tuberculosis", 658], [",", 670], ["the", 672], ["screening", 676], ["should", 686], ["be", 693], ["done", 696], ["before", 701], ["starting", 708], ["antitumor", 717], ["necrosis", 727], ["factor", 736], ["alpha", 743], ["therapy", 749], [".", 756], ["This", 758], ["includes", 763], ["complete", 772], ["medical", 781], ["history", 789], ["and", 797], ["posterior", 801], ["-", 810], ["anterior", 811], [",", 819], ["lateral", 821], ["chest", 829], ["radiography", 835], [".", 846], ["Tuberculin", 848], ["skin", 859], ["test", 864], ["using", 869], ["the", 875], ["Mantoux", 879], ["method", 887], ["with", 894], ["5", 899], ["tuberculin", 901], ["units", 912], ["and", 918], ["interferon", 922], ["-", 932], ["gamma", 933], ["release", 939], ["assay", 947], ["should", 953], ["be", 960], ["performed", 963], ["in", 973], ["patients", 976], ["without", 985], ["posttuberculous", 993], ["radiological", 1009], ["lesions", 1022], [".", 1029], ["If", 1031], ["Ghon", 1034], ["'s", 1038], ["complex", 1041], ["or", 1049], ["untreated", 1052], ["posttuberculous", 1062], ["lesions", 1078], ["are", 1086], ["present", 1090], [",", 1097], ["or", 1099], ["if", 1102], ["the", 1105], ["results", 1109], ["the", 1117], ["Mantoux", 1121], ["test", 1129], ["or", 1134], ["interferon", 1137], ["-", 1147], ["gamma", 1148], ["release", 1154], ["assay", 1162], ["are", 1168], ["positive", 1172], [",", 1180], ["the", 1182], ["patient", 1186], ["should", 1194], ["be", 1201], ["treated", 1204], ["for", 1212], ["latent", 1216], ["tuberculosis", 1223], [".", 1235], ["For", 1237], ["the", 1241], ["treatment", 1245], ["of", 1255], ["latent", 1258], ["tuberculosis", 1265], [",", 1277], ["isoniazid", 1279], ["and", 1289], ["rifampicin", 1293], ["are", 1304], ["given", 1308], ["for", 1314], ["3", 1318], ["months", 1320], [",", 1326], ["and", 1328], ["the", 1332], ["introduction", 1336], ["of", 1349], ["antitumor", 1352], ["necrosis", 1362], ["factor", 1371], ["alpha", 1378], ["therapy", 1384], ["is", 1392], ["delayed", 1395], ["at", 1403], ["least", 1406], ["for", 1412], ["one", 1416], ["month", 1420], [".", 1425], ["In", 1427], ["cases", 1430], ["of", 1436], ["suspected", 1439], ["active", 1449], ["Mycobacterium", 1456], ["tuberculosis", 1470], ["infection", 1483], [",", 1492], ["tuberculosis", 1494], ["should", 1507], ["be", 1514], ["confirmed", 1517], ["microbiologically", 1527], ["or", 1545], ["morphologically", 1548], [",", 1563], ["and", 1565], ["adequate", 1569], ["antituberculosis", 1578], ["treatment", 1595], ["should", 1605], ["be", 1612], ["initiated", 1615], [".", 1624]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus-(CA-MRSA) strains have emerged in Argentina. We investigated the clinical and molecular evolution of community-onset MRSA infections (CO-MRSA) in children of C\u00f3rdoba, Argentina, 2005-2008. Additionally, data from 2007 were compared with the epidemiology of these infections in other regions of the country. Two datasets were used: i) lab-based prospective surveillance of CA-MRSA isolates from 3 C\u00f3rdoba pediatric hospitals-(CBAH1-H3) in 2007-2008 (compared to previously published data of 2005) and ii) a sampling of CO-MRSA from a study involving both, healthcare-associated community-onset-(HACO) infections in children with risk-factors for healthcare-associated infections-(HRFs), and CA-MRSA infections in patients without HRFs detected in multiple centers of Argentina in 2007. Molecular typing was performed on the CA-MRSA-(n: 99) isolates from the CBAH1-H3-dataset and on the HACO-MRSA-(n: 51) and CA-MRSA-(n: 213) isolates from other regions. Between 2005-2008, the annual proportion of CA-MRSA/CA-S. aureus in C\u00f3rdoba hospitals increased from 25% to 49%, P<0.01. Total CA-MRSA infections increased 3.6 fold-(5.1 to 18.6 cases/100,000 annual-visits, P<0.0001), associated with an important increase of invasive CA-MRSA infections-(8.5 fold). In all regions analyzed, a single genotype prevailed in both CA-MRSA (82%) and HACO-MRSA(57%), which showed pulsed-field-gel electrophoresis-(PFGE)-type-\"I\", sequence-type-5-(ST5), SCCmec-type-IVa, spa-t311, and was positive for PVL. The second clone, pulsotype-N/ST30/CC30/SCCmecIVc/t019/PVL(+), accounted for 11.5% of total CA-MRSA infections. Importantly, the first 4 isolates of Argentina belonging to South American-USA300 clone-(USA300/ST8/CC8/SCCmecIVc/t008/PVL(+)/ACME(-)) were detected. We also demonstrated that a HA-MRSA clone-(pulsotype-C/ST100/CC5) caused 2% and 10% of CA-MRSA and HACO-MRSA infections respectively and was associated with a SCCmec type closely related to SCCmecIV(2B&5). The dissemination of epidemic MRSA clone, ST5-IV-PVL(+) was the main cause of increasing staphylococcal community-onset infections in Argentinean children (2003-2008), conversely to other countries. The predominance of this clone, which has capacity to express the h-VISA phenotype, in healthcare-associated community-onset cases suggests that it has infiltrated into hospital-settings.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e471eaad8b7f456298a4d3d189d07e9f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[226, 226], [384, 384], [141, 141], [250, 250], [28, 28], [204, 204], [9, 9], [268, 268], [332, 332], [364, 364], [380, 380], [404, 404], [110, 110], [33, 33], [81, 81]], "char_spans": [[1148, 1151], [1917, 1920], [758, 761], [1289, 1292], [182, 185], [1065, 1068], [69, 72], [1381, 1384], [1646, 1649], [1844, 1847], [1903, 1906], [2049, 2052], [586, 589], [202, 205], [440, 443]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus-(CA", 58], ["-", 68], ["MRSA", 69], [")", 73], ["strains", 75], ["have", 83], ["emerged", 88], ["in", 96], ["Argentina", 99], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["clinical", 130], ["and", 139], ["molecular", 143], ["evolution", 153], ["of", 163], ["community", 166], ["-", 175], ["onset", 176], ["MRSA", 182], ["infections", 187], ["(", 198], ["CO", 199], ["-", 201], ["MRSA", 202], [")", 206], ["in", 208], ["children", 211], ["of", 220], ["C\u00f3rdoba", 223], [",", 230], ["Argentina", 232], [",", 241], ["2005", 243], ["-", 247], ["2008", 248], [".", 252], ["Additionally", 254], [",", 266], ["data", 268], ["from", 273], ["2007", 278], ["were", 283], ["compared", 288], ["with", 297], ["the", 302], ["epidemiology", 306], ["of", 319], ["these", 322], ["infections", 328], ["in", 339], ["other", 342], ["regions", 348], ["of", 356], ["the", 359], ["country", 363], [".", 370], ["Two", 372], ["datasets", 376], ["were", 385], ["used", 390], [":", 394], ["i", 396], [")", 397], ["lab", 399], ["-", 402], ["based", 403], ["prospective", 409], ["surveillance", 421], ["of", 434], ["CA", 437], ["-", 439], ["MRSA", 440], ["isolates", 445], ["from", 454], ["3", 459], ["C\u00f3rdoba", 461], ["pediatric", 469], ["hospitals-(CBAH1-H3", 479], [")", 498], ["in", 500], ["2007", 503], ["-", 507], ["2008", 508], ["(", 513], ["compared", 514], ["to", 523], ["previously", 526], ["published", 537], ["data", 547], ["of", 552], ["2005", 555], [")", 559], ["and", 561], ["ii", 565], [")", 567], ["a", 569], ["sampling", 571], ["of", 580], ["CO", 583], ["-", 585], ["MRSA", 586], ["from", 591], ["a", 596], ["study", 598], ["involving", 604], ["both", 614], [",", 618], ["healthcare", 620], ["-", 630], ["associated", 631], ["community", 642], ["-", 651], ["onset-(HACO", 652], [")", 663], ["infections", 665], ["in", 676], ["children", 679], ["with", 688], ["risk", 693], ["-", 697], ["factors", 698], ["for", 706], ["healthcare", 710], ["-", 720], ["associated", 721], ["infections-(HRFs", 732], [")", 748], [",", 749], ["and", 751], ["CA", 755], ["-", 757], ["MRSA", 758], ["infections", 763], ["in", 774], ["patients", 777], ["without", 786], ["HRFs", 794], ["detected", 799], ["in", 808], ["multiple", 811], ["centers", 820], ["of", 828], ["Argentina", 831], ["in", 841], ["2007", 844], [".", 848], ["Molecular", 850], ["typing", 860], ["was", 867], ["performed", 871], ["on", 881], ["the", 884], ["CA", 888], ["-", 890], ["MRSA-(n", 891], [":", 898], ["99", 900], [")", 902], ["isolates", 904], ["from", 913], ["the", 918], ["CBAH1-H3-dataset", 922], ["and", 939], ["on", 943], ["the", 946], ["HACO", 950], ["-", 954], ["MRSA-(n", 955], [":", 962], ["51", 964], [")", 966], ["and", 968], ["CA", 972], ["-", 974], ["MRSA-(n", 975], [":", 982], ["213", 984], [")", 987], ["isolates", 989], ["from", 998], ["other", 1003], ["regions", 1009], [".", 1016], ["Between", 1018], ["2005", 1026], ["-", 1030], ["2008", 1031], [",", 1035], ["the", 1037], ["annual", 1041], ["proportion", 1048], ["of", 1059], ["CA", 1062], ["-", 1064], ["MRSA", 1065], ["/", 1069], ["CA", 1070], ["-", 1072], ["S.", 1073], ["aureus", 1076], ["in", 1083], ["C\u00f3rdoba", 1086], ["hospitals", 1094], ["increased", 1104], ["from", 1114], ["25", 1119], ["%", 1121], ["to", 1123], ["49", 1126], ["%", 1128], [",", 1129], ["P<0.01", 1131], [".", 1137], ["Total", 1139], ["CA", 1145], ["-", 1147], ["MRSA", 1148], ["infections", 1153], ["increased", 1164], ["3.6", 1174], ["fold-(5.1", 1178], ["to", 1188], ["18.6", 1191], ["cases/100,000", 1196], ["annual", 1210], ["-", 1216], ["visits", 1217], [",", 1223], ["P<0.0001", 1225], [")", 1233], [",", 1234], ["associated", 1236], ["with", 1247], ["an", 1252], ["important", 1255], ["increase", 1265], ["of", 1274], ["invasive", 1277], ["CA", 1286], ["-", 1288], ["MRSA", 1289], ["infections-(8.5", 1294], ["fold", 1310], [")", 1314], [".", 1315], ["In", 1317], ["all", 1320], ["regions", 1324], ["analyzed", 1332], [",", 1340], ["a", 1342], ["single", 1344], ["genotype", 1351], ["prevailed", 1360], ["in", 1370], ["both", 1373], ["CA", 1378], ["-", 1380], ["MRSA", 1381], ["(", 1386], ["82", 1387], ["%", 1389], [")", 1390], ["and", 1392], ["HACO", 1396], ["-", 1400], ["MRSA(57", 1401], ["%", 1408], [")", 1409], [",", 1410], ["which", 1412], ["showed", 1418], ["pulsed", 1425], ["-", 1431], ["field", 1432], ["-", 1437], ["gel", 1438], ["electrophoresis-(PFGE)-type-\"I", 1442], ["\"", 1472], [",", 1473], ["sequence", 1475], ["-", 1483], ["type-5-(ST5", 1484], [")", 1495], [",", 1496], ["SCCmec", 1498], ["-", 1504], ["type", 1505], ["-", 1509], ["IVa", 1510], [",", 1513], ["spa", 1515], ["-", 1518], ["t311", 1519], [",", 1523], ["and", 1525], ["was", 1529], ["positive", 1533], ["for", 1542], ["PVL", 1546], [".", 1549], ["The", 1551], ["second", 1555], ["clone", 1562], [",", 1567], ["pulsotype", 1569], ["-", 1578], ["N", 1579], ["/", 1580], ["ST30/CC30/SCCmecIVc", 1581], ["/", 1600], ["t019/PVL(+", 1601], [")", 1611], [",", 1612], ["accounted", 1614], ["for", 1624], ["11.5", 1628], ["%", 1632], ["of", 1634], ["total", 1637], ["CA", 1643], ["-", 1645], ["MRSA", 1646], ["infections", 1651], [".", 1661], ["Importantly", 1663], [",", 1674], ["the", 1676], ["first", 1680], ["4", 1686], ["isolates", 1688], ["of", 1697], ["Argentina", 1700], ["belonging", 1710], ["to", 1720], ["South", 1723], ["American", 1729], ["-", 1737], ["USA300", 1738], ["clone-(USA300/ST8/CC8/SCCmecIVc", 1745], ["/", 1776], ["t008/PVL(+)/ACME(-", 1777], [")", 1795], [")", 1796], ["were", 1798], ["detected", 1803], [".", 1811], ["We", 1813], ["also", 1816], ["demonstrated", 1821], ["that", 1834], ["a", 1839], ["HA", 1841], ["-", 1843], ["MRSA", 1844], ["clone-(pulsotype", 1849], ["-", 1865], ["C", 1866], ["/", 1867], ["ST100/CC5", 1868], [")", 1877], ["caused", 1879], ["2", 1886], ["%", 1887], ["and", 1889], ["10", 1893], ["%", 1895], ["of", 1897], ["CA", 1900], ["-", 1902], ["MRSA", 1903], ["and", 1908], ["HACO", 1912], ["-", 1916], ["MRSA", 1917], ["infections", 1922], ["respectively", 1933], ["and", 1946], ["was", 1950], ["associated", 1954], ["with", 1965], ["a", 1970], ["SCCmec", 1972], ["type", 1979], ["closely", 1984], ["related", 1992], ["to", 2000], ["SCCmecIV(2B&5", 2003], [")", 2016], [".", 2017], ["The", 2019], ["dissemination", 2023], ["of", 2037], ["epidemic", 2040], ["MRSA", 2049], ["clone", 2054], [",", 2059], ["ST5-IV", 2061], ["-", 2067], ["PVL(+", 2068], [")", 2073], ["was", 2075], ["the", 2079], ["main", 2083], ["cause", 2088], ["of", 2094], ["increasing", 2097], ["staphylococcal", 2108], ["community", 2123], ["-", 2132], ["onset", 2133], ["infections", 2139], ["in", 2150], ["Argentinean", 2153], ["children", 2165], ["(", 2174], ["2003", 2175], ["-", 2179], ["2008", 2180], [")", 2184], [",", 2185], ["conversely", 2187], ["to", 2198], ["other", 2201], ["countries", 2207], [".", 2216], ["The", 2218], ["predominance", 2222], ["of", 2235], ["this", 2238], ["clone", 2243], [",", 2248], ["which", 2250], ["has", 2256], ["capacity", 2260], ["to", 2269], ["express", 2272], ["the", 2280], ["h", 2284], ["-", 2285], ["VISA", 2286], ["phenotype", 2291], [",", 2300], ["in", 2302], ["healthcare", 2305], ["-", 2315], ["associated", 2316], ["community", 2327], ["-", 2336], ["onset", 2337], ["cases", 2343], ["suggests", 2349], ["that", 2358], ["it", 2363], ["has", 2366], ["infiltrated", 2370], ["into", 2382], ["hospital", 2387], ["-", 2395], ["settings", 2396], [".", 2404]]}
{"context": "A 50-year-old man presented with worsening, virtually lifelong, chorea and progressive behavioural disturbance, involving disinhibition and hoarding, over 10 years. Clinical assessment revealed chorea, dysarthria, areflexia, an inappropriately jovial, impulsive manner and neuropsychological evidence of frontosubcortical dysfunction. Investigation results included an elevated creatine kinase, caudate atrophy and hypoperfusion, acanthocytes in the peripheral blood and the McLeod phenotype. DNA studies demonstrated a single-base deletion at position 172 in exon 1 of the XK gene, giving rise to a premature stop codon at position 129 in exon 2.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c44de3a52803425c8e515bdb5fb039ac", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[88, 88]], "char_spans": [[574, 575]]}]}], "context_tokens": [["A", 0], ["50-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["worsening", 33], [",", 42], ["virtually", 44], ["lifelong", 54], [",", 62], ["chorea", 64], ["and", 71], ["progressive", 75], ["behavioural", 87], ["disturbance", 99], [",", 110], ["involving", 112], ["disinhibition", 122], ["and", 136], ["hoarding", 140], [",", 148], ["over", 150], ["10", 155], ["years", 158], [".", 163], ["Clinical", 165], ["assessment", 174], ["revealed", 185], ["chorea", 194], [",", 200], ["dysarthria", 202], [",", 212], ["areflexia", 214], [",", 223], ["an", 225], ["inappropriately", 228], ["jovial", 244], [",", 250], ["impulsive", 252], ["manner", 262], ["and", 269], ["neuropsychological", 273], ["evidence", 292], ["of", 301], ["frontosubcortical", 304], ["dysfunction", 322], [".", 333], ["Investigation", 335], ["results", 349], ["included", 357], ["an", 366], ["elevated", 369], ["creatine", 378], ["kinase", 387], [",", 393], ["caudate", 395], ["atrophy", 403], ["and", 411], ["hypoperfusion", 415], [",", 428], ["acanthocytes", 430], ["in", 443], ["the", 446], ["peripheral", 450], ["blood", 461], ["and", 467], ["the", 471], ["McLeod", 475], ["phenotype", 482], [".", 491], ["DNA", 493], ["studies", 497], ["demonstrated", 505], ["a", 518], ["single", 520], ["-", 526], ["base", 527], ["deletion", 532], ["at", 541], ["position", 544], ["172", 553], ["in", 557], ["exon", 560], ["1", 565], ["of", 567], ["the", 570], ["XK", 574], ["gene", 577], [",", 581], ["giving", 583], ["rise", 590], ["to", 595], ["a", 598], ["premature", 600], ["stop", 610], ["codon", 615], ["at", 621], ["position", 624], ["129", 633], ["in", 637], ["exon", 640], ["2", 645], [".", 646]]}
{"context": "Ubiquilin proteins facilitate delivery of ubiquitinated proteins to the proteasome for degradation. Interest in the proteins has been heightened by the discovery that gene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS). However, the mechanisms by which the mutations cause ALS are not known. Here we report on the underlying defect of ubiquilin-2 proteins containing ALS-linked mutations in affecting proteasome-mediated degradation. We found that overexpression of ubiquilin-2 proteins containing any one of five different ALS mutations slow degradation of Myc, a prototypic proteasome substrate. Examination of coprecipitating proteins indicated that the mutant proteins are generally capable of binding polyubiquitinated proteins, but defective in binding the proteasome. GST-pulldown studies revealed that many of the mutants bind weaker to the S5a subunit of the proteasome, compared with wild type (WT) ubiquilin-2 protein. The results suggest the mutant proteins are unable to deliver their captured cargo to the proteasome for degradation, which presumably leads to toxicity. Quantification of cell death is consistent with this idea. Measurement of protein turnover further indicated the mutant proteins have longer half-lives than WT ubiquilin-2. Our studies provide novel insight into the mechanism by which ALS-linked mutations in UBQLN2 interfere with protein degradation.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "512ddca4bf4d4b0b858b5f2fc87b8f28", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[48, 48], [64, 64], [36, 36], [217, 217], [88, 88]], "char_spans": [[312, 314], [406, 408], [253, 255], [1358, 1360], [563, 565]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[32, 34]], "char_spans": [[222, 250]]}]}], "context_tokens": [["Ubiquilin", 0], ["proteins", 10], ["facilitate", 19], ["delivery", 30], ["of", 39], ["ubiquitinated", 42], ["proteins", 56], ["to", 65], ["the", 68], ["proteasome", 72], ["for", 83], ["degradation", 87], [".", 98], ["Interest", 100], ["in", 109], ["the", 112], ["proteins", 116], ["has", 125], ["been", 129], ["heightened", 134], ["by", 145], ["the", 148], ["discovery", 152], ["that", 162], ["gene", 167], ["mutations", 172], ["in", 182], ["UBQLN2", 185], ["cause", 192], ["dominant", 198], ["inheritance", 207], ["of", 219], ["amyotrophic", 222], ["lateral", 234], ["sclerosis", 242], ["(", 252], ["ALS", 253], [")", 256], [".", 257], ["However", 259], [",", 266], ["the", 268], ["mechanisms", 272], ["by", 283], ["which", 286], ["the", 292], ["mutations", 296], ["cause", 306], ["ALS", 312], ["are", 316], ["not", 320], ["known", 324], [".", 329], ["Here", 331], ["we", 336], ["report", 339], ["on", 346], ["the", 349], ["underlying", 353], ["defect", 364], ["of", 371], ["ubiquilin-2", 374], ["proteins", 386], ["containing", 395], ["ALS", 406], ["-", 409], ["linked", 410], ["mutations", 417], ["in", 427], ["affecting", 430], ["proteasome", 440], ["-", 450], ["mediated", 451], ["degradation", 460], [".", 471], ["We", 473], ["found", 476], ["that", 482], ["overexpression", 487], ["of", 502], ["ubiquilin-2", 505], ["proteins", 517], ["containing", 526], ["any", 537], ["one", 541], ["of", 545], ["five", 548], ["different", 553], ["ALS", 563], ["mutations", 567], ["slow", 577], ["degradation", 582], ["of", 594], ["Myc", 597], [",", 600], ["a", 602], ["prototypic", 604], ["proteasome", 615], ["substrate", 626], [".", 635], ["Examination", 637], ["of", 649], ["coprecipitating", 652], ["proteins", 668], ["indicated", 677], ["that", 687], ["the", 692], ["mutant", 696], ["proteins", 703], ["are", 712], ["generally", 716], ["capable", 726], ["of", 734], ["binding", 737], ["polyubiquitinated", 745], ["proteins", 763], [",", 771], ["but", 773], ["defective", 777], ["in", 787], ["binding", 790], ["the", 798], ["proteasome", 802], [".", 812], ["GST", 814], ["-", 817], ["pulldown", 818], ["studies", 827], ["revealed", 835], ["that", 844], ["many", 849], ["of", 854], ["the", 857], ["mutants", 861], ["bind", 869], ["weaker", 874], ["to", 881], ["the", 884], ["S5a", 888], ["subunit", 892], ["of", 900], ["the", 903], ["proteasome", 907], [",", 917], ["compared", 919], ["with", 928], ["wild", 933], ["type", 938], ["(", 943], ["WT", 944], [")", 946], ["ubiquilin-2", 948], ["protein", 960], [".", 967], ["The", 969], ["results", 973], ["suggest", 981], ["the", 989], ["mutant", 993], ["proteins", 1000], ["are", 1009], ["unable", 1013], ["to", 1020], ["deliver", 1023], ["their", 1031], ["captured", 1037], ["cargo", 1046], ["to", 1052], ["the", 1055], ["proteasome", 1059], ["for", 1070], ["degradation", 1074], [",", 1085], ["which", 1087], ["presumably", 1093], ["leads", 1104], ["to", 1110], ["toxicity", 1113], [".", 1121], ["Quantification", 1123], ["of", 1138], ["cell", 1141], ["death", 1146], ["is", 1152], ["consistent", 1155], ["with", 1166], ["this", 1171], ["idea", 1176], [".", 1180], ["Measurement", 1182], ["of", 1194], ["protein", 1197], ["turnover", 1205], ["further", 1214], ["indicated", 1222], ["the", 1232], ["mutant", 1236], ["proteins", 1243], ["have", 1252], ["longer", 1257], ["half", 1264], ["-", 1268], ["lives", 1269], ["than", 1275], ["WT", 1280], ["ubiquilin-2", 1283], [".", 1294], ["Our", 1296], ["studies", 1300], ["provide", 1308], ["novel", 1316], ["insight", 1322], ["into", 1330], ["the", 1335], ["mechanism", 1339], ["by", 1349], ["which", 1352], ["ALS", 1358], ["-", 1361], ["linked", 1362], ["mutations", 1369], ["in", 1379], ["UBQLN2", 1382], ["interfere", 1389], ["with", 1399], ["protein", 1404], ["degradation", 1412], [".", 1423]]}
{"context": "The two major virulence factors of Bacillus anthracis are the tripartite toxin and the polyglutamate capsule, which are encoded by genes on the large plasmids, pXO1 and pXO2, respectively. The genes atxA, located on pXO1, and acpA, located on pXO2, encode positive trans-acting proteins that are involved in bicarbonate-mediated regulation of toxin and capsule production, respectively. A derivative strain cured of pXO1 produced less capsular substance than the parent strain harbouring both pXO1 and pXO2, and electroporation of the strain cured of pXO1 with a plasmid containing the cloned atxA gene resulted in an increased level of capsule production. An acpA-null mutant was complemented by not only acpA but also the atxA gene. The cap region, which is essential for encapsulation, contains three genes capB, capC, and capA, arranged in that order. The atxA gene stimulated capsule synthesis from the cloned cap region. Transcriptional analysis of cap by RNA slot-blot hybridization and primer-extension analysis revealed that atxA activated expression of cap in trans at the transcriptional level. These results indicate that cross-talk occurs, in which the pXO1-located gene, atxA, activates transcription of the cap region genes located on pXO2. We identified two major apparent transcriptional start sites, designated P1 and P2, located at positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1 site. These results suggest that cross-talk by atxA to the genes encoding capsule synthesis is caused by the interaction of the atxA gene product with a regulatory sequence upstream of cap.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "cf65aa1d62524b4690d8d12f1565be18", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[281, 281], [58, 58]], "char_spans": [[1568, 1578], [308, 318]]}]}], "context_tokens": [["The", 0], ["two", 4], ["major", 8], ["virulence", 14], ["factors", 24], ["of", 32], ["Bacillus", 35], ["anthracis", 44], ["are", 54], ["the", 58], ["tripartite", 62], ["toxin", 73], ["and", 79], ["the", 83], ["polyglutamate", 87], ["capsule", 101], [",", 108], ["which", 110], ["are", 116], ["encoded", 120], ["by", 128], ["genes", 131], ["on", 137], ["the", 140], ["large", 144], ["plasmids", 150], [",", 158], ["pXO1", 160], ["and", 165], ["pXO2", 169], [",", 173], ["respectively", 175], [".", 187], ["The", 189], ["genes", 193], ["atxA", 199], [",", 203], ["located", 205], ["on", 213], ["pXO1", 216], [",", 220], ["and", 222], ["acpA", 226], [",", 230], ["located", 232], ["on", 240], ["pXO2", 243], [",", 247], ["encode", 249], ["positive", 256], ["trans", 265], ["-", 270], ["acting", 271], ["proteins", 278], ["that", 287], ["are", 292], ["involved", 296], ["in", 305], ["bicarbonate", 308], ["-", 319], ["mediated", 320], ["regulation", 329], ["of", 340], ["toxin", 343], ["and", 349], ["capsule", 353], ["production", 361], [",", 371], ["respectively", 373], [".", 385], ["A", 387], ["derivative", 389], ["strain", 400], ["cured", 407], ["of", 413], ["pXO1", 416], ["produced", 421], ["less", 430], ["capsular", 435], ["substance", 444], ["than", 454], ["the", 459], ["parent", 463], ["strain", 470], ["harbouring", 477], ["both", 488], ["pXO1", 493], ["and", 498], ["pXO2", 502], [",", 506], ["and", 508], ["electroporation", 512], ["of", 528], ["the", 531], ["strain", 535], ["cured", 542], ["of", 548], ["pXO1", 551], ["with", 556], ["a", 561], ["plasmid", 563], ["containing", 571], ["the", 582], ["cloned", 586], ["atxA", 593], ["gene", 598], ["resulted", 603], ["in", 612], ["an", 615], ["increased", 618], ["level", 628], ["of", 634], ["capsule", 637], ["production", 645], [".", 655], ["An", 657], ["acpA", 660], ["-", 664], ["null", 665], ["mutant", 670], ["was", 677], ["complemented", 681], ["by", 694], ["not", 697], ["only", 701], ["acpA", 706], ["but", 711], ["also", 715], ["the", 720], ["atxA", 724], ["gene", 729], [".", 733], ["The", 735], ["cap", 739], ["region", 743], [",", 749], ["which", 751], ["is", 757], ["essential", 760], ["for", 770], ["encapsulation", 774], [",", 787], ["contains", 789], ["three", 798], ["genes", 804], ["capB", 810], [",", 814], ["capC", 816], [",", 820], ["and", 822], ["capA", 826], [",", 830], ["arranged", 832], ["in", 841], ["that", 844], ["order", 849], [".", 854], ["The", 856], ["atxA", 860], ["gene", 865], ["stimulated", 870], ["capsule", 881], ["synthesis", 889], ["from", 899], ["the", 904], ["cloned", 908], ["cap", 915], ["region", 919], [".", 925], ["Transcriptional", 927], ["analysis", 943], ["of", 952], ["cap", 955], ["by", 959], ["RNA", 962], ["slot", 966], ["-", 970], ["blot", 971], ["hybridization", 976], ["and", 990], ["primer", 994], ["-", 1000], ["extension", 1001], ["analysis", 1011], ["revealed", 1020], ["that", 1029], ["atxA", 1034], ["activated", 1039], ["expression", 1049], ["of", 1060], ["cap", 1063], ["in", 1067], ["trans", 1070], ["at", 1076], ["the", 1079], ["transcriptional", 1083], ["level", 1099], [".", 1104], ["These", 1106], ["results", 1112], ["indicate", 1120], ["that", 1129], ["cross", 1134], ["-", 1139], ["talk", 1140], ["occurs", 1145], [",", 1151], ["in", 1153], ["which", 1156], ["the", 1162], ["pXO1-located", 1166], ["gene", 1179], [",", 1183], ["atxA", 1185], [",", 1189], ["activates", 1191], ["transcription", 1201], ["of", 1215], ["the", 1218], ["cap", 1222], ["region", 1226], ["genes", 1233], ["located", 1239], ["on", 1247], ["pXO2", 1250], [".", 1254], ["We", 1256], ["identified", 1259], ["two", 1270], ["major", 1274], ["apparent", 1280], ["transcriptional", 1289], ["start", 1305], ["sites", 1311], [",", 1316], ["designated", 1318], ["P1", 1329], ["and", 1332], ["P2", 1336], [",", 1338], ["located", 1340], ["at", 1348], ["positions", 1351], ["731", 1361], ["bp", 1365], ["and", 1368], ["625", 1372], ["bp", 1376], [",", 1378], ["respectively", 1380], [",", 1392], ["upstream", 1394], ["of", 1403], ["the", 1406], ["translation", 1410], ["-", 1421], ["initiation", 1422], ["codon", 1433], ["of", 1439], ["capB.", 1442], ["Transcription", 1448], ["initiated", 1462], ["from", 1472], ["P1", 1477], ["and", 1480], ["P2", 1484], ["was", 1487], ["activated", 1491], ["by", 1501], ["both", 1504], ["atxA", 1509], ["and", 1514], ["acpA", 1518], [",", 1522], ["and", 1524], ["activation", 1528], ["appeared", 1539], ["to", 1548], ["be", 1551], ["stimulated", 1554], ["by", 1565], ["bicarbonate", 1568], [".", 1579], ["Deletion", 1581], ["analysis", 1590], ["of", 1599], ["the", 1602], ["upstream", 1606], ["region", 1615], ["of", 1622], ["the", 1625], ["cap", 1629], ["promoter", 1633], ["revealed", 1642], ["that", 1651], ["activation", 1656], ["by", 1667], ["both", 1670], ["atxA", 1675], ["and", 1680], ["acpA", 1684], ["required", 1689], ["a", 1698], ["DNA", 1700], ["segment", 1704], ["of", 1712], ["70", 1715], ["bp", 1718], ["extending", 1721], ["upstream", 1731], ["of", 1740], ["the", 1743], ["P1", 1747], ["site", 1750], [".", 1754], ["These", 1756], ["results", 1762], ["suggest", 1770], ["that", 1778], ["cross", 1783], ["-", 1788], ["talk", 1789], ["by", 1794], ["atxA", 1797], ["to", 1802], ["the", 1805], ["genes", 1809], ["encoding", 1815], ["capsule", 1824], ["synthesis", 1832], ["is", 1842], ["caused", 1845], ["by", 1852], ["the", 1855], ["interaction", 1859], ["of", 1871], ["the", 1874], ["atxA", 1878], ["gene", 1883], ["product", 1888], ["with", 1896], ["a", 1901], ["regulatory", 1903], ["sequence", 1914], ["upstream", 1923], ["of", 1932], ["cap", 1935], [".", 1938]]}
{"context": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma. Prevalence rates of PTSD and subthreshold PTSD with impairment were 2.2 and 4.1%, respectively. In this general population sample, 438 subjects endorsed at least one trauma, and four groups were generated: A) threshold PTSD (n = 13), B) subthreshold PTSD with impairment (n = 26), C) subthreshold PTSD without impairment (n = 78), and D) no PTSD (n = 321). Mean (SD) DTS score in the entire population was 11.0 +/- 18.1. Differences were found in four of the five pairwise between-group contrasts. In a second sample of 447 clinical trial participants from three SSRI vs. placebo studies, we assessed treatment effect size according to different measures. In all three clinical trials, effect size with the DTS was equal to, or better than, those found for the Impact of Event Scale (IES), Clinician Administered PTSD Scale (CAPS), and Structured Interview for PTSD (SIP). These results further affirm the utility of the DTS as a self-rating measure of PTSD symptom severity and in evaluating treatment response.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "73a1af5a2b084b75a3a2d56d9cdceaf4", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[26, 30]], "char_spans": [[141, 170]]}, {"text": "PTSD", "token_spans": [[32, 32], [91, 91], [101, 101], [54, 54], [253, 253], [57, 57], [222, 222], [232, 232], [126, 126], [113, 113]], "char_spans": [[173, 176], [491, 494], [522, 525], [292, 295], [1225, 1228], [314, 317], [1085, 1088], [1133, 1136], [613, 616], [569, 572]]}]}], "context_tokens": [["The", 0], ["Davidson", 4], ["Trauma", 13], ["Scale", 20], ["(", 26], ["DTS", 27], [")", 30], ["was", 32], ["developed", 36], ["as", 46], ["a", 49], ["self", 51], ["-", 55], ["rating", 56], ["for", 63], ["use", 67], ["in", 71], ["diagnosing", 74], ["and", 85], ["measuring", 89], ["symptom", 99], ["severity", 107], ["and", 116], ["treatment", 120], ["outcome", 130], ["in", 138], ["post", 141], ["-", 145], ["traumatic", 146], ["stress", 156], ["disorder", 163], ["(", 172], ["PTSD", 173], [")", 177], [";", 178], ["630", 180], ["subjects", 184], ["were", 193], ["identified", 198], ["by", 209], ["random", 212], ["digit", 219], ["dialing", 225], ["and", 233], ["evaluated", 237], ["for", 247], ["a", 251], ["history", 253], ["of", 261], ["trauma", 264], [".", 270], ["Prevalence", 272], ["rates", 283], ["of", 289], ["PTSD", 292], ["and", 297], ["subthreshold", 301], ["PTSD", 314], ["with", 319], ["impairment", 324], ["were", 335], ["2.2", 340], ["and", 344], ["4.1", 348], ["%", 351], [",", 352], ["respectively", 354], [".", 366], ["In", 368], ["this", 371], ["general", 376], ["population", 384], ["sample", 395], [",", 401], ["438", 403], ["subjects", 407], ["endorsed", 416], ["at", 425], ["least", 428], ["one", 434], ["trauma", 438], [",", 444], ["and", 446], ["four", 450], ["groups", 455], ["were", 462], ["generated", 467], [":", 476], ["A", 478], [")", 479], ["threshold", 481], ["PTSD", 491], ["(", 496], ["n", 497], ["=", 499], ["13", 501], [")", 503], [",", 504], ["B", 506], [")", 507], ["subthreshold", 509], ["PTSD", 522], ["with", 527], ["impairment", 532], ["(", 543], ["n", 544], ["=", 546], ["26", 548], [")", 550], [",", 551], ["C", 553], [")", 554], ["subthreshold", 556], ["PTSD", 569], ["without", 574], ["impairment", 582], ["(", 593], ["n", 594], ["=", 596], ["78", 598], [")", 600], [",", 601], ["and", 603], ["D", 607], [")", 608], ["no", 610], ["PTSD", 613], ["(", 618], ["n", 619], ["=", 621], ["321", 623], [")", 626], [".", 627], ["Mean", 629], ["(", 634], ["SD", 635], [")", 637], ["DTS", 639], ["score", 643], ["in", 649], ["the", 652], ["entire", 656], ["population", 663], ["was", 674], ["11.0", 678], ["+", 683], ["/-", 684], ["18.1", 687], [".", 691], ["Differences", 693], ["were", 705], ["found", 710], ["in", 716], ["four", 719], ["of", 724], ["the", 727], ["five", 731], ["pairwise", 736], ["between", 745], ["-", 752], ["group", 753], ["contrasts", 759], [".", 768], ["In", 770], ["a", 773], ["second", 775], ["sample", 782], ["of", 789], ["447", 792], ["clinical", 796], ["trial", 805], ["participants", 811], ["from", 824], ["three", 829], ["SSRI", 835], ["vs.", 840], ["placebo", 844], ["studies", 852], [",", 859], ["we", 861], ["assessed", 864], ["treatment", 873], ["effect", 883], ["size", 890], ["according", 895], ["to", 905], ["different", 908], ["measures", 918], [".", 926], ["In", 928], ["all", 931], ["three", 935], ["clinical", 941], ["trials", 950], [",", 956], ["effect", 958], ["size", 965], ["with", 970], ["the", 975], ["DTS", 979], ["was", 983], ["equal", 987], ["to", 993], [",", 995], ["or", 997], ["better", 1000], ["than", 1007], [",", 1011], ["those", 1013], ["found", 1019], ["for", 1025], ["the", 1029], ["Impact", 1033], ["of", 1040], ["Event", 1043], ["Scale", 1049], ["(", 1055], ["IES", 1056], [")", 1059], [",", 1060], ["Clinician", 1062], ["Administered", 1072], ["PTSD", 1085], ["Scale", 1090], ["(", 1096], ["CAPS", 1097], [")", 1101], [",", 1102], ["and", 1104], ["Structured", 1108], ["Interview", 1119], ["for", 1129], ["PTSD", 1133], ["(", 1138], ["SIP", 1139], [")", 1142], [".", 1143], ["These", 1145], ["results", 1151], ["further", 1159], ["affirm", 1167], ["the", 1174], ["utility", 1178], ["of", 1186], ["the", 1189], ["DTS", 1193], ["as", 1197], ["a", 1200], ["self", 1202], ["-", 1206], ["rating", 1207], ["measure", 1214], ["of", 1222], ["PTSD", 1225], ["symptom", 1230], ["severity", 1238], ["and", 1247], ["in", 1251], ["evaluating", 1254], ["treatment", 1265], ["response", 1275], [".", 1283]]}
{"context": "The objective of this guideline is to assist poison center personnel in the appropriate out-of-hospital triage and initial out-of-hospital management of patients with a suspected ingestion of dextromethorphan by 1) describing the process by which an ingestion of dextromethorphan might be managed, 2) identifying the key decision elements in managing cases of dextromethorphan ingestion, 3) providing clear and practical recommendations that reflect the current state of knowledge, and 4) identifying needs for research. This guideline applies to the ingestion of dextromethorphan alone. Co-ingestion of additional substances could require different referral and management recommendations depending on the combined toxicities of the substances. This guideline is based on an assessment of current scientific and clinical information. The expert consensus panel recognizes that specific patient care decisions might be at variance with this guideline and are the prerogative of the patient and the health professionals providing care, considering all of the circumstances involved. This guideline does not substitute for clinical judgment. The grade of recommendation is in parentheses. 1) All patients with suicidal intent, intentional abuse, or in cases in which a malicious intent is suspected (e.g., child abuse or neglect) should be referred to an emergency department (Grade D). 2) Patients who exhibit more than mild effects (e.g., infrequent vomiting or somnolence [lightly sedated and arousable with speaking voice or light touch]) after an acute dextromethorphan ingestion should be referred to an emergency department (Grade C). 3) Patients who have ingested 5-7.5 mg/kg should receive poison center-initiated follow-up approximately every 2 hours for up to 4 hours after ingestion. Refer to an emergency department if more than mild symptoms develop (Grade D). 4) Patients who have ingested more than 7.5 mg/kg should be referred to an emergency department for evaluation (Grade C). 5) If the patient is taking other medications likely to interact with dextromethorphan and cause serotonin syndrome, such as monoamine oxidase inhibitors or selective serotonin reuptake inhibitors, poison center-initiated follow-up every 2 hours for 8 hours is recommended (Grade D). 6) Patients who are asymptomatic and more than 4 hours have elapsed since the time of ingestion can be observed at home (Grade C). 7) Do not induce emesis (Grade D). 8) Do not use activated charcoal at home. Activated charcoal can be administered to asymptomatic patients who have ingested overdoses of dextromethorphan within the preceding hour. Its administration, if available, should only be carried out by health professionals and only if no contraindications are present. Do not delay transportation in order to administer activated charcoal (Grade D). 9) For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in the usual doses for treatment of opioid overdose, can be considered for prehospital administration, particularly if the patient has respiratory depression (Grade C). 10) Use intravenous benzodiazepines for seizures and benzodiazepines and external cooling measures for hyperthermia (>104 degrees F, >40 degrees C) for serotonin syndrome. This should be done in consultation with and authorized by EMS medical direction, by a written treatment protocol or policy, or with direct medical oversight (Grade C). 11) Carefully ascertain by history whether other drugs, such as acetaminophen, were involved in the incident and assess the risk for toxicity or for a drug interaction.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "bb05ffd715264fdf8fc2a8c7edaf0d04", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[520, 520]], "char_spans": [[2918, 2925]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["of", 14], ["this", 17], ["guideline", 22], ["is", 32], ["to", 35], ["assist", 38], ["poison", 45], ["center", 52], ["personnel", 59], ["in", 69], ["the", 72], ["appropriate", 76], ["out", 88], ["-", 91], ["of", 92], ["-", 94], ["hospital", 95], ["triage", 104], ["and", 111], ["initial", 115], ["out", 123], ["-", 126], ["of", 127], ["-", 129], ["hospital", 130], ["management", 139], ["of", 150], ["patients", 153], ["with", 162], ["a", 167], ["suspected", 169], ["ingestion", 179], ["of", 189], ["dextromethorphan", 192], ["by", 209], ["1", 212], [")", 213], ["describing", 215], ["the", 226], ["process", 230], ["by", 238], ["which", 241], ["an", 247], ["ingestion", 250], ["of", 260], ["dextromethorphan", 263], ["might", 280], ["be", 286], ["managed", 289], [",", 296], ["2", 298], [")", 299], ["identifying", 301], ["the", 313], ["key", 317], ["decision", 321], ["elements", 330], ["in", 339], ["managing", 342], ["cases", 351], ["of", 357], ["dextromethorphan", 360], ["ingestion", 377], [",", 386], ["3", 388], [")", 389], ["providing", 391], ["clear", 401], ["and", 407], ["practical", 411], ["recommendations", 421], ["that", 437], ["reflect", 442], ["the", 450], ["current", 454], ["state", 462], ["of", 468], ["knowledge", 471], [",", 480], ["and", 482], ["4", 486], [")", 487], ["identifying", 489], ["needs", 501], ["for", 507], ["research", 511], [".", 519], ["This", 521], ["guideline", 526], ["applies", 536], ["to", 544], ["the", 547], ["ingestion", 551], ["of", 561], ["dextromethorphan", 564], ["alone", 581], [".", 586], ["Co", 588], ["-", 590], ["ingestion", 591], ["of", 601], ["additional", 604], ["substances", 615], ["could", 626], ["require", 632], ["different", 640], ["referral", 650], ["and", 659], ["management", 663], ["recommendations", 674], ["depending", 690], ["on", 700], ["the", 703], ["combined", 707], ["toxicities", 716], ["of", 727], ["the", 730], ["substances", 734], [".", 744], ["This", 746], ["guideline", 751], ["is", 761], ["based", 764], ["on", 770], ["an", 773], ["assessment", 776], ["of", 787], ["current", 790], ["scientific", 798], ["and", 809], ["clinical", 813], ["information", 822], [".", 833], ["The", 835], ["expert", 839], ["consensus", 846], ["panel", 856], ["recognizes", 862], ["that", 873], ["specific", 878], ["patient", 887], ["care", 895], ["decisions", 900], ["might", 910], ["be", 916], ["at", 919], ["variance", 922], ["with", 931], ["this", 936], ["guideline", 941], ["and", 951], ["are", 955], ["the", 959], ["prerogative", 963], ["of", 975], ["the", 978], ["patient", 982], ["and", 990], ["the", 994], ["health", 998], ["professionals", 1005], ["providing", 1019], ["care", 1029], [",", 1033], ["considering", 1035], ["all", 1047], ["of", 1051], ["the", 1054], ["circumstances", 1058], ["involved", 1072], [".", 1080], ["This", 1082], ["guideline", 1087], ["does", 1097], ["not", 1102], ["substitute", 1106], ["for", 1117], ["clinical", 1121], ["judgment", 1130], [".", 1138], ["The", 1140], ["grade", 1144], ["of", 1150], ["recommendation", 1153], ["is", 1168], ["in", 1171], ["parentheses", 1174], [".", 1185], ["1", 1187], [")", 1188], ["All", 1190], ["patients", 1194], ["with", 1203], ["suicidal", 1208], ["intent", 1217], [",", 1223], ["intentional", 1225], ["abuse", 1237], [",", 1242], ["or", 1244], ["in", 1247], ["cases", 1250], ["in", 1256], ["which", 1259], ["a", 1265], ["malicious", 1267], ["intent", 1277], ["is", 1284], ["suspected", 1287], ["(", 1297], ["e.g.", 1298], [",", 1302], ["child", 1304], ["abuse", 1310], ["or", 1316], ["neglect", 1319], [")", 1326], ["should", 1328], ["be", 1335], ["referred", 1338], ["to", 1347], ["an", 1350], ["emergency", 1353], ["department", 1363], ["(", 1374], ["Grade", 1375], ["D", 1381], [")", 1382], [".", 1383], ["2", 1385], [")", 1386], ["Patients", 1388], ["who", 1397], ["exhibit", 1401], ["more", 1409], ["than", 1414], ["mild", 1419], ["effects", 1424], ["(", 1432], ["e.g.", 1433], [",", 1437], ["infrequent", 1439], ["vomiting", 1450], ["or", 1459], ["somnolence", 1462], ["[", 1473], ["lightly", 1474], ["sedated", 1482], ["and", 1490], ["arousable", 1494], ["with", 1504], ["speaking", 1509], ["voice", 1518], ["or", 1524], ["light", 1527], ["touch", 1533], ["]", 1538], [")", 1539], ["after", 1541], ["an", 1547], ["acute", 1550], ["dextromethorphan", 1556], ["ingestion", 1573], ["should", 1583], ["be", 1590], ["referred", 1593], ["to", 1602], ["an", 1605], ["emergency", 1608], ["department", 1618], ["(", 1629], ["Grade", 1630], ["C", 1636], [")", 1637], [".", 1638], ["3", 1640], [")", 1641], ["Patients", 1643], ["who", 1652], ["have", 1656], ["ingested", 1661], ["5", 1670], ["-", 1671], ["7.5", 1672], ["mg", 1676], ["/", 1678], ["kg", 1679], ["should", 1682], ["receive", 1689], ["poison", 1697], ["center", 1704], ["-", 1710], ["initiated", 1711], ["follow", 1721], ["-", 1727], ["up", 1728], ["approximately", 1731], ["every", 1745], ["2", 1751], ["hours", 1753], ["for", 1759], ["up", 1763], ["to", 1766], ["4", 1769], ["hours", 1771], ["after", 1777], ["ingestion", 1783], [".", 1792], ["Refer", 1794], ["to", 1800], ["an", 1803], ["emergency", 1806], ["department", 1816], ["if", 1827], ["more", 1830], ["than", 1835], ["mild", 1840], ["symptoms", 1845], ["develop", 1854], ["(", 1862], ["Grade", 1863], ["D", 1869], [")", 1870], [".", 1871], ["4", 1873], [")", 1874], ["Patients", 1876], ["who", 1885], ["have", 1889], ["ingested", 1894], ["more", 1903], ["than", 1908], ["7.5", 1913], ["mg", 1917], ["/", 1919], ["kg", 1920], ["should", 1923], ["be", 1930], ["referred", 1933], ["to", 1942], ["an", 1945], ["emergency", 1948], ["department", 1958], ["for", 1969], ["evaluation", 1973], ["(", 1984], ["Grade", 1985], ["C", 1991], [")", 1992], [".", 1993], ["5", 1995], [")", 1996], ["If", 1998], ["the", 2001], ["patient", 2005], ["is", 2013], ["taking", 2016], ["other", 2023], ["medications", 2029], ["likely", 2041], ["to", 2048], ["interact", 2051], ["with", 2060], ["dextromethorphan", 2065], ["and", 2082], ["cause", 2086], ["serotonin", 2092], ["syndrome", 2102], [",", 2110], ["such", 2112], ["as", 2117], ["monoamine", 2120], ["oxidase", 2130], ["inhibitors", 2138], ["or", 2149], ["selective", 2152], ["serotonin", 2162], ["reuptake", 2172], ["inhibitors", 2181], [",", 2191], ["poison", 2193], ["center", 2200], ["-", 2206], ["initiated", 2207], ["follow", 2217], ["-", 2223], ["up", 2224], ["every", 2227], ["2", 2233], ["hours", 2235], ["for", 2241], ["8", 2245], ["hours", 2247], ["is", 2253], ["recommended", 2256], ["(", 2268], ["Grade", 2269], ["D", 2275], [")", 2276], [".", 2277], ["6", 2279], [")", 2280], ["Patients", 2282], ["who", 2291], ["are", 2295], ["asymptomatic", 2299], ["and", 2312], ["more", 2316], ["than", 2321], ["4", 2326], ["hours", 2328], ["have", 2334], ["elapsed", 2339], ["since", 2347], ["the", 2353], ["time", 2357], ["of", 2362], ["ingestion", 2365], ["can", 2375], ["be", 2379], ["observed", 2382], ["at", 2391], ["home", 2394], ["(", 2399], ["Grade", 2400], ["C", 2406], [")", 2407], [".", 2408], ["7", 2410], [")", 2411], ["Do", 2413], ["not", 2416], ["induce", 2420], ["emesis", 2427], ["(", 2434], ["Grade", 2435], ["D", 2441], [")", 2442], [".", 2443], ["8)", 2445], ["Do", 2448], ["not", 2451], ["use", 2455], ["activated", 2459], ["charcoal", 2469], ["at", 2478], ["home", 2481], [".", 2485], ["Activated", 2487], ["charcoal", 2497], ["can", 2506], ["be", 2510], ["administered", 2513], ["to", 2526], ["asymptomatic", 2529], ["patients", 2542], ["who", 2551], ["have", 2555], ["ingested", 2560], ["overdoses", 2569], ["of", 2579], ["dextromethorphan", 2582], ["within", 2599], ["the", 2606], ["preceding", 2610], ["hour", 2620], [".", 2624], ["Its", 2626], ["administration", 2630], [",", 2644], ["if", 2646], ["available", 2649], [",", 2658], ["should", 2660], ["only", 2667], ["be", 2672], ["carried", 2675], ["out", 2683], ["by", 2687], ["health", 2690], ["professionals", 2697], ["and", 2711], ["only", 2715], ["if", 2720], ["no", 2723], ["contraindications", 2726], ["are", 2744], ["present", 2748], [".", 2755], ["Do", 2757], ["not", 2760], ["delay", 2764], ["transportation", 2770], ["in", 2785], ["order", 2788], ["to", 2794], ["administer", 2797], ["activated", 2808], ["charcoal", 2818], ["(", 2827], ["Grade", 2828], ["D", 2834], [")", 2835], [".", 2836], ["9", 2838], [")", 2839], ["For", 2841], ["patients", 2845], ["who", 2854], ["have", 2858], ["ingested", 2863], ["dextromethorphan", 2872], ["and", 2889], ["are", 2893], ["sedated", 2897], ["or", 2905], ["comatose", 2908], [",", 2916], ["naloxone", 2918], [",", 2926], ["in", 2928], ["the", 2931], ["usual", 2935], ["doses", 2941], ["for", 2947], ["treatment", 2951], ["of", 2961], ["opioid", 2964], ["overdose", 2971], [",", 2979], ["can", 2981], ["be", 2985], ["considered", 2988], ["for", 2999], ["prehospital", 3003], ["administration", 3015], [",", 3029], ["particularly", 3031], ["if", 3044], ["the", 3047], ["patient", 3051], ["has", 3059], ["respiratory", 3063], ["depression", 3075], ["(", 3086], ["Grade", 3087], ["C", 3093], [")", 3094], [".", 3095], ["10", 3097], [")", 3099], ["Use", 3101], ["intravenous", 3105], ["benzodiazepines", 3117], ["for", 3133], ["seizures", 3137], ["and", 3146], ["benzodiazepines", 3150], ["and", 3166], ["external", 3170], ["cooling", 3179], ["measures", 3187], ["for", 3196], ["hyperthermia", 3200], ["(", 3213], [">", 3214], ["104", 3215], ["degrees", 3219], ["F", 3227], [",", 3228], [">", 3230], ["40", 3231], ["degrees", 3234], ["C", 3242], [")", 3243], ["for", 3245], ["serotonin", 3249], ["syndrome", 3259], [".", 3267], ["This", 3269], ["should", 3274], ["be", 3281], ["done", 3284], ["in", 3289], ["consultation", 3292], ["with", 3305], ["and", 3310], ["authorized", 3314], ["by", 3325], ["EMS", 3328], ["medical", 3332], ["direction", 3340], [",", 3349], ["by", 3351], ["a", 3354], ["written", 3356], ["treatment", 3364], ["protocol", 3374], ["or", 3383], ["policy", 3386], [",", 3392], ["or", 3394], ["with", 3397], ["direct", 3402], ["medical", 3409], ["oversight", 3417], ["(", 3427], ["Grade", 3428], ["C", 3434], [")", 3435], [".", 3436], ["11", 3438], [")", 3440], ["Carefully", 3442], ["ascertain", 3452], ["by", 3462], ["history", 3465], ["whether", 3473], ["other", 3481], ["drugs", 3487], [",", 3492], ["such", 3494], ["as", 3499], ["acetaminophen", 3502], [",", 3515], ["were", 3517], ["involved", 3522], ["in", 3531], ["the", 3534], ["incident", 3538], ["and", 3547], ["assess", 3551], ["the", 3558], ["risk", 3562], ["for", 3567], ["toxicity", 3571], ["or", 3580], ["for", 3583], ["a", 3587], ["drug", 3589], ["interaction", 3594], [".", 3605]]}
{"context": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues. It is usually ascertained due to abnormal skin texture, scarring complications, vascular fragility, or chronic symptoms, such as fatigue and musculoskeletal pain. Sometimes, Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas. In this scenario, the misdiagnosis of Ehlers-Danlos syndrome with child abuse is a possibility, as occasionally reported in the literature. Recently, more attention was posed by lay people between the possible association of Ehlers-Danlos syndrome and bone fragility. Literature and personal experience show a strong association between Ehlers-Danlos syndrome, generalized joint hypermobility and reduced bone mass density in older children and adults, especially fertile women. The existence of a true increased risk of fracture in Ehlers-Danlos syndrome is still a matter of debate in children and adults with little and conflicting evidence. In case of suspected child abuse, Ehlers-Danlos syndrome is certainly on the differential for bruising, especially in EDS types with marked cutaneous and capillary involvement. In suspected child abuse cases, careful examination of the index case and her/his extended family is routine, as well as exclusion of other disorders such as osteogenesis imperfecta. The hypothesis of Ehlers-Danlos syndrome as an alternative explanation for infantile fractures remains speculative.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "ea17a6333c81457d803d594917b8f0b9", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[10, 11]], "char_spans": [[61, 77]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["heterogeneous", 28], ["group", 42], ["of", 48], ["heritable", 51], ["connective", 61], ["tissue", 72], ["disorders", 79], ["characterized", 89], ["by", 103], ["increased", 106], ["fragility", 116], ["of", 126], ["various", 129], ["non", 137], ["-", 140], ["ossified", 141], ["tissues", 150], [".", 157], ["It", 159], ["is", 162], ["usually", 165], ["ascertained", 173], ["due", 185], ["to", 189], ["abnormal", 192], ["skin", 201], ["texture", 206], [",", 213], ["scarring", 215], ["complications", 224], [",", 237], ["vascular", 239], ["fragility", 248], [",", 257], ["or", 259], ["chronic", 262], ["symptoms", 270], [",", 278], ["such", 280], ["as", 285], ["fatigue", 288], ["and", 296], ["musculoskeletal", 300], ["pain", 316], [".", 320], ["Sometimes", 322], [",", 331], ["Ehlers", 333], ["-", 339], ["Danlos", 340], ["syndrome", 347], ["remains", 356], ["undetected", 364], ["until", 375], ["the", 381], ["patient", 385], [",", 392], ["usually", 394], ["in", 402], ["the", 405], ["pediatric", 409], ["age", 419], [",", 422], ["shows", 424], ["extensive", 430], ["or", 440], ["severe", 443], ["mucocutaneous", 450], ["injuries", 464], ["after", 473], ["only", 479], ["minor", 484], ["traumas", 490], [".", 497], ["In", 499], ["this", 502], ["scenario", 507], [",", 515], ["the", 517], ["misdiagnosis", 521], ["of", 534], ["Ehlers", 537], ["-", 543], ["Danlos", 544], ["syndrome", 551], ["with", 560], ["child", 565], ["abuse", 571], ["is", 577], ["a", 580], ["possibility", 582], [",", 593], ["as", 595], ["occasionally", 598], ["reported", 611], ["in", 620], ["the", 623], ["literature", 627], [".", 637], ["Recently", 639], [",", 647], ["more", 649], ["attention", 654], ["was", 664], ["posed", 668], ["by", 674], ["lay", 677], ["people", 681], ["between", 688], ["the", 696], ["possible", 700], ["association", 709], ["of", 721], ["Ehlers", 724], ["-", 730], ["Danlos", 731], ["syndrome", 738], ["and", 747], ["bone", 751], ["fragility", 756], [".", 765], ["Literature", 767], ["and", 778], ["personal", 782], ["experience", 791], ["show", 802], ["a", 807], ["strong", 809], ["association", 816], ["between", 828], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], [",", 858], ["generalized", 860], ["joint", 872], ["hypermobility", 878], ["and", 892], ["reduced", 896], ["bone", 904], ["mass", 909], ["density", 914], ["in", 922], ["older", 925], ["children", 931], ["and", 940], ["adults", 944], [",", 950], ["especially", 952], ["fertile", 963], ["women", 971], [".", 976], ["The", 978], ["existence", 982], ["of", 992], ["a", 995], ["true", 997], ["increased", 1002], ["risk", 1012], ["of", 1017], ["fracture", 1020], ["in", 1029], ["Ehlers", 1032], ["-", 1038], ["Danlos", 1039], ["syndrome", 1046], ["is", 1055], ["still", 1058], ["a", 1064], ["matter", 1066], ["of", 1073], ["debate", 1076], ["in", 1083], ["children", 1086], ["and", 1095], ["adults", 1099], ["with", 1106], ["little", 1111], ["and", 1118], ["conflicting", 1122], ["evidence", 1134], [".", 1142], ["In", 1144], ["case", 1147], ["of", 1152], ["suspected", 1155], ["child", 1165], ["abuse", 1171], [",", 1176], ["Ehlers", 1178], ["-", 1184], ["Danlos", 1185], ["syndrome", 1192], ["is", 1201], ["certainly", 1204], ["on", 1214], ["the", 1217], ["differential", 1221], ["for", 1234], ["bruising", 1238], [",", 1246], ["especially", 1248], ["in", 1259], ["EDS", 1262], ["types", 1266], ["with", 1272], ["marked", 1277], ["cutaneous", 1284], ["and", 1294], ["capillary", 1298], ["involvement", 1308], [".", 1319], ["In", 1321], ["suspected", 1324], ["child", 1334], ["abuse", 1340], ["cases", 1346], [",", 1351], ["careful", 1353], ["examination", 1361], ["of", 1373], ["the", 1376], ["index", 1380], ["case", 1386], ["and", 1391], ["her", 1395], ["/", 1398], ["his", 1399], ["extended", 1403], ["family", 1412], ["is", 1419], ["routine", 1422], [",", 1429], ["as", 1431], ["well", 1434], ["as", 1439], ["exclusion", 1442], ["of", 1452], ["other", 1455], ["disorders", 1461], ["such", 1471], ["as", 1476], ["osteogenesis", 1479], ["imperfecta", 1492], [".", 1502], ["The", 1504], ["hypothesis", 1508], ["of", 1519], ["Ehlers", 1522], ["-", 1528], ["Danlos", 1529], ["syndrome", 1536], ["as", 1545], ["an", 1548], ["alternative", 1551], ["explanation", 1563], ["for", 1575], ["infantile", 1579], ["fractures", 1589], ["remains", 1599], ["speculative", 1607], [".", 1618]]}
{"context": "A 29-year-old man with a history of elevated creatine kinase and necrotizing myopathy was reviewed. Prominent red cell acanthocytosis in association with reduced Kell antigen expression was present, findings consistent with the McLeod syndrome. Investigation of the patient's XK gene revealed a novel TGG- to-TAG transition at position 1023 in exon 3. This point mutation creates an in-frame stop codon (W314X), and predicts a truncated XK protein of 313 amino acids, compared with 444 amino acids in the normal XK protein. The mutation was not identified in the patient's mother or sister indicating that this mutation was spontaneous.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "d82fcc5243f04463a79983358c686ff9", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[44, 44], [79, 79], [94, 94]], "char_spans": [[276, 277], [437, 438], [512, 513]]}]}], "context_tokens": [["A", 0], ["29-year", 2], ["-", 9], ["old", 10], ["man", 14], ["with", 18], ["a", 23], ["history", 25], ["of", 33], ["elevated", 36], ["creatine", 45], ["kinase", 54], ["and", 61], ["necrotizing", 65], ["myopathy", 77], ["was", 86], ["reviewed", 90], [".", 98], ["Prominent", 100], ["red", 110], ["cell", 114], ["acanthocytosis", 119], ["in", 134], ["association", 137], ["with", 149], ["reduced", 154], ["Kell", 162], ["antigen", 167], ["expression", 175], ["was", 186], ["present", 190], [",", 197], ["findings", 199], ["consistent", 208], ["with", 219], ["the", 224], ["McLeod", 228], ["syndrome", 235], [".", 243], ["Investigation", 245], ["of", 259], ["the", 262], ["patient", 266], ["'s", 273], ["XK", 276], ["gene", 279], ["revealed", 284], ["a", 293], ["novel", 295], ["TGG-", 301], ["to", 306], ["-", 308], ["TAG", 309], ["transition", 313], ["at", 324], ["position", 327], ["1023", 336], ["in", 341], ["exon", 344], ["3", 349], [".", 350], ["This", 352], ["point", 357], ["mutation", 363], ["creates", 372], ["an", 380], ["in", 383], ["-", 385], ["frame", 386], ["stop", 392], ["codon", 397], ["(", 403], ["W314X", 404], [")", 409], [",", 410], ["and", 412], ["predicts", 416], ["a", 425], ["truncated", 427], ["XK", 437], ["protein", 440], ["of", 448], ["313", 451], ["amino", 455], ["acids", 461], [",", 466], ["compared", 468], ["with", 477], ["444", 482], ["amino", 486], ["acids", 492], ["in", 498], ["the", 501], ["normal", 505], ["XK", 512], ["protein", 515], [".", 522], ["The", 524], ["mutation", 528], ["was", 537], ["not", 541], ["identified", 545], ["in", 556], ["the", 559], ["patient", 563], ["'s", 570], ["mother", 573], ["or", 580], ["sister", 583], ["indicating", 590], ["that", 601], ["this", 606], ["mutation", 611], ["was", 620], ["spontaneous", 624], [".", 635]]}
{"context": "Cap analysis of gene expression (CAGE) is a high-throughput method for transcriptome analysis that provides a single base-pair resolution map of transcription start sites (TSS) and their relative usage. Despite their high resolution and functional significance, published CAGE data are still underused in promoter analysis due to the absence of tools that enable its efficient manipulation and integration with other genome data types. Here we present CAGEr, an R implementation of novel methods for the analysis of differential TSS usage and promoter dynamics, integrated with CAGE data processing and promoterome mining into a first comprehensive CAGE toolbox on a common analysis platform. Crucially, we provide collections of TSSs derived from most published CAGE datasets, as well as direct access to FANTOM5 resource of TSSs for numerous human and mouse cell/tissue types from within R, greatly increasing the accessibility of precise context-specific TSS data for integrative analyses. The CAGEr package is freely available from Bioconductor at http://www.bioconductor.org/packages/release/bioc/html/CAGEr.html.", "qas": [{"question": "Which tool is used for promoterome mining using CAGE data?", "answers": ["CAGEr"], "qid": "510b9aa3109f4e7c94f4cee443af85d9", "question_tokens": [["Which", 0], ["tool", 6], ["is", 11], ["used", 14], ["for", 19], ["promoterome", 23], ["mining", 35], ["using", 42], ["CAGE", 48], ["data", 53], ["?", 57]], "detected_answers": [{"text": "CAGEr", "token_spans": [[169, 169], [77, 77]], "char_spans": [[997, 1001], [452, 456]]}]}], "context_tokens": [["Cap", 0], ["analysis", 4], ["of", 13], ["gene", 16], ["expression", 21], ["(", 32], ["CAGE", 33], [")", 37], ["is", 39], ["a", 42], ["high", 44], ["-", 48], ["throughput", 49], ["method", 60], ["for", 67], ["transcriptome", 71], ["analysis", 85], ["that", 94], ["provides", 99], ["a", 108], ["single", 110], ["base", 117], ["-", 121], ["pair", 122], ["resolution", 127], ["map", 138], ["of", 142], ["transcription", 145], ["start", 159], ["sites", 165], ["(", 171], ["TSS", 172], [")", 175], ["and", 177], ["their", 181], ["relative", 187], ["usage", 196], [".", 201], ["Despite", 203], ["their", 211], ["high", 217], ["resolution", 222], ["and", 233], ["functional", 237], ["significance", 248], [",", 260], ["published", 262], ["CAGE", 272], ["data", 277], ["are", 282], ["still", 286], ["underused", 292], ["in", 302], ["promoter", 305], ["analysis", 314], ["due", 323], ["to", 327], ["the", 330], ["absence", 334], ["of", 342], ["tools", 345], ["that", 351], ["enable", 356], ["its", 363], ["efficient", 367], ["manipulation", 377], ["and", 390], ["integration", 394], ["with", 406], ["other", 411], ["genome", 417], ["data", 424], ["types", 429], [".", 434], ["Here", 436], ["we", 441], ["present", 444], ["CAGEr", 452], [",", 457], ["an", 459], ["R", 462], ["implementation", 464], ["of", 479], ["novel", 482], ["methods", 488], ["for", 496], ["the", 500], ["analysis", 504], ["of", 513], ["differential", 516], ["TSS", 529], ["usage", 533], ["and", 539], ["promoter", 543], ["dynamics", 552], [",", 560], ["integrated", 562], ["with", 573], ["CAGE", 578], ["data", 583], ["processing", 588], ["and", 599], ["promoterome", 603], ["mining", 615], ["into", 622], ["a", 627], ["first", 629], ["comprehensive", 635], ["CAGE", 649], ["toolbox", 654], ["on", 662], ["a", 665], ["common", 667], ["analysis", 674], ["platform", 683], [".", 691], ["Crucially", 693], [",", 702], ["we", 704], ["provide", 707], ["collections", 715], ["of", 727], ["TSSs", 730], ["derived", 735], ["from", 743], ["most", 748], ["published", 753], ["CAGE", 763], ["datasets", 768], [",", 776], ["as", 778], ["well", 781], ["as", 786], ["direct", 789], ["access", 796], ["to", 803], ["FANTOM5", 806], ["resource", 814], ["of", 823], ["TSSs", 826], ["for", 831], ["numerous", 835], ["human", 844], ["and", 850], ["mouse", 854], ["cell", 860], ["/", 864], ["tissue", 865], ["types", 872], ["from", 878], ["within", 883], ["R", 890], [",", 891], ["greatly", 893], ["increasing", 901], ["the", 912], ["accessibility", 916], ["of", 930], ["precise", 933], ["context", 941], ["-", 948], ["specific", 949], ["TSS", 958], ["data", 962], ["for", 967], ["integrative", 971], ["analyses", 983], [".", 991], ["The", 993], ["CAGEr", 997], ["package", 1003], ["is", 1011], ["freely", 1014], ["available", 1021], ["from", 1031], ["Bioconductor", 1036], ["at", 1049], ["http://www.bioconductor.org/packages/release/bioc/html/CAGEr.html", 1052], [".", 1117]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA) in the clinical laboratory. Under disk diffusion testing conditions designed to maximize detection of MRSA (incubation at 32 degrees C, pre-induction with methicillin, or plating on 4% NaCl-supplemented agar), BORSA strains also tend to appear resistant to semisynthetic penicillins. Under these conditions, ampicillin/sulbactam appears to be more accurate than amoxicillin/clavulanic acid for differentiating BORSA from MRSA.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "a859d7dd48d14f7ba82f37892f524538", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["may", 61], ["be", 65], ["misidentified", 68], ["as", 82], ["intrinsically", 85], ["methicillin", 99], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["MRSA", 144], [")", 148], ["in", 150], ["the", 153], ["clinical", 157], ["laboratory", 166], [".", 176], ["Under", 178], ["disk", 184], ["diffusion", 189], ["testing", 199], ["conditions", 207], ["designed", 218], ["to", 227], ["maximize", 230], ["detection", 239], ["of", 249], ["MRSA", 252], ["(", 257], ["incubation", 258], ["at", 269], ["32", 272], ["degrees", 275], ["C", 283], [",", 284], ["pre", 286], ["-", 289], ["induction", 290], ["with", 300], ["methicillin", 305], [",", 316], ["or", 318], ["plating", 321], ["on", 329], ["4", 332], ["%", 333], ["NaCl", 335], ["-", 339], ["supplemented", 340], ["agar", 353], [")", 357], [",", 358], ["BORSA", 360], ["strains", 366], ["also", 374], ["tend", 379], ["to", 384], ["appear", 387], ["resistant", 394], ["to", 404], ["semisynthetic", 407], ["penicillins", 421], [".", 432], ["Under", 434], ["these", 440], ["conditions", 446], [",", 456], ["ampicillin", 458], ["/", 468], ["sulbactam", 469], ["appears", 479], ["to", 487], ["be", 490], ["more", 493], ["accurate", 498], ["than", 507], ["amoxicillin", 512], ["/", 523], ["clavulanic", 524], ["acid", 535], ["for", 540], ["differentiating", 544], ["BORSA", 560], ["from", 566], ["MRSA", 571], [".", 575]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "In 1957, Simpson published a seminal paper defining the risk factors for recurrence following surgical treatment of intracranial meningiomas. Given that Simpson's study was published more than 50 years ago, preceding image guidance technology and MR imaging, the authors reviewed their own experience with surgical treatment of Grade I meningiomas to determine if Simpson's grading scale is still relevant to modern neurosurgical practice. From this cohort, the authors evaluated all patients undergoing craniotomy for resection of a histologically proven WHO Grade I meningioma as their initial therapy. Clinical information was retrospectively reconstructed using patient medical records and radiological data. Recurrence analysis was performed using the Kaplan-Meier method. The 5-year recurrence/progression-free survival for all patients receiving a Simpson Grade I, II, III, or IV resection was 95, 85, 88, and 81%, respectively (p = not significant, log-rank test). Kaplan-Meier analysis revealed no significant difference in recurrence-free survival between patients receiving a Simpson Grade I, II, III, or IV resection. Analysis limited to meningiomas arising from the skull base (excluding the cavernous sinus) similarly found no significant benefit to Simpson Grade I or II resection, and the survival curves were nearly superimposed. In this study of a cohort of patients undergoing surgery for WHO Grade I meningiomas, the authors demonstrate that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with simply removing the entire tumor, or even leaving small amounts of tumor attached to critical structures. The authors believe that these data reflect an evolution in the nature of meningioma surgery over the past 2 decades, and bring into question the relevance of using Simpson's grading system as the sole predictor of recurrence.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "2ae2864e473745f697faa29712bfb28c", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[303, 303], [90, 90]], "char_spans": [[1761, 1770], [568, 577]]}]}], "context_tokens": [["In", 0], ["1957", 3], [",", 7], ["Simpson", 9], ["published", 17], ["a", 27], ["seminal", 29], ["paper", 37], ["defining", 43], ["the", 52], ["risk", 56], ["factors", 61], ["for", 69], ["recurrence", 73], ["following", 84], ["surgical", 94], ["treatment", 103], ["of", 113], ["intracranial", 116], ["meningiomas", 129], [".", 140], ["Given", 142], ["that", 148], ["Simpson", 153], ["'s", 160], ["study", 163], ["was", 169], ["published", 173], ["more", 183], ["than", 188], ["50", 193], ["years", 196], ["ago", 202], [",", 205], ["preceding", 207], ["image", 217], ["guidance", 223], ["technology", 232], ["and", 243], ["MR", 247], ["imaging", 250], [",", 257], ["the", 259], ["authors", 263], ["reviewed", 271], ["their", 280], ["own", 286], ["experience", 290], ["with", 301], ["surgical", 306], ["treatment", 315], ["of", 325], ["Grade", 328], ["I", 334], ["meningiomas", 336], ["to", 348], ["determine", 351], ["if", 361], ["Simpson", 364], ["'s", 371], ["grading", 374], ["scale", 382], ["is", 388], ["still", 391], ["relevant", 397], ["to", 406], ["modern", 409], ["neurosurgical", 416], ["practice", 430], [".", 438], ["From", 440], ["this", 445], ["cohort", 450], [",", 456], ["the", 458], ["authors", 462], ["evaluated", 470], ["all", 480], ["patients", 484], ["undergoing", 493], ["craniotomy", 504], ["for", 515], ["resection", 519], ["of", 529], ["a", 532], ["histologically", 534], ["proven", 549], ["WHO", 556], ["Grade", 560], ["I", 566], ["meningioma", 568], ["as", 579], ["their", 582], ["initial", 588], ["therapy", 596], [".", 603], ["Clinical", 605], ["information", 614], ["was", 626], ["retrospectively", 630], ["reconstructed", 646], ["using", 660], ["patient", 666], ["medical", 674], ["records", 682], ["and", 690], ["radiological", 694], ["data", 707], [".", 711], ["Recurrence", 713], ["analysis", 724], ["was", 733], ["performed", 737], ["using", 747], ["the", 753], ["Kaplan", 757], ["-", 763], ["Meier", 764], ["method", 770], [".", 776], ["The", 778], ["5-year", 782], ["recurrence", 789], ["/", 799], ["progression", 800], ["-", 811], ["free", 812], ["survival", 817], ["for", 826], ["all", 830], ["patients", 834], ["receiving", 843], ["a", 853], ["Simpson", 855], ["Grade", 863], ["I", 869], [",", 870], ["II", 872], [",", 874], ["III", 876], [",", 879], ["or", 881], ["IV", 884], ["resection", 887], ["was", 897], ["95", 901], [",", 903], ["85", 905], [",", 907], ["88", 909], [",", 911], ["and", 913], ["81", 917], ["%", 919], [",", 920], ["respectively", 922], ["(", 935], ["p", 936], ["=", 938], ["not", 940], ["significant", 944], [",", 955], ["log", 957], ["-", 960], ["rank", 961], ["test", 966], [")", 970], [".", 971], ["Kaplan", 973], ["-", 979], ["Meier", 980], ["analysis", 986], ["revealed", 995], ["no", 1004], ["significant", 1007], ["difference", 1019], ["in", 1030], ["recurrence", 1033], ["-", 1043], ["free", 1044], ["survival", 1049], ["between", 1058], ["patients", 1066], ["receiving", 1075], ["a", 1085], ["Simpson", 1087], ["Grade", 1095], ["I", 1101], [",", 1102], ["II", 1104], [",", 1106], ["III", 1108], [",", 1111], ["or", 1113], ["IV", 1116], ["resection", 1119], [".", 1128], ["Analysis", 1130], ["limited", 1139], ["to", 1147], ["meningiomas", 1150], ["arising", 1162], ["from", 1170], ["the", 1175], ["skull", 1179], ["base", 1185], ["(", 1190], ["excluding", 1191], ["the", 1201], ["cavernous", 1205], ["sinus", 1215], [")", 1220], ["similarly", 1222], ["found", 1232], ["no", 1238], ["significant", 1241], ["benefit", 1253], ["to", 1261], ["Simpson", 1264], ["Grade", 1272], ["I", 1278], ["or", 1280], ["II", 1283], ["resection", 1286], [",", 1295], ["and", 1297], ["the", 1301], ["survival", 1305], ["curves", 1314], ["were", 1321], ["nearly", 1326], ["superimposed", 1333], [".", 1345], ["In", 1347], ["this", 1350], ["study", 1355], ["of", 1361], ["a", 1364], ["cohort", 1366], ["of", 1373], ["patients", 1376], ["undergoing", 1385], ["surgery", 1396], ["for", 1404], ["WHO", 1408], ["Grade", 1412], ["I", 1418], ["meningiomas", 1420], [",", 1431], ["the", 1433], ["authors", 1437], ["demonstrate", 1445], ["that", 1457], ["the", 1462], ["benefit", 1466], ["of", 1474], ["more", 1477], ["aggressive", 1482], ["attempts", 1493], ["to", 1502], ["resect", 1505], ["the", 1512], ["tumor", 1516], ["with", 1522], ["dura", 1527], ["and", 1532], ["underlying", 1536], ["bone", 1547], ["was", 1552], ["negligible", 1556], ["compared", 1567], ["with", 1576], ["simply", 1581], ["removing", 1588], ["the", 1597], ["entire", 1601], ["tumor", 1608], [",", 1613], ["or", 1615], ["even", 1618], ["leaving", 1623], ["small", 1631], ["amounts", 1637], ["of", 1645], ["tumor", 1648], ["attached", 1654], ["to", 1663], ["critical", 1666], ["structures", 1675], [".", 1685], ["The", 1687], ["authors", 1691], ["believe", 1699], ["that", 1707], ["these", 1712], ["data", 1718], ["reflect", 1723], ["an", 1731], ["evolution", 1734], ["in", 1744], ["the", 1747], ["nature", 1751], ["of", 1758], ["meningioma", 1761], ["surgery", 1772], ["over", 1780], ["the", 1785], ["past", 1789], ["2", 1794], ["decades", 1796], [",", 1803], ["and", 1805], ["bring", 1809], ["into", 1815], ["question", 1820], ["the", 1829], ["relevance", 1833], ["of", 1843], ["using", 1846], ["Simpson", 1852], ["'s", 1859], ["grading", 1862], ["system", 1870], ["as", 1877], ["the", 1880], ["sole", 1884], ["predictor", 1889], ["of", 1899], ["recurrence", 1902], [".", 1912]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) seems to be a frequent cause of intractable chronic insomnia (ICI) but is under-recognized in children/adolescents with neurodevelopmental conditions (NDCs), as many patients do not have the ability to express the underlying \"urge-to-move\". In light of this, we aim to develop a protocol for behavioral observations supporting the diagnosis of WED/RLS. We investigated 26 pediatric patients (age 1-16 years, median 8) with NDCs, ICI and evidence of familial WED/RLS employing (1) \"emplotted narratives\" for description of the various \"urge-to-move\" presentations and (2) self-description and \"behavioral observations\" during a \"suggested clinical immobilization test\" (SCIT). Parental narratives reflected typical WED/RLS-related \"urge-to-move\" symptoms during day-, bed-, and nighttime in all patients. Fifteen out of 26 patients could describe the \"urge-to-move\" during the SCIT. Ten out of 26 patients, unable to describe their symptoms due to cognitive disabilities, showed patterns of \"relieving-movements\" upon observation. Sensory processing abnormalities were reported in all patients, with tactile sensitivities (26/26) (including shifted pain threshold) as the most common sensory domain. \"Emplotted narratives\" and structured \"behavioral observations\" support recognition of familial WED/RLS associated movement patterns and provide a useful tool for the diagnosis of WED/RLS in children with NDCs in a clinical office setting.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "b7c3669e630a465892c5b64dbd7a9d82", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["seems", 54], ["to", 60], ["be", 63], ["a", 66], ["frequent", 68], ["cause", 77], ["of", 83], ["intractable", 86], ["chronic", 98], ["insomnia", 106], ["(", 115], ["ICI", 116], [")", 119], ["but", 121], ["is", 125], ["under", 128], ["-", 133], ["recognized", 134], ["in", 145], ["children", 148], ["/", 156], ["adolescents", 157], ["with", 169], ["neurodevelopmental", 174], ["conditions", 193], ["(", 204], ["NDCs", 205], [")", 209], [",", 210], ["as", 212], ["many", 215], ["patients", 220], ["do", 229], ["not", 232], ["have", 236], ["the", 241], ["ability", 245], ["to", 253], ["express", 256], ["the", 264], ["underlying", 268], ["\"", 279], ["urge", 280], ["-", 284], ["to", 285], ["-", 287], ["move", 288], ["\"", 292], [".", 293], ["In", 295], ["light", 298], ["of", 304], ["this", 307], [",", 311], ["we", 313], ["aim", 316], ["to", 320], ["develop", 323], ["a", 331], ["protocol", 333], ["for", 342], ["behavioral", 346], ["observations", 357], ["supporting", 370], ["the", 381], ["diagnosis", 385], ["of", 395], ["WED", 398], ["/", 401], ["RLS", 402], [".", 405], ["We", 407], ["investigated", 410], ["26", 423], ["pediatric", 426], ["patients", 436], ["(", 445], ["age", 446], ["1", 450], ["-", 451], ["16", 452], ["years", 455], [",", 460], ["median", 462], ["8)", 469], ["with", 472], ["NDCs", 477], [",", 481], ["ICI", 483], ["and", 487], ["evidence", 491], ["of", 500], ["familial", 503], ["WED", 512], ["/", 515], ["RLS", 516], ["employing", 520], ["(", 530], ["1", 531], [")", 532], ["\"", 534], ["emplotted", 535], ["narratives", 545], ["\"", 555], ["for", 557], ["description", 561], ["of", 573], ["the", 576], ["various", 580], ["\"", 588], ["urge", 589], ["-", 593], ["to", 594], ["-", 596], ["move", 597], ["\"", 601], ["presentations", 603], ["and", 617], ["(", 621], ["2", 622], [")", 623], ["self", 625], ["-", 629], ["description", 630], ["and", 642], ["\"", 646], ["behavioral", 647], ["observations", 658], ["\"", 670], ["during", 672], ["a", 679], ["\"", 681], ["suggested", 682], ["clinical", 692], ["immobilization", 701], ["test", 716], ["\"", 720], ["(", 722], ["SCIT", 723], [")", 727], [".", 728], ["Parental", 730], ["narratives", 739], ["reflected", 750], ["typical", 760], ["WED", 768], ["/", 771], ["RLS", 772], ["-", 775], ["related", 776], ["\"", 784], ["urge", 785], ["-", 789], ["to", 790], ["-", 792], ["move", 793], ["\"", 797], ["symptoms", 799], ["during", 808], ["day-", 815], [",", 819], ["bed-", 821], [",", 825], ["and", 827], ["nighttime", 831], ["in", 841], ["all", 844], ["patients", 848], [".", 856], ["Fifteen", 858], ["out", 866], ["of", 870], ["26", 873], ["patients", 876], ["could", 885], ["describe", 891], ["the", 900], ["\"", 904], ["urge", 905], ["-", 909], ["to", 910], ["-", 912], ["move", 913], ["\"", 917], ["during", 919], ["the", 926], ["SCIT", 930], [".", 934], ["Ten", 936], ["out", 940], ["of", 944], ["26", 947], ["patients", 950], [",", 958], ["unable", 960], ["to", 967], ["describe", 970], ["their", 979], ["symptoms", 985], ["due", 994], ["to", 998], ["cognitive", 1001], ["disabilities", 1011], [",", 1023], ["showed", 1025], ["patterns", 1032], ["of", 1041], ["\"", 1044], ["relieving", 1045], ["-", 1054], ["movements", 1055], ["\"", 1064], ["upon", 1066], ["observation", 1071], [".", 1082], ["Sensory", 1084], ["processing", 1092], ["abnormalities", 1103], ["were", 1117], ["reported", 1122], ["in", 1131], ["all", 1134], ["patients", 1138], [",", 1146], ["with", 1148], ["tactile", 1153], ["sensitivities", 1161], ["(", 1175], ["26/26", 1176], [")", 1181], ["(", 1183], ["including", 1184], ["shifted", 1194], ["pain", 1202], ["threshold", 1207], [")", 1216], ["as", 1218], ["the", 1221], ["most", 1225], ["common", 1230], ["sensory", 1237], ["domain", 1245], [".", 1251], ["\"", 1253], ["Emplotted", 1254], ["narratives", 1264], ["\"", 1274], ["and", 1276], ["structured", 1280], ["\"", 1291], ["behavioral", 1292], ["observations", 1303], ["\"", 1315], ["support", 1317], ["recognition", 1325], ["of", 1337], ["familial", 1340], ["WED", 1349], ["/", 1352], ["RLS", 1353], ["associated", 1357], ["movement", 1368], ["patterns", 1377], ["and", 1386], ["provide", 1390], ["a", 1398], ["useful", 1400], ["tool", 1407], ["for", 1412], ["the", 1416], ["diagnosis", 1420], ["of", 1430], ["WED", 1433], ["/", 1436], ["RLS", 1437], ["in", 1441], ["children", 1444], ["with", 1453], ["NDCs", 1458], ["in", 1463], ["a", 1466], ["clinical", 1468], ["office", 1477], ["setting", 1484], [".", 1491]]}
{"context": "Women in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using daily or coitally-dependent products have found low adherence. Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges. ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection. We describe the baseline characteristics of African women enrolled in the ASPIRE trial. Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 seronegative women between 18-45 years of age were enrolled from 15 research sites in Malawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22-31) and the majority (59%) were unmarried. Nearly 100% of participants reported having a primary sex partner in the prior three months but 43% did not know the HIV-1 status of their primary partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported having disclosed to primary partners about planned vaginal ring use in the trial. Sexually transmitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis. African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into a phase III trial of dapivirine vaginal ring for HIV-1 prevention.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "5c077ce1a2b84aa199040b93309cc5b6", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[294, 294]], "char_spans": [[1622, 1624]]}]}], "context_tokens": [["Women", 0], ["in", 6], ["sub", 9], ["-", 12], ["Saharan", 13], ["Africa", 21], ["are", 28], ["a", 32], ["priority", 34], ["population", 43], ["for", 54], ["evaluation", 58], ["of", 69], ["new", 72], ["biomedical", 76], ["HIV-1", 87], ["prevention", 93], ["strategies", 104], [".", 114], ["Antiretroviral", 116], ["pre", 131], ["-", 134], ["exposure", 135], ["prophylaxis", 144], ["is", 156], ["a", 159], ["promising", 161], ["prevention", 171], ["approach", 182], [";", 190], ["however", 192], [",", 199], ["clinical", 201], ["trials", 210], ["among", 217], ["young", 223], ["women", 229], ["using", 235], ["daily", 241], ["or", 247], ["coitally", 250], ["-", 258], ["dependent", 259], ["products", 269], ["have", 278], ["found", 283], ["low", 289], ["adherence", 293], [".", 302], ["Antiretroviral", 304], ["-", 318], ["containing", 319], ["vaginal", 330], ["microbicide", 338], ["rings", 350], [",", 355], ["which", 357], ["release", 363], ["medication", 371], ["over", 382], ["a", 387], ["month", 389], ["or", 395], ["longer", 398], [",", 404], ["may", 406], ["reduce", 410], ["these", 417], ["adherence", 423], ["challenges", 433], [".", 443], ["ASPIRE", 445], ["(", 452], ["A", 453], ["Study", 455], ["to", 461], ["Prevent", 464], ["Infection", 472], ["with", 482], ["a", 487], ["Ring", 489], ["for", 494], ["Extended", 498], ["Use", 507], [")", 510], ["is", 512], ["a", 515], ["phase", 517], ["III", 523], [",", 526], ["randomized", 528], [",", 538], ["double", 540], ["-", 546], ["blind", 547], [",", 552], ["placebo", 554], ["-", 561], ["controlled", 562], ["trial", 573], ["testing", 579], ["the", 587], ["safety", 591], ["and", 598], ["effectiveness", 602], ["of", 616], ["a", 619], ["vaginal", 621], ["ring", 629], ["containing", 634], ["the", 645], ["non", 649], ["-", 652], ["nucleoside", 653], ["reverse", 664], ["transcriptase", 672], ["inhibitor", 686], ["dapivirine", 696], ["for", 707], ["prevention", 711], ["of", 722], ["HIV-1", 725], ["infection", 731], [".", 740], ["We", 742], ["describe", 745], ["the", 754], ["baseline", 758], ["characteristics", 767], ["of", 783], ["African", 786], ["women", 794], ["enrolled", 800], ["in", 809], ["the", 812], ["ASPIRE", 816], ["trial", 823], [".", 828], ["Between", 830], ["August", 838], ["2012", 845], ["and", 850], ["June", 854], ["2014", 859], [",", 863], ["5516", 865], ["women", 870], ["were", 876], ["screened", 881], ["and", 890], ["2629", 894], ["HIV-1", 899], ["seronegative", 905], ["women", 918], ["between", 924], ["18", 932], ["-", 934], ["45", 935], ["years", 938], ["of", 944], ["age", 947], ["were", 951], ["enrolled", 956], ["from", 965], ["15", 970], ["research", 973], ["sites", 982], ["in", 988], ["Malawi", 991], [",", 997], ["South", 999], ["Africa", 1005], [",", 1011], ["Uganda", 1013], [",", 1019], ["and", 1021], ["Zimbabwe", 1025], [".", 1033], ["The", 1035], ["median", 1039], ["age", 1046], ["was", 1050], ["26", 1054], ["years", 1057], ["(", 1063], ["IQR", 1064], ["22", 1068], ["-", 1070], ["31", 1071], [")", 1073], ["and", 1075], ["the", 1079], ["majority", 1083], ["(", 1092], ["59", 1093], ["%", 1095], [")", 1096], ["were", 1098], ["unmarried", 1103], [".", 1112], ["Nearly", 1114], ["100", 1121], ["%", 1124], ["of", 1126], ["participants", 1129], ["reported", 1142], ["having", 1151], ["a", 1158], ["primary", 1160], ["sex", 1168], ["partner", 1172], ["in", 1180], ["the", 1183], ["prior", 1187], ["three", 1193], ["months", 1199], ["but", 1206], ["43", 1210], ["%", 1212], ["did", 1214], ["not", 1218], ["know", 1222], ["the", 1227], ["HIV-1", 1231], ["status", 1237], ["of", 1244], ["their", 1247], ["primary", 1253], ["partner", 1261], [";", 1268], ["17", 1270], ["%", 1272], ["reported", 1274], ["additional", 1283], ["concurrent", 1294], ["partners", 1305], [".", 1313], ["Nearly", 1315], ["two", 1322], ["-", 1325], ["thirds", 1326], ["(", 1333], ["64", 1334], ["%", 1336], [")", 1337], ["reported", 1339], ["having", 1348], ["disclosed", 1355], ["to", 1365], ["primary", 1368], ["partners", 1376], ["about", 1385], ["planned", 1391], ["vaginal", 1399], ["ring", 1407], ["use", 1412], ["in", 1416], ["the", 1419], ["trial", 1423], [".", 1428], ["Sexually", 1430], ["transmitted", 1439], ["infections", 1451], ["were", 1462], ["prevalent", 1467], [":", 1476], ["12", 1478], ["%", 1480], ["had", 1482], ["Chlamydia", 1486], ["trachomatis", 1496], [",", 1507], ["7", 1509], ["%", 1510], ["Trichomonas", 1512], ["vaginalis", 1524], [",", 1533], ["4", 1535], ["%", 1536], ["Neisseria", 1538], ["gonorrhoeae", 1548], [",", 1559], ["and", 1561], ["1", 1565], ["%", 1566], ["syphilis", 1568], [".", 1576], ["African", 1578], ["HIV-1", 1586], ["seronegative", 1592], ["women", 1605], ["at", 1611], ["risk", 1614], ["of", 1619], ["HIV", 1622], ["-1", 1626], ["infection", 1629], ["were", 1639], ["successfully", 1644], ["enrolled", 1657], ["into", 1666], ["a", 1671], ["phase", 1673], ["III", 1679], ["trial", 1683], ["of", 1689], ["dapivirine", 1692], ["vaginal", 1703], ["ring", 1711], ["for", 1716], ["HIV-1", 1720], ["prevention", 1726], [".", 1736]]}
{"context": "Protein methylation is a common posttranslational modification that mostly occurs on arginine and lysine residues. Arginine methylation has been reported to regulate RNA processing, gene transcription, DNA damage repair, protein translocation, and signal transduction. Lysine methylation is best known to regulate histone function and is involved in epigenetic regulation of gene transcription. To better study protein methylation, we have developed highly specific antibodies against monomethyl arginine; asymmetric dimethyl arginine; and monomethyl, dimethyl, and trimethyl lysine motifs. These antibodies were used to perform immunoaffinity purification of methyl peptides followed by LC-MS/MS analysis to identify and quantify arginine and lysine methylation sites in several model studies. Overall, we identified over 1000 arginine methylation sites in human cell line and mouse tissues, and \u223c160 lysine methylation sites in human cell line HCT116. The number of methylation sites identified in this study exceeds those found in the literature to date. Detailed analysis of arginine-methylated proteins observed in mouse brain compared with those found in mouse embryo shows a tissue-specific distribution of arginine methylation, and extends the types of proteins that are known to be arginine methylated to include many new protein types. Many arginine-methylated proteins that we identified from the brain, including receptors, ion channels, transporters, and vesicle proteins, are involved in synaptic transmission, whereas the most abundant methylated proteins identified from mouse embryo are transcriptional regulators and RNA processing proteins.", "qas": [{"question": "Name a method for enrichment of arginine-methylated peptides.", "answers": ["Immunoaffinity purification"], "qid": "d40f8b57b37941beac2d486723c72a73", "question_tokens": [["Name", 0], ["a", 5], ["method", 7], ["for", 14], ["enrichment", 18], ["of", 29], ["arginine", 32], ["-", 40], ["methylated", 41], ["peptides", 52], [".", 60]], "detected_answers": [{"text": "Immunoaffinity purification", "token_spans": [[95, 96]], "char_spans": [[629, 655]]}]}], "context_tokens": [["Protein", 0], ["methylation", 8], ["is", 20], ["a", 23], ["common", 25], ["posttranslational", 32], ["modification", 50], ["that", 63], ["mostly", 68], ["occurs", 75], ["on", 82], ["arginine", 85], ["and", 94], ["lysine", 98], ["residues", 105], [".", 113], ["Arginine", 115], ["methylation", 124], ["has", 136], ["been", 140], ["reported", 145], ["to", 154], ["regulate", 157], ["RNA", 166], ["processing", 170], [",", 180], ["gene", 182], ["transcription", 187], [",", 200], ["DNA", 202], ["damage", 206], ["repair", 213], [",", 219], ["protein", 221], ["translocation", 229], [",", 242], ["and", 244], ["signal", 248], ["transduction", 255], [".", 267], ["Lysine", 269], ["methylation", 276], ["is", 288], ["best", 291], ["known", 296], ["to", 302], ["regulate", 305], ["histone", 314], ["function", 322], ["and", 331], ["is", 335], ["involved", 338], ["in", 347], ["epigenetic", 350], ["regulation", 361], ["of", 372], ["gene", 375], ["transcription", 380], [".", 393], ["To", 395], ["better", 398], ["study", 405], ["protein", 411], ["methylation", 419], [",", 430], ["we", 432], ["have", 435], ["developed", 440], ["highly", 450], ["specific", 457], ["antibodies", 466], ["against", 477], ["monomethyl", 485], ["arginine", 496], [";", 504], ["asymmetric", 506], ["dimethyl", 517], ["arginine", 526], [";", 534], ["and", 536], ["monomethyl", 540], [",", 550], ["dimethyl", 552], [",", 560], ["and", 562], ["trimethyl", 566], ["lysine", 576], ["motifs", 583], [".", 589], ["These", 591], ["antibodies", 597], ["were", 608], ["used", 613], ["to", 618], ["perform", 621], ["immunoaffinity", 629], ["purification", 644], ["of", 657], ["methyl", 660], ["peptides", 667], ["followed", 676], ["by", 685], ["LC", 688], ["-", 690], ["MS", 691], ["/", 693], ["MS", 694], ["analysis", 697], ["to", 706], ["identify", 709], ["and", 718], ["quantify", 722], ["arginine", 731], ["and", 740], ["lysine", 744], ["methylation", 751], ["sites", 763], ["in", 769], ["several", 772], ["model", 780], ["studies", 786], [".", 793], ["Overall", 795], [",", 802], ["we", 804], ["identified", 807], ["over", 818], ["1000", 823], ["arginine", 828], ["methylation", 837], ["sites", 849], ["in", 855], ["human", 858], ["cell", 864], ["line", 869], ["and", 874], ["mouse", 878], ["tissues", 884], [",", 891], ["and", 893], ["\u223c160", 897], ["lysine", 902], ["methylation", 909], ["sites", 921], ["in", 927], ["human", 930], ["cell", 936], ["line", 941], ["HCT116", 946], [".", 952], ["The", 954], ["number", 958], ["of", 965], ["methylation", 968], ["sites", 980], ["identified", 986], ["in", 997], ["this", 1000], ["study", 1005], ["exceeds", 1011], ["those", 1019], ["found", 1025], ["in", 1031], ["the", 1034], ["literature", 1038], ["to", 1049], ["date", 1052], [".", 1056], ["Detailed", 1058], ["analysis", 1067], ["of", 1076], ["arginine", 1079], ["-", 1087], ["methylated", 1088], ["proteins", 1099], ["observed", 1108], ["in", 1117], ["mouse", 1120], ["brain", 1126], ["compared", 1132], ["with", 1141], ["those", 1146], ["found", 1152], ["in", 1158], ["mouse", 1161], ["embryo", 1167], ["shows", 1174], ["a", 1180], ["tissue", 1182], ["-", 1188], ["specific", 1189], ["distribution", 1198], ["of", 1211], ["arginine", 1214], ["methylation", 1223], [",", 1234], ["and", 1236], ["extends", 1240], ["the", 1248], ["types", 1252], ["of", 1258], ["proteins", 1261], ["that", 1270], ["are", 1275], ["known", 1279], ["to", 1285], ["be", 1288], ["arginine", 1291], ["methylated", 1300], ["to", 1311], ["include", 1314], ["many", 1322], ["new", 1327], ["protein", 1331], ["types", 1339], [".", 1344], ["Many", 1346], ["arginine", 1351], ["-", 1359], ["methylated", 1360], ["proteins", 1371], ["that", 1380], ["we", 1385], ["identified", 1388], ["from", 1399], ["the", 1404], ["brain", 1408], [",", 1413], ["including", 1415], ["receptors", 1425], [",", 1434], ["ion", 1436], ["channels", 1440], [",", 1448], ["transporters", 1450], [",", 1462], ["and", 1464], ["vesicle", 1468], ["proteins", 1476], [",", 1484], ["are", 1486], ["involved", 1490], ["in", 1499], ["synaptic", 1502], ["transmission", 1511], [",", 1523], ["whereas", 1525], ["the", 1533], ["most", 1537], ["abundant", 1542], ["methylated", 1551], ["proteins", 1562], ["identified", 1571], ["from", 1582], ["mouse", 1587], ["embryo", 1593], ["are", 1600], ["transcriptional", 1604], ["regulators", 1620], ["and", 1631], ["RNA", 1635], ["processing", 1639], ["proteins", 1650], [".", 1658]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "Centrosome forms the backbone of cell cycle progression mechanism. Recent debates have occurred regarding the essentiality of centrosome in cell cycle regulation. CEP family protein is the active component of centrosome and plays a vital role in centriole biogenesis and cell cycle progression control. A total of 31 proteins have been categorized into CEP family protein category and many more are under candidate evaluation. Furthermore, by the recent advancements in genomics and proteomics researches, several new CEP proteins have also been characterized. Here we have summarized the importance of CEP family proteins and their regulation mechanism involved in proper cell cycle progression. Further, we have reviewed the detailed molecular mechanism behind the associated pathological phenotypes and the possible therapeutic approaches. Proteins such as CEP57, CEP63, CEP152, CEP164, and CEP215 have been extensively studied with a detailed description of their molecular mechanisms, which are among the primary targets for drug discovery. Moreover, CEP27, CEP55, CEP70, CEP110, CEP120, CEP135, CEP192, CEP250, CEP290, and CEP350 also seem promising for future drug discovery approaches. Since the overview implicates that the overall researches on CEP proteins are not yet able to present significant details required for effective therapeutics development, thus, it is timely to discuss the importance of future investigations in this field.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "bc41177a6b044b729aab22fd26e9d225", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[0, 0], [32, 32], [18, 18]], "char_spans": [[0, 9], [209, 218], [126, 135]]}]}], "context_tokens": [["Centrosome", 0], ["forms", 11], ["the", 17], ["backbone", 21], ["of", 30], ["cell", 33], ["cycle", 38], ["progression", 44], ["mechanism", 56], [".", 65], ["Recent", 67], ["debates", 74], ["have", 82], ["occurred", 87], ["regarding", 96], ["the", 106], ["essentiality", 110], ["of", 123], ["centrosome", 126], ["in", 137], ["cell", 140], ["cycle", 145], ["regulation", 151], [".", 161], ["CEP", 163], ["family", 167], ["protein", 174], ["is", 182], ["the", 185], ["active", 189], ["component", 196], ["of", 206], ["centrosome", 209], ["and", 220], ["plays", 224], ["a", 230], ["vital", 232], ["role", 238], ["in", 243], ["centriole", 246], ["biogenesis", 256], ["and", 267], ["cell", 271], ["cycle", 276], ["progression", 282], ["control", 294], [".", 301], ["A", 303], ["total", 305], ["of", 311], ["31", 314], ["proteins", 317], ["have", 326], ["been", 331], ["categorized", 336], ["into", 348], ["CEP", 353], ["family", 357], ["protein", 364], ["category", 372], ["and", 381], ["many", 385], ["more", 390], ["are", 395], ["under", 399], ["candidate", 405], ["evaluation", 415], [".", 425], ["Furthermore", 427], [",", 438], ["by", 440], ["the", 443], ["recent", 447], ["advancements", 454], ["in", 467], ["genomics", 470], ["and", 479], ["proteomics", 483], ["researches", 494], [",", 504], ["several", 506], ["new", 514], ["CEP", 518], ["proteins", 522], ["have", 531], ["also", 536], ["been", 541], ["characterized", 546], [".", 559], ["Here", 561], ["we", 566], ["have", 569], ["summarized", 574], ["the", 585], ["importance", 589], ["of", 600], ["CEP", 603], ["family", 607], ["proteins", 614], ["and", 623], ["their", 627], ["regulation", 633], ["mechanism", 644], ["involved", 654], ["in", 663], ["proper", 666], ["cell", 673], ["cycle", 678], ["progression", 684], [".", 695], ["Further", 697], [",", 704], ["we", 706], ["have", 709], ["reviewed", 714], ["the", 723], ["detailed", 727], ["molecular", 736], ["mechanism", 746], ["behind", 756], ["the", 763], ["associated", 767], ["pathological", 778], ["phenotypes", 791], ["and", 802], ["the", 806], ["possible", 810], ["therapeutic", 819], ["approaches", 831], [".", 841], ["Proteins", 843], ["such", 852], ["as", 857], ["CEP57", 860], [",", 865], ["CEP63", 867], [",", 872], ["CEP152", 874], [",", 880], ["CEP164", 882], [",", 888], ["and", 890], ["CEP215", 894], ["have", 901], ["been", 906], ["extensively", 911], ["studied", 923], ["with", 931], ["a", 936], ["detailed", 938], ["description", 947], ["of", 959], ["their", 962], ["molecular", 968], ["mechanisms", 978], [",", 988], ["which", 990], ["are", 996], ["among", 1000], ["the", 1006], ["primary", 1010], ["targets", 1018], ["for", 1026], ["drug", 1030], ["discovery", 1035], [".", 1044], ["Moreover", 1046], [",", 1054], ["CEP27", 1056], [",", 1061], ["CEP55", 1063], [",", 1068], ["CEP70", 1070], [",", 1075], ["CEP110", 1077], [",", 1083], ["CEP120", 1085], [",", 1091], ["CEP135", 1093], [",", 1099], ["CEP192", 1101], [",", 1107], ["CEP250", 1109], [",", 1115], ["CEP290", 1117], [",", 1123], ["and", 1125], ["CEP350", 1129], ["also", 1136], ["seem", 1141], ["promising", 1146], ["for", 1156], ["future", 1160], ["drug", 1167], ["discovery", 1172], ["approaches", 1182], [".", 1192], ["Since", 1194], ["the", 1200], ["overview", 1204], ["implicates", 1213], ["that", 1224], ["the", 1229], ["overall", 1233], ["researches", 1241], ["on", 1252], ["CEP", 1255], ["proteins", 1259], ["are", 1268], ["not", 1272], ["yet", 1276], ["able", 1280], ["to", 1285], ["present", 1288], ["significant", 1296], ["details", 1308], ["required", 1316], ["for", 1325], ["effective", 1329], ["therapeutics", 1339], ["development", 1352], [",", 1363], ["thus", 1365], [",", 1369], ["it", 1371], ["is", 1374], ["timely", 1377], ["to", 1384], ["discuss", 1387], ["the", 1395], ["importance", 1399], ["of", 1410], ["future", 1413], ["investigations", 1420], ["in", 1435], ["this", 1438], ["field", 1443], [".", 1448]]}
{"context": "The rarity and the inconsistent criteria for defining atypical meningioma prior to the WHO 2007 classification made its management and prognostic factors poorly understood. Only few articles have addressed the survival rates of WHO-classified atypical meningiomas. The small number or the disproportionate representation of irradiated patients was a weakness for these articles. This study evaluated whether the extent of surgery and receiving adjuvant radiotherapy after an initial operation along with other patient characteristics influenced the recurrence and survival rates of atypical meningiomas. The clinical and surgical notes of the 79 patients with grade II atypical meningioma treated at our center over 13 years were retrospectively evaluated. The histology grading was consistent with WHO 2007 classification. The Simpson grading system was used to assess the extent of surgical resection. Kaplan Meier analysis, Cox multivariate regression analysis, and the Log-rank test were conducted using STATA\u00ae statistical package. The average age at the time of initial operation was 58 years, and 54 % were males. The mean follow-up period was 50 months. In Cox multivariate analysis, only Simpson grading was predictive of recurrence (hazard ratio = 2.22 / 1 increase in Simpson grade. p\u2009=\u20090.003). Simpson grade I patients had a relapse-free survival rate of 97 and 74 % at one and five years, respectively, compared with 88 and 32 % in the subtotal resection group (Simpson grades II to IV). There was no statistically significant correlation between recurrence and subjecting patients to postoperative radiotherapy. Apart from Simpson grade I patients, there was a general trend for worse outcome in irradiated patients. The most important prognostic factor in determining recurrence was Simpson grading. There was no statistically significant impact of adjuvant radiotherapy on the recurrence of atypical meningiomas. Meta-analysis for the existing literature is needed.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "8a4e9bb9b22a4d77b479e8ccadb64015", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[9, 9], [101, 101]], "char_spans": [[63, 72], [678, 687]]}]}], "context_tokens": [["The", 0], ["rarity", 4], ["and", 11], ["the", 15], ["inconsistent", 19], ["criteria", 32], ["for", 41], ["defining", 45], ["atypical", 54], ["meningioma", 63], ["prior", 74], ["to", 80], ["the", 83], ["WHO", 87], ["2007", 91], ["classification", 96], ["made", 111], ["its", 116], ["management", 120], ["and", 131], ["prognostic", 135], ["factors", 146], ["poorly", 154], ["understood", 161], [".", 171], ["Only", 173], ["few", 178], ["articles", 182], ["have", 191], ["addressed", 196], ["the", 206], ["survival", 210], ["rates", 219], ["of", 225], ["WHO", 228], ["-", 231], ["classified", 232], ["atypical", 243], ["meningiomas", 252], [".", 263], ["The", 265], ["small", 269], ["number", 275], ["or", 282], ["the", 285], ["disproportionate", 289], ["representation", 306], ["of", 321], ["irradiated", 324], ["patients", 335], ["was", 344], ["a", 348], ["weakness", 350], ["for", 359], ["these", 363], ["articles", 369], [".", 377], ["This", 379], ["study", 384], ["evaluated", 390], ["whether", 400], ["the", 408], ["extent", 412], ["of", 419], ["surgery", 422], ["and", 430], ["receiving", 434], ["adjuvant", 444], ["radiotherapy", 453], ["after", 466], ["an", 472], ["initial", 475], ["operation", 483], ["along", 493], ["with", 499], ["other", 504], ["patient", 510], ["characteristics", 518], ["influenced", 534], ["the", 545], ["recurrence", 549], ["and", 560], ["survival", 564], ["rates", 573], ["of", 579], ["atypical", 582], ["meningiomas", 591], [".", 602], ["The", 604], ["clinical", 608], ["and", 617], ["surgical", 621], ["notes", 630], ["of", 636], ["the", 639], ["79", 643], ["patients", 646], ["with", 655], ["grade", 660], ["II", 666], ["atypical", 669], ["meningioma", 678], ["treated", 689], ["at", 697], ["our", 700], ["center", 704], ["over", 711], ["13", 716], ["years", 719], ["were", 725], ["retrospectively", 730], ["evaluated", 746], [".", 755], ["The", 757], ["histology", 761], ["grading", 771], ["was", 779], ["consistent", 783], ["with", 794], ["WHO", 799], ["2007", 803], ["classification", 808], [".", 822], ["The", 824], ["Simpson", 828], ["grading", 836], ["system", 844], ["was", 851], ["used", 855], ["to", 860], ["assess", 863], ["the", 870], ["extent", 874], ["of", 881], ["surgical", 884], ["resection", 893], [".", 902], ["Kaplan", 904], ["Meier", 911], ["analysis", 917], [",", 925], ["Cox", 927], ["multivariate", 931], ["regression", 944], ["analysis", 955], [",", 963], ["and", 965], ["the", 969], ["Log", 973], ["-", 976], ["rank", 977], ["test", 982], ["were", 987], ["conducted", 992], ["using", 1002], ["STATA", 1008], ["\u00ae", 1013], ["statistical", 1015], ["package", 1027], [".", 1034], ["The", 1036], ["average", 1040], ["age", 1048], ["at", 1052], ["the", 1055], ["time", 1059], ["of", 1064], ["initial", 1067], ["operation", 1075], ["was", 1085], ["58", 1089], ["years", 1092], [",", 1097], ["and", 1099], ["54", 1103], ["%", 1106], ["were", 1108], ["males", 1113], [".", 1118], ["The", 1120], ["mean", 1124], ["follow", 1129], ["-", 1135], ["up", 1136], ["period", 1139], ["was", 1146], ["50", 1150], ["months", 1153], [".", 1159], ["In", 1161], ["Cox", 1164], ["multivariate", 1168], ["analysis", 1181], [",", 1189], ["only", 1191], ["Simpson", 1196], ["grading", 1204], ["was", 1212], ["predictive", 1216], ["of", 1227], ["recurrence", 1230], ["(", 1241], ["hazard", 1242], ["ratio", 1249], ["=", 1255], ["2.22", 1257], ["/", 1262], ["1", 1264], ["increase", 1266], ["in", 1275], ["Simpson", 1278], ["grade", 1286], [".", 1291], ["p", 1293], ["=", 1295], ["0.003", 1297], [")", 1302], [".", 1303], ["Simpson", 1305], ["grade", 1313], ["I", 1319], ["patients", 1321], ["had", 1330], ["a", 1334], ["relapse", 1336], ["-", 1343], ["free", 1344], ["survival", 1349], ["rate", 1358], ["of", 1363], ["97", 1366], ["and", 1369], ["74", 1373], ["%", 1376], ["at", 1378], ["one", 1381], ["and", 1385], ["five", 1389], ["years", 1394], [",", 1399], ["respectively", 1401], [",", 1413], ["compared", 1415], ["with", 1424], ["88", 1429], ["and", 1432], ["32", 1436], ["%", 1439], ["in", 1441], ["the", 1444], ["subtotal", 1448], ["resection", 1457], ["group", 1467], ["(", 1473], ["Simpson", 1474], ["grades", 1482], ["II", 1489], ["to", 1492], ["IV", 1495], [")", 1497], [".", 1498], ["There", 1500], ["was", 1506], ["no", 1510], ["statistically", 1513], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["recurrence", 1559], ["and", 1570], ["subjecting", 1574], ["patients", 1585], ["to", 1594], ["postoperative", 1597], ["radiotherapy", 1611], [".", 1623], ["Apart", 1625], ["from", 1631], ["Simpson", 1636], ["grade", 1644], ["I", 1650], ["patients", 1652], [",", 1660], ["there", 1662], ["was", 1668], ["a", 1672], ["general", 1674], ["trend", 1682], ["for", 1688], ["worse", 1692], ["outcome", 1698], ["in", 1706], ["irradiated", 1709], ["patients", 1720], [".", 1728], ["The", 1730], ["most", 1734], ["important", 1739], ["prognostic", 1749], ["factor", 1760], ["in", 1767], ["determining", 1770], ["recurrence", 1782], ["was", 1793], ["Simpson", 1797], ["grading", 1805], [".", 1812], ["There", 1814], ["was", 1820], ["no", 1824], ["statistically", 1827], ["significant", 1841], ["impact", 1853], ["of", 1860], ["adjuvant", 1863], ["radiotherapy", 1872], ["on", 1885], ["the", 1888], ["recurrence", 1892], ["of", 1903], ["atypical", 1906], ["meningiomas", 1915], [".", 1926], ["Meta", 1928], ["-", 1932], ["analysis", 1933], ["for", 1942], ["the", 1946], ["existing", 1950], ["literature", 1959], ["is", 1970], ["needed", 1973], [".", 1979]]}
{"context": "Mowat-Wilson syndrome (MWS) is a relatively newly described multiple congenital anomaly/mental retardation syndrome. Haploinsufficiency of a gene termed ZFHX1B (also known as SIP1) on chromosome 2 is responsible for this condition, and clinical genetic testing for MWS recently became available. The majority of reports in the literature originate from Northern Europe and Australia. Here we report our clinical experience with 12 patients diagnosed with MWS within a 2-year period of time in the United States, with particular emphasis on clinical characteristics and management strategies. Individuals with this condition have characteristic facial features, including microcephaly, hypertelorism, medially flared and broad eyebrows, prominent columella, pointed chin, and uplifted earlobes, which typically prompt the clinician to consider the diagnosis. Medical issues in our cohort of patients included seizures (75%) with no predeliction for any particular seizure type; agenesis of the corpus callosum (60% of our patients studied); congenital heart defects (75%), particularly involving the pulmonary arteries and/or valves; hypospadias (55% of males); severely impaired or absent speech (100% of individuals over 1 year of age) with relatively spared receptive language; and Hirschsprung disease (50%) or chronic constipation (25%). The incidence of MWS is unknown, but based on the number of patients identified in a short period of time within the US, it is likely greatly under recognized. MWS should be considered in any individual with severely impaired or absent speech, especially in the presence of seizures and anomalies involving the pulmonary arteries (particularly pulmonary artery sling) or pulmonary valves.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ba508f5b8dfb4fbc83ecf9831706b686", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[25, 25]], "char_spans": [[153, 158]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["newly", 44], ["described", 50], ["multiple", 60], ["congenital", 69], ["anomaly", 80], ["/", 87], ["mental", 88], ["retardation", 95], ["syndrome", 107], [".", 115], ["Haploinsufficiency", 117], ["of", 136], ["a", 139], ["gene", 141], ["termed", 146], ["ZFHX1B", 153], ["(", 160], ["also", 161], ["known", 166], ["as", 172], ["SIP1", 175], [")", 179], ["on", 181], ["chromosome", 184], ["2", 195], ["is", 197], ["responsible", 200], ["for", 212], ["this", 216], ["condition", 221], [",", 230], ["and", 232], ["clinical", 236], ["genetic", 245], ["testing", 253], ["for", 261], ["MWS", 265], ["recently", 269], ["became", 278], ["available", 285], [".", 294], ["The", 296], ["majority", 300], ["of", 309], ["reports", 312], ["in", 320], ["the", 323], ["literature", 327], ["originate", 338], ["from", 348], ["Northern", 353], ["Europe", 362], ["and", 369], ["Australia", 373], [".", 382], ["Here", 384], ["we", 389], ["report", 392], ["our", 399], ["clinical", 403], ["experience", 412], ["with", 423], ["12", 428], ["patients", 431], ["diagnosed", 440], ["with", 450], ["MWS", 455], ["within", 459], ["a", 466], ["2-year", 468], ["period", 475], ["of", 482], ["time", 485], ["in", 490], ["the", 493], ["United", 497], ["States", 504], [",", 510], ["with", 512], ["particular", 517], ["emphasis", 528], ["on", 537], ["clinical", 540], ["characteristics", 549], ["and", 565], ["management", 569], ["strategies", 580], [".", 590], ["Individuals", 592], ["with", 604], ["this", 609], ["condition", 614], ["have", 624], ["characteristic", 629], ["facial", 644], ["features", 651], [",", 659], ["including", 661], ["microcephaly", 671], [",", 683], ["hypertelorism", 685], [",", 698], ["medially", 700], ["flared", 709], ["and", 716], ["broad", 720], ["eyebrows", 726], [",", 734], ["prominent", 736], ["columella", 746], [",", 755], ["pointed", 757], ["chin", 765], [",", 769], ["and", 771], ["uplifted", 775], ["earlobes", 784], [",", 792], ["which", 794], ["typically", 800], ["prompt", 810], ["the", 817], ["clinician", 821], ["to", 831], ["consider", 834], ["the", 843], ["diagnosis", 847], [".", 856], ["Medical", 858], ["issues", 866], ["in", 873], ["our", 876], ["cohort", 880], ["of", 887], ["patients", 890], ["included", 899], ["seizures", 908], ["(", 917], ["75", 918], ["%", 920], [")", 921], ["with", 923], ["no", 928], ["predeliction", 931], ["for", 944], ["any", 948], ["particular", 952], ["seizure", 963], ["type", 971], [";", 975], ["agenesis", 977], ["of", 986], ["the", 989], ["corpus", 993], ["callosum", 1000], ["(", 1009], ["60", 1010], ["%", 1012], ["of", 1014], ["our", 1017], ["patients", 1021], ["studied", 1030], [")", 1037], [";", 1038], ["congenital", 1040], ["heart", 1051], ["defects", 1057], ["(", 1065], ["75", 1066], ["%", 1068], [")", 1069], [",", 1070], ["particularly", 1072], ["involving", 1085], ["the", 1095], ["pulmonary", 1099], ["arteries", 1109], ["and/or", 1118], ["valves", 1125], [";", 1131], ["hypospadias", 1133], ["(", 1145], ["55", 1146], ["%", 1148], ["of", 1150], ["males", 1153], [")", 1158], [";", 1159], ["severely", 1161], ["impaired", 1170], ["or", 1179], ["absent", 1182], ["speech", 1189], ["(", 1196], ["100", 1197], ["%", 1200], ["of", 1202], ["individuals", 1205], ["over", 1217], ["1", 1222], ["year", 1224], ["of", 1229], ["age", 1232], [")", 1235], ["with", 1237], ["relatively", 1242], ["spared", 1253], ["receptive", 1260], ["language", 1270], [";", 1278], ["and", 1280], ["Hirschsprung", 1284], ["disease", 1297], ["(", 1305], ["50", 1306], ["%", 1308], [")", 1309], ["or", 1311], ["chronic", 1314], ["constipation", 1322], ["(", 1335], ["25", 1336], ["%", 1338], [")", 1339], [".", 1340], ["The", 1342], ["incidence", 1346], ["of", 1356], ["MWS", 1359], ["is", 1363], ["unknown", 1366], [",", 1373], ["but", 1375], ["based", 1379], ["on", 1385], ["the", 1388], ["number", 1392], ["of", 1399], ["patients", 1402], ["identified", 1411], ["in", 1422], ["a", 1425], ["short", 1427], ["period", 1433], ["of", 1440], ["time", 1443], ["within", 1448], ["the", 1455], ["US", 1459], [",", 1461], ["it", 1463], ["is", 1466], ["likely", 1469], ["greatly", 1476], ["under", 1484], ["recognized", 1490], [".", 1500], ["MWS", 1502], ["should", 1506], ["be", 1513], ["considered", 1516], ["in", 1527], ["any", 1530], ["individual", 1534], ["with", 1545], ["severely", 1550], ["impaired", 1559], ["or", 1568], ["absent", 1571], ["speech", 1578], [",", 1584], ["especially", 1586], ["in", 1597], ["the", 1600], ["presence", 1604], ["of", 1613], ["seizures", 1616], ["and", 1625], ["anomalies", 1629], ["involving", 1639], ["the", 1649], ["pulmonary", 1653], ["arteries", 1663], ["(", 1672], ["particularly", 1673], ["pulmonary", 1686], ["artery", 1696], ["sling", 1703], [")", 1708], ["or", 1710], ["pulmonary", 1713], ["valves", 1723], [".", 1729]]}
